Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
Npas4 is a GENE-Y, melatonin is a CHEMICAL, Cry1 is a GENE-Y
23598442_task0
Sentence: Npas4 is activated by melatonin, and drives the clock gene Cry1 in the ovine pars tuberalis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]
Npas4 is activated by melatonin, and drives the clock gene Cry1 in the ovine pars tuberalis.
[ "Npas4", "is", "activated", "by", "melatonin", ",", "and", "drives", "the", "clock", "gene", "Cry1", "in", "the", "ovine", "pars", "tuberalis", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Npas4 is a GENE-Y, melatonin is a CHEMICAL, Cry1 is a GENE-Y
23598442_task1
Sentence: Npas4 is activated by melatonin, and drives the clock gene Cry1 in the ovine pars tuberalis. Instructions: please typing these entity words according to sentence: Npas4, melatonin, Cry1 Options: GENE-Y, CHEMICAL
[ "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]
Npas4 is activated by melatonin, and drives the clock gene Cry1 in the ovine pars tuberalis.
[ "Npas4", "is", "activated", "by", "melatonin", ",", "and", "drives", "the", "clock", "gene", "Cry1", "in", "the", "ovine", "pars", "tuberalis", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Npas4, melatonin, Cry1
23598442_task2
Sentence: Npas4 is activated by melatonin, and drives the clock gene Cry1 in the ovine pars tuberalis. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]
Npas4 is activated by melatonin, and drives the clock gene Cry1 in the ovine pars tuberalis.
[ "Npas4", "is", "activated", "by", "melatonin", ",", "and", "drives", "the", "clock", "gene", "Cry1", "in", "the", "ovine", "pars", "tuberalis", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
IL-5 synthesis is an other_name, atopic diseases is an other_name, allergen - specific human helper T cells is a cell_line
56125_task0
Sentence: Cellular and molecular mechanisms of IL-5 synthesis in atopic diseases: a study with allergen-specific human helper T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_line, other_name
[ "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]
Cellular and molecular mechanisms of IL-5 synthesis in atopic diseases: a study with allergen-specific human helper T cells.
[ "Cellular", "and", "molecular", "mechanisms", "of", "IL-5", "synthesis", "in", "atopic", "diseases", ":", "a", "study", "with", "allergen", "-", "specific", "human", "helper", "T", "cells", "." ]
[ "DNA_molecule", "cell_line", "other_name", "cell_type", "protein_family_or_group", "multi_cell", "DNA_domain_or_region", "protein_molecule" ]
IL-5 synthesis is an other_name, atopic diseases is an other_name, allergen - specific human helper T cells is a cell_line
56125_task1
Sentence: Cellular and molecular mechanisms of IL-5 synthesis in atopic diseases: a study with allergen-specific human helper T cells. Instructions: please typing these entity words according to sentence: IL-5 synthesis, atopic diseases, allergen - specific human helper T cells Options: cell_line, other_name
[ "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]
Cellular and molecular mechanisms of IL-5 synthesis in atopic diseases: a study with allergen-specific human helper T cells.
[ "Cellular", "and", "molecular", "mechanisms", "of", "IL-5", "synthesis", "in", "atopic", "diseases", ":", "a", "study", "with", "allergen", "-", "specific", "human", "helper", "T", "cells", "." ]
[ "DNA_molecule", "cell_line", "other_name", "cell_type", "protein_family_or_group", "multi_cell", "DNA_domain_or_region", "protein_molecule" ]
IL-5 synthesis, atopic diseases, allergen - specific human helper T cells
56125_task2
Sentence: Cellular and molecular mechanisms of IL-5 synthesis in atopic diseases: a study with allergen-specific human helper T cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]
Cellular and molecular mechanisms of IL-5 synthesis in atopic diseases: a study with allergen-specific human helper T cells.
[ "Cellular", "and", "molecular", "mechanisms", "of", "IL-5", "synthesis", "in", "atopic", "diseases", ":", "a", "study", "with", "allergen", "-", "specific", "human", "helper", "T", "cells", "." ]
[ "DNA_molecule", "cell_line", "other_name", "cell_type", "protein_family_or_group", "multi_cell", "DNA_domain_or_region", "protein_molecule" ]
Schulterluxation is an umlsterm, Patient is an umlsterm, Kombinationsverletzung is an umlsterm, Diagnostik is an umlsterm, Schulter is an umlsterm, Verletzung is an umlsterm, Schulter is an umlsterm, Gelenkflaeche is an umlsterm, Patient is an umlsterm, Behandlung is an umlsterm, Wiederherstellung is an umlsterm, Schultergelenk is an umlsterm
DerChirurg.90701361.ger.abstr_task0
Sentence: Zusammenfassung . Wir berichten ueber den Fall einer subacromialen Schulterluxation , die durch die Kombination von einer cranialen Glenoidfraktur und einer Acromionfraktur moeglich wurde . Der Patient hatte sich diese ungewoehnliche Kombinationsverletzung im Rahmen eines Handballspiels zugezogen . Erst die weiterfuehrende Diagnostik mit einem CT der Schulter zeigte das ganze Ausmass der Verletzung . Es erfolgte die osteosynthetische Versorgung der Glenoidfraktur nach Reposition der Schulter . Das postoperative Ergebnis zeigte eine gute anatomische Rekonstruktion der glenoidalen Gelenkflaeche . Der Patient hat nach Abschluss unserer Behandlung eine gute funktionelle Wiederherstellung der Beweglichkeit im Schultergelenk mit Abduktion bis 180 Grad und ist wieder voll berufstaetig . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Wir berichten ueber den Fall einer subacromialen Schulterluxation , die durch die Kombination von einer cranialen Glenoidfraktur und einer Acromionfraktur moeglich wurde . Der Patient hatte sich diese ungewoehnliche Kombinationsverletzung im Rahmen eines Handballspiels zugezogen . Erst die weiterfuehrende Diagnostik mit einem CT der Schulter zeigte das ganze Ausmass der Verletzung . Es erfolgte die osteosynthetische Versorgung der Glenoidfraktur nach Reposition der Schulter . Das postoperative Ergebnis zeigte eine gute anatomische Rekonstruktion der glenoidalen Gelenkflaeche . Der Patient hat nach Abschluss unserer Behandlung eine gute funktionelle Wiederherstellung der Beweglichkeit im Schultergelenk mit Abduktion bis 180 Grad und ist wieder voll berufstaetig .
[ "Zusammenfassung", ".", "Wir", "berichten", "ueber", "den", "Fall", "einer", "subacromialen", "Schulterluxation", ",", "die", "durch", "die", "Kombination", "von", "einer", "cranialen", "Glenoidfraktur", "und", "einer", "Acromionfraktur", "moeglich", "wurde", ".", "Der", "Patient", "hatte", "sich", "diese", "ungewoehnliche", "Kombinationsverletzung", "im", "Rahmen", "eines", "Handballspiels", "zugezogen", ".", "Erst", "die", "weiterfuehrende", "Diagnostik", "mit", "einem", "CT", "der", "Schulter", "zeigte", "das", "ganze", "Ausmass", "der", "Verletzung", ".", "Es", "erfolgte", "die", "osteosynthetische", "Versorgung", "der", "Glenoidfraktur", "nach", "Reposition", "der", "Schulter", ".", "Das", "postoperative", "Ergebnis", "zeigte", "eine", "gute", "anatomische", "Rekonstruktion", "der", "glenoidalen", "Gelenkflaeche", ".", "Der", "Patient", "hat", "nach", "Abschluss", "unserer", "Behandlung", "eine", "gute", "funktionelle", "Wiederherstellung", "der", "Beweglichkeit", "im", "Schultergelenk", "mit", "Abduktion", "bis", "180", "Grad", "und", "ist", "wieder", "voll", "berufstaetig", "." ]
[ "umlsterm" ]
Schulterluxation is an umlsterm, Patient is an umlsterm, Kombinationsverletzung is an umlsterm, Diagnostik is an umlsterm, Schulter is an umlsterm, Verletzung is an umlsterm, Schulter is an umlsterm, Gelenkflaeche is an umlsterm, Patient is an umlsterm, Behandlung is an umlsterm, Wiederherstellung is an umlsterm, Schultergelenk is an umlsterm
DerChirurg.90701361.ger.abstr_task1
Sentence: Zusammenfassung . Wir berichten ueber den Fall einer subacromialen Schulterluxation , die durch die Kombination von einer cranialen Glenoidfraktur und einer Acromionfraktur moeglich wurde . Der Patient hatte sich diese ungewoehnliche Kombinationsverletzung im Rahmen eines Handballspiels zugezogen . Erst die weiterfuehrende Diagnostik mit einem CT der Schulter zeigte das ganze Ausmass der Verletzung . Es erfolgte die osteosynthetische Versorgung der Glenoidfraktur nach Reposition der Schulter . Das postoperative Ergebnis zeigte eine gute anatomische Rekonstruktion der glenoidalen Gelenkflaeche . Der Patient hat nach Abschluss unserer Behandlung eine gute funktionelle Wiederherstellung der Beweglichkeit im Schultergelenk mit Abduktion bis 180 Grad und ist wieder voll berufstaetig . Instructions: please typing these entity words according to sentence: Schulterluxation, Patient, Kombinationsverletzung, Diagnostik, Schulter, Verletzung, Schulter, Gelenkflaeche, Patient, Behandlung, Wiederherstellung, Schultergelenk Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Wir berichten ueber den Fall einer subacromialen Schulterluxation , die durch die Kombination von einer cranialen Glenoidfraktur und einer Acromionfraktur moeglich wurde . Der Patient hatte sich diese ungewoehnliche Kombinationsverletzung im Rahmen eines Handballspiels zugezogen . Erst die weiterfuehrende Diagnostik mit einem CT der Schulter zeigte das ganze Ausmass der Verletzung . Es erfolgte die osteosynthetische Versorgung der Glenoidfraktur nach Reposition der Schulter . Das postoperative Ergebnis zeigte eine gute anatomische Rekonstruktion der glenoidalen Gelenkflaeche . Der Patient hat nach Abschluss unserer Behandlung eine gute funktionelle Wiederherstellung der Beweglichkeit im Schultergelenk mit Abduktion bis 180 Grad und ist wieder voll berufstaetig .
[ "Zusammenfassung", ".", "Wir", "berichten", "ueber", "den", "Fall", "einer", "subacromialen", "Schulterluxation", ",", "die", "durch", "die", "Kombination", "von", "einer", "cranialen", "Glenoidfraktur", "und", "einer", "Acromionfraktur", "moeglich", "wurde", ".", "Der", "Patient", "hatte", "sich", "diese", "ungewoehnliche", "Kombinationsverletzung", "im", "Rahmen", "eines", "Handballspiels", "zugezogen", ".", "Erst", "die", "weiterfuehrende", "Diagnostik", "mit", "einem", "CT", "der", "Schulter", "zeigte", "das", "ganze", "Ausmass", "der", "Verletzung", ".", "Es", "erfolgte", "die", "osteosynthetische", "Versorgung", "der", "Glenoidfraktur", "nach", "Reposition", "der", "Schulter", ".", "Das", "postoperative", "Ergebnis", "zeigte", "eine", "gute", "anatomische", "Rekonstruktion", "der", "glenoidalen", "Gelenkflaeche", ".", "Der", "Patient", "hat", "nach", "Abschluss", "unserer", "Behandlung", "eine", "gute", "funktionelle", "Wiederherstellung", "der", "Beweglichkeit", "im", "Schultergelenk", "mit", "Abduktion", "bis", "180", "Grad", "und", "ist", "wieder", "voll", "berufstaetig", "." ]
[ "umlsterm" ]
Schulterluxation, Patient, Kombinationsverletzung, Diagnostik, Schulter, Verletzung, Schulter, Gelenkflaeche, Patient, Behandlung, Wiederherstellung, Schultergelenk
DerChirurg.90701361.ger.abstr_task2
Sentence: Zusammenfassung . Wir berichten ueber den Fall einer subacromialen Schulterluxation , die durch die Kombination von einer cranialen Glenoidfraktur und einer Acromionfraktur moeglich wurde . Der Patient hatte sich diese ungewoehnliche Kombinationsverletzung im Rahmen eines Handballspiels zugezogen . Erst die weiterfuehrende Diagnostik mit einem CT der Schulter zeigte das ganze Ausmass der Verletzung . Es erfolgte die osteosynthetische Versorgung der Glenoidfraktur nach Reposition der Schulter . Das postoperative Ergebnis zeigte eine gute anatomische Rekonstruktion der glenoidalen Gelenkflaeche . Der Patient hat nach Abschluss unserer Behandlung eine gute funktionelle Wiederherstellung der Beweglichkeit im Schultergelenk mit Abduktion bis 180 Grad und ist wieder voll berufstaetig . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Wir berichten ueber den Fall einer subacromialen Schulterluxation , die durch die Kombination von einer cranialen Glenoidfraktur und einer Acromionfraktur moeglich wurde . Der Patient hatte sich diese ungewoehnliche Kombinationsverletzung im Rahmen eines Handballspiels zugezogen . Erst die weiterfuehrende Diagnostik mit einem CT der Schulter zeigte das ganze Ausmass der Verletzung . Es erfolgte die osteosynthetische Versorgung der Glenoidfraktur nach Reposition der Schulter . Das postoperative Ergebnis zeigte eine gute anatomische Rekonstruktion der glenoidalen Gelenkflaeche . Der Patient hat nach Abschluss unserer Behandlung eine gute funktionelle Wiederherstellung der Beweglichkeit im Schultergelenk mit Abduktion bis 180 Grad und ist wieder voll berufstaetig .
[ "Zusammenfassung", ".", "Wir", "berichten", "ueber", "den", "Fall", "einer", "subacromialen", "Schulterluxation", ",", "die", "durch", "die", "Kombination", "von", "einer", "cranialen", "Glenoidfraktur", "und", "einer", "Acromionfraktur", "moeglich", "wurde", ".", "Der", "Patient", "hatte", "sich", "diese", "ungewoehnliche", "Kombinationsverletzung", "im", "Rahmen", "eines", "Handballspiels", "zugezogen", ".", "Erst", "die", "weiterfuehrende", "Diagnostik", "mit", "einem", "CT", "der", "Schulter", "zeigte", "das", "ganze", "Ausmass", "der", "Verletzung", ".", "Es", "erfolgte", "die", "osteosynthetische", "Versorgung", "der", "Glenoidfraktur", "nach", "Reposition", "der", "Schulter", ".", "Das", "postoperative", "Ergebnis", "zeigte", "eine", "gute", "anatomische", "Rekonstruktion", "der", "glenoidalen", "Gelenkflaeche", ".", "Der", "Patient", "hat", "nach", "Abschluss", "unserer", "Behandlung", "eine", "gute", "funktionelle", "Wiederherstellung", "der", "Beweglichkeit", "im", "Schultergelenk", "mit", "Abduktion", "bis", "180", "Grad", "und", "ist", "wieder", "voll", "berufstaetig", "." ]
[ "umlsterm" ]
implantes tumorales is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, implantes peritoneales is a MORFOLOGIA_NEOPLASIA, Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV ( afectación hepática is a MORFOLOGIA_NEOPLASIA, tumores is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA, metastásicos is a MORFOLOGIA_NEOPLASIA, ( LOE ) hepáticas is a MORFOLOGIA_NEOPLASIA, masa suprarrenal is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, masa pélvica is a MORFOLOGIA_NEOPLASIA, masa pélvica is a MORFOLOGIA_NEOPLASIA, masa pélvica is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA
473_task0
Sentence: Anamnesis Varón de 34 años, sin alergias conocidas ni hábitos tóxicos, amigdalectomizado a los 6 años, casado, padre de una hija y con vida laboral activa como abogado. En mayo de 2014, el paciente comienza con cuadro de dispepsia, epigastralgia, aumento del perímetro abdominal y pérdida de peso progresiva de unos 6 kg de peso. Acude a centro privado donde se objetiva, en tomografía computarizada de tórax-abdomen y pelvis (TC-TAP), una gran masa abdominal de aproximadamente 22 x 15 x 22 cm que desplaza estómago y colon y en contacto con páncreas, bazo y duodeno. Es entonces cuando se remite al Servicio de Cirugía General y Digestiva de nuestro hospital. El 24/02/2015 el paciente es sometido a exéresis en bloque con gastrectomía total, segmentectomía II-III, resección de cola pancreática, bazo e implantes tumorales en diafragma izquierdo y adenopatía en cabeza de páncreas, con reconstrucción mediante Y de Roux con anastomosis esófago-yeyunal. Macroscópicamente, el tumor tenía un tamaño de 35 x 19 x 16 cm. Microscópicamente, el tumor mostraba un 10-15 % de necrosis. La inmunohistoquímica fue Cam 5,2+, vimentina+, CKAE1-AE3 débilmente, EMA+, enolasa neuronal específica+, desmina positiva focal, WT-1 (Nterminal)-, mioglobina-, CD99-, S-100-, Melan A-, calretinina-, CK-, 34 beta E12-, DOG-1-, c-kit-, CD34-, calponina-, LCA-, RCC-, cromogranina-, sinaptofisina-, C56+/-, actina+/-, inhibina+/- focal. Exploración física Buen estado general. Eastern Cooperative Oncology Group (ECOG) 1. Hemodinámicamente, estable. Destaca masa abdominal indurada, fija y dolorosa a palpación en hemiabdomen superior. Resto de exploración física por órganos y aparatos dentro de la normalidad. Pruebas complementarias » Analítica sanguínea: bioquímica con función renal y perfil hepático dentro de la normalidad. hemograma y coagulación normal. Marcadores tumorales: destaca la elevación de CA-125 de 159 UI/ml (valor de normalidad menor o igual a 35 UI/ml). » TC-TAP con contraste de diciembre 2014: objetiva masa sólida abdominal de 23 x 15 x 23 cm que comprime cámara gástrica, improntanto lóbulo hepático izquierdo con desplazamiento de estructuras intraabdominales e imágenes nodulares sugestivas de implantes peritoneales. Diagnóstico Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV (afectación hepática y peritoneal). Tratamiento En marzo de 2015 es valorado en consultas externas de Oncología Médica y, dada la inexistencia de datos acerca de tratamiento adyuvante en este tipo de tumores, se consensúa seguimiento clínico estrecho. Evolución En agosto de 2015, se evidencia en TC-TAP progresión tumoral a expensas de múltiples implantes tumorales metastásicos (retroperitoneal, paraaórticos, intraabdominales, iliaca izquierda y retroumbilical), lesiones ocupantes de espacio (LOE) hepáticas y masa suprarrenal izquierda. Tras revisión de la literatura disponible, se consensúa inicio de quimioterapia según esquema vincristina, doxorrubicina, ciclofosfamida, isofosfamida y etopósido (VIDE) en régimen de hospitalización y con factores de estimulación de colonias de granulocitos (G-CSF) profilácticos, recibiendo un total de 8 ciclos entre septiembre de 2015 y marzo de 2016, con excelente tolerancia y respuesta tumoral de los nódulos abdominopélvicos por estudio de imagen. Dado que el paciente mantenía ECOG 0, se mantuvo tratamiento de mantenimiento con etopósido oral, por el elevado riesgo de recidiva con el cese de tratamiento oncológico. El paciente presenta buena tolerancia salvo diarreas moderadas que obligan a reducir dosis al 80 %. En noviembre de 2016, se palpa masa pélvica, confirmándose en TC-TAP progresión a dicho nivel. Tras ser valorado el caso clínico en comité multidisciplinar de tumores, no siendo resecable quirúrgicamente, se inicia tratamiento quimioterápico según esquema carboplatino-paclitaxel recibiendo un total de 6 ciclos consiguiéndose reducción de la masa pélvica, motivo por el que se consensúa tratamiento radioterápico sobre ésta. En junio de 2017, finaliza radioterapia y dada la excelente respuesta, con una reducción de la masa pélvica de 8,9 x 5,8 x 6,9 cm a 7,4 x 4 x 5,7 cm, el paciente es intervenido en julio de 2017. Se practica exéresis de los implantes tumorales (umbilical, pelvis, mesocolon transverso, fosa iliaca izquierda, flanco izquierdo, diafragma izquierdo y derecho, lóbulo hepático izquierdo y suprarrenal izquierdo), así como apendicetomía e ileostomía de protección en asa de fosa iliaca derecha, con un Patient State Index (PSI) de 16 y administración de quimioterapia hipertérmica peritoneal (HIPEC) con oxaliplatino con 5-fluorouracilo previo. En TC de octubre de 2017 se evidencia progresión ganglionar abdominal, iniciándose entonces tratamiento de 3ª línea según esquema de ácido folínico, fluorouracilo e irinotecán (FOLFIRI). Durante el año 2017, el paciente sufre varios cuadros de suboclusión intestinal, que se resuelven con tratamiento médico sin necesidad de intervención quirúrgica. El paciente recibe un total de 26 ciclos, manteniéndose durante 15 meses respuesta parcial mantenida, hasta progresión tumoral en enero de 2019 a expensas de implantes tumorales en ligamento gastrohepático, glándula suprarrenal izquierda y cadena ilíaca externa izquierda. Dado el excelente estado general del paciente, se inicia 4ª línea de tratamiento con esquema irinotecán-bevacizumab-temozolamida recibiendo, hasta la fecha, 5 ciclos. El paciente actualmente mantiene un buen estado general, con un ECOG 0, incorporado a la vida laboral y pendiente de nueva reevaluación. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Varón de 34 años, sin alergias conocidas ni hábitos tóxicos, amigdalectomizado a los 6 años, casado, padre de una hija y con vida laboral activa como abogado. En mayo de 2014, el paciente comienza con cuadro de dispepsia, epigastralgia, aumento del perímetro abdominal y pérdida de peso progresiva de unos 6 kg de peso. Acude a centro privado donde se objetiva, en tomografía computarizada de tórax-abdomen y pelvis (TC-TAP), una gran masa abdominal de aproximadamente 22 x 15 x 22 cm que desplaza estómago y colon y en contacto con páncreas, bazo y duodeno. Es entonces cuando se remite al Servicio de Cirugía General y Digestiva de nuestro hospital. El 24/02/2015 el paciente es sometido a exéresis en bloque con gastrectomía total, segmentectomía II-III, resección de cola pancreática, bazo e implantes tumorales en diafragma izquierdo y adenopatía en cabeza de páncreas, con reconstrucción mediante Y de Roux con anastomosis esófago-yeyunal. Macroscópicamente, el tumor tenía un tamaño de 35 x 19 x 16 cm. Microscópicamente, el tumor mostraba un 10-15 % de necrosis. La inmunohistoquímica fue Cam 5,2+, vimentina+, CKAE1-AE3 débilmente, EMA+, enolasa neuronal específica+, desmina positiva focal, WT-1 (Nterminal)-, mioglobina-, CD99-, S-100-, Melan A-, calretinina-, CK-, 34 beta E12-, DOG-1-, c-kit-, CD34-, calponina-, LCA-, RCC-, cromogranina-, sinaptofisina-, C56+/-, actina+/-, inhibina+/- focal. Exploración física Buen estado general. Eastern Cooperative Oncology Group (ECOG) 1. Hemodinámicamente, estable. Destaca masa abdominal indurada, fija y dolorosa a palpación en hemiabdomen superior. Resto de exploración física por órganos y aparatos dentro de la normalidad. Pruebas complementarias » Analítica sanguínea: bioquímica con función renal y perfil hepático dentro de la normalidad. hemograma y coagulación normal. Marcadores tumorales: destaca la elevación de CA-125 de 159 UI/ml (valor de normalidad menor o igual a 35 UI/ml). » TC-TAP con contraste de diciembre 2014: objetiva masa sólida abdominal de 23 x 15 x 23 cm que comprime cámara gástrica, improntanto lóbulo hepático izquierdo con desplazamiento de estructuras intraabdominales e imágenes nodulares sugestivas de implantes peritoneales. Diagnóstico Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV (afectación hepática y peritoneal). Tratamiento En marzo de 2015 es valorado en consultas externas de Oncología Médica y, dada la inexistencia de datos acerca de tratamiento adyuvante en este tipo de tumores, se consensúa seguimiento clínico estrecho. Evolución En agosto de 2015, se evidencia en TC-TAP progresión tumoral a expensas de múltiples implantes tumorales metastásicos (retroperitoneal, paraaórticos, intraabdominales, iliaca izquierda y retroumbilical), lesiones ocupantes de espacio (LOE) hepáticas y masa suprarrenal izquierda. Tras revisión de la literatura disponible, se consensúa inicio de quimioterapia según esquema vincristina, doxorrubicina, ciclofosfamida, isofosfamida y etopósido (VIDE) en régimen de hospitalización y con factores de estimulación de colonias de granulocitos (G-CSF) profilácticos, recibiendo un total de 8 ciclos entre septiembre de 2015 y marzo de 2016, con excelente tolerancia y respuesta tumoral de los nódulos abdominopélvicos por estudio de imagen. Dado que el paciente mantenía ECOG 0, se mantuvo tratamiento de mantenimiento con etopósido oral, por el elevado riesgo de recidiva con el cese de tratamiento oncológico. El paciente presenta buena tolerancia salvo diarreas moderadas que obligan a reducir dosis al 80 %. En noviembre de 2016, se palpa masa pélvica, confirmándose en TC-TAP progresión a dicho nivel. Tras ser valorado el caso clínico en comité multidisciplinar de tumores, no siendo resecable quirúrgicamente, se inicia tratamiento quimioterápico según esquema carboplatino-paclitaxel recibiendo un total de 6 ciclos consiguiéndose reducción de la masa pélvica, motivo por el que se consensúa tratamiento radioterápico sobre ésta. En junio de 2017, finaliza radioterapia y dada la excelente respuesta, con una reducción de la masa pélvica de 8,9 x 5,8 x 6,9 cm a 7,4 x 4 x 5,7 cm, el paciente es intervenido en julio de 2017. Se practica exéresis de los implantes tumorales (umbilical, pelvis, mesocolon transverso, fosa iliaca izquierda, flanco izquierdo, diafragma izquierdo y derecho, lóbulo hepático izquierdo y suprarrenal izquierdo), así como apendicetomía e ileostomía de protección en asa de fosa iliaca derecha, con un Patient State Index (PSI) de 16 y administración de quimioterapia hipertérmica peritoneal (HIPEC) con oxaliplatino con 5-fluorouracilo previo. En TC de octubre de 2017 se evidencia progresión ganglionar abdominal, iniciándose entonces tratamiento de 3ª línea según esquema de ácido folínico, fluorouracilo e irinotecán (FOLFIRI). Durante el año 2017, el paciente sufre varios cuadros de suboclusión intestinal, que se resuelven con tratamiento médico sin necesidad de intervención quirúrgica. El paciente recibe un total de 26 ciclos, manteniéndose durante 15 meses respuesta parcial mantenida, hasta progresión tumoral en enero de 2019 a expensas de implantes tumorales en ligamento gastrohepático, glándula suprarrenal izquierda y cadena ilíaca externa izquierda. Dado el excelente estado general del paciente, se inicia 4ª línea de tratamiento con esquema irinotecán-bevacizumab-temozolamida recibiendo, hasta la fecha, 5 ciclos. El paciente actualmente mantiene un buen estado general, con un ECOG 0, incorporado a la vida laboral y pendiente de nueva reevaluación.
[ "Anamnesis", "\n", "Varón", "de", "34", "años", ",", "sin", "alergias", "conocidas", "ni", "hábitos", "tóxicos", ",", "amigdalectomizado", "a", "los", "6", "años", ",", "casado", ",", "padre", "de", "una", "hija", "y", "con", "vida", "laboral", "activa", "como", "abogado", ".", "\n", "En", "mayo", "de", "2014", ",", "el", "paciente", "comienza", "con", "cuadro", "de", "dispepsia", ",", "epigastralgia", ",", "aumento", "del", "perímetro", "abdominal", "y", "pérdida", "de", "peso", "progresiva", "de", "unos", "6", "kg", "de", "peso", ".", "Acude", "a", "centro", "privado", "donde", "se", "objetiva", ",", "en", "tomografía", "computarizada", "de", "tórax", "-", "abdomen", "y", "pelvis", "(", "TC", "-", "TAP", ")", ",", "una", "gran", "masa", "abdominal", "de", "aproximadamente", "22", "x", "15", "x", "22", "cm", "que", "desplaza", "estómago", "y", "colon", "y", "en", "contacto", "con", "páncreas", ",", "bazo", "y", "duodeno", ".", "\n", "Es", "entonces", "cuando", "se", "remite", "al", "Servicio", "de", "Cirugía", "General", "y", "Digestiva", "de", "nuestro", "hospital", ".", "El", "24/02/2015", "el", "paciente", "es", "sometido", "a", "exéresis", "en", "bloque", "con", "gastrectomía", "total", ",", "segmentectomía", "II", "-", "III", ",", "resección", "de", "cola", "pancreática", ",", "bazo", "e", "implantes", "tumorales", "en", "diafragma", "izquierdo", "y", "adenopatía", "en", "cabeza", "de", "páncreas", ",", "con", "reconstrucción", "mediante", "Y", "de", "Roux", "con", "anastomosis", "esófago", "-", "yeyunal", ".", "\n", "Macroscópicamente", ",", "el", "tumor", "tenía", "un", "tamaño", "de", "35", "x", "19", "x", "16", "cm", ".", "Microscópicamente", ",", "el", "tumor", "mostraba", "un", "10", "-", "15", "%", "de", "necrosis", ".", "La", "inmunohistoquímica", "fue", "Cam", "5,2", "+", ",", "vimentina+", ",", "CKAE1-AE3", "débilmente", ",", "EMA+", ",", "enolasa", "neuronal", "específica+", ",", "desmina", "positiva", "focal", ",", "WT-1", "(", "Nterminal)-", ",", "mioglobina-", ",", "CD99-", ",", "S-100-", ",", "Melan", "A-", ",", "calretinina-", ",", "CK-", ",", "34", "beta", "E12-", ",", "DOG-1-", ",", "c", "-", "kit-", ",", "CD34-", ",", "calponina-", ",", "LCA-", ",", "RCC-", ",", "cromogranina-", ",", "sinaptofisina-", ",", "C56+/-", ",", "actina+/-", ",", "inhibina+/-", "focal", ".", "\n\n", "Exploración", "física", "\n", "Buen", "estado", "general", ".", "Eastern", "Cooperative", "Oncology", "Group", "(", "ECOG", ")", "1", ".", "Hemodinámicamente", ",", "estable", ".", "Destaca", "masa", "abdominal", "indurada", ",", "fija", "y", "dolorosa", "a", "palpación", "en", "hemiabdomen", "superior", ".", "Resto", "de", "exploración", "física", "por", "órganos", "y", "aparatos", "dentro", "de", "la", "normalidad", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Analítica", "sanguínea", ":", "bioquímica", "con", "función", "renal", "y", "perfil", "hepático", "dentro", "de", "la", "normalidad", ".", "hemograma", "y", "coagulación", "normal", ".", "Marcadores", "tumorales", ":", "destaca", "la", "elevación", "de", "CA-125", "de", "159", "UI", "/", "ml", "(", "valor", "de", "normalidad", "menor", "o", "igual", "a", "35", "UI", "/", "ml", ")", ".", "\n", "»", "TC", "-", "TAP", "con", "contraste", "de", "diciembre", "2014", ":", "objetiva", "masa", "sólida", "abdominal", "de", "23", "x", "15", "x", "23", "cm", "que", "comprime", "cámara", "gástrica", ",", "improntanto", "lóbulo", "hepático", "izquierdo", "con", "desplazamiento", "de", "estructuras", "intraabdominales", "e", "imágenes", "nodulares", "sugestivas", "de", "implantes", "peritoneales", ".", "\n\n", "Diagnóstico", "\n", "Tumor", "desmoplásico", "abdominal", "de", "células", "pequeñas", "y", "redondas", "estadio", "IV", "(", "afectación", "hepática", "y", "peritoneal", ")", ".", "\n\n", "Tratamiento", "\n", "En", "marzo", "de", "2015", "es", "valorado", "en", "consultas", "externas", "de", "Oncología", "Médica", "y", ",", "dada", "la", "inexistencia", "de", "datos", "acerca", "de", "tratamiento", "adyuvante", "en", "este", "tipo", "de", "tumores", ",", "se", "consensúa", "seguimiento", "clínico", "estrecho", ".", "\n\n", "Evolución", "\n", "En", "agosto", "de", "2015", ",", "se", "evidencia", "en", "TC", "-", "TAP", "progresión", "tumoral", "a", "expensas", "de", "múltiples", "implantes", "tumorales", "metastásicos", "(", "retroperitoneal", ",", "paraaórticos", ",", "intraabdominales", ",", "iliaca", "izquierda", "y", "retroumbilical", ")", ",", "lesiones", "ocupantes", "de", "espacio", "(", "LOE", ")", "hepáticas", "y", "masa", "suprarrenal", "izquierda", ".", "Tras", "revisión", "de", "la", "literatura", "disponible", ",", "se", "consensúa", "inicio", "de", "quimioterapia", "según", "esquema", "vincristina", ",", "doxorrubicina", ",", "ciclofosfamida", ",", "isofosfamida", "y", "etopósido", "(", "VIDE", ")", "en", "régimen", "de", "hospitalización", "y", "con", "factores", "de", "estimulación", "de", "colonias", "de", "granulocitos", "(", "G", "-", "CSF", ")", "profilácticos", ",", "recibiendo", "un", "total", "de", "8", "ciclos", "entre", "septiembre", "de", "2015", "y", "marzo", "de", "2016", ",", "con", "excelente", "tolerancia", "y", "respuesta", "tumoral", "de", "los", "nódulos", "abdominopélvicos", "por", "estudio", "de", "imagen", ".", "\n", "Dado", "que", "el", "paciente", "mantenía", "ECOG", "0", ",", "se", "mantuvo", "tratamiento", "de", "mantenimiento", "con", "etopósido", "oral", ",", "por", "el", "elevado", "riesgo", "de", "recidiva", "con", "el", "cese", "de", "tratamiento", "oncológico", ".", "El", "paciente", "presenta", "buena", "tolerancia", "salvo", "diarreas", "moderadas", "que", "obligan", "a", "reducir", "dosis", "al", "80", "%", ".", "\n", "En", "noviembre", "de", "2016", ",", "se", "palpa", "masa", "pélvica", ",", "confirmándose", "en", "TC", "-", "TAP", "progresión", "a", "dicho", "nivel", ".", "Tras", "ser", "valorado", "el", "caso", "clínico", "en", "comité", "multidisciplinar", "de", "tumores", ",", "no", "siendo", "resecable", "quirúrgicamente", ",", "se", "inicia", "tratamiento", "quimioterápico", "según", "esquema", "carboplatino", "-", "paclitaxel", "recibiendo", "un", "total", "de", "6", "ciclos", "consiguiéndose", "reducción", "de", "la", "masa", "pélvica", ",", "motivo", "por", "el", "que", "se", "consensúa", "tratamiento", "radioterápico", "sobre", "ésta", ".", "\n", "En", "junio", "de", "2017", ",", "finaliza", "radioterapia", "y", "dada", "la", "excelente", "respuesta", ",", "con", "una", "reducción", "de", "la", "masa", "pélvica", "de", "8,9", "x", "5,8", "x", "6,9", "cm", "a", "7,4", "x", "4", "x", "5,7", "cm", ",", "el", "paciente", "es", "intervenido", "en", "julio", "de", "2017", ".", "Se", "practica", "exéresis", "de", "los", "implantes", "tumorales", "(", "umbilical", ",", "pelvis", ",", "mesocolon", "transverso", ",", "fosa", "iliaca", "izquierda", ",", "flanco", "izquierdo", ",", "diafragma", "izquierdo", "y", "derecho", ",", "lóbulo", "hepático", "izquierdo", "y", "suprarrenal", "izquierdo", ")", ",", "así", "como", "apendicetomía", "e", "ileostomía", "de", "protección", "en", "asa", "de", "fosa", "iliaca", "derecha", ",", "con", "un", "Patient", "State", "Index", "(", "PSI", ")", "de", "16", "y", "administración", "de", "quimioterapia", "hipertérmica", "peritoneal", "(", "HIPEC", ")", "con", "oxaliplatino", "con", "5-fluorouracilo", "previo", ".", "\n", "En", "TC", "de", "octubre", "de", "2017", "se", "evidencia", "progresión", "ganglionar", "abdominal", ",", "iniciándose", "entonces", "tratamiento", "de", "3ª", "línea", "según", "esquema", "de", "ácido", "folínico", ",", "fluorouracilo", "e", "irinotecán", "(", "FOLFIRI", ")", ".", "Durante", "el", "año", "2017", ",", "el", "paciente", "sufre", "varios", "cuadros", "de", "suboclusión", "intestinal", ",", "que", "se", "resuelven", "con", "tratamiento", "médico", "sin", "necesidad", "de", "intervención", "quirúrgica", ".", "\n", "El", "paciente", "recibe", "un", "total", "de", "26", "ciclos", ",", "manteniéndose", "durante", "15", "meses", "respuesta", "parcial", "mantenida", ",", "hasta", "progresión", "tumoral", "en", "enero", "de", "2019", "a", "expensas", "de", "implantes", "tumorales", "en", "ligamento", "gastrohepático", ",", "glándula", "suprarrenal", "izquierda", "y", "cadena", "ilíaca", "externa", "izquierda", ".", "Dado", "el", "excelente", "estado", "general", "del", "paciente", ",", "se", "inicia", "4ª", "línea", "de", "tratamiento", "con", "esquema", "irinotecán", "-", "bevacizumab", "-", "temozolamida", "recibiendo", ",", "hasta", "la", "fecha", ",", "5", "ciclos", ".", "El", "paciente", "actualmente", "mantiene", "un", "buen", "estado", "general", ",", "con", "un", "ECOG", "0", ",", "incorporado", "a", "la", "vida", "laboral", "y", "pendiente", "de", "nueva", "reevaluación", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
implantes tumorales is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, implantes peritoneales is a MORFOLOGIA_NEOPLASIA, Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV ( afectación hepática is a MORFOLOGIA_NEOPLASIA, tumores is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA, metastásicos is a MORFOLOGIA_NEOPLASIA, ( LOE ) hepáticas is a MORFOLOGIA_NEOPLASIA, masa suprarrenal is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, masa pélvica is a MORFOLOGIA_NEOPLASIA, masa pélvica is a MORFOLOGIA_NEOPLASIA, masa pélvica is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA
473_task1
Sentence: Anamnesis Varón de 34 años, sin alergias conocidas ni hábitos tóxicos, amigdalectomizado a los 6 años, casado, padre de una hija y con vida laboral activa como abogado. En mayo de 2014, el paciente comienza con cuadro de dispepsia, epigastralgia, aumento del perímetro abdominal y pérdida de peso progresiva de unos 6 kg de peso. Acude a centro privado donde se objetiva, en tomografía computarizada de tórax-abdomen y pelvis (TC-TAP), una gran masa abdominal de aproximadamente 22 x 15 x 22 cm que desplaza estómago y colon y en contacto con páncreas, bazo y duodeno. Es entonces cuando se remite al Servicio de Cirugía General y Digestiva de nuestro hospital. El 24/02/2015 el paciente es sometido a exéresis en bloque con gastrectomía total, segmentectomía II-III, resección de cola pancreática, bazo e implantes tumorales en diafragma izquierdo y adenopatía en cabeza de páncreas, con reconstrucción mediante Y de Roux con anastomosis esófago-yeyunal. Macroscópicamente, el tumor tenía un tamaño de 35 x 19 x 16 cm. Microscópicamente, el tumor mostraba un 10-15 % de necrosis. La inmunohistoquímica fue Cam 5,2+, vimentina+, CKAE1-AE3 débilmente, EMA+, enolasa neuronal específica+, desmina positiva focal, WT-1 (Nterminal)-, mioglobina-, CD99-, S-100-, Melan A-, calretinina-, CK-, 34 beta E12-, DOG-1-, c-kit-, CD34-, calponina-, LCA-, RCC-, cromogranina-, sinaptofisina-, C56+/-, actina+/-, inhibina+/- focal. Exploración física Buen estado general. Eastern Cooperative Oncology Group (ECOG) 1. Hemodinámicamente, estable. Destaca masa abdominal indurada, fija y dolorosa a palpación en hemiabdomen superior. Resto de exploración física por órganos y aparatos dentro de la normalidad. Pruebas complementarias » Analítica sanguínea: bioquímica con función renal y perfil hepático dentro de la normalidad. hemograma y coagulación normal. Marcadores tumorales: destaca la elevación de CA-125 de 159 UI/ml (valor de normalidad menor o igual a 35 UI/ml). » TC-TAP con contraste de diciembre 2014: objetiva masa sólida abdominal de 23 x 15 x 23 cm que comprime cámara gástrica, improntanto lóbulo hepático izquierdo con desplazamiento de estructuras intraabdominales e imágenes nodulares sugestivas de implantes peritoneales. Diagnóstico Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV (afectación hepática y peritoneal). Tratamiento En marzo de 2015 es valorado en consultas externas de Oncología Médica y, dada la inexistencia de datos acerca de tratamiento adyuvante en este tipo de tumores, se consensúa seguimiento clínico estrecho. Evolución En agosto de 2015, se evidencia en TC-TAP progresión tumoral a expensas de múltiples implantes tumorales metastásicos (retroperitoneal, paraaórticos, intraabdominales, iliaca izquierda y retroumbilical), lesiones ocupantes de espacio (LOE) hepáticas y masa suprarrenal izquierda. Tras revisión de la literatura disponible, se consensúa inicio de quimioterapia según esquema vincristina, doxorrubicina, ciclofosfamida, isofosfamida y etopósido (VIDE) en régimen de hospitalización y con factores de estimulación de colonias de granulocitos (G-CSF) profilácticos, recibiendo un total de 8 ciclos entre septiembre de 2015 y marzo de 2016, con excelente tolerancia y respuesta tumoral de los nódulos abdominopélvicos por estudio de imagen. Dado que el paciente mantenía ECOG 0, se mantuvo tratamiento de mantenimiento con etopósido oral, por el elevado riesgo de recidiva con el cese de tratamiento oncológico. El paciente presenta buena tolerancia salvo diarreas moderadas que obligan a reducir dosis al 80 %. En noviembre de 2016, se palpa masa pélvica, confirmándose en TC-TAP progresión a dicho nivel. Tras ser valorado el caso clínico en comité multidisciplinar de tumores, no siendo resecable quirúrgicamente, se inicia tratamiento quimioterápico según esquema carboplatino-paclitaxel recibiendo un total de 6 ciclos consiguiéndose reducción de la masa pélvica, motivo por el que se consensúa tratamiento radioterápico sobre ésta. En junio de 2017, finaliza radioterapia y dada la excelente respuesta, con una reducción de la masa pélvica de 8,9 x 5,8 x 6,9 cm a 7,4 x 4 x 5,7 cm, el paciente es intervenido en julio de 2017. Se practica exéresis de los implantes tumorales (umbilical, pelvis, mesocolon transverso, fosa iliaca izquierda, flanco izquierdo, diafragma izquierdo y derecho, lóbulo hepático izquierdo y suprarrenal izquierdo), así como apendicetomía e ileostomía de protección en asa de fosa iliaca derecha, con un Patient State Index (PSI) de 16 y administración de quimioterapia hipertérmica peritoneal (HIPEC) con oxaliplatino con 5-fluorouracilo previo. En TC de octubre de 2017 se evidencia progresión ganglionar abdominal, iniciándose entonces tratamiento de 3ª línea según esquema de ácido folínico, fluorouracilo e irinotecán (FOLFIRI). Durante el año 2017, el paciente sufre varios cuadros de suboclusión intestinal, que se resuelven con tratamiento médico sin necesidad de intervención quirúrgica. El paciente recibe un total de 26 ciclos, manteniéndose durante 15 meses respuesta parcial mantenida, hasta progresión tumoral en enero de 2019 a expensas de implantes tumorales en ligamento gastrohepático, glándula suprarrenal izquierda y cadena ilíaca externa izquierda. Dado el excelente estado general del paciente, se inicia 4ª línea de tratamiento con esquema irinotecán-bevacizumab-temozolamida recibiendo, hasta la fecha, 5 ciclos. El paciente actualmente mantiene un buen estado general, con un ECOG 0, incorporado a la vida laboral y pendiente de nueva reevaluación. Instructions: please typing these entity words according to sentence: implantes tumorales, tumor, tumor, implantes peritoneales, Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV ( afectación hepática, tumores, tumoral, implantes tumorales, metastásicos, ( LOE ) hepáticas, masa suprarrenal, tumoral, masa pélvica, masa pélvica, masa pélvica, implantes tumorales, tumoral, implantes tumorales Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Varón de 34 años, sin alergias conocidas ni hábitos tóxicos, amigdalectomizado a los 6 años, casado, padre de una hija y con vida laboral activa como abogado. En mayo de 2014, el paciente comienza con cuadro de dispepsia, epigastralgia, aumento del perímetro abdominal y pérdida de peso progresiva de unos 6 kg de peso. Acude a centro privado donde se objetiva, en tomografía computarizada de tórax-abdomen y pelvis (TC-TAP), una gran masa abdominal de aproximadamente 22 x 15 x 22 cm que desplaza estómago y colon y en contacto con páncreas, bazo y duodeno. Es entonces cuando se remite al Servicio de Cirugía General y Digestiva de nuestro hospital. El 24/02/2015 el paciente es sometido a exéresis en bloque con gastrectomía total, segmentectomía II-III, resección de cola pancreática, bazo e implantes tumorales en diafragma izquierdo y adenopatía en cabeza de páncreas, con reconstrucción mediante Y de Roux con anastomosis esófago-yeyunal. Macroscópicamente, el tumor tenía un tamaño de 35 x 19 x 16 cm. Microscópicamente, el tumor mostraba un 10-15 % de necrosis. La inmunohistoquímica fue Cam 5,2+, vimentina+, CKAE1-AE3 débilmente, EMA+, enolasa neuronal específica+, desmina positiva focal, WT-1 (Nterminal)-, mioglobina-, CD99-, S-100-, Melan A-, calretinina-, CK-, 34 beta E12-, DOG-1-, c-kit-, CD34-, calponina-, LCA-, RCC-, cromogranina-, sinaptofisina-, C56+/-, actina+/-, inhibina+/- focal. Exploración física Buen estado general. Eastern Cooperative Oncology Group (ECOG) 1. Hemodinámicamente, estable. Destaca masa abdominal indurada, fija y dolorosa a palpación en hemiabdomen superior. Resto de exploración física por órganos y aparatos dentro de la normalidad. Pruebas complementarias » Analítica sanguínea: bioquímica con función renal y perfil hepático dentro de la normalidad. hemograma y coagulación normal. Marcadores tumorales: destaca la elevación de CA-125 de 159 UI/ml (valor de normalidad menor o igual a 35 UI/ml). » TC-TAP con contraste de diciembre 2014: objetiva masa sólida abdominal de 23 x 15 x 23 cm que comprime cámara gástrica, improntanto lóbulo hepático izquierdo con desplazamiento de estructuras intraabdominales e imágenes nodulares sugestivas de implantes peritoneales. Diagnóstico Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV (afectación hepática y peritoneal). Tratamiento En marzo de 2015 es valorado en consultas externas de Oncología Médica y, dada la inexistencia de datos acerca de tratamiento adyuvante en este tipo de tumores, se consensúa seguimiento clínico estrecho. Evolución En agosto de 2015, se evidencia en TC-TAP progresión tumoral a expensas de múltiples implantes tumorales metastásicos (retroperitoneal, paraaórticos, intraabdominales, iliaca izquierda y retroumbilical), lesiones ocupantes de espacio (LOE) hepáticas y masa suprarrenal izquierda. Tras revisión de la literatura disponible, se consensúa inicio de quimioterapia según esquema vincristina, doxorrubicina, ciclofosfamida, isofosfamida y etopósido (VIDE) en régimen de hospitalización y con factores de estimulación de colonias de granulocitos (G-CSF) profilácticos, recibiendo un total de 8 ciclos entre septiembre de 2015 y marzo de 2016, con excelente tolerancia y respuesta tumoral de los nódulos abdominopélvicos por estudio de imagen. Dado que el paciente mantenía ECOG 0, se mantuvo tratamiento de mantenimiento con etopósido oral, por el elevado riesgo de recidiva con el cese de tratamiento oncológico. El paciente presenta buena tolerancia salvo diarreas moderadas que obligan a reducir dosis al 80 %. En noviembre de 2016, se palpa masa pélvica, confirmándose en TC-TAP progresión a dicho nivel. Tras ser valorado el caso clínico en comité multidisciplinar de tumores, no siendo resecable quirúrgicamente, se inicia tratamiento quimioterápico según esquema carboplatino-paclitaxel recibiendo un total de 6 ciclos consiguiéndose reducción de la masa pélvica, motivo por el que se consensúa tratamiento radioterápico sobre ésta. En junio de 2017, finaliza radioterapia y dada la excelente respuesta, con una reducción de la masa pélvica de 8,9 x 5,8 x 6,9 cm a 7,4 x 4 x 5,7 cm, el paciente es intervenido en julio de 2017. Se practica exéresis de los implantes tumorales (umbilical, pelvis, mesocolon transverso, fosa iliaca izquierda, flanco izquierdo, diafragma izquierdo y derecho, lóbulo hepático izquierdo y suprarrenal izquierdo), así como apendicetomía e ileostomía de protección en asa de fosa iliaca derecha, con un Patient State Index (PSI) de 16 y administración de quimioterapia hipertérmica peritoneal (HIPEC) con oxaliplatino con 5-fluorouracilo previo. En TC de octubre de 2017 se evidencia progresión ganglionar abdominal, iniciándose entonces tratamiento de 3ª línea según esquema de ácido folínico, fluorouracilo e irinotecán (FOLFIRI). Durante el año 2017, el paciente sufre varios cuadros de suboclusión intestinal, que se resuelven con tratamiento médico sin necesidad de intervención quirúrgica. El paciente recibe un total de 26 ciclos, manteniéndose durante 15 meses respuesta parcial mantenida, hasta progresión tumoral en enero de 2019 a expensas de implantes tumorales en ligamento gastrohepático, glándula suprarrenal izquierda y cadena ilíaca externa izquierda. Dado el excelente estado general del paciente, se inicia 4ª línea de tratamiento con esquema irinotecán-bevacizumab-temozolamida recibiendo, hasta la fecha, 5 ciclos. El paciente actualmente mantiene un buen estado general, con un ECOG 0, incorporado a la vida laboral y pendiente de nueva reevaluación.
[ "Anamnesis", "\n", "Varón", "de", "34", "años", ",", "sin", "alergias", "conocidas", "ni", "hábitos", "tóxicos", ",", "amigdalectomizado", "a", "los", "6", "años", ",", "casado", ",", "padre", "de", "una", "hija", "y", "con", "vida", "laboral", "activa", "como", "abogado", ".", "\n", "En", "mayo", "de", "2014", ",", "el", "paciente", "comienza", "con", "cuadro", "de", "dispepsia", ",", "epigastralgia", ",", "aumento", "del", "perímetro", "abdominal", "y", "pérdida", "de", "peso", "progresiva", "de", "unos", "6", "kg", "de", "peso", ".", "Acude", "a", "centro", "privado", "donde", "se", "objetiva", ",", "en", "tomografía", "computarizada", "de", "tórax", "-", "abdomen", "y", "pelvis", "(", "TC", "-", "TAP", ")", ",", "una", "gran", "masa", "abdominal", "de", "aproximadamente", "22", "x", "15", "x", "22", "cm", "que", "desplaza", "estómago", "y", "colon", "y", "en", "contacto", "con", "páncreas", ",", "bazo", "y", "duodeno", ".", "\n", "Es", "entonces", "cuando", "se", "remite", "al", "Servicio", "de", "Cirugía", "General", "y", "Digestiva", "de", "nuestro", "hospital", ".", "El", "24/02/2015", "el", "paciente", "es", "sometido", "a", "exéresis", "en", "bloque", "con", "gastrectomía", "total", ",", "segmentectomía", "II", "-", "III", ",", "resección", "de", "cola", "pancreática", ",", "bazo", "e", "implantes", "tumorales", "en", "diafragma", "izquierdo", "y", "adenopatía", "en", "cabeza", "de", "páncreas", ",", "con", "reconstrucción", "mediante", "Y", "de", "Roux", "con", "anastomosis", "esófago", "-", "yeyunal", ".", "\n", "Macroscópicamente", ",", "el", "tumor", "tenía", "un", "tamaño", "de", "35", "x", "19", "x", "16", "cm", ".", "Microscópicamente", ",", "el", "tumor", "mostraba", "un", "10", "-", "15", "%", "de", "necrosis", ".", "La", "inmunohistoquímica", "fue", "Cam", "5,2", "+", ",", "vimentina+", ",", "CKAE1-AE3", "débilmente", ",", "EMA+", ",", "enolasa", "neuronal", "específica+", ",", "desmina", "positiva", "focal", ",", "WT-1", "(", "Nterminal)-", ",", "mioglobina-", ",", "CD99-", ",", "S-100-", ",", "Melan", "A-", ",", "calretinina-", ",", "CK-", ",", "34", "beta", "E12-", ",", "DOG-1-", ",", "c", "-", "kit-", ",", "CD34-", ",", "calponina-", ",", "LCA-", ",", "RCC-", ",", "cromogranina-", ",", "sinaptofisina-", ",", "C56+/-", ",", "actina+/-", ",", "inhibina+/-", "focal", ".", "\n\n", "Exploración", "física", "\n", "Buen", "estado", "general", ".", "Eastern", "Cooperative", "Oncology", "Group", "(", "ECOG", ")", "1", ".", "Hemodinámicamente", ",", "estable", ".", "Destaca", "masa", "abdominal", "indurada", ",", "fija", "y", "dolorosa", "a", "palpación", "en", "hemiabdomen", "superior", ".", "Resto", "de", "exploración", "física", "por", "órganos", "y", "aparatos", "dentro", "de", "la", "normalidad", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Analítica", "sanguínea", ":", "bioquímica", "con", "función", "renal", "y", "perfil", "hepático", "dentro", "de", "la", "normalidad", ".", "hemograma", "y", "coagulación", "normal", ".", "Marcadores", "tumorales", ":", "destaca", "la", "elevación", "de", "CA-125", "de", "159", "UI", "/", "ml", "(", "valor", "de", "normalidad", "menor", "o", "igual", "a", "35", "UI", "/", "ml", ")", ".", "\n", "»", "TC", "-", "TAP", "con", "contraste", "de", "diciembre", "2014", ":", "objetiva", "masa", "sólida", "abdominal", "de", "23", "x", "15", "x", "23", "cm", "que", "comprime", "cámara", "gástrica", ",", "improntanto", "lóbulo", "hepático", "izquierdo", "con", "desplazamiento", "de", "estructuras", "intraabdominales", "e", "imágenes", "nodulares", "sugestivas", "de", "implantes", "peritoneales", ".", "\n\n", "Diagnóstico", "\n", "Tumor", "desmoplásico", "abdominal", "de", "células", "pequeñas", "y", "redondas", "estadio", "IV", "(", "afectación", "hepática", "y", "peritoneal", ")", ".", "\n\n", "Tratamiento", "\n", "En", "marzo", "de", "2015", "es", "valorado", "en", "consultas", "externas", "de", "Oncología", "Médica", "y", ",", "dada", "la", "inexistencia", "de", "datos", "acerca", "de", "tratamiento", "adyuvante", "en", "este", "tipo", "de", "tumores", ",", "se", "consensúa", "seguimiento", "clínico", "estrecho", ".", "\n\n", "Evolución", "\n", "En", "agosto", "de", "2015", ",", "se", "evidencia", "en", "TC", "-", "TAP", "progresión", "tumoral", "a", "expensas", "de", "múltiples", "implantes", "tumorales", "metastásicos", "(", "retroperitoneal", ",", "paraaórticos", ",", "intraabdominales", ",", "iliaca", "izquierda", "y", "retroumbilical", ")", ",", "lesiones", "ocupantes", "de", "espacio", "(", "LOE", ")", "hepáticas", "y", "masa", "suprarrenal", "izquierda", ".", "Tras", "revisión", "de", "la", "literatura", "disponible", ",", "se", "consensúa", "inicio", "de", "quimioterapia", "según", "esquema", "vincristina", ",", "doxorrubicina", ",", "ciclofosfamida", ",", "isofosfamida", "y", "etopósido", "(", "VIDE", ")", "en", "régimen", "de", "hospitalización", "y", "con", "factores", "de", "estimulación", "de", "colonias", "de", "granulocitos", "(", "G", "-", "CSF", ")", "profilácticos", ",", "recibiendo", "un", "total", "de", "8", "ciclos", "entre", "septiembre", "de", "2015", "y", "marzo", "de", "2016", ",", "con", "excelente", "tolerancia", "y", "respuesta", "tumoral", "de", "los", "nódulos", "abdominopélvicos", "por", "estudio", "de", "imagen", ".", "\n", "Dado", "que", "el", "paciente", "mantenía", "ECOG", "0", ",", "se", "mantuvo", "tratamiento", "de", "mantenimiento", "con", "etopósido", "oral", ",", "por", "el", "elevado", "riesgo", "de", "recidiva", "con", "el", "cese", "de", "tratamiento", "oncológico", ".", "El", "paciente", "presenta", "buena", "tolerancia", "salvo", "diarreas", "moderadas", "que", "obligan", "a", "reducir", "dosis", "al", "80", "%", ".", "\n", "En", "noviembre", "de", "2016", ",", "se", "palpa", "masa", "pélvica", ",", "confirmándose", "en", "TC", "-", "TAP", "progresión", "a", "dicho", "nivel", ".", "Tras", "ser", "valorado", "el", "caso", "clínico", "en", "comité", "multidisciplinar", "de", "tumores", ",", "no", "siendo", "resecable", "quirúrgicamente", ",", "se", "inicia", "tratamiento", "quimioterápico", "según", "esquema", "carboplatino", "-", "paclitaxel", "recibiendo", "un", "total", "de", "6", "ciclos", "consiguiéndose", "reducción", "de", "la", "masa", "pélvica", ",", "motivo", "por", "el", "que", "se", "consensúa", "tratamiento", "radioterápico", "sobre", "ésta", ".", "\n", "En", "junio", "de", "2017", ",", "finaliza", "radioterapia", "y", "dada", "la", "excelente", "respuesta", ",", "con", "una", "reducción", "de", "la", "masa", "pélvica", "de", "8,9", "x", "5,8", "x", "6,9", "cm", "a", "7,4", "x", "4", "x", "5,7", "cm", ",", "el", "paciente", "es", "intervenido", "en", "julio", "de", "2017", ".", "Se", "practica", "exéresis", "de", "los", "implantes", "tumorales", "(", "umbilical", ",", "pelvis", ",", "mesocolon", "transverso", ",", "fosa", "iliaca", "izquierda", ",", "flanco", "izquierdo", ",", "diafragma", "izquierdo", "y", "derecho", ",", "lóbulo", "hepático", "izquierdo", "y", "suprarrenal", "izquierdo", ")", ",", "así", "como", "apendicetomía", "e", "ileostomía", "de", "protección", "en", "asa", "de", "fosa", "iliaca", "derecha", ",", "con", "un", "Patient", "State", "Index", "(", "PSI", ")", "de", "16", "y", "administración", "de", "quimioterapia", "hipertérmica", "peritoneal", "(", "HIPEC", ")", "con", "oxaliplatino", "con", "5-fluorouracilo", "previo", ".", "\n", "En", "TC", "de", "octubre", "de", "2017", "se", "evidencia", "progresión", "ganglionar", "abdominal", ",", "iniciándose", "entonces", "tratamiento", "de", "3ª", "línea", "según", "esquema", "de", "ácido", "folínico", ",", "fluorouracilo", "e", "irinotecán", "(", "FOLFIRI", ")", ".", "Durante", "el", "año", "2017", ",", "el", "paciente", "sufre", "varios", "cuadros", "de", "suboclusión", "intestinal", ",", "que", "se", "resuelven", "con", "tratamiento", "médico", "sin", "necesidad", "de", "intervención", "quirúrgica", ".", "\n", "El", "paciente", "recibe", "un", "total", "de", "26", "ciclos", ",", "manteniéndose", "durante", "15", "meses", "respuesta", "parcial", "mantenida", ",", "hasta", "progresión", "tumoral", "en", "enero", "de", "2019", "a", "expensas", "de", "implantes", "tumorales", "en", "ligamento", "gastrohepático", ",", "glándula", "suprarrenal", "izquierda", "y", "cadena", "ilíaca", "externa", "izquierda", ".", "Dado", "el", "excelente", "estado", "general", "del", "paciente", ",", "se", "inicia", "4ª", "línea", "de", "tratamiento", "con", "esquema", "irinotecán", "-", "bevacizumab", "-", "temozolamida", "recibiendo", ",", "hasta", "la", "fecha", ",", "5", "ciclos", ".", "El", "paciente", "actualmente", "mantiene", "un", "buen", "estado", "general", ",", "con", "un", "ECOG", "0", ",", "incorporado", "a", "la", "vida", "laboral", "y", "pendiente", "de", "nueva", "reevaluación", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
implantes tumorales, tumor, tumor, implantes peritoneales, Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV ( afectación hepática, tumores, tumoral, implantes tumorales, metastásicos, ( LOE ) hepáticas, masa suprarrenal, tumoral, masa pélvica, masa pélvica, masa pélvica, implantes tumorales, tumoral, implantes tumorales
473_task2
Sentence: Anamnesis Varón de 34 años, sin alergias conocidas ni hábitos tóxicos, amigdalectomizado a los 6 años, casado, padre de una hija y con vida laboral activa como abogado. En mayo de 2014, el paciente comienza con cuadro de dispepsia, epigastralgia, aumento del perímetro abdominal y pérdida de peso progresiva de unos 6 kg de peso. Acude a centro privado donde se objetiva, en tomografía computarizada de tórax-abdomen y pelvis (TC-TAP), una gran masa abdominal de aproximadamente 22 x 15 x 22 cm que desplaza estómago y colon y en contacto con páncreas, bazo y duodeno. Es entonces cuando se remite al Servicio de Cirugía General y Digestiva de nuestro hospital. El 24/02/2015 el paciente es sometido a exéresis en bloque con gastrectomía total, segmentectomía II-III, resección de cola pancreática, bazo e implantes tumorales en diafragma izquierdo y adenopatía en cabeza de páncreas, con reconstrucción mediante Y de Roux con anastomosis esófago-yeyunal. Macroscópicamente, el tumor tenía un tamaño de 35 x 19 x 16 cm. Microscópicamente, el tumor mostraba un 10-15 % de necrosis. La inmunohistoquímica fue Cam 5,2+, vimentina+, CKAE1-AE3 débilmente, EMA+, enolasa neuronal específica+, desmina positiva focal, WT-1 (Nterminal)-, mioglobina-, CD99-, S-100-, Melan A-, calretinina-, CK-, 34 beta E12-, DOG-1-, c-kit-, CD34-, calponina-, LCA-, RCC-, cromogranina-, sinaptofisina-, C56+/-, actina+/-, inhibina+/- focal. Exploración física Buen estado general. Eastern Cooperative Oncology Group (ECOG) 1. Hemodinámicamente, estable. Destaca masa abdominal indurada, fija y dolorosa a palpación en hemiabdomen superior. Resto de exploración física por órganos y aparatos dentro de la normalidad. Pruebas complementarias » Analítica sanguínea: bioquímica con función renal y perfil hepático dentro de la normalidad. hemograma y coagulación normal. Marcadores tumorales: destaca la elevación de CA-125 de 159 UI/ml (valor de normalidad menor o igual a 35 UI/ml). » TC-TAP con contraste de diciembre 2014: objetiva masa sólida abdominal de 23 x 15 x 23 cm que comprime cámara gástrica, improntanto lóbulo hepático izquierdo con desplazamiento de estructuras intraabdominales e imágenes nodulares sugestivas de implantes peritoneales. Diagnóstico Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV (afectación hepática y peritoneal). Tratamiento En marzo de 2015 es valorado en consultas externas de Oncología Médica y, dada la inexistencia de datos acerca de tratamiento adyuvante en este tipo de tumores, se consensúa seguimiento clínico estrecho. Evolución En agosto de 2015, se evidencia en TC-TAP progresión tumoral a expensas de múltiples implantes tumorales metastásicos (retroperitoneal, paraaórticos, intraabdominales, iliaca izquierda y retroumbilical), lesiones ocupantes de espacio (LOE) hepáticas y masa suprarrenal izquierda. Tras revisión de la literatura disponible, se consensúa inicio de quimioterapia según esquema vincristina, doxorrubicina, ciclofosfamida, isofosfamida y etopósido (VIDE) en régimen de hospitalización y con factores de estimulación de colonias de granulocitos (G-CSF) profilácticos, recibiendo un total de 8 ciclos entre septiembre de 2015 y marzo de 2016, con excelente tolerancia y respuesta tumoral de los nódulos abdominopélvicos por estudio de imagen. Dado que el paciente mantenía ECOG 0, se mantuvo tratamiento de mantenimiento con etopósido oral, por el elevado riesgo de recidiva con el cese de tratamiento oncológico. El paciente presenta buena tolerancia salvo diarreas moderadas que obligan a reducir dosis al 80 %. En noviembre de 2016, se palpa masa pélvica, confirmándose en TC-TAP progresión a dicho nivel. Tras ser valorado el caso clínico en comité multidisciplinar de tumores, no siendo resecable quirúrgicamente, se inicia tratamiento quimioterápico según esquema carboplatino-paclitaxel recibiendo un total de 6 ciclos consiguiéndose reducción de la masa pélvica, motivo por el que se consensúa tratamiento radioterápico sobre ésta. En junio de 2017, finaliza radioterapia y dada la excelente respuesta, con una reducción de la masa pélvica de 8,9 x 5,8 x 6,9 cm a 7,4 x 4 x 5,7 cm, el paciente es intervenido en julio de 2017. Se practica exéresis de los implantes tumorales (umbilical, pelvis, mesocolon transverso, fosa iliaca izquierda, flanco izquierdo, diafragma izquierdo y derecho, lóbulo hepático izquierdo y suprarrenal izquierdo), así como apendicetomía e ileostomía de protección en asa de fosa iliaca derecha, con un Patient State Index (PSI) de 16 y administración de quimioterapia hipertérmica peritoneal (HIPEC) con oxaliplatino con 5-fluorouracilo previo. En TC de octubre de 2017 se evidencia progresión ganglionar abdominal, iniciándose entonces tratamiento de 3ª línea según esquema de ácido folínico, fluorouracilo e irinotecán (FOLFIRI). Durante el año 2017, el paciente sufre varios cuadros de suboclusión intestinal, que se resuelven con tratamiento médico sin necesidad de intervención quirúrgica. El paciente recibe un total de 26 ciclos, manteniéndose durante 15 meses respuesta parcial mantenida, hasta progresión tumoral en enero de 2019 a expensas de implantes tumorales en ligamento gastrohepático, glándula suprarrenal izquierda y cadena ilíaca externa izquierda. Dado el excelente estado general del paciente, se inicia 4ª línea de tratamiento con esquema irinotecán-bevacizumab-temozolamida recibiendo, hasta la fecha, 5 ciclos. El paciente actualmente mantiene un buen estado general, con un ECOG 0, incorporado a la vida laboral y pendiente de nueva reevaluación. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Varón de 34 años, sin alergias conocidas ni hábitos tóxicos, amigdalectomizado a los 6 años, casado, padre de una hija y con vida laboral activa como abogado. En mayo de 2014, el paciente comienza con cuadro de dispepsia, epigastralgia, aumento del perímetro abdominal y pérdida de peso progresiva de unos 6 kg de peso. Acude a centro privado donde se objetiva, en tomografía computarizada de tórax-abdomen y pelvis (TC-TAP), una gran masa abdominal de aproximadamente 22 x 15 x 22 cm que desplaza estómago y colon y en contacto con páncreas, bazo y duodeno. Es entonces cuando se remite al Servicio de Cirugía General y Digestiva de nuestro hospital. El 24/02/2015 el paciente es sometido a exéresis en bloque con gastrectomía total, segmentectomía II-III, resección de cola pancreática, bazo e implantes tumorales en diafragma izquierdo y adenopatía en cabeza de páncreas, con reconstrucción mediante Y de Roux con anastomosis esófago-yeyunal. Macroscópicamente, el tumor tenía un tamaño de 35 x 19 x 16 cm. Microscópicamente, el tumor mostraba un 10-15 % de necrosis. La inmunohistoquímica fue Cam 5,2+, vimentina+, CKAE1-AE3 débilmente, EMA+, enolasa neuronal específica+, desmina positiva focal, WT-1 (Nterminal)-, mioglobina-, CD99-, S-100-, Melan A-, calretinina-, CK-, 34 beta E12-, DOG-1-, c-kit-, CD34-, calponina-, LCA-, RCC-, cromogranina-, sinaptofisina-, C56+/-, actina+/-, inhibina+/- focal. Exploración física Buen estado general. Eastern Cooperative Oncology Group (ECOG) 1. Hemodinámicamente, estable. Destaca masa abdominal indurada, fija y dolorosa a palpación en hemiabdomen superior. Resto de exploración física por órganos y aparatos dentro de la normalidad. Pruebas complementarias » Analítica sanguínea: bioquímica con función renal y perfil hepático dentro de la normalidad. hemograma y coagulación normal. Marcadores tumorales: destaca la elevación de CA-125 de 159 UI/ml (valor de normalidad menor o igual a 35 UI/ml). » TC-TAP con contraste de diciembre 2014: objetiva masa sólida abdominal de 23 x 15 x 23 cm que comprime cámara gástrica, improntanto lóbulo hepático izquierdo con desplazamiento de estructuras intraabdominales e imágenes nodulares sugestivas de implantes peritoneales. Diagnóstico Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV (afectación hepática y peritoneal). Tratamiento En marzo de 2015 es valorado en consultas externas de Oncología Médica y, dada la inexistencia de datos acerca de tratamiento adyuvante en este tipo de tumores, se consensúa seguimiento clínico estrecho. Evolución En agosto de 2015, se evidencia en TC-TAP progresión tumoral a expensas de múltiples implantes tumorales metastásicos (retroperitoneal, paraaórticos, intraabdominales, iliaca izquierda y retroumbilical), lesiones ocupantes de espacio (LOE) hepáticas y masa suprarrenal izquierda. Tras revisión de la literatura disponible, se consensúa inicio de quimioterapia según esquema vincristina, doxorrubicina, ciclofosfamida, isofosfamida y etopósido (VIDE) en régimen de hospitalización y con factores de estimulación de colonias de granulocitos (G-CSF) profilácticos, recibiendo un total de 8 ciclos entre septiembre de 2015 y marzo de 2016, con excelente tolerancia y respuesta tumoral de los nódulos abdominopélvicos por estudio de imagen. Dado que el paciente mantenía ECOG 0, se mantuvo tratamiento de mantenimiento con etopósido oral, por el elevado riesgo de recidiva con el cese de tratamiento oncológico. El paciente presenta buena tolerancia salvo diarreas moderadas que obligan a reducir dosis al 80 %. En noviembre de 2016, se palpa masa pélvica, confirmándose en TC-TAP progresión a dicho nivel. Tras ser valorado el caso clínico en comité multidisciplinar de tumores, no siendo resecable quirúrgicamente, se inicia tratamiento quimioterápico según esquema carboplatino-paclitaxel recibiendo un total de 6 ciclos consiguiéndose reducción de la masa pélvica, motivo por el que se consensúa tratamiento radioterápico sobre ésta. En junio de 2017, finaliza radioterapia y dada la excelente respuesta, con una reducción de la masa pélvica de 8,9 x 5,8 x 6,9 cm a 7,4 x 4 x 5,7 cm, el paciente es intervenido en julio de 2017. Se practica exéresis de los implantes tumorales (umbilical, pelvis, mesocolon transverso, fosa iliaca izquierda, flanco izquierdo, diafragma izquierdo y derecho, lóbulo hepático izquierdo y suprarrenal izquierdo), así como apendicetomía e ileostomía de protección en asa de fosa iliaca derecha, con un Patient State Index (PSI) de 16 y administración de quimioterapia hipertérmica peritoneal (HIPEC) con oxaliplatino con 5-fluorouracilo previo. En TC de octubre de 2017 se evidencia progresión ganglionar abdominal, iniciándose entonces tratamiento de 3ª línea según esquema de ácido folínico, fluorouracilo e irinotecán (FOLFIRI). Durante el año 2017, el paciente sufre varios cuadros de suboclusión intestinal, que se resuelven con tratamiento médico sin necesidad de intervención quirúrgica. El paciente recibe un total de 26 ciclos, manteniéndose durante 15 meses respuesta parcial mantenida, hasta progresión tumoral en enero de 2019 a expensas de implantes tumorales en ligamento gastrohepático, glándula suprarrenal izquierda y cadena ilíaca externa izquierda. Dado el excelente estado general del paciente, se inicia 4ª línea de tratamiento con esquema irinotecán-bevacizumab-temozolamida recibiendo, hasta la fecha, 5 ciclos. El paciente actualmente mantiene un buen estado general, con un ECOG 0, incorporado a la vida laboral y pendiente de nueva reevaluación.
[ "Anamnesis", "\n", "Varón", "de", "34", "años", ",", "sin", "alergias", "conocidas", "ni", "hábitos", "tóxicos", ",", "amigdalectomizado", "a", "los", "6", "años", ",", "casado", ",", "padre", "de", "una", "hija", "y", "con", "vida", "laboral", "activa", "como", "abogado", ".", "\n", "En", "mayo", "de", "2014", ",", "el", "paciente", "comienza", "con", "cuadro", "de", "dispepsia", ",", "epigastralgia", ",", "aumento", "del", "perímetro", "abdominal", "y", "pérdida", "de", "peso", "progresiva", "de", "unos", "6", "kg", "de", "peso", ".", "Acude", "a", "centro", "privado", "donde", "se", "objetiva", ",", "en", "tomografía", "computarizada", "de", "tórax", "-", "abdomen", "y", "pelvis", "(", "TC", "-", "TAP", ")", ",", "una", "gran", "masa", "abdominal", "de", "aproximadamente", "22", "x", "15", "x", "22", "cm", "que", "desplaza", "estómago", "y", "colon", "y", "en", "contacto", "con", "páncreas", ",", "bazo", "y", "duodeno", ".", "\n", "Es", "entonces", "cuando", "se", "remite", "al", "Servicio", "de", "Cirugía", "General", "y", "Digestiva", "de", "nuestro", "hospital", ".", "El", "24/02/2015", "el", "paciente", "es", "sometido", "a", "exéresis", "en", "bloque", "con", "gastrectomía", "total", ",", "segmentectomía", "II", "-", "III", ",", "resección", "de", "cola", "pancreática", ",", "bazo", "e", "implantes", "tumorales", "en", "diafragma", "izquierdo", "y", "adenopatía", "en", "cabeza", "de", "páncreas", ",", "con", "reconstrucción", "mediante", "Y", "de", "Roux", "con", "anastomosis", "esófago", "-", "yeyunal", ".", "\n", "Macroscópicamente", ",", "el", "tumor", "tenía", "un", "tamaño", "de", "35", "x", "19", "x", "16", "cm", ".", "Microscópicamente", ",", "el", "tumor", "mostraba", "un", "10", "-", "15", "%", "de", "necrosis", ".", "La", "inmunohistoquímica", "fue", "Cam", "5,2", "+", ",", "vimentina+", ",", "CKAE1-AE3", "débilmente", ",", "EMA+", ",", "enolasa", "neuronal", "específica+", ",", "desmina", "positiva", "focal", ",", "WT-1", "(", "Nterminal)-", ",", "mioglobina-", ",", "CD99-", ",", "S-100-", ",", "Melan", "A-", ",", "calretinina-", ",", "CK-", ",", "34", "beta", "E12-", ",", "DOG-1-", ",", "c", "-", "kit-", ",", "CD34-", ",", "calponina-", ",", "LCA-", ",", "RCC-", ",", "cromogranina-", ",", "sinaptofisina-", ",", "C56+/-", ",", "actina+/-", ",", "inhibina+/-", "focal", ".", "\n\n", "Exploración", "física", "\n", "Buen", "estado", "general", ".", "Eastern", "Cooperative", "Oncology", "Group", "(", "ECOG", ")", "1", ".", "Hemodinámicamente", ",", "estable", ".", "Destaca", "masa", "abdominal", "indurada", ",", "fija", "y", "dolorosa", "a", "palpación", "en", "hemiabdomen", "superior", ".", "Resto", "de", "exploración", "física", "por", "órganos", "y", "aparatos", "dentro", "de", "la", "normalidad", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Analítica", "sanguínea", ":", "bioquímica", "con", "función", "renal", "y", "perfil", "hepático", "dentro", "de", "la", "normalidad", ".", "hemograma", "y", "coagulación", "normal", ".", "Marcadores", "tumorales", ":", "destaca", "la", "elevación", "de", "CA-125", "de", "159", "UI", "/", "ml", "(", "valor", "de", "normalidad", "menor", "o", "igual", "a", "35", "UI", "/", "ml", ")", ".", "\n", "»", "TC", "-", "TAP", "con", "contraste", "de", "diciembre", "2014", ":", "objetiva", "masa", "sólida", "abdominal", "de", "23", "x", "15", "x", "23", "cm", "que", "comprime", "cámara", "gástrica", ",", "improntanto", "lóbulo", "hepático", "izquierdo", "con", "desplazamiento", "de", "estructuras", "intraabdominales", "e", "imágenes", "nodulares", "sugestivas", "de", "implantes", "peritoneales", ".", "\n\n", "Diagnóstico", "\n", "Tumor", "desmoplásico", "abdominal", "de", "células", "pequeñas", "y", "redondas", "estadio", "IV", "(", "afectación", "hepática", "y", "peritoneal", ")", ".", "\n\n", "Tratamiento", "\n", "En", "marzo", "de", "2015", "es", "valorado", "en", "consultas", "externas", "de", "Oncología", "Médica", "y", ",", "dada", "la", "inexistencia", "de", "datos", "acerca", "de", "tratamiento", "adyuvante", "en", "este", "tipo", "de", "tumores", ",", "se", "consensúa", "seguimiento", "clínico", "estrecho", ".", "\n\n", "Evolución", "\n", "En", "agosto", "de", "2015", ",", "se", "evidencia", "en", "TC", "-", "TAP", "progresión", "tumoral", "a", "expensas", "de", "múltiples", "implantes", "tumorales", "metastásicos", "(", "retroperitoneal", ",", "paraaórticos", ",", "intraabdominales", ",", "iliaca", "izquierda", "y", "retroumbilical", ")", ",", "lesiones", "ocupantes", "de", "espacio", "(", "LOE", ")", "hepáticas", "y", "masa", "suprarrenal", "izquierda", ".", "Tras", "revisión", "de", "la", "literatura", "disponible", ",", "se", "consensúa", "inicio", "de", "quimioterapia", "según", "esquema", "vincristina", ",", "doxorrubicina", ",", "ciclofosfamida", ",", "isofosfamida", "y", "etopósido", "(", "VIDE", ")", "en", "régimen", "de", "hospitalización", "y", "con", "factores", "de", "estimulación", "de", "colonias", "de", "granulocitos", "(", "G", "-", "CSF", ")", "profilácticos", ",", "recibiendo", "un", "total", "de", "8", "ciclos", "entre", "septiembre", "de", "2015", "y", "marzo", "de", "2016", ",", "con", "excelente", "tolerancia", "y", "respuesta", "tumoral", "de", "los", "nódulos", "abdominopélvicos", "por", "estudio", "de", "imagen", ".", "\n", "Dado", "que", "el", "paciente", "mantenía", "ECOG", "0", ",", "se", "mantuvo", "tratamiento", "de", "mantenimiento", "con", "etopósido", "oral", ",", "por", "el", "elevado", "riesgo", "de", "recidiva", "con", "el", "cese", "de", "tratamiento", "oncológico", ".", "El", "paciente", "presenta", "buena", "tolerancia", "salvo", "diarreas", "moderadas", "que", "obligan", "a", "reducir", "dosis", "al", "80", "%", ".", "\n", "En", "noviembre", "de", "2016", ",", "se", "palpa", "masa", "pélvica", ",", "confirmándose", "en", "TC", "-", "TAP", "progresión", "a", "dicho", "nivel", ".", "Tras", "ser", "valorado", "el", "caso", "clínico", "en", "comité", "multidisciplinar", "de", "tumores", ",", "no", "siendo", "resecable", "quirúrgicamente", ",", "se", "inicia", "tratamiento", "quimioterápico", "según", "esquema", "carboplatino", "-", "paclitaxel", "recibiendo", "un", "total", "de", "6", "ciclos", "consiguiéndose", "reducción", "de", "la", "masa", "pélvica", ",", "motivo", "por", "el", "que", "se", "consensúa", "tratamiento", "radioterápico", "sobre", "ésta", ".", "\n", "En", "junio", "de", "2017", ",", "finaliza", "radioterapia", "y", "dada", "la", "excelente", "respuesta", ",", "con", "una", "reducción", "de", "la", "masa", "pélvica", "de", "8,9", "x", "5,8", "x", "6,9", "cm", "a", "7,4", "x", "4", "x", "5,7", "cm", ",", "el", "paciente", "es", "intervenido", "en", "julio", "de", "2017", ".", "Se", "practica", "exéresis", "de", "los", "implantes", "tumorales", "(", "umbilical", ",", "pelvis", ",", "mesocolon", "transverso", ",", "fosa", "iliaca", "izquierda", ",", "flanco", "izquierdo", ",", "diafragma", "izquierdo", "y", "derecho", ",", "lóbulo", "hepático", "izquierdo", "y", "suprarrenal", "izquierdo", ")", ",", "así", "como", "apendicetomía", "e", "ileostomía", "de", "protección", "en", "asa", "de", "fosa", "iliaca", "derecha", ",", "con", "un", "Patient", "State", "Index", "(", "PSI", ")", "de", "16", "y", "administración", "de", "quimioterapia", "hipertérmica", "peritoneal", "(", "HIPEC", ")", "con", "oxaliplatino", "con", "5-fluorouracilo", "previo", ".", "\n", "En", "TC", "de", "octubre", "de", "2017", "se", "evidencia", "progresión", "ganglionar", "abdominal", ",", "iniciándose", "entonces", "tratamiento", "de", "3ª", "línea", "según", "esquema", "de", "ácido", "folínico", ",", "fluorouracilo", "e", "irinotecán", "(", "FOLFIRI", ")", ".", "Durante", "el", "año", "2017", ",", "el", "paciente", "sufre", "varios", "cuadros", "de", "suboclusión", "intestinal", ",", "que", "se", "resuelven", "con", "tratamiento", "médico", "sin", "necesidad", "de", "intervención", "quirúrgica", ".", "\n", "El", "paciente", "recibe", "un", "total", "de", "26", "ciclos", ",", "manteniéndose", "durante", "15", "meses", "respuesta", "parcial", "mantenida", ",", "hasta", "progresión", "tumoral", "en", "enero", "de", "2019", "a", "expensas", "de", "implantes", "tumorales", "en", "ligamento", "gastrohepático", ",", "glándula", "suprarrenal", "izquierda", "y", "cadena", "ilíaca", "externa", "izquierda", ".", "Dado", "el", "excelente", "estado", "general", "del", "paciente", ",", "se", "inicia", "4ª", "línea", "de", "tratamiento", "con", "esquema", "irinotecán", "-", "bevacizumab", "-", "temozolamida", "recibiendo", ",", "hasta", "la", "fecha", ",", "5", "ciclos", ".", "El", "paciente", "actualmente", "mantiene", "un", "buen", "estado", "general", ",", "con", "un", "ECOG", "0", ",", "incorporado", "a", "la", "vida", "laboral", "y", "pendiente", "de", "nueva", "reevaluación", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
colorectal is a body-part, carcinoma is a disease, CRC is a disease, CRC is a disease, tumors is a disease, CRC is a disease, CRC is a disease, primary is a Concepts_Ideas, colon is a body-part, carcinoma is a disease, normal is a disease, colon is a body-part, patient is a cohort-patient, colon cancer is a disease, colorectal cancer is a disease, patients is a cohort-patient
78_task0
Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Though some experimental data recently became available linking microarray expression with DNA copy number analyses in some solid tumors [12-16] the knowledge about the existence of genomic islands of coordinated expression in colorectal carcinoma (CRC) is still limited. During the preparation of this manuscript a first assessment of chromosomal expression patterns in CRC in conjunction with genome-wide DNA copy number analyses became available [17]. Tsafrir et al. described a correlation of gene copy number and expression for both, deleted and amplified genes. They claimed that the described alterations become more frequent as the tumors progress from benign to metastatic forms, highlighting the need for a more precise characterization of regions of coordinate expression and gene copy number change. In addition to this most recent work, a substantial body of literature on chromosomal aberrations in CRC has accumulated [7,15,18-25] that could help to interpret findings on islands of coordinated chromosomal expression. The need for a more precise definition of chromosomal regions of altered gene expression prompted us to find a new approach to investigate chromosomal co-expression domains in CRC. The focus of our study was the identification of up- or down-regulated gene expression in primary colon carcinoma cells compared to normal colon epithelia of the same patient. By using laser capture microdissection (LCM) we aimed to investigate transcript abundance in relatively pure cell populations, trying to minimize the influence of contaminating stroma tissue or infiltrating peripheral blood cells on expression measurements. The use of Affymetrix DNA microarray technology allowed us to simultaneously assess mRNA levels of all known human genes using only small amounts of cells obtained by LCM. Finally, we developed a new bioinformatic approach to identify regions of chromosomal deregulation which enabled the most precise survey of chromosomal expression domains in colon cancer available today. In particular, we were interested in the question whether our data correlated with the data of Tsafrir et al. who performed genome scale arrayCGH and chip-based expression analyses on a different set of colorectal cancer patients [17]. In contrast to Tsafrir et al. we put more emphasis on the identification of precise boundaries of expression domains and therefore we consider our work as complementary to their pioneering study. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: disease, Concepts_Ideas, body-part, cohort-patient
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-body-part", "B-disease", "O", "O", "O", "B-disease", "B-body-part", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Though some experimental data recently became available linking microarray expression with DNA copy number analyses in some solid tumors [12-16] the knowledge about the existence of genomic islands of coordinated expression in colorectal carcinoma (CRC) is still limited. During the preparation of this manuscript a first assessment of chromosomal expression patterns in CRC in conjunction with genome-wide DNA copy number analyses became available [17]. Tsafrir et al. described a correlation of gene copy number and expression for both, deleted and amplified genes. They claimed that the described alterations become more frequent as the tumors progress from benign to metastatic forms, highlighting the need for a more precise characterization of regions of coordinate expression and gene copy number change. In addition to this most recent work, a substantial body of literature on chromosomal aberrations in CRC has accumulated [7,15,18-25] that could help to interpret findings on islands of coordinated chromosomal expression. The need for a more precise definition of chromosomal regions of altered gene expression prompted us to find a new approach to investigate chromosomal co-expression domains in CRC. The focus of our study was the identification of up- or down-regulated gene expression in primary colon carcinoma cells compared to normal colon epithelia of the same patient. By using laser capture microdissection (LCM) we aimed to investigate transcript abundance in relatively pure cell populations, trying to minimize the influence of contaminating stroma tissue or infiltrating peripheral blood cells on expression measurements. The use of Affymetrix DNA microarray technology allowed us to simultaneously assess mRNA levels of all known human genes using only small amounts of cells obtained by LCM. Finally, we developed a new bioinformatic approach to identify regions of chromosomal deregulation which enabled the most precise survey of chromosomal expression domains in colon cancer available today. In particular, we were interested in the question whether our data correlated with the data of Tsafrir et al. who performed genome scale arrayCGH and chip-based expression analyses on a different set of colorectal cancer patients [17]. In contrast to Tsafrir et al. we put more emphasis on the identification of precise boundaries of expression domains and therefore we consider our work as complementary to their pioneering study.
[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Though", "some", "experimental", "data", "recently", "became", "available", "linking", "microarray", "expression", "with", "DNA", "copy", "number", "analyses", "in", "some", "solid", "tumors", "[", "12", "-", "16", "]", "the", "knowledge", "about", "the", "existence", "of", "genomic", "islands", "of", "coordinated", "expression", "in", "colorectal", "carcinoma", "(", "CRC", ")", "is", "still", "limited", ".", "During", "the", "preparation", "of", "this", "manuscript", "a", "first", "assessment", "of", "chromosomal", "expression", "patterns", "in", "CRC", "in", "conjunction", "with", "genome", "-", "wide", "DNA", "copy", "number", "analyses", "became", "available", "[", "17", "]", ".", "Tsafrir", "et", "al", ".", "described", "a", "correlation", "of", "gene", "copy", "number", "and", "expression", "for", "both", ",", "deleted", "and", "amplified", "genes", ".", "They", "claimed", "that", "the", "described", "alterations", "become", "more", "frequent", "as", "the", "tumors", "progress", "from", "benign", "to", "metastatic", "forms", ",", "highlighting", "the", "need", "for", "a", "more", "precise", "characterization", "of", "regions", "of", "coordinate", "expression", "and", "gene", "copy", "number", "change", ".", "In", "addition", "to", "this", "most", "recent", "work", ",", "a", "substantial", "body", "of", "literature", "on", "chromosomal", "aberrations", "in", "CRC", "has", "accumulated", "[", "7,15,18", "-", "25", "]", "that", "could", "help", "to", "interpret", "findings", "on", "islands", "of", "coordinated", "chromosomal", "expression", ".", "\n\n", "The", "need", "for", "a", "more", "precise", "definition", "of", "chromosomal", "regions", "of", "altered", "gene", "expression", "prompted", "us", "to", "find", "a", "new", "approach", "to", "investigate", "chromosomal", "co", "-", "expression", "domains", "in", "CRC", ".", "The", "focus", "of", "our", "study", "was", "the", "identification", "of", "up-", "or", "down", "-", "regulated", "gene", "expression", "in", "primary", "colon", "carcinoma", "cells", "compared", "to", "normal", "colon", "epithelia", "of", "the", "same", "patient", ".", "By", "using", "laser", "capture", "microdissection", "(", "LCM", ")", "we", "aimed", "to", "investigate", "transcript", "abundance", "in", "relatively", "pure", "cell", "populations", ",", "trying", "to", "minimize", "the", "influence", "of", "contaminating", "stroma", "tissue", "or", "infiltrating", "peripheral", "blood", "cells", "on", "expression", "measurements", ".", "The", "use", "of", "Affymetrix", "DNA", "microarray", "technology", "allowed", "us", "to", "simultaneously", "assess", "mRNA", "levels", "of", "all", "known", "human", "genes", "using", "only", "small", "amounts", "of", "cells", "obtained", "by", "LCM", ".", "Finally", ",", "we", "developed", "a", "new", "bioinformatic", "approach", "to", "identify", "regions", "of", "chromosomal", "deregulation", "which", "enabled", "the", "most", "precise", "survey", "of", "chromosomal", "expression", "domains", "in", "colon", "cancer", "available", "today", ".", "In", "particular", ",", "we", "were", "interested", "in", "the", "question", "whether", "our", "data", "correlated", "with", "the", "data", "of", "Tsafrir", "et", "al", ".", "who", "performed", "genome", "scale", "arrayCGH", "and", "chip", "-", "based", "expression", "analyses", "on", "a", "different", "set", "of", "colorectal", "cancer", "patients", "[", "17", "]", ".", "In", "contrast", "to", "Tsafrir", "et", "al", ".", "we", "put", "more", "emphasis", "on", "the", "identification", "of", "precise", "boundaries", "of", "expression", "domains", "and", "therefore", "we", "consider", "our", "work", "as", "complementary", "to", "their", "pioneering", "study", ".", "\n\n" ]
[ "disease", "body-part", "cohort-patient", "Concepts_Ideas" ]
colorectal is a body-part, carcinoma is a disease, CRC is a disease, CRC is a disease, tumors is a disease, CRC is a disease, CRC is a disease, primary is a Concepts_Ideas, colon is a body-part, carcinoma is a disease, normal is a disease, colon is a body-part, patient is a cohort-patient, colon cancer is a disease, colorectal cancer is a disease, patients is a cohort-patient
78_task1
Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Though some experimental data recently became available linking microarray expression with DNA copy number analyses in some solid tumors [12-16] the knowledge about the existence of genomic islands of coordinated expression in colorectal carcinoma (CRC) is still limited. During the preparation of this manuscript a first assessment of chromosomal expression patterns in CRC in conjunction with genome-wide DNA copy number analyses became available [17]. Tsafrir et al. described a correlation of gene copy number and expression for both, deleted and amplified genes. They claimed that the described alterations become more frequent as the tumors progress from benign to metastatic forms, highlighting the need for a more precise characterization of regions of coordinate expression and gene copy number change. In addition to this most recent work, a substantial body of literature on chromosomal aberrations in CRC has accumulated [7,15,18-25] that could help to interpret findings on islands of coordinated chromosomal expression. The need for a more precise definition of chromosomal regions of altered gene expression prompted us to find a new approach to investigate chromosomal co-expression domains in CRC. The focus of our study was the identification of up- or down-regulated gene expression in primary colon carcinoma cells compared to normal colon epithelia of the same patient. By using laser capture microdissection (LCM) we aimed to investigate transcript abundance in relatively pure cell populations, trying to minimize the influence of contaminating stroma tissue or infiltrating peripheral blood cells on expression measurements. The use of Affymetrix DNA microarray technology allowed us to simultaneously assess mRNA levels of all known human genes using only small amounts of cells obtained by LCM. Finally, we developed a new bioinformatic approach to identify regions of chromosomal deregulation which enabled the most precise survey of chromosomal expression domains in colon cancer available today. In particular, we were interested in the question whether our data correlated with the data of Tsafrir et al. who performed genome scale arrayCGH and chip-based expression analyses on a different set of colorectal cancer patients [17]. In contrast to Tsafrir et al. we put more emphasis on the identification of precise boundaries of expression domains and therefore we consider our work as complementary to their pioneering study. Instructions: please typing these entity words according to sentence: colorectal, carcinoma, CRC, CRC, tumors, CRC, CRC, primary, colon, carcinoma, normal, colon, patient, colon cancer, colorectal cancer, patients Options: disease, Concepts_Ideas, body-part, cohort-patient
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-body-part", "B-disease", "O", "O", "O", "B-disease", "B-body-part", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Though some experimental data recently became available linking microarray expression with DNA copy number analyses in some solid tumors [12-16] the knowledge about the existence of genomic islands of coordinated expression in colorectal carcinoma (CRC) is still limited. During the preparation of this manuscript a first assessment of chromosomal expression patterns in CRC in conjunction with genome-wide DNA copy number analyses became available [17]. Tsafrir et al. described a correlation of gene copy number and expression for both, deleted and amplified genes. They claimed that the described alterations become more frequent as the tumors progress from benign to metastatic forms, highlighting the need for a more precise characterization of regions of coordinate expression and gene copy number change. In addition to this most recent work, a substantial body of literature on chromosomal aberrations in CRC has accumulated [7,15,18-25] that could help to interpret findings on islands of coordinated chromosomal expression. The need for a more precise definition of chromosomal regions of altered gene expression prompted us to find a new approach to investigate chromosomal co-expression domains in CRC. The focus of our study was the identification of up- or down-regulated gene expression in primary colon carcinoma cells compared to normal colon epithelia of the same patient. By using laser capture microdissection (LCM) we aimed to investigate transcript abundance in relatively pure cell populations, trying to minimize the influence of contaminating stroma tissue or infiltrating peripheral blood cells on expression measurements. The use of Affymetrix DNA microarray technology allowed us to simultaneously assess mRNA levels of all known human genes using only small amounts of cells obtained by LCM. Finally, we developed a new bioinformatic approach to identify regions of chromosomal deregulation which enabled the most precise survey of chromosomal expression domains in colon cancer available today. In particular, we were interested in the question whether our data correlated with the data of Tsafrir et al. who performed genome scale arrayCGH and chip-based expression analyses on a different set of colorectal cancer patients [17]. In contrast to Tsafrir et al. we put more emphasis on the identification of precise boundaries of expression domains and therefore we consider our work as complementary to their pioneering study.
[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Though", "some", "experimental", "data", "recently", "became", "available", "linking", "microarray", "expression", "with", "DNA", "copy", "number", "analyses", "in", "some", "solid", "tumors", "[", "12", "-", "16", "]", "the", "knowledge", "about", "the", "existence", "of", "genomic", "islands", "of", "coordinated", "expression", "in", "colorectal", "carcinoma", "(", "CRC", ")", "is", "still", "limited", ".", "During", "the", "preparation", "of", "this", "manuscript", "a", "first", "assessment", "of", "chromosomal", "expression", "patterns", "in", "CRC", "in", "conjunction", "with", "genome", "-", "wide", "DNA", "copy", "number", "analyses", "became", "available", "[", "17", "]", ".", "Tsafrir", "et", "al", ".", "described", "a", "correlation", "of", "gene", "copy", "number", "and", "expression", "for", "both", ",", "deleted", "and", "amplified", "genes", ".", "They", "claimed", "that", "the", "described", "alterations", "become", "more", "frequent", "as", "the", "tumors", "progress", "from", "benign", "to", "metastatic", "forms", ",", "highlighting", "the", "need", "for", "a", "more", "precise", "characterization", "of", "regions", "of", "coordinate", "expression", "and", "gene", "copy", "number", "change", ".", "In", "addition", "to", "this", "most", "recent", "work", ",", "a", "substantial", "body", "of", "literature", "on", "chromosomal", "aberrations", "in", "CRC", "has", "accumulated", "[", "7,15,18", "-", "25", "]", "that", "could", "help", "to", "interpret", "findings", "on", "islands", "of", "coordinated", "chromosomal", "expression", ".", "\n\n", "The", "need", "for", "a", "more", "precise", "definition", "of", "chromosomal", "regions", "of", "altered", "gene", "expression", "prompted", "us", "to", "find", "a", "new", "approach", "to", "investigate", "chromosomal", "co", "-", "expression", "domains", "in", "CRC", ".", "The", "focus", "of", "our", "study", "was", "the", "identification", "of", "up-", "or", "down", "-", "regulated", "gene", "expression", "in", "primary", "colon", "carcinoma", "cells", "compared", "to", "normal", "colon", "epithelia", "of", "the", "same", "patient", ".", "By", "using", "laser", "capture", "microdissection", "(", "LCM", ")", "we", "aimed", "to", "investigate", "transcript", "abundance", "in", "relatively", "pure", "cell", "populations", ",", "trying", "to", "minimize", "the", "influence", "of", "contaminating", "stroma", "tissue", "or", "infiltrating", "peripheral", "blood", "cells", "on", "expression", "measurements", ".", "The", "use", "of", "Affymetrix", "DNA", "microarray", "technology", "allowed", "us", "to", "simultaneously", "assess", "mRNA", "levels", "of", "all", "known", "human", "genes", "using", "only", "small", "amounts", "of", "cells", "obtained", "by", "LCM", ".", "Finally", ",", "we", "developed", "a", "new", "bioinformatic", "approach", "to", "identify", "regions", "of", "chromosomal", "deregulation", "which", "enabled", "the", "most", "precise", "survey", "of", "chromosomal", "expression", "domains", "in", "colon", "cancer", "available", "today", ".", "In", "particular", ",", "we", "were", "interested", "in", "the", "question", "whether", "our", "data", "correlated", "with", "the", "data", "of", "Tsafrir", "et", "al", ".", "who", "performed", "genome", "scale", "arrayCGH", "and", "chip", "-", "based", "expression", "analyses", "on", "a", "different", "set", "of", "colorectal", "cancer", "patients", "[", "17", "]", ".", "In", "contrast", "to", "Tsafrir", "et", "al", ".", "we", "put", "more", "emphasis", "on", "the", "identification", "of", "precise", "boundaries", "of", "expression", "domains", "and", "therefore", "we", "consider", "our", "work", "as", "complementary", "to", "their", "pioneering", "study", ".", "\n\n" ]
[ "disease", "body-part", "cohort-patient", "Concepts_Ideas" ]
colorectal, carcinoma, CRC, CRC, tumors, CRC, CRC, primary, colon, carcinoma, normal, colon, patient, colon cancer, colorectal cancer, patients
78_task2
Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Though some experimental data recently became available linking microarray expression with DNA copy number analyses in some solid tumors [12-16] the knowledge about the existence of genomic islands of coordinated expression in colorectal carcinoma (CRC) is still limited. During the preparation of this manuscript a first assessment of chromosomal expression patterns in CRC in conjunction with genome-wide DNA copy number analyses became available [17]. Tsafrir et al. described a correlation of gene copy number and expression for both, deleted and amplified genes. They claimed that the described alterations become more frequent as the tumors progress from benign to metastatic forms, highlighting the need for a more precise characterization of regions of coordinate expression and gene copy number change. In addition to this most recent work, a substantial body of literature on chromosomal aberrations in CRC has accumulated [7,15,18-25] that could help to interpret findings on islands of coordinated chromosomal expression. The need for a more precise definition of chromosomal regions of altered gene expression prompted us to find a new approach to investigate chromosomal co-expression domains in CRC. The focus of our study was the identification of up- or down-regulated gene expression in primary colon carcinoma cells compared to normal colon epithelia of the same patient. By using laser capture microdissection (LCM) we aimed to investigate transcript abundance in relatively pure cell populations, trying to minimize the influence of contaminating stroma tissue or infiltrating peripheral blood cells on expression measurements. The use of Affymetrix DNA microarray technology allowed us to simultaneously assess mRNA levels of all known human genes using only small amounts of cells obtained by LCM. Finally, we developed a new bioinformatic approach to identify regions of chromosomal deregulation which enabled the most precise survey of chromosomal expression domains in colon cancer available today. In particular, we were interested in the question whether our data correlated with the data of Tsafrir et al. who performed genome scale arrayCGH and chip-based expression analyses on a different set of colorectal cancer patients [17]. In contrast to Tsafrir et al. we put more emphasis on the identification of precise boundaries of expression domains and therefore we consider our work as complementary to their pioneering study. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-body-part", "B-disease", "O", "O", "O", "B-disease", "B-body-part", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Though some experimental data recently became available linking microarray expression with DNA copy number analyses in some solid tumors [12-16] the knowledge about the existence of genomic islands of coordinated expression in colorectal carcinoma (CRC) is still limited. During the preparation of this manuscript a first assessment of chromosomal expression patterns in CRC in conjunction with genome-wide DNA copy number analyses became available [17]. Tsafrir et al. described a correlation of gene copy number and expression for both, deleted and amplified genes. They claimed that the described alterations become more frequent as the tumors progress from benign to metastatic forms, highlighting the need for a more precise characterization of regions of coordinate expression and gene copy number change. In addition to this most recent work, a substantial body of literature on chromosomal aberrations in CRC has accumulated [7,15,18-25] that could help to interpret findings on islands of coordinated chromosomal expression. The need for a more precise definition of chromosomal regions of altered gene expression prompted us to find a new approach to investigate chromosomal co-expression domains in CRC. The focus of our study was the identification of up- or down-regulated gene expression in primary colon carcinoma cells compared to normal colon epithelia of the same patient. By using laser capture microdissection (LCM) we aimed to investigate transcript abundance in relatively pure cell populations, trying to minimize the influence of contaminating stroma tissue or infiltrating peripheral blood cells on expression measurements. The use of Affymetrix DNA microarray technology allowed us to simultaneously assess mRNA levels of all known human genes using only small amounts of cells obtained by LCM. Finally, we developed a new bioinformatic approach to identify regions of chromosomal deregulation which enabled the most precise survey of chromosomal expression domains in colon cancer available today. In particular, we were interested in the question whether our data correlated with the data of Tsafrir et al. who performed genome scale arrayCGH and chip-based expression analyses on a different set of colorectal cancer patients [17]. In contrast to Tsafrir et al. we put more emphasis on the identification of precise boundaries of expression domains and therefore we consider our work as complementary to their pioneering study.
[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Though", "some", "experimental", "data", "recently", "became", "available", "linking", "microarray", "expression", "with", "DNA", "copy", "number", "analyses", "in", "some", "solid", "tumors", "[", "12", "-", "16", "]", "the", "knowledge", "about", "the", "existence", "of", "genomic", "islands", "of", "coordinated", "expression", "in", "colorectal", "carcinoma", "(", "CRC", ")", "is", "still", "limited", ".", "During", "the", "preparation", "of", "this", "manuscript", "a", "first", "assessment", "of", "chromosomal", "expression", "patterns", "in", "CRC", "in", "conjunction", "with", "genome", "-", "wide", "DNA", "copy", "number", "analyses", "became", "available", "[", "17", "]", ".", "Tsafrir", "et", "al", ".", "described", "a", "correlation", "of", "gene", "copy", "number", "and", "expression", "for", "both", ",", "deleted", "and", "amplified", "genes", ".", "They", "claimed", "that", "the", "described", "alterations", "become", "more", "frequent", "as", "the", "tumors", "progress", "from", "benign", "to", "metastatic", "forms", ",", "highlighting", "the", "need", "for", "a", "more", "precise", "characterization", "of", "regions", "of", "coordinate", "expression", "and", "gene", "copy", "number", "change", ".", "In", "addition", "to", "this", "most", "recent", "work", ",", "a", "substantial", "body", "of", "literature", "on", "chromosomal", "aberrations", "in", "CRC", "has", "accumulated", "[", "7,15,18", "-", "25", "]", "that", "could", "help", "to", "interpret", "findings", "on", "islands", "of", "coordinated", "chromosomal", "expression", ".", "\n\n", "The", "need", "for", "a", "more", "precise", "definition", "of", "chromosomal", "regions", "of", "altered", "gene", "expression", "prompted", "us", "to", "find", "a", "new", "approach", "to", "investigate", "chromosomal", "co", "-", "expression", "domains", "in", "CRC", ".", "The", "focus", "of", "our", "study", "was", "the", "identification", "of", "up-", "or", "down", "-", "regulated", "gene", "expression", "in", "primary", "colon", "carcinoma", "cells", "compared", "to", "normal", "colon", "epithelia", "of", "the", "same", "patient", ".", "By", "using", "laser", "capture", "microdissection", "(", "LCM", ")", "we", "aimed", "to", "investigate", "transcript", "abundance", "in", "relatively", "pure", "cell", "populations", ",", "trying", "to", "minimize", "the", "influence", "of", "contaminating", "stroma", "tissue", "or", "infiltrating", "peripheral", "blood", "cells", "on", "expression", "measurements", ".", "The", "use", "of", "Affymetrix", "DNA", "microarray", "technology", "allowed", "us", "to", "simultaneously", "assess", "mRNA", "levels", "of", "all", "known", "human", "genes", "using", "only", "small", "amounts", "of", "cells", "obtained", "by", "LCM", ".", "Finally", ",", "we", "developed", "a", "new", "bioinformatic", "approach", "to", "identify", "regions", "of", "chromosomal", "deregulation", "which", "enabled", "the", "most", "precise", "survey", "of", "chromosomal", "expression", "domains", "in", "colon", "cancer", "available", "today", ".", "In", "particular", ",", "we", "were", "interested", "in", "the", "question", "whether", "our", "data", "correlated", "with", "the", "data", "of", "Tsafrir", "et", "al", ".", "who", "performed", "genome", "scale", "arrayCGH", "and", "chip", "-", "based", "expression", "analyses", "on", "a", "different", "set", "of", "colorectal", "cancer", "patients", "[", "17", "]", ".", "In", "contrast", "to", "Tsafrir", "et", "al", ".", "we", "put", "more", "emphasis", "on", "the", "identification", "of", "precise", "boundaries", "of", "expression", "domains", "and", "therefore", "we", "consider", "our", "work", "as", "complementary", "to", "their", "pioneering", "study", ".", "\n\n" ]
[ "disease", "body-part", "cohort-patient", "Concepts_Ideas" ]
Kranker is an umlsterm, Deutschland is an umlsterm, Querschnittsuntersuchungen is an umlsterm, Analysen is an umlsterm, Langzeitverlauf is an umlsterm, Patienten is an umlsterm, Schizophrenie is an umlsterm, Langzeitverlauf is an umlsterm, Patienten is an umlsterm, Schizophrenie is an umlsterm, Dauerunterbringung is an umlsterm, psychiatrischen Krankenhaus is an umlsterm
DerNervenarzt.90700817.ger.abstr_task0
Sentence: Empirische Studien ueber die Kosten der psychiatrischen Versorgung chronisch psychisch Kranker in Deutschland sind immer noch selten . Es fehlt nicht nur an Querschnittsuntersuchungen , sondern noch gravierender an Analysen ueber den Langzeitverlauf der psychiatrischen Versorgungskosten . Die vorliegende Studie stellt Daten aus zwei Kostenuntersuchungen , die im gleichen Versorgungsgebiet im Abstand von 15 Jahren an Patienten mit Schizophrenie durchgefuehrt wurden , gegenueber und zieht Schlussfolgerungen ueber den Langzeitverlauf der Versorgungskosten von Patienten mit Schizophrenie . Die empirisch ermittelten gemeindepsychiatrischen Versorgungskosten sind im 15-Jahreszeitraum um 77,0% , die der Dauerunterbringung im psychiatrischen Krankenhaus um 78,5% der Ausgangswerte gestiegen . Der Anstieg liegt damit um 27 bzw. 28,5 Prozentpunkte ueber der allgemeinen Preissteigerungsrate . Dem ueberproportionalen Anstieg der psychiatrischen Versorgungskosten steht eine parallel dazu erheblich gestiegene Versorgungseffektivitaet gegenueber . Dieser Anstieg muss zusaetzlich auf dem Hintergrund der grossen Qualitaetsdefizite und des daraus resultierenden Nachholbedarfs der psychiatrischen Versorgung seit der Psychiatrie-Enquête gesehen werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Empirische Studien ueber die Kosten der psychiatrischen Versorgung chronisch psychisch Kranker in Deutschland sind immer noch selten . Es fehlt nicht nur an Querschnittsuntersuchungen , sondern noch gravierender an Analysen ueber den Langzeitverlauf der psychiatrischen Versorgungskosten . Die vorliegende Studie stellt Daten aus zwei Kostenuntersuchungen , die im gleichen Versorgungsgebiet im Abstand von 15 Jahren an Patienten mit Schizophrenie durchgefuehrt wurden , gegenueber und zieht Schlussfolgerungen ueber den Langzeitverlauf der Versorgungskosten von Patienten mit Schizophrenie . Die empirisch ermittelten gemeindepsychiatrischen Versorgungskosten sind im 15-Jahreszeitraum um 77,0% , die der Dauerunterbringung im psychiatrischen Krankenhaus um 78,5% der Ausgangswerte gestiegen . Der Anstieg liegt damit um 27 bzw. 28,5 Prozentpunkte ueber der allgemeinen Preissteigerungsrate . Dem ueberproportionalen Anstieg der psychiatrischen Versorgungskosten steht eine parallel dazu erheblich gestiegene Versorgungseffektivitaet gegenueber . Dieser Anstieg muss zusaetzlich auf dem Hintergrund der grossen Qualitaetsdefizite und des daraus resultierenden Nachholbedarfs der psychiatrischen Versorgung seit der Psychiatrie-Enquête gesehen werden .
[ "Empirische", "Studien", "ueber", "die", "Kosten", "der", "psychiatrischen", "Versorgung", "chronisch", "psychisch", "Kranker", "in", "Deutschland", "sind", "immer", "noch", "selten", ".", "Es", "fehlt", "nicht", "nur", "an", "Querschnittsuntersuchungen", ",", "sondern", "noch", "gravierender", "an", "Analysen", "ueber", "den", "Langzeitverlauf", "der", "psychiatrischen", "Versorgungskosten", ".", "Die", "vorliegende", "Studie", "stellt", "Daten", "aus", "zwei", "Kostenuntersuchungen", ",", "die", "im", "gleichen", "Versorgungsgebiet", "im", "Abstand", "von", "15", "Jahren", "an", "Patienten", "mit", "Schizophrenie", "durchgefuehrt", "wurden", ",", "gegenueber", "und", "zieht", "Schlussfolgerungen", "ueber", "den", "Langzeitverlauf", "der", "Versorgungskosten", "von", "Patienten", "mit", "Schizophrenie", ".", "Die", "empirisch", "ermittelten", "gemeindepsychiatrischen", "Versorgungskosten", "sind", "im", "15-Jahreszeitraum", "um", "77,0", "%", ",", "die", "der", "Dauerunterbringung", "im", "psychiatrischen", "Krankenhaus", "um", "78,5", "%", "der", "Ausgangswerte", "gestiegen", ".", "Der", "Anstieg", "liegt", "damit", "um", "27", "bzw", ".", "28,5", "Prozentpunkte", "ueber", "der", "allgemeinen", "Preissteigerungsrate", ".", "Dem", "ueberproportionalen", "Anstieg", "der", "psychiatrischen", "Versorgungskosten", "steht", "eine", "parallel", "dazu", "erheblich", "gestiegene", "Versorgungseffektivitaet", "gegenueber", ".", "Dieser", "Anstieg", "muss", "zusaetzlich", "auf", "dem", "Hintergrund", "der", "grossen", "Qualitaetsdefizite", "und", "des", "daraus", "resultierenden", "Nachholbedarfs", "der", "psychiatrischen", "Versorgung", "seit", "der", "Psychiatrie", "-", "Enquête", "gesehen", "werden", "." ]
[ "umlsterm" ]
Kranker is an umlsterm, Deutschland is an umlsterm, Querschnittsuntersuchungen is an umlsterm, Analysen is an umlsterm, Langzeitverlauf is an umlsterm, Patienten is an umlsterm, Schizophrenie is an umlsterm, Langzeitverlauf is an umlsterm, Patienten is an umlsterm, Schizophrenie is an umlsterm, Dauerunterbringung is an umlsterm, psychiatrischen Krankenhaus is an umlsterm
DerNervenarzt.90700817.ger.abstr_task1
Sentence: Empirische Studien ueber die Kosten der psychiatrischen Versorgung chronisch psychisch Kranker in Deutschland sind immer noch selten . Es fehlt nicht nur an Querschnittsuntersuchungen , sondern noch gravierender an Analysen ueber den Langzeitverlauf der psychiatrischen Versorgungskosten . Die vorliegende Studie stellt Daten aus zwei Kostenuntersuchungen , die im gleichen Versorgungsgebiet im Abstand von 15 Jahren an Patienten mit Schizophrenie durchgefuehrt wurden , gegenueber und zieht Schlussfolgerungen ueber den Langzeitverlauf der Versorgungskosten von Patienten mit Schizophrenie . Die empirisch ermittelten gemeindepsychiatrischen Versorgungskosten sind im 15-Jahreszeitraum um 77,0% , die der Dauerunterbringung im psychiatrischen Krankenhaus um 78,5% der Ausgangswerte gestiegen . Der Anstieg liegt damit um 27 bzw. 28,5 Prozentpunkte ueber der allgemeinen Preissteigerungsrate . Dem ueberproportionalen Anstieg der psychiatrischen Versorgungskosten steht eine parallel dazu erheblich gestiegene Versorgungseffektivitaet gegenueber . Dieser Anstieg muss zusaetzlich auf dem Hintergrund der grossen Qualitaetsdefizite und des daraus resultierenden Nachholbedarfs der psychiatrischen Versorgung seit der Psychiatrie-Enquête gesehen werden . Instructions: please typing these entity words according to sentence: Kranker, Deutschland, Querschnittsuntersuchungen, Analysen, Langzeitverlauf, Patienten, Schizophrenie, Langzeitverlauf, Patienten, Schizophrenie, Dauerunterbringung, psychiatrischen Krankenhaus Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Empirische Studien ueber die Kosten der psychiatrischen Versorgung chronisch psychisch Kranker in Deutschland sind immer noch selten . Es fehlt nicht nur an Querschnittsuntersuchungen , sondern noch gravierender an Analysen ueber den Langzeitverlauf der psychiatrischen Versorgungskosten . Die vorliegende Studie stellt Daten aus zwei Kostenuntersuchungen , die im gleichen Versorgungsgebiet im Abstand von 15 Jahren an Patienten mit Schizophrenie durchgefuehrt wurden , gegenueber und zieht Schlussfolgerungen ueber den Langzeitverlauf der Versorgungskosten von Patienten mit Schizophrenie . Die empirisch ermittelten gemeindepsychiatrischen Versorgungskosten sind im 15-Jahreszeitraum um 77,0% , die der Dauerunterbringung im psychiatrischen Krankenhaus um 78,5% der Ausgangswerte gestiegen . Der Anstieg liegt damit um 27 bzw. 28,5 Prozentpunkte ueber der allgemeinen Preissteigerungsrate . Dem ueberproportionalen Anstieg der psychiatrischen Versorgungskosten steht eine parallel dazu erheblich gestiegene Versorgungseffektivitaet gegenueber . Dieser Anstieg muss zusaetzlich auf dem Hintergrund der grossen Qualitaetsdefizite und des daraus resultierenden Nachholbedarfs der psychiatrischen Versorgung seit der Psychiatrie-Enquête gesehen werden .
[ "Empirische", "Studien", "ueber", "die", "Kosten", "der", "psychiatrischen", "Versorgung", "chronisch", "psychisch", "Kranker", "in", "Deutschland", "sind", "immer", "noch", "selten", ".", "Es", "fehlt", "nicht", "nur", "an", "Querschnittsuntersuchungen", ",", "sondern", "noch", "gravierender", "an", "Analysen", "ueber", "den", "Langzeitverlauf", "der", "psychiatrischen", "Versorgungskosten", ".", "Die", "vorliegende", "Studie", "stellt", "Daten", "aus", "zwei", "Kostenuntersuchungen", ",", "die", "im", "gleichen", "Versorgungsgebiet", "im", "Abstand", "von", "15", "Jahren", "an", "Patienten", "mit", "Schizophrenie", "durchgefuehrt", "wurden", ",", "gegenueber", "und", "zieht", "Schlussfolgerungen", "ueber", "den", "Langzeitverlauf", "der", "Versorgungskosten", "von", "Patienten", "mit", "Schizophrenie", ".", "Die", "empirisch", "ermittelten", "gemeindepsychiatrischen", "Versorgungskosten", "sind", "im", "15-Jahreszeitraum", "um", "77,0", "%", ",", "die", "der", "Dauerunterbringung", "im", "psychiatrischen", "Krankenhaus", "um", "78,5", "%", "der", "Ausgangswerte", "gestiegen", ".", "Der", "Anstieg", "liegt", "damit", "um", "27", "bzw", ".", "28,5", "Prozentpunkte", "ueber", "der", "allgemeinen", "Preissteigerungsrate", ".", "Dem", "ueberproportionalen", "Anstieg", "der", "psychiatrischen", "Versorgungskosten", "steht", "eine", "parallel", "dazu", "erheblich", "gestiegene", "Versorgungseffektivitaet", "gegenueber", ".", "Dieser", "Anstieg", "muss", "zusaetzlich", "auf", "dem", "Hintergrund", "der", "grossen", "Qualitaetsdefizite", "und", "des", "daraus", "resultierenden", "Nachholbedarfs", "der", "psychiatrischen", "Versorgung", "seit", "der", "Psychiatrie", "-", "Enquête", "gesehen", "werden", "." ]
[ "umlsterm" ]
Kranker, Deutschland, Querschnittsuntersuchungen, Analysen, Langzeitverlauf, Patienten, Schizophrenie, Langzeitverlauf, Patienten, Schizophrenie, Dauerunterbringung, psychiatrischen Krankenhaus
DerNervenarzt.90700817.ger.abstr_task2
Sentence: Empirische Studien ueber die Kosten der psychiatrischen Versorgung chronisch psychisch Kranker in Deutschland sind immer noch selten . Es fehlt nicht nur an Querschnittsuntersuchungen , sondern noch gravierender an Analysen ueber den Langzeitverlauf der psychiatrischen Versorgungskosten . Die vorliegende Studie stellt Daten aus zwei Kostenuntersuchungen , die im gleichen Versorgungsgebiet im Abstand von 15 Jahren an Patienten mit Schizophrenie durchgefuehrt wurden , gegenueber und zieht Schlussfolgerungen ueber den Langzeitverlauf der Versorgungskosten von Patienten mit Schizophrenie . Die empirisch ermittelten gemeindepsychiatrischen Versorgungskosten sind im 15-Jahreszeitraum um 77,0% , die der Dauerunterbringung im psychiatrischen Krankenhaus um 78,5% der Ausgangswerte gestiegen . Der Anstieg liegt damit um 27 bzw. 28,5 Prozentpunkte ueber der allgemeinen Preissteigerungsrate . Dem ueberproportionalen Anstieg der psychiatrischen Versorgungskosten steht eine parallel dazu erheblich gestiegene Versorgungseffektivitaet gegenueber . Dieser Anstieg muss zusaetzlich auf dem Hintergrund der grossen Qualitaetsdefizite und des daraus resultierenden Nachholbedarfs der psychiatrischen Versorgung seit der Psychiatrie-Enquête gesehen werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Empirische Studien ueber die Kosten der psychiatrischen Versorgung chronisch psychisch Kranker in Deutschland sind immer noch selten . Es fehlt nicht nur an Querschnittsuntersuchungen , sondern noch gravierender an Analysen ueber den Langzeitverlauf der psychiatrischen Versorgungskosten . Die vorliegende Studie stellt Daten aus zwei Kostenuntersuchungen , die im gleichen Versorgungsgebiet im Abstand von 15 Jahren an Patienten mit Schizophrenie durchgefuehrt wurden , gegenueber und zieht Schlussfolgerungen ueber den Langzeitverlauf der Versorgungskosten von Patienten mit Schizophrenie . Die empirisch ermittelten gemeindepsychiatrischen Versorgungskosten sind im 15-Jahreszeitraum um 77,0% , die der Dauerunterbringung im psychiatrischen Krankenhaus um 78,5% der Ausgangswerte gestiegen . Der Anstieg liegt damit um 27 bzw. 28,5 Prozentpunkte ueber der allgemeinen Preissteigerungsrate . Dem ueberproportionalen Anstieg der psychiatrischen Versorgungskosten steht eine parallel dazu erheblich gestiegene Versorgungseffektivitaet gegenueber . Dieser Anstieg muss zusaetzlich auf dem Hintergrund der grossen Qualitaetsdefizite und des daraus resultierenden Nachholbedarfs der psychiatrischen Versorgung seit der Psychiatrie-Enquête gesehen werden .
[ "Empirische", "Studien", "ueber", "die", "Kosten", "der", "psychiatrischen", "Versorgung", "chronisch", "psychisch", "Kranker", "in", "Deutschland", "sind", "immer", "noch", "selten", ".", "Es", "fehlt", "nicht", "nur", "an", "Querschnittsuntersuchungen", ",", "sondern", "noch", "gravierender", "an", "Analysen", "ueber", "den", "Langzeitverlauf", "der", "psychiatrischen", "Versorgungskosten", ".", "Die", "vorliegende", "Studie", "stellt", "Daten", "aus", "zwei", "Kostenuntersuchungen", ",", "die", "im", "gleichen", "Versorgungsgebiet", "im", "Abstand", "von", "15", "Jahren", "an", "Patienten", "mit", "Schizophrenie", "durchgefuehrt", "wurden", ",", "gegenueber", "und", "zieht", "Schlussfolgerungen", "ueber", "den", "Langzeitverlauf", "der", "Versorgungskosten", "von", "Patienten", "mit", "Schizophrenie", ".", "Die", "empirisch", "ermittelten", "gemeindepsychiatrischen", "Versorgungskosten", "sind", "im", "15-Jahreszeitraum", "um", "77,0", "%", ",", "die", "der", "Dauerunterbringung", "im", "psychiatrischen", "Krankenhaus", "um", "78,5", "%", "der", "Ausgangswerte", "gestiegen", ".", "Der", "Anstieg", "liegt", "damit", "um", "27", "bzw", ".", "28,5", "Prozentpunkte", "ueber", "der", "allgemeinen", "Preissteigerungsrate", ".", "Dem", "ueberproportionalen", "Anstieg", "der", "psychiatrischen", "Versorgungskosten", "steht", "eine", "parallel", "dazu", "erheblich", "gestiegene", "Versorgungseffektivitaet", "gegenueber", ".", "Dieser", "Anstieg", "muss", "zusaetzlich", "auf", "dem", "Hintergrund", "der", "grossen", "Qualitaetsdefizite", "und", "des", "daraus", "resultierenden", "Nachholbedarfs", "der", "psychiatrischen", "Versorgung", "seit", "der", "Psychiatrie", "-", "Enquête", "gesehen", "werden", "." ]
[ "umlsterm" ]
paradoxical embolism is an umlsterm, association is an umlsterm, patent foramen ovale is an umlsterm, stroke is an umlsterm, clinical studies is an umlsterm, recurrence is an umlsterm, cerebral ischemia is an umlsterm, patients is an umlsterm, stroke is an umlsterm, right is an umlsterm, pressure is an umlsterm, pulmonary embolism is an umlsterm, risk is an umlsterm, patients is an umlsterm, findings is an umlsterm, aneurysm is an umlsterm, defect is an umlsterm, risk factors is an umlsterm, investigators is an umlsterm, prevention is an umlsterm, paradoxical embolism is an umlsterm, anticoagulants is an umlsterm, risk of is an umlsterm, Surgery is an umlsterm, patients is an umlsterm, atrial septal defect is an umlsterm, procedure is an umlsterm, patients is an umlsterm, surgical is an umlsterm, treatment is an umlsterm, choice is an umlsterm, secondary is an umlsterm, prevention is an umlsterm, paradoxical embolism is an umlsterm, surgical treatment is an umlsterm, Devices is an umlsterm, clinical trials is an umlsterm, use is an umlsterm, delivery is an umlsterm, complications is an umlsterm
ZfuerKardiologie.00890063.eng.abstr_task0
Sentence: Notwithstanding the difficulties in definitely confirming paradoxical embolism , the association between patent foramen ovale ( PFO ) and cryptogenic stroke has repeatedly been demonstrated in clinical studies . Moreover , the recurrence rate of cerebral ischemia in patients with PFO and an unexplained stroke was found to be 3-4% per year in two recently published series . With the exception of right atrial pressure elevation in the setting of major pulmonary embolism , a reliable risk stratification of patients with PFO based on clinical or echocardiographic findings is not yet possible . The presence of atrial septal aneurysm , a wide opening of the defect during the cardiac cycle and a large atrial shunt have been implicated as risk factors by some investigators . Long-term prevention of paradoxical embolism with oral anticoagulants seems to be of questionable benefit . Besides , these agents are poorly tolerated and carry the risk of significant or fatal bleeding at a rate of 2-5% per year . Surgery of the atrial septum has been performed for many decades in patients with atrial septal defect and evidence accumulates that it is a safe and highly effective procedure in patients with PFO . At present , surgical closure of the PFO appears to be the treatment of choice for secondary prevention of paradoxical embolism . However , further studies are needed to define the appropriate candidates for surgical treatment . Devices for catheter-based sealing of PFO are also available and are currently being evaluated in clinical trials . However , experience with their use remains confined to specialized centers . Furthermore , further technical improvements of these systems are needed in order to optimize successful delivery and positioning , increase their long-term stability , and reduce periprocedural complications . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Notwithstanding the difficulties in definitely confirming paradoxical embolism , the association between patent foramen ovale ( PFO ) and cryptogenic stroke has repeatedly been demonstrated in clinical studies . Moreover , the recurrence rate of cerebral ischemia in patients with PFO and an unexplained stroke was found to be 3-4% per year in two recently published series . With the exception of right atrial pressure elevation in the setting of major pulmonary embolism , a reliable risk stratification of patients with PFO based on clinical or echocardiographic findings is not yet possible . The presence of atrial septal aneurysm , a wide opening of the defect during the cardiac cycle and a large atrial shunt have been implicated as risk factors by some investigators . Long-term prevention of paradoxical embolism with oral anticoagulants seems to be of questionable benefit . Besides , these agents are poorly tolerated and carry the risk of significant or fatal bleeding at a rate of 2-5% per year . Surgery of the atrial septum has been performed for many decades in patients with atrial septal defect and evidence accumulates that it is a safe and highly effective procedure in patients with PFO . At present , surgical closure of the PFO appears to be the treatment of choice for secondary prevention of paradoxical embolism . However , further studies are needed to define the appropriate candidates for surgical treatment . Devices for catheter-based sealing of PFO are also available and are currently being evaluated in clinical trials . However , experience with their use remains confined to specialized centers . Furthermore , further technical improvements of these systems are needed in order to optimize successful delivery and positioning , increase their long-term stability , and reduce periprocedural complications .
[ "Notwithstanding", "the", "difficulties", "in", "definitely", "confirming", "paradoxical", "embolism", ",", "the", "association", "between", "patent", "foramen", "ovale", "(", "PFO", ")", "and", "cryptogenic", "stroke", "has", "repeatedly", "been", "demonstrated", "in", "clinical", "studies", ".", "Moreover", ",", "the", "recurrence", "rate", "of", "cerebral", "ischemia", "in", "patients", "with", "PFO", "and", "an", "unexplained", "stroke", "was", "found", "to", "be", "3", "-", "4", "%", "per", "year", "in", "two", "recently", "published", "series", ".", "With", "the", "exception", "of", "right", "atrial", "pressure", "elevation", "in", "the", "setting", "of", "major", "pulmonary", "embolism", ",", "a", "reliable", "risk", "stratification", "of", "patients", "with", "PFO", "based", "on", "clinical", "or", "echocardiographic", "findings", "is", "not", "yet", "possible", ".", "The", "presence", "of", "atrial", "septal", "aneurysm", ",", "a", "wide", "opening", "of", "the", "defect", "during", "the", "cardiac", "cycle", "and", "a", "large", "atrial", "shunt", "have", "been", "implicated", "as", "risk", "factors", "by", "some", "investigators", ".", "Long", "-", "term", "prevention", "of", "paradoxical", "embolism", "with", "oral", "anticoagulants", "seems", "to", "be", "of", "questionable", "benefit", ".", "Besides", ",", "these", "agents", "are", "poorly", "tolerated", "and", "carry", "the", "risk", "of", "significant", "or", "fatal", "bleeding", "at", "a", "rate", "of", "2", "-", "5", "%", "per", "year", ".", "Surgery", "of", "the", "atrial", "septum", "has", "been", "performed", "for", "many", "decades", "in", "patients", "with", "atrial", "septal", "defect", "and", "evidence", "accumulates", "that", "it", "is", "a", "safe", "and", "highly", "effective", "procedure", "in", "patients", "with", "PFO", ".", "At", "present", ",", "surgical", "closure", "of", "the", "PFO", "appears", "to", "be", "the", "treatment", "of", "choice", "for", "secondary", "prevention", "of", "paradoxical", "embolism", ".", "However", ",", "further", "studies", "are", "needed", "to", "define", "the", "appropriate", "candidates", "for", "surgical", "treatment", ".", "Devices", "for", "catheter", "-", "based", "sealing", "of", "PFO", "are", "also", "available", "and", "are", "currently", "being", "evaluated", "in", "clinical", "trials", ".", "However", ",", "experience", "with", "their", "use", "remains", "confined", "to", "specialized", "centers", ".", "Furthermore", ",", "further", "technical", "improvements", "of", "these", "systems", "are", "needed", "in", "order", "to", "optimize", "successful", "delivery", "and", "positioning", ",", "increase", "their", "long", "-", "term", "stability", ",", "and", "reduce", "periprocedural", "complications", "." ]
[ "umlsterm" ]
paradoxical embolism is an umlsterm, association is an umlsterm, patent foramen ovale is an umlsterm, stroke is an umlsterm, clinical studies is an umlsterm, recurrence is an umlsterm, cerebral ischemia is an umlsterm, patients is an umlsterm, stroke is an umlsterm, right is an umlsterm, pressure is an umlsterm, pulmonary embolism is an umlsterm, risk is an umlsterm, patients is an umlsterm, findings is an umlsterm, aneurysm is an umlsterm, defect is an umlsterm, risk factors is an umlsterm, investigators is an umlsterm, prevention is an umlsterm, paradoxical embolism is an umlsterm, anticoagulants is an umlsterm, risk of is an umlsterm, Surgery is an umlsterm, patients is an umlsterm, atrial septal defect is an umlsterm, procedure is an umlsterm, patients is an umlsterm, surgical is an umlsterm, treatment is an umlsterm, choice is an umlsterm, secondary is an umlsterm, prevention is an umlsterm, paradoxical embolism is an umlsterm, surgical treatment is an umlsterm, Devices is an umlsterm, clinical trials is an umlsterm, use is an umlsterm, delivery is an umlsterm, complications is an umlsterm
ZfuerKardiologie.00890063.eng.abstr_task1
Sentence: Notwithstanding the difficulties in definitely confirming paradoxical embolism , the association between patent foramen ovale ( PFO ) and cryptogenic stroke has repeatedly been demonstrated in clinical studies . Moreover , the recurrence rate of cerebral ischemia in patients with PFO and an unexplained stroke was found to be 3-4% per year in two recently published series . With the exception of right atrial pressure elevation in the setting of major pulmonary embolism , a reliable risk stratification of patients with PFO based on clinical or echocardiographic findings is not yet possible . The presence of atrial septal aneurysm , a wide opening of the defect during the cardiac cycle and a large atrial shunt have been implicated as risk factors by some investigators . Long-term prevention of paradoxical embolism with oral anticoagulants seems to be of questionable benefit . Besides , these agents are poorly tolerated and carry the risk of significant or fatal bleeding at a rate of 2-5% per year . Surgery of the atrial septum has been performed for many decades in patients with atrial septal defect and evidence accumulates that it is a safe and highly effective procedure in patients with PFO . At present , surgical closure of the PFO appears to be the treatment of choice for secondary prevention of paradoxical embolism . However , further studies are needed to define the appropriate candidates for surgical treatment . Devices for catheter-based sealing of PFO are also available and are currently being evaluated in clinical trials . However , experience with their use remains confined to specialized centers . Furthermore , further technical improvements of these systems are needed in order to optimize successful delivery and positioning , increase their long-term stability , and reduce periprocedural complications . Instructions: please typing these entity words according to sentence: paradoxical embolism, association, patent foramen ovale, stroke, clinical studies, recurrence, cerebral ischemia, patients, stroke, right, pressure, pulmonary embolism, risk, patients, findings, aneurysm, defect, risk factors, investigators, prevention, paradoxical embolism, anticoagulants, risk of, Surgery, patients, atrial septal defect, procedure, patients, surgical, treatment, choice, secondary, prevention, paradoxical embolism, surgical treatment, Devices, clinical trials, use, delivery, complications Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Notwithstanding the difficulties in definitely confirming paradoxical embolism , the association between patent foramen ovale ( PFO ) and cryptogenic stroke has repeatedly been demonstrated in clinical studies . Moreover , the recurrence rate of cerebral ischemia in patients with PFO and an unexplained stroke was found to be 3-4% per year in two recently published series . With the exception of right atrial pressure elevation in the setting of major pulmonary embolism , a reliable risk stratification of patients with PFO based on clinical or echocardiographic findings is not yet possible . The presence of atrial septal aneurysm , a wide opening of the defect during the cardiac cycle and a large atrial shunt have been implicated as risk factors by some investigators . Long-term prevention of paradoxical embolism with oral anticoagulants seems to be of questionable benefit . Besides , these agents are poorly tolerated and carry the risk of significant or fatal bleeding at a rate of 2-5% per year . Surgery of the atrial septum has been performed for many decades in patients with atrial septal defect and evidence accumulates that it is a safe and highly effective procedure in patients with PFO . At present , surgical closure of the PFO appears to be the treatment of choice for secondary prevention of paradoxical embolism . However , further studies are needed to define the appropriate candidates for surgical treatment . Devices for catheter-based sealing of PFO are also available and are currently being evaluated in clinical trials . However , experience with their use remains confined to specialized centers . Furthermore , further technical improvements of these systems are needed in order to optimize successful delivery and positioning , increase their long-term stability , and reduce periprocedural complications .
[ "Notwithstanding", "the", "difficulties", "in", "definitely", "confirming", "paradoxical", "embolism", ",", "the", "association", "between", "patent", "foramen", "ovale", "(", "PFO", ")", "and", "cryptogenic", "stroke", "has", "repeatedly", "been", "demonstrated", "in", "clinical", "studies", ".", "Moreover", ",", "the", "recurrence", "rate", "of", "cerebral", "ischemia", "in", "patients", "with", "PFO", "and", "an", "unexplained", "stroke", "was", "found", "to", "be", "3", "-", "4", "%", "per", "year", "in", "two", "recently", "published", "series", ".", "With", "the", "exception", "of", "right", "atrial", "pressure", "elevation", "in", "the", "setting", "of", "major", "pulmonary", "embolism", ",", "a", "reliable", "risk", "stratification", "of", "patients", "with", "PFO", "based", "on", "clinical", "or", "echocardiographic", "findings", "is", "not", "yet", "possible", ".", "The", "presence", "of", "atrial", "septal", "aneurysm", ",", "a", "wide", "opening", "of", "the", "defect", "during", "the", "cardiac", "cycle", "and", "a", "large", "atrial", "shunt", "have", "been", "implicated", "as", "risk", "factors", "by", "some", "investigators", ".", "Long", "-", "term", "prevention", "of", "paradoxical", "embolism", "with", "oral", "anticoagulants", "seems", "to", "be", "of", "questionable", "benefit", ".", "Besides", ",", "these", "agents", "are", "poorly", "tolerated", "and", "carry", "the", "risk", "of", "significant", "or", "fatal", "bleeding", "at", "a", "rate", "of", "2", "-", "5", "%", "per", "year", ".", "Surgery", "of", "the", "atrial", "septum", "has", "been", "performed", "for", "many", "decades", "in", "patients", "with", "atrial", "septal", "defect", "and", "evidence", "accumulates", "that", "it", "is", "a", "safe", "and", "highly", "effective", "procedure", "in", "patients", "with", "PFO", ".", "At", "present", ",", "surgical", "closure", "of", "the", "PFO", "appears", "to", "be", "the", "treatment", "of", "choice", "for", "secondary", "prevention", "of", "paradoxical", "embolism", ".", "However", ",", "further", "studies", "are", "needed", "to", "define", "the", "appropriate", "candidates", "for", "surgical", "treatment", ".", "Devices", "for", "catheter", "-", "based", "sealing", "of", "PFO", "are", "also", "available", "and", "are", "currently", "being", "evaluated", "in", "clinical", "trials", ".", "However", ",", "experience", "with", "their", "use", "remains", "confined", "to", "specialized", "centers", ".", "Furthermore", ",", "further", "technical", "improvements", "of", "these", "systems", "are", "needed", "in", "order", "to", "optimize", "successful", "delivery", "and", "positioning", ",", "increase", "their", "long", "-", "term", "stability", ",", "and", "reduce", "periprocedural", "complications", "." ]
[ "umlsterm" ]
paradoxical embolism, association, patent foramen ovale, stroke, clinical studies, recurrence, cerebral ischemia, patients, stroke, right, pressure, pulmonary embolism, risk, patients, findings, aneurysm, defect, risk factors, investigators, prevention, paradoxical embolism, anticoagulants, risk of, Surgery, patients, atrial septal defect, procedure, patients, surgical, treatment, choice, secondary, prevention, paradoxical embolism, surgical treatment, Devices, clinical trials, use, delivery, complications
ZfuerKardiologie.00890063.eng.abstr_task2
Sentence: Notwithstanding the difficulties in definitely confirming paradoxical embolism , the association between patent foramen ovale ( PFO ) and cryptogenic stroke has repeatedly been demonstrated in clinical studies . Moreover , the recurrence rate of cerebral ischemia in patients with PFO and an unexplained stroke was found to be 3-4% per year in two recently published series . With the exception of right atrial pressure elevation in the setting of major pulmonary embolism , a reliable risk stratification of patients with PFO based on clinical or echocardiographic findings is not yet possible . The presence of atrial septal aneurysm , a wide opening of the defect during the cardiac cycle and a large atrial shunt have been implicated as risk factors by some investigators . Long-term prevention of paradoxical embolism with oral anticoagulants seems to be of questionable benefit . Besides , these agents are poorly tolerated and carry the risk of significant or fatal bleeding at a rate of 2-5% per year . Surgery of the atrial septum has been performed for many decades in patients with atrial septal defect and evidence accumulates that it is a safe and highly effective procedure in patients with PFO . At present , surgical closure of the PFO appears to be the treatment of choice for secondary prevention of paradoxical embolism . However , further studies are needed to define the appropriate candidates for surgical treatment . Devices for catheter-based sealing of PFO are also available and are currently being evaluated in clinical trials . However , experience with their use remains confined to specialized centers . Furthermore , further technical improvements of these systems are needed in order to optimize successful delivery and positioning , increase their long-term stability , and reduce periprocedural complications . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Notwithstanding the difficulties in definitely confirming paradoxical embolism , the association between patent foramen ovale ( PFO ) and cryptogenic stroke has repeatedly been demonstrated in clinical studies . Moreover , the recurrence rate of cerebral ischemia in patients with PFO and an unexplained stroke was found to be 3-4% per year in two recently published series . With the exception of right atrial pressure elevation in the setting of major pulmonary embolism , a reliable risk stratification of patients with PFO based on clinical or echocardiographic findings is not yet possible . The presence of atrial septal aneurysm , a wide opening of the defect during the cardiac cycle and a large atrial shunt have been implicated as risk factors by some investigators . Long-term prevention of paradoxical embolism with oral anticoagulants seems to be of questionable benefit . Besides , these agents are poorly tolerated and carry the risk of significant or fatal bleeding at a rate of 2-5% per year . Surgery of the atrial septum has been performed for many decades in patients with atrial septal defect and evidence accumulates that it is a safe and highly effective procedure in patients with PFO . At present , surgical closure of the PFO appears to be the treatment of choice for secondary prevention of paradoxical embolism . However , further studies are needed to define the appropriate candidates for surgical treatment . Devices for catheter-based sealing of PFO are also available and are currently being evaluated in clinical trials . However , experience with their use remains confined to specialized centers . Furthermore , further technical improvements of these systems are needed in order to optimize successful delivery and positioning , increase their long-term stability , and reduce periprocedural complications .
[ "Notwithstanding", "the", "difficulties", "in", "definitely", "confirming", "paradoxical", "embolism", ",", "the", "association", "between", "patent", "foramen", "ovale", "(", "PFO", ")", "and", "cryptogenic", "stroke", "has", "repeatedly", "been", "demonstrated", "in", "clinical", "studies", ".", "Moreover", ",", "the", "recurrence", "rate", "of", "cerebral", "ischemia", "in", "patients", "with", "PFO", "and", "an", "unexplained", "stroke", "was", "found", "to", "be", "3", "-", "4", "%", "per", "year", "in", "two", "recently", "published", "series", ".", "With", "the", "exception", "of", "right", "atrial", "pressure", "elevation", "in", "the", "setting", "of", "major", "pulmonary", "embolism", ",", "a", "reliable", "risk", "stratification", "of", "patients", "with", "PFO", "based", "on", "clinical", "or", "echocardiographic", "findings", "is", "not", "yet", "possible", ".", "The", "presence", "of", "atrial", "septal", "aneurysm", ",", "a", "wide", "opening", "of", "the", "defect", "during", "the", "cardiac", "cycle", "and", "a", "large", "atrial", "shunt", "have", "been", "implicated", "as", "risk", "factors", "by", "some", "investigators", ".", "Long", "-", "term", "prevention", "of", "paradoxical", "embolism", "with", "oral", "anticoagulants", "seems", "to", "be", "of", "questionable", "benefit", ".", "Besides", ",", "these", "agents", "are", "poorly", "tolerated", "and", "carry", "the", "risk", "of", "significant", "or", "fatal", "bleeding", "at", "a", "rate", "of", "2", "-", "5", "%", "per", "year", ".", "Surgery", "of", "the", "atrial", "septum", "has", "been", "performed", "for", "many", "decades", "in", "patients", "with", "atrial", "septal", "defect", "and", "evidence", "accumulates", "that", "it", "is", "a", "safe", "and", "highly", "effective", "procedure", "in", "patients", "with", "PFO", ".", "At", "present", ",", "surgical", "closure", "of", "the", "PFO", "appears", "to", "be", "the", "treatment", "of", "choice", "for", "secondary", "prevention", "of", "paradoxical", "embolism", ".", "However", ",", "further", "studies", "are", "needed", "to", "define", "the", "appropriate", "candidates", "for", "surgical", "treatment", ".", "Devices", "for", "catheter", "-", "based", "sealing", "of", "PFO", "are", "also", "available", "and", "are", "currently", "being", "evaluated", "in", "clinical", "trials", ".", "However", ",", "experience", "with", "their", "use", "remains", "confined", "to", "specialized", "centers", ".", "Furthermore", ",", "further", "technical", "improvements", "of", "these", "systems", "are", "needed", "in", "order", "to", "optimize", "successful", "delivery", "and", "positioning", ",", "increase", "their", "long", "-", "term", "stability", ",", "and", "reduce", "periprocedural", "complications", "." ]
[ "umlsterm" ]
hearing aids is an umlsterm, research is an umlsterm, electronic is an umlsterm, hearing is an umlsterm, devices is an umlsterm, transducer is an umlsterm, hearing aid is an umlsterm, sensorineural hearing losses is an umlsterm, transmission is an umlsterm, sound - pressure is an umlsterm, balance is an umlsterm, implantation is an umlsterm, transducer is an umlsterm, power is an umlsterm, consumption is an umlsterm, transducer is an umlsterm, transducer is an umlsterm
HNO.70450775.eng.abstr_task0
Sentence: In order to overcome the disadvantages of hearing aids , a significant amount of research aimed at replacing them by implanted ossicular-coupled electronic hearing devices is being carried out . The technical and audiological demands on the electromechanical transducer of an implantable hearing aid for moderate to severe sensorineural hearing losses include high transmission quality of the equivalent sound-pressure level without significant linear or nonlinear distortion , and an energy balance suitable for implantation . Fundamental specifications for a transducer are a high spectral bandwidth of up to 10 kHz , an elongation amplitude of at least 100 nm within this range , a small ripple of the elongation frequence response of around +/- 3 dB , a total harmonic distortion ( THD ) of less than 0.5% , and a maximum electric power consumption of 0.1 mW . The demands on construction , such as hermetic sealing , biocompatibility , and biostability , are also discussed in detail . It appears that optimum transducer design is essentially a compromise between the physical requirements which are in part conflicting regardless of the transducer principle employed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
In order to overcome the disadvantages of hearing aids , a significant amount of research aimed at replacing them by implanted ossicular-coupled electronic hearing devices is being carried out . The technical and audiological demands on the electromechanical transducer of an implantable hearing aid for moderate to severe sensorineural hearing losses include high transmission quality of the equivalent sound-pressure level without significant linear or nonlinear distortion , and an energy balance suitable for implantation . Fundamental specifications for a transducer are a high spectral bandwidth of up to 10 kHz , an elongation amplitude of at least 100 nm within this range , a small ripple of the elongation frequence response of around +/- 3 dB , a total harmonic distortion ( THD ) of less than 0.5% , and a maximum electric power consumption of 0.1 mW . The demands on construction , such as hermetic sealing , biocompatibility , and biostability , are also discussed in detail . It appears that optimum transducer design is essentially a compromise between the physical requirements which are in part conflicting regardless of the transducer principle employed .
[ "In", "order", "to", "overcome", "the", "disadvantages", "of", "hearing", "aids", ",", "a", "significant", "amount", "of", "research", "aimed", "at", "replacing", "them", "by", "implanted", "ossicular", "-", "coupled", "electronic", "hearing", "devices", "is", "being", "carried", "out", ".", "The", "technical", "and", "audiological", "demands", "on", "the", "electromechanical", "transducer", "of", "an", "implantable", "hearing", "aid", "for", "moderate", "to", "severe", "sensorineural", "hearing", "losses", "include", "high", "transmission", "quality", "of", "the", "equivalent", "sound", "-", "pressure", "level", "without", "significant", "linear", "or", "nonlinear", "distortion", ",", "and", "an", "energy", "balance", "suitable", "for", "implantation", ".", "Fundamental", "specifications", "for", "a", "transducer", "are", "a", "high", "spectral", "bandwidth", "of", "up", "to", "10", "kHz", ",", "an", "elongation", "amplitude", "of", "at", "least", "100", "nm", "within", "this", "range", ",", "a", "small", "ripple", "of", "the", "elongation", "frequence", "response", "of", "around", "+", "/-", "3", "dB", ",", "a", "total", "harmonic", "distortion", "(", "THD", ")", "of", "less", "than", "0.5", "%", ",", "and", "a", "maximum", "electric", "power", "consumption", "of", "0.1", "mW", ".", "The", "demands", "on", "construction", ",", "such", "as", "hermetic", "sealing", ",", "biocompatibility", ",", "and", "biostability", ",", "are", "also", "discussed", "in", "detail", ".", "It", "appears", "that", "optimum", "transducer", "design", "is", "essentially", "a", "compromise", "between", "the", "physical", "requirements", "which", "are", "in", "part", "conflicting", "regardless", "of", "the", "transducer", "principle", "employed", "." ]
[ "umlsterm" ]
hearing aids is an umlsterm, research is an umlsterm, electronic is an umlsterm, hearing is an umlsterm, devices is an umlsterm, transducer is an umlsterm, hearing aid is an umlsterm, sensorineural hearing losses is an umlsterm, transmission is an umlsterm, sound - pressure is an umlsterm, balance is an umlsterm, implantation is an umlsterm, transducer is an umlsterm, power is an umlsterm, consumption is an umlsterm, transducer is an umlsterm, transducer is an umlsterm
HNO.70450775.eng.abstr_task1
Sentence: In order to overcome the disadvantages of hearing aids , a significant amount of research aimed at replacing them by implanted ossicular-coupled electronic hearing devices is being carried out . The technical and audiological demands on the electromechanical transducer of an implantable hearing aid for moderate to severe sensorineural hearing losses include high transmission quality of the equivalent sound-pressure level without significant linear or nonlinear distortion , and an energy balance suitable for implantation . Fundamental specifications for a transducer are a high spectral bandwidth of up to 10 kHz , an elongation amplitude of at least 100 nm within this range , a small ripple of the elongation frequence response of around +/- 3 dB , a total harmonic distortion ( THD ) of less than 0.5% , and a maximum electric power consumption of 0.1 mW . The demands on construction , such as hermetic sealing , biocompatibility , and biostability , are also discussed in detail . It appears that optimum transducer design is essentially a compromise between the physical requirements which are in part conflicting regardless of the transducer principle employed . Instructions: please typing these entity words according to sentence: hearing aids, research, electronic, hearing, devices, transducer, hearing aid, sensorineural hearing losses, transmission, sound - pressure, balance, implantation, transducer, power, consumption, transducer, transducer Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
In order to overcome the disadvantages of hearing aids , a significant amount of research aimed at replacing them by implanted ossicular-coupled electronic hearing devices is being carried out . The technical and audiological demands on the electromechanical transducer of an implantable hearing aid for moderate to severe sensorineural hearing losses include high transmission quality of the equivalent sound-pressure level without significant linear or nonlinear distortion , and an energy balance suitable for implantation . Fundamental specifications for a transducer are a high spectral bandwidth of up to 10 kHz , an elongation amplitude of at least 100 nm within this range , a small ripple of the elongation frequence response of around +/- 3 dB , a total harmonic distortion ( THD ) of less than 0.5% , and a maximum electric power consumption of 0.1 mW . The demands on construction , such as hermetic sealing , biocompatibility , and biostability , are also discussed in detail . It appears that optimum transducer design is essentially a compromise between the physical requirements which are in part conflicting regardless of the transducer principle employed .
[ "In", "order", "to", "overcome", "the", "disadvantages", "of", "hearing", "aids", ",", "a", "significant", "amount", "of", "research", "aimed", "at", "replacing", "them", "by", "implanted", "ossicular", "-", "coupled", "electronic", "hearing", "devices", "is", "being", "carried", "out", ".", "The", "technical", "and", "audiological", "demands", "on", "the", "electromechanical", "transducer", "of", "an", "implantable", "hearing", "aid", "for", "moderate", "to", "severe", "sensorineural", "hearing", "losses", "include", "high", "transmission", "quality", "of", "the", "equivalent", "sound", "-", "pressure", "level", "without", "significant", "linear", "or", "nonlinear", "distortion", ",", "and", "an", "energy", "balance", "suitable", "for", "implantation", ".", "Fundamental", "specifications", "for", "a", "transducer", "are", "a", "high", "spectral", "bandwidth", "of", "up", "to", "10", "kHz", ",", "an", "elongation", "amplitude", "of", "at", "least", "100", "nm", "within", "this", "range", ",", "a", "small", "ripple", "of", "the", "elongation", "frequence", "response", "of", "around", "+", "/-", "3", "dB", ",", "a", "total", "harmonic", "distortion", "(", "THD", ")", "of", "less", "than", "0.5", "%", ",", "and", "a", "maximum", "electric", "power", "consumption", "of", "0.1", "mW", ".", "The", "demands", "on", "construction", ",", "such", "as", "hermetic", "sealing", ",", "biocompatibility", ",", "and", "biostability", ",", "are", "also", "discussed", "in", "detail", ".", "It", "appears", "that", "optimum", "transducer", "design", "is", "essentially", "a", "compromise", "between", "the", "physical", "requirements", "which", "are", "in", "part", "conflicting", "regardless", "of", "the", "transducer", "principle", "employed", "." ]
[ "umlsterm" ]
hearing aids, research, electronic, hearing, devices, transducer, hearing aid, sensorineural hearing losses, transmission, sound - pressure, balance, implantation, transducer, power, consumption, transducer, transducer
HNO.70450775.eng.abstr_task2
Sentence: In order to overcome the disadvantages of hearing aids , a significant amount of research aimed at replacing them by implanted ossicular-coupled electronic hearing devices is being carried out . The technical and audiological demands on the electromechanical transducer of an implantable hearing aid for moderate to severe sensorineural hearing losses include high transmission quality of the equivalent sound-pressure level without significant linear or nonlinear distortion , and an energy balance suitable for implantation . Fundamental specifications for a transducer are a high spectral bandwidth of up to 10 kHz , an elongation amplitude of at least 100 nm within this range , a small ripple of the elongation frequence response of around +/- 3 dB , a total harmonic distortion ( THD ) of less than 0.5% , and a maximum electric power consumption of 0.1 mW . The demands on construction , such as hermetic sealing , biocompatibility , and biostability , are also discussed in detail . It appears that optimum transducer design is essentially a compromise between the physical requirements which are in part conflicting regardless of the transducer principle employed . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
In order to overcome the disadvantages of hearing aids , a significant amount of research aimed at replacing them by implanted ossicular-coupled electronic hearing devices is being carried out . The technical and audiological demands on the electromechanical transducer of an implantable hearing aid for moderate to severe sensorineural hearing losses include high transmission quality of the equivalent sound-pressure level without significant linear or nonlinear distortion , and an energy balance suitable for implantation . Fundamental specifications for a transducer are a high spectral bandwidth of up to 10 kHz , an elongation amplitude of at least 100 nm within this range , a small ripple of the elongation frequence response of around +/- 3 dB , a total harmonic distortion ( THD ) of less than 0.5% , and a maximum electric power consumption of 0.1 mW . The demands on construction , such as hermetic sealing , biocompatibility , and biostability , are also discussed in detail . It appears that optimum transducer design is essentially a compromise between the physical requirements which are in part conflicting regardless of the transducer principle employed .
[ "In", "order", "to", "overcome", "the", "disadvantages", "of", "hearing", "aids", ",", "a", "significant", "amount", "of", "research", "aimed", "at", "replacing", "them", "by", "implanted", "ossicular", "-", "coupled", "electronic", "hearing", "devices", "is", "being", "carried", "out", ".", "The", "technical", "and", "audiological", "demands", "on", "the", "electromechanical", "transducer", "of", "an", "implantable", "hearing", "aid", "for", "moderate", "to", "severe", "sensorineural", "hearing", "losses", "include", "high", "transmission", "quality", "of", "the", "equivalent", "sound", "-", "pressure", "level", "without", "significant", "linear", "or", "nonlinear", "distortion", ",", "and", "an", "energy", "balance", "suitable", "for", "implantation", ".", "Fundamental", "specifications", "for", "a", "transducer", "are", "a", "high", "spectral", "bandwidth", "of", "up", "to", "10", "kHz", ",", "an", "elongation", "amplitude", "of", "at", "least", "100", "nm", "within", "this", "range", ",", "a", "small", "ripple", "of", "the", "elongation", "frequence", "response", "of", "around", "+", "/-", "3", "dB", ",", "a", "total", "harmonic", "distortion", "(", "THD", ")", "of", "less", "than", "0.5", "%", ",", "and", "a", "maximum", "electric", "power", "consumption", "of", "0.1", "mW", ".", "The", "demands", "on", "construction", ",", "such", "as", "hermetic", "sealing", ",", "biocompatibility", ",", "and", "biostability", ",", "are", "also", "discussed", "in", "detail", ".", "It", "appears", "that", "optimum", "transducer", "design", "is", "essentially", "a", "compromise", "between", "the", "physical", "requirements", "which", "are", "in", "part", "conflicting", "regardless", "of", "the", "transducer", "principle", "employed", "." ]
[ "umlsterm" ]
Serotonin transporter is a GENE-Y
9928259_task0
Sentence: Serotonin transporter function in vivo: assessment by chronoamperometry. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y
[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]
Serotonin transporter function in vivo: assessment by chronoamperometry.
[ "Serotonin", "transporter", "function", "in", "vivo", ":", "assessment", "by", "chronoamperometry", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Serotonin transporter is a GENE-Y
9928259_task1
Sentence: Serotonin transporter function in vivo: assessment by chronoamperometry. Instructions: please typing these entity words according to sentence: Serotonin transporter Options: GENE-Y
[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]
Serotonin transporter function in vivo: assessment by chronoamperometry.
[ "Serotonin", "transporter", "function", "in", "vivo", ":", "assessment", "by", "chronoamperometry", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Serotonin transporter
9928259_task2
Sentence: Serotonin transporter function in vivo: assessment by chronoamperometry. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]
Serotonin transporter function in vivo: assessment by chronoamperometry.
[ "Serotonin", "transporter", "function", "in", "vivo", ":", "assessment", "by", "chronoamperometry", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Chronic diseases is an umlsterm, juvenile chronic arthritis is an umlsterm, diseases is an umlsterm, Germany is an umlsterm, psychologist 's is an umlsterm, worker 's is an umlsterm
MonatsschriftKinderheilkunde.61440872.eng.abstr_task0
Sentence: Chronic diseases in general and juvenile chronic arthritis in particular are often considered as diseases which should best be treated in an interdisciplinary manner . However , the evereyday practice of a multidisciplinary team approach often remains unclear . The article outlines the different tasks and the ways of cooperation of the team in Hannover , Germany . Special emphasis is laid on the psychologist's and the social worker's part. The modern idea of a multidisciplinary team approach should be more than mere words . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Chronic diseases in general and juvenile chronic arthritis in particular are often considered as diseases which should best be treated in an interdisciplinary manner . However , the evereyday practice of a multidisciplinary team approach often remains unclear . The article outlines the different tasks and the ways of cooperation of the team in Hannover , Germany . Special emphasis is laid on the psychologist's and the social worker's part. The modern idea of a multidisciplinary team approach should be more than mere words .
[ "Chronic", "diseases", "in", "general", "and", "juvenile", "chronic", "arthritis", "in", "particular", "are", "often", "considered", "as", "diseases", "which", "should", "best", "be", "treated", "in", "an", "interdisciplinary", "manner", ".", "However", ",", "the", "evereyday", "practice", "of", "a", "multidisciplinary", "team", "approach", "often", "remains", "unclear", ".", "The", "article", "outlines", "the", "different", "tasks", "and", "the", "ways", "of", "cooperation", "of", "the", "team", "in", "Hannover", ",", "Germany", ".", "Special", "emphasis", "is", "laid", "on", "the", "psychologist", "'s", "and", "the", "social", "worker", "'s", "part", ".", "The", "modern", "idea", "of", "a", "multidisciplinary", "team", "approach", "should", "be", "more", "than", "mere", "words", "." ]
[ "umlsterm" ]
Chronic diseases is an umlsterm, juvenile chronic arthritis is an umlsterm, diseases is an umlsterm, Germany is an umlsterm, psychologist 's is an umlsterm, worker 's is an umlsterm
MonatsschriftKinderheilkunde.61440872.eng.abstr_task1
Sentence: Chronic diseases in general and juvenile chronic arthritis in particular are often considered as diseases which should best be treated in an interdisciplinary manner . However , the evereyday practice of a multidisciplinary team approach often remains unclear . The article outlines the different tasks and the ways of cooperation of the team in Hannover , Germany . Special emphasis is laid on the psychologist's and the social worker's part. The modern idea of a multidisciplinary team approach should be more than mere words . Instructions: please typing these entity words according to sentence: Chronic diseases, juvenile chronic arthritis, diseases, Germany, psychologist 's, worker 's Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Chronic diseases in general and juvenile chronic arthritis in particular are often considered as diseases which should best be treated in an interdisciplinary manner . However , the evereyday practice of a multidisciplinary team approach often remains unclear . The article outlines the different tasks and the ways of cooperation of the team in Hannover , Germany . Special emphasis is laid on the psychologist's and the social worker's part. The modern idea of a multidisciplinary team approach should be more than mere words .
[ "Chronic", "diseases", "in", "general", "and", "juvenile", "chronic", "arthritis", "in", "particular", "are", "often", "considered", "as", "diseases", "which", "should", "best", "be", "treated", "in", "an", "interdisciplinary", "manner", ".", "However", ",", "the", "evereyday", "practice", "of", "a", "multidisciplinary", "team", "approach", "often", "remains", "unclear", ".", "The", "article", "outlines", "the", "different", "tasks", "and", "the", "ways", "of", "cooperation", "of", "the", "team", "in", "Hannover", ",", "Germany", ".", "Special", "emphasis", "is", "laid", "on", "the", "psychologist", "'s", "and", "the", "social", "worker", "'s", "part", ".", "The", "modern", "idea", "of", "a", "multidisciplinary", "team", "approach", "should", "be", "more", "than", "mere", "words", "." ]
[ "umlsterm" ]
Chronic diseases, juvenile chronic arthritis, diseases, Germany, psychologist 's, worker 's
MonatsschriftKinderheilkunde.61440872.eng.abstr_task2
Sentence: Chronic diseases in general and juvenile chronic arthritis in particular are often considered as diseases which should best be treated in an interdisciplinary manner . However , the evereyday practice of a multidisciplinary team approach often remains unclear . The article outlines the different tasks and the ways of cooperation of the team in Hannover , Germany . Special emphasis is laid on the psychologist's and the social worker's part. The modern idea of a multidisciplinary team approach should be more than mere words . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Chronic diseases in general and juvenile chronic arthritis in particular are often considered as diseases which should best be treated in an interdisciplinary manner . However , the evereyday practice of a multidisciplinary team approach often remains unclear . The article outlines the different tasks and the ways of cooperation of the team in Hannover , Germany . Special emphasis is laid on the psychologist's and the social worker's part. The modern idea of a multidisciplinary team approach should be more than mere words .
[ "Chronic", "diseases", "in", "general", "and", "juvenile", "chronic", "arthritis", "in", "particular", "are", "often", "considered", "as", "diseases", "which", "should", "best", "be", "treated", "in", "an", "interdisciplinary", "manner", ".", "However", ",", "the", "evereyday", "practice", "of", "a", "multidisciplinary", "team", "approach", "often", "remains", "unclear", ".", "The", "article", "outlines", "the", "different", "tasks", "and", "the", "ways", "of", "cooperation", "of", "the", "team", "in", "Hannover", ",", "Germany", ".", "Special", "emphasis", "is", "laid", "on", "the", "psychologist", "'s", "and", "the", "social", "worker", "'s", "part", ".", "The", "modern", "idea", "of", "a", "multidisciplinary", "team", "approach", "should", "be", "more", "than", "mere", "words", "." ]
[ "umlsterm" ]
Exanthem is an umlsterm, -Injektion is an umlsterm, Heparinpraeparaten is an umlsterm, Heparinexantheme is an umlsterm, Literatur is an umlsterm
DerHautarzt.40450569.ger.abstr_task0
Sentence: Zusammenfassung . Es wird ueber eine 75jaehrige Patientin mit generalisiertem makulopapuloesem Exanthem und indurierten erythematoesen Plaques an den Einstichstellen nach s.c. -Injektion berichtet . Diese Reaktionen traten sowohl nach der Gabe von fraktionierten als auch hochmolekularen Heparinpraeparaten auf und konnten durch Reexposition wiederholt ausgeloest werden . Generalisierte Heparinexantheme sind seltene Reaktionen . Neben der Fallbeschreibung unserer Patientin werden die verschiedenen Varianten der Heparinunvertraeglichkeits-Reaktionen anhand der aktuellen Literatur diskutiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Es wird ueber eine 75jaehrige Patientin mit generalisiertem makulopapuloesem Exanthem und indurierten erythematoesen Plaques an den Einstichstellen nach s.c. -Injektion berichtet . Diese Reaktionen traten sowohl nach der Gabe von fraktionierten als auch hochmolekularen Heparinpraeparaten auf und konnten durch Reexposition wiederholt ausgeloest werden . Generalisierte Heparinexantheme sind seltene Reaktionen . Neben der Fallbeschreibung unserer Patientin werden die verschiedenen Varianten der Heparinunvertraeglichkeits-Reaktionen anhand der aktuellen Literatur diskutiert .
[ "Zusammenfassung", ".", "Es", "wird", "ueber", "eine", "75jaehrige", "Patientin", "mit", "generalisiertem", "makulopapuloesem", "Exanthem", "und", "indurierten", "erythematoesen", "Plaques", "an", "den", "Einstichstellen", "nach", "s.c", ".", "-Injektion", "berichtet", ".", "Diese", "Reaktionen", "traten", "sowohl", "nach", "der", "Gabe", "von", "fraktionierten", "als", "auch", "hochmolekularen", "Heparinpraeparaten", "auf", "und", "konnten", "durch", "Reexposition", "wiederholt", "ausgeloest", "werden", ".", "Generalisierte", "Heparinexantheme", "sind", "seltene", "Reaktionen", ".", "Neben", "der", "Fallbeschreibung", "unserer", "Patientin", "werden", "die", "verschiedenen", "Varianten", "der", "Heparinunvertraeglichkeits", "-", "Reaktionen", "anhand", "der", "aktuellen", "Literatur", "diskutiert", "." ]
[ "umlsterm" ]
Exanthem is an umlsterm, -Injektion is an umlsterm, Heparinpraeparaten is an umlsterm, Heparinexantheme is an umlsterm, Literatur is an umlsterm
DerHautarzt.40450569.ger.abstr_task1
Sentence: Zusammenfassung . Es wird ueber eine 75jaehrige Patientin mit generalisiertem makulopapuloesem Exanthem und indurierten erythematoesen Plaques an den Einstichstellen nach s.c. -Injektion berichtet . Diese Reaktionen traten sowohl nach der Gabe von fraktionierten als auch hochmolekularen Heparinpraeparaten auf und konnten durch Reexposition wiederholt ausgeloest werden . Generalisierte Heparinexantheme sind seltene Reaktionen . Neben der Fallbeschreibung unserer Patientin werden die verschiedenen Varianten der Heparinunvertraeglichkeits-Reaktionen anhand der aktuellen Literatur diskutiert . Instructions: please typing these entity words according to sentence: Exanthem, -Injektion, Heparinpraeparaten, Heparinexantheme, Literatur Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Es wird ueber eine 75jaehrige Patientin mit generalisiertem makulopapuloesem Exanthem und indurierten erythematoesen Plaques an den Einstichstellen nach s.c. -Injektion berichtet . Diese Reaktionen traten sowohl nach der Gabe von fraktionierten als auch hochmolekularen Heparinpraeparaten auf und konnten durch Reexposition wiederholt ausgeloest werden . Generalisierte Heparinexantheme sind seltene Reaktionen . Neben der Fallbeschreibung unserer Patientin werden die verschiedenen Varianten der Heparinunvertraeglichkeits-Reaktionen anhand der aktuellen Literatur diskutiert .
[ "Zusammenfassung", ".", "Es", "wird", "ueber", "eine", "75jaehrige", "Patientin", "mit", "generalisiertem", "makulopapuloesem", "Exanthem", "und", "indurierten", "erythematoesen", "Plaques", "an", "den", "Einstichstellen", "nach", "s.c", ".", "-Injektion", "berichtet", ".", "Diese", "Reaktionen", "traten", "sowohl", "nach", "der", "Gabe", "von", "fraktionierten", "als", "auch", "hochmolekularen", "Heparinpraeparaten", "auf", "und", "konnten", "durch", "Reexposition", "wiederholt", "ausgeloest", "werden", ".", "Generalisierte", "Heparinexantheme", "sind", "seltene", "Reaktionen", ".", "Neben", "der", "Fallbeschreibung", "unserer", "Patientin", "werden", "die", "verschiedenen", "Varianten", "der", "Heparinunvertraeglichkeits", "-", "Reaktionen", "anhand", "der", "aktuellen", "Literatur", "diskutiert", "." ]
[ "umlsterm" ]
Exanthem, -Injektion, Heparinpraeparaten, Heparinexantheme, Literatur
DerHautarzt.40450569.ger.abstr_task2
Sentence: Zusammenfassung . Es wird ueber eine 75jaehrige Patientin mit generalisiertem makulopapuloesem Exanthem und indurierten erythematoesen Plaques an den Einstichstellen nach s.c. -Injektion berichtet . Diese Reaktionen traten sowohl nach der Gabe von fraktionierten als auch hochmolekularen Heparinpraeparaten auf und konnten durch Reexposition wiederholt ausgeloest werden . Generalisierte Heparinexantheme sind seltene Reaktionen . Neben der Fallbeschreibung unserer Patientin werden die verschiedenen Varianten der Heparinunvertraeglichkeits-Reaktionen anhand der aktuellen Literatur diskutiert . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Es wird ueber eine 75jaehrige Patientin mit generalisiertem makulopapuloesem Exanthem und indurierten erythematoesen Plaques an den Einstichstellen nach s.c. -Injektion berichtet . Diese Reaktionen traten sowohl nach der Gabe von fraktionierten als auch hochmolekularen Heparinpraeparaten auf und konnten durch Reexposition wiederholt ausgeloest werden . Generalisierte Heparinexantheme sind seltene Reaktionen . Neben der Fallbeschreibung unserer Patientin werden die verschiedenen Varianten der Heparinunvertraeglichkeits-Reaktionen anhand der aktuellen Literatur diskutiert .
[ "Zusammenfassung", ".", "Es", "wird", "ueber", "eine", "75jaehrige", "Patientin", "mit", "generalisiertem", "makulopapuloesem", "Exanthem", "und", "indurierten", "erythematoesen", "Plaques", "an", "den", "Einstichstellen", "nach", "s.c", ".", "-Injektion", "berichtet", ".", "Diese", "Reaktionen", "traten", "sowohl", "nach", "der", "Gabe", "von", "fraktionierten", "als", "auch", "hochmolekularen", "Heparinpraeparaten", "auf", "und", "konnten", "durch", "Reexposition", "wiederholt", "ausgeloest", "werden", ".", "Generalisierte", "Heparinexantheme", "sind", "seltene", "Reaktionen", ".", "Neben", "der", "Fallbeschreibung", "unserer", "Patientin", "werden", "die", "verschiedenen", "Varianten", "der", "Heparinunvertraeglichkeits", "-", "Reaktionen", "anhand", "der", "aktuellen", "Literatur", "diskutiert", "." ]
[ "umlsterm" ]
regulatory is a Relation_Trigger, microRNA is a Non-Specific_miRNAs, miRNA is a Non-Specific_miRNAs, regulatory is a Relation_Trigger, activated is a Relation_Trigger
5521_task0
Sentence: Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Relation_Trigger, Non-Specific_miRNAs
[ "O", "O", "O", "B-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O" ]
Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes.
[ "Positioning", "of", "RNA", "regulatory", "mechanisms", "on", "endolysosomal", "membranes", "might", "permit", "rapid", "and", "localized", "control", "of", "microRNA", "(", "miRNA", ")", "gene", "regulatory", "programs", "and", "mRNA", "translation", "in", "response", "to", "environmental", "signals", ",", "such", "as", "activated", "plasma", "membrane", "receptors", "transported", "on", "endosomes", "." ]
[ "Diseases", "Relation_Trigger", "Non-Specific_miRNAs" ]
regulatory is a Relation_Trigger, microRNA is a Non-Specific_miRNAs, miRNA is a Non-Specific_miRNAs, regulatory is a Relation_Trigger, activated is a Relation_Trigger
5521_task1
Sentence: Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes. Instructions: please typing these entity words according to sentence: regulatory, microRNA, miRNA, regulatory, activated Options: Relation_Trigger, Non-Specific_miRNAs
[ "O", "O", "O", "B-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O" ]
Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes.
[ "Positioning", "of", "RNA", "regulatory", "mechanisms", "on", "endolysosomal", "membranes", "might", "permit", "rapid", "and", "localized", "control", "of", "microRNA", "(", "miRNA", ")", "gene", "regulatory", "programs", "and", "mRNA", "translation", "in", "response", "to", "environmental", "signals", ",", "such", "as", "activated", "plasma", "membrane", "receptors", "transported", "on", "endosomes", "." ]
[ "Diseases", "Relation_Trigger", "Non-Specific_miRNAs" ]
regulatory, microRNA, miRNA, regulatory, activated
5521_task2
Sentence: Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O" ]
Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes.
[ "Positioning", "of", "RNA", "regulatory", "mechanisms", "on", "endolysosomal", "membranes", "might", "permit", "rapid", "and", "localized", "control", "of", "microRNA", "(", "miRNA", ")", "gene", "regulatory", "programs", "and", "mRNA", "translation", "in", "response", "to", "environmental", "signals", ",", "such", "as", "activated", "plasma", "membrane", "receptors", "transported", "on", "endosomes", "." ]
[ "Diseases", "Relation_Trigger", "Non-Specific_miRNAs" ]
jaws is an umlsterm, method is an umlsterm, choice is an umlsterm, assessment is an umlsterm, mandible is an umlsterm, maxilla is an umlsterm, anatomy is an umlsterm, technique is an umlsterm, evaluation is an umlsterm, oral cavity is an umlsterm, pathology is an umlsterm, congenital is an umlsterm
DerRadiologe.90391035.eng.abstr_task0
Sentence: CT with multiplanar reconstruction of the jaws ( DentaScan ) is the method of choice for the radiographic assessment of the mandible and maxilla . It is instrumental in delineating the relationship between bony lesions and the adjacent anatomy . Therefore , this technique allows precise evaluation of the intricate details of the oral cavity . Using it , distinct characterization of pathology including infectious , metabolic , congenital and neoplastic lesions can be obtained . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
CT with multiplanar reconstruction of the jaws ( DentaScan ) is the method of choice for the radiographic assessment of the mandible and maxilla . It is instrumental in delineating the relationship between bony lesions and the adjacent anatomy . Therefore , this technique allows precise evaluation of the intricate details of the oral cavity . Using it , distinct characterization of pathology including infectious , metabolic , congenital and neoplastic lesions can be obtained .
[ "CT", "with", "multiplanar", "reconstruction", "of", "the", "jaws", "(", "DentaScan", ")", "is", "the", "method", "of", "choice", "for", "the", "radiographic", "assessment", "of", "the", "mandible", "and", "maxilla", ".", "It", "is", "instrumental", "in", "delineating", "the", "relationship", "between", "bony", "lesions", "and", "the", "adjacent", "anatomy", ".", "Therefore", ",", "this", "technique", "allows", "precise", "evaluation", "of", "the", "intricate", "details", "of", "the", "oral", "cavity", ".", "Using", "it", ",", "distinct", "characterization", "of", "pathology", "including", "infectious", ",", "metabolic", ",", "congenital", "and", "neoplastic", "lesions", "can", "be", "obtained", "." ]
[ "umlsterm" ]
jaws is an umlsterm, method is an umlsterm, choice is an umlsterm, assessment is an umlsterm, mandible is an umlsterm, maxilla is an umlsterm, anatomy is an umlsterm, technique is an umlsterm, evaluation is an umlsterm, oral cavity is an umlsterm, pathology is an umlsterm, congenital is an umlsterm
DerRadiologe.90391035.eng.abstr_task1
Sentence: CT with multiplanar reconstruction of the jaws ( DentaScan ) is the method of choice for the radiographic assessment of the mandible and maxilla . It is instrumental in delineating the relationship between bony lesions and the adjacent anatomy . Therefore , this technique allows precise evaluation of the intricate details of the oral cavity . Using it , distinct characterization of pathology including infectious , metabolic , congenital and neoplastic lesions can be obtained . Instructions: please typing these entity words according to sentence: jaws, method, choice, assessment, mandible, maxilla, anatomy, technique, evaluation, oral cavity, pathology, congenital Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
CT with multiplanar reconstruction of the jaws ( DentaScan ) is the method of choice for the radiographic assessment of the mandible and maxilla . It is instrumental in delineating the relationship between bony lesions and the adjacent anatomy . Therefore , this technique allows precise evaluation of the intricate details of the oral cavity . Using it , distinct characterization of pathology including infectious , metabolic , congenital and neoplastic lesions can be obtained .
[ "CT", "with", "multiplanar", "reconstruction", "of", "the", "jaws", "(", "DentaScan", ")", "is", "the", "method", "of", "choice", "for", "the", "radiographic", "assessment", "of", "the", "mandible", "and", "maxilla", ".", "It", "is", "instrumental", "in", "delineating", "the", "relationship", "between", "bony", "lesions", "and", "the", "adjacent", "anatomy", ".", "Therefore", ",", "this", "technique", "allows", "precise", "evaluation", "of", "the", "intricate", "details", "of", "the", "oral", "cavity", ".", "Using", "it", ",", "distinct", "characterization", "of", "pathology", "including", "infectious", ",", "metabolic", ",", "congenital", "and", "neoplastic", "lesions", "can", "be", "obtained", "." ]
[ "umlsterm" ]
jaws, method, choice, assessment, mandible, maxilla, anatomy, technique, evaluation, oral cavity, pathology, congenital
DerRadiologe.90391035.eng.abstr_task2
Sentence: CT with multiplanar reconstruction of the jaws ( DentaScan ) is the method of choice for the radiographic assessment of the mandible and maxilla . It is instrumental in delineating the relationship between bony lesions and the adjacent anatomy . Therefore , this technique allows precise evaluation of the intricate details of the oral cavity . Using it , distinct characterization of pathology including infectious , metabolic , congenital and neoplastic lesions can be obtained . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
CT with multiplanar reconstruction of the jaws ( DentaScan ) is the method of choice for the radiographic assessment of the mandible and maxilla . It is instrumental in delineating the relationship between bony lesions and the adjacent anatomy . Therefore , this technique allows precise evaluation of the intricate details of the oral cavity . Using it , distinct characterization of pathology including infectious , metabolic , congenital and neoplastic lesions can be obtained .
[ "CT", "with", "multiplanar", "reconstruction", "of", "the", "jaws", "(", "DentaScan", ")", "is", "the", "method", "of", "choice", "for", "the", "radiographic", "assessment", "of", "the", "mandible", "and", "maxilla", ".", "It", "is", "instrumental", "in", "delineating", "the", "relationship", "between", "bony", "lesions", "and", "the", "adjacent", "anatomy", ".", "Therefore", ",", "this", "technique", "allows", "precise", "evaluation", "of", "the", "intricate", "details", "of", "the", "oral", "cavity", ".", "Using", "it", ",", "distinct", "characterization", "of", "pathology", "including", "infectious", ",", "metabolic", ",", "congenital", "and", "neoplastic", "lesions", "can", "be", "obtained", "." ]
[ "umlsterm" ]
cardiovascular toxicity is a ADVERSE
example-78_task0
Sentence: Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. STUDY OBJECTIVE: To evaluate the pharmacokinetic profile of 0.35 mL/kg of 0.5% levobupivacaine during superficial and combined (deep and superficial) cervical plexus block (CPB) in patients undergoing minimally invasive parathyroidectomy. DESIGN: Prospective randomized study. SETTING: Operating theater of a university hospital. PATIENTS: 12 ASA physical status II and III patients (11 women and 1 man), scheduled for minimally invasive parathyroidectomy. INTERVENTIONS: Seven and 5 patients were randomly assigned to receive either superficial or combined CPB, respectively. The superficial CPB was performed with an injection of 0.35 mL/kg of 0.5% levobupivacaine subcutaneously along the posterior border of the sternocleidomastoid muscle and deeper on its medial surface. The combined CPB was initiated by the deep block at the C3 level vertebra by injecting 0.2 mL/kg of 0.5% levobupivacaine, followed by the superficial block with an injection of the remaining 0.15 mL/kg. After completion of the block, venous blood was sampled at the intervals of 5, 10, 15, 20, 30, 45, and 60 minutes. MEASUREMENTS AND MAIN RESULTS: Venous plasma concentrations were measured using gas chromatography-mass spectroscopy. Mean +/- SD of maximal concentrations of levobupivacaine was 0.58 +/- 0.41 mg/L in group superficial and 0.52 +/- 0.28 mg/L in group combined (P = 0.71). The median (range) time required to reach the maximal concentrations was 30 minutes (20-30 min) in group superficial and 20 minutes (15-30 min) in group combined (P = 0.45). The areas under the drug concentration/time curve (AUC(10-60)) were also similar in both groups. No signs of central nervous system or cardiovascular toxicity or other untoward events were observed in any patient. CONCLUSION: With the given dose regimen, levobupivacaine plasma concentrations were within safe ranges. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. STUDY OBJECTIVE: To evaluate the pharmacokinetic profile of 0.35 mL/kg of 0.5% levobupivacaine during superficial and combined (deep and superficial) cervical plexus block (CPB) in patients undergoing minimally invasive parathyroidectomy. DESIGN: Prospective randomized study. SETTING: Operating theater of a university hospital. PATIENTS: 12 ASA physical status II and III patients (11 women and 1 man), scheduled for minimally invasive parathyroidectomy. INTERVENTIONS: Seven and 5 patients were randomly assigned to receive either superficial or combined CPB, respectively. The superficial CPB was performed with an injection of 0.35 mL/kg of 0.5% levobupivacaine subcutaneously along the posterior border of the sternocleidomastoid muscle and deeper on its medial surface. The combined CPB was initiated by the deep block at the C3 level vertebra by injecting 0.2 mL/kg of 0.5% levobupivacaine, followed by the superficial block with an injection of the remaining 0.15 mL/kg. After completion of the block, venous blood was sampled at the intervals of 5, 10, 15, 20, 30, 45, and 60 minutes. MEASUREMENTS AND MAIN RESULTS: Venous plasma concentrations were measured using gas chromatography-mass spectroscopy. Mean +/- SD of maximal concentrations of levobupivacaine was 0.58 +/- 0.41 mg/L in group superficial and 0.52 +/- 0.28 mg/L in group combined (P = 0.71). The median (range) time required to reach the maximal concentrations was 30 minutes (20-30 min) in group superficial and 20 minutes (15-30 min) in group combined (P = 0.45). The areas under the drug concentration/time curve (AUC(10-60)) were also similar in both groups. No signs of central nervous system or cardiovascular toxicity or other untoward events were observed in any patient. CONCLUSION: With the given dose regimen, levobupivacaine plasma concentrations were within safe ranges.
[ "Pharmacokinetics", "of", "levobupivacaine", "0.5", "%", "after", "superficial", "or", "combined", "(", "deep", "and", "superficial", ")", "cervical", "plexus", "block", "in", "patients", "undergoing", "minimally", "invasive", "parathyroidectomy", ".", " ", "STUDY", "OBJECTIVE", ":", "To", "evaluate", "the", "pharmacokinetic", "profile", "of", "0.35", "mL", "/", "kg", "of", "0.5", "%", "levobupivacaine", "during", "superficial", "and", "combined", "(", "deep", "and", "superficial", ")", "cervical", "plexus", "block", "(", "CPB", ")", "in", "patients", "undergoing", "minimally", "invasive", "parathyroidectomy", ".", "DESIGN", ":", "Prospective", "randomized", "study", ".", "SETTING", ":", "Operating", "theater", "of", "a", "university", "hospital", ".", "PATIENTS", ":", "12", "ASA", "physical", "status", "II", "and", "III", "patients", "(", "11", "women", "and", "1", "man", ")", ",", "scheduled", "for", "minimally", "invasive", "parathyroidectomy", ".", "INTERVENTIONS", ":", "Seven", "and", "5", "patients", "were", "randomly", "assigned", "to", "receive", "either", "superficial", "or", "combined", "CPB", ",", "respectively", ".", "The", "superficial", "CPB", "was", "performed", "with", "an", "injection", "of", "0.35", "mL", "/", "kg", "of", "0.5", "%", "levobupivacaine", "subcutaneously", "along", "the", "posterior", "border", "of", "the", "sternocleidomastoid", "muscle", "and", "deeper", "on", "its", "medial", "surface", ".", "The", "combined", "CPB", "was", "initiated", "by", "the", "deep", "block", "at", "the", "C3", "level", "vertebra", "by", "injecting", "0.2", "mL", "/", "kg", "of", "0.5", "%", "levobupivacaine", ",", "followed", "by", "the", "superficial", "block", "with", "an", "injection", "of", "the", "remaining", "0.15", "mL", "/", "kg", ".", "After", "completion", "of", "the", "block", ",", "venous", "blood", "was", "sampled", "at", "the", "intervals", "of", "5", ",", "10", ",", "15", ",", "20", ",", "30", ",", "45", ",", "and", "60", "minutes", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", ":", "Venous", "plasma", "concentrations", "were", "measured", "using", "gas", "chromatography", "-", "mass", "spectroscopy", ".", "Mean", "+", "/-", "SD", "of", "maximal", "concentrations", "of", "levobupivacaine", "was", "0.58", "+", "/-", "0.41", "mg", "/", "L", "in", "group", "superficial", "and", "0.52", "+", "/-", "0.28", "mg", "/", "L", "in", "group", "combined", "(", "P", "=", "0.71", ")", ".", "The", "median", "(", "range", ")", "time", "required", "to", "reach", "the", "maximal", "concentrations", "was", "30", "minutes", "(", "20", "-", "30", "min", ")", "in", "group", "superficial", "and", "20", "minutes", "(", "15", "-", "30", "min", ")", "in", "group", "combined", "(", "P", "=", "0.45", ")", ".", "The", "areas", "under", "the", "drug", "concentration", "/", "time", "curve", "(", "AUC(10", "-", "60", ")", ")", "were", "also", "similar", "in", "both", "groups", ".", "No", "signs", "of", "central", "nervous", "system", "or", "cardiovascular", "toxicity", "or", "other", "untoward", "events", "were", "observed", "in", "any", "patient", ".", "CONCLUSION", ":", "With", "the", "given", "dose", "regimen", ",", "levobupivacaine", "plasma", "concentrations", "were", "within", "safe", "ranges", "." ]
[ "ADVERSE" ]
cardiovascular toxicity is a ADVERSE
example-78_task1
Sentence: Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. STUDY OBJECTIVE: To evaluate the pharmacokinetic profile of 0.35 mL/kg of 0.5% levobupivacaine during superficial and combined (deep and superficial) cervical plexus block (CPB) in patients undergoing minimally invasive parathyroidectomy. DESIGN: Prospective randomized study. SETTING: Operating theater of a university hospital. PATIENTS: 12 ASA physical status II and III patients (11 women and 1 man), scheduled for minimally invasive parathyroidectomy. INTERVENTIONS: Seven and 5 patients were randomly assigned to receive either superficial or combined CPB, respectively. The superficial CPB was performed with an injection of 0.35 mL/kg of 0.5% levobupivacaine subcutaneously along the posterior border of the sternocleidomastoid muscle and deeper on its medial surface. The combined CPB was initiated by the deep block at the C3 level vertebra by injecting 0.2 mL/kg of 0.5% levobupivacaine, followed by the superficial block with an injection of the remaining 0.15 mL/kg. After completion of the block, venous blood was sampled at the intervals of 5, 10, 15, 20, 30, 45, and 60 minutes. MEASUREMENTS AND MAIN RESULTS: Venous plasma concentrations were measured using gas chromatography-mass spectroscopy. Mean +/- SD of maximal concentrations of levobupivacaine was 0.58 +/- 0.41 mg/L in group superficial and 0.52 +/- 0.28 mg/L in group combined (P = 0.71). The median (range) time required to reach the maximal concentrations was 30 minutes (20-30 min) in group superficial and 20 minutes (15-30 min) in group combined (P = 0.45). The areas under the drug concentration/time curve (AUC(10-60)) were also similar in both groups. No signs of central nervous system or cardiovascular toxicity or other untoward events were observed in any patient. CONCLUSION: With the given dose regimen, levobupivacaine plasma concentrations were within safe ranges. Instructions: please typing these entity words according to sentence: cardiovascular toxicity Options: ADVERSE
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. STUDY OBJECTIVE: To evaluate the pharmacokinetic profile of 0.35 mL/kg of 0.5% levobupivacaine during superficial and combined (deep and superficial) cervical plexus block (CPB) in patients undergoing minimally invasive parathyroidectomy. DESIGN: Prospective randomized study. SETTING: Operating theater of a university hospital. PATIENTS: 12 ASA physical status II and III patients (11 women and 1 man), scheduled for minimally invasive parathyroidectomy. INTERVENTIONS: Seven and 5 patients were randomly assigned to receive either superficial or combined CPB, respectively. The superficial CPB was performed with an injection of 0.35 mL/kg of 0.5% levobupivacaine subcutaneously along the posterior border of the sternocleidomastoid muscle and deeper on its medial surface. The combined CPB was initiated by the deep block at the C3 level vertebra by injecting 0.2 mL/kg of 0.5% levobupivacaine, followed by the superficial block with an injection of the remaining 0.15 mL/kg. After completion of the block, venous blood was sampled at the intervals of 5, 10, 15, 20, 30, 45, and 60 minutes. MEASUREMENTS AND MAIN RESULTS: Venous plasma concentrations were measured using gas chromatography-mass spectroscopy. Mean +/- SD of maximal concentrations of levobupivacaine was 0.58 +/- 0.41 mg/L in group superficial and 0.52 +/- 0.28 mg/L in group combined (P = 0.71). The median (range) time required to reach the maximal concentrations was 30 minutes (20-30 min) in group superficial and 20 minutes (15-30 min) in group combined (P = 0.45). The areas under the drug concentration/time curve (AUC(10-60)) were also similar in both groups. No signs of central nervous system or cardiovascular toxicity or other untoward events were observed in any patient. CONCLUSION: With the given dose regimen, levobupivacaine plasma concentrations were within safe ranges.
[ "Pharmacokinetics", "of", "levobupivacaine", "0.5", "%", "after", "superficial", "or", "combined", "(", "deep", "and", "superficial", ")", "cervical", "plexus", "block", "in", "patients", "undergoing", "minimally", "invasive", "parathyroidectomy", ".", " ", "STUDY", "OBJECTIVE", ":", "To", "evaluate", "the", "pharmacokinetic", "profile", "of", "0.35", "mL", "/", "kg", "of", "0.5", "%", "levobupivacaine", "during", "superficial", "and", "combined", "(", "deep", "and", "superficial", ")", "cervical", "plexus", "block", "(", "CPB", ")", "in", "patients", "undergoing", "minimally", "invasive", "parathyroidectomy", ".", "DESIGN", ":", "Prospective", "randomized", "study", ".", "SETTING", ":", "Operating", "theater", "of", "a", "university", "hospital", ".", "PATIENTS", ":", "12", "ASA", "physical", "status", "II", "and", "III", "patients", "(", "11", "women", "and", "1", "man", ")", ",", "scheduled", "for", "minimally", "invasive", "parathyroidectomy", ".", "INTERVENTIONS", ":", "Seven", "and", "5", "patients", "were", "randomly", "assigned", "to", "receive", "either", "superficial", "or", "combined", "CPB", ",", "respectively", ".", "The", "superficial", "CPB", "was", "performed", "with", "an", "injection", "of", "0.35", "mL", "/", "kg", "of", "0.5", "%", "levobupivacaine", "subcutaneously", "along", "the", "posterior", "border", "of", "the", "sternocleidomastoid", "muscle", "and", "deeper", "on", "its", "medial", "surface", ".", "The", "combined", "CPB", "was", "initiated", "by", "the", "deep", "block", "at", "the", "C3", "level", "vertebra", "by", "injecting", "0.2", "mL", "/", "kg", "of", "0.5", "%", "levobupivacaine", ",", "followed", "by", "the", "superficial", "block", "with", "an", "injection", "of", "the", "remaining", "0.15", "mL", "/", "kg", ".", "After", "completion", "of", "the", "block", ",", "venous", "blood", "was", "sampled", "at", "the", "intervals", "of", "5", ",", "10", ",", "15", ",", "20", ",", "30", ",", "45", ",", "and", "60", "minutes", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", ":", "Venous", "plasma", "concentrations", "were", "measured", "using", "gas", "chromatography", "-", "mass", "spectroscopy", ".", "Mean", "+", "/-", "SD", "of", "maximal", "concentrations", "of", "levobupivacaine", "was", "0.58", "+", "/-", "0.41", "mg", "/", "L", "in", "group", "superficial", "and", "0.52", "+", "/-", "0.28", "mg", "/", "L", "in", "group", "combined", "(", "P", "=", "0.71", ")", ".", "The", "median", "(", "range", ")", "time", "required", "to", "reach", "the", "maximal", "concentrations", "was", "30", "minutes", "(", "20", "-", "30", "min", ")", "in", "group", "superficial", "and", "20", "minutes", "(", "15", "-", "30", "min", ")", "in", "group", "combined", "(", "P", "=", "0.45", ")", ".", "The", "areas", "under", "the", "drug", "concentration", "/", "time", "curve", "(", "AUC(10", "-", "60", ")", ")", "were", "also", "similar", "in", "both", "groups", ".", "No", "signs", "of", "central", "nervous", "system", "or", "cardiovascular", "toxicity", "or", "other", "untoward", "events", "were", "observed", "in", "any", "patient", ".", "CONCLUSION", ":", "With", "the", "given", "dose", "regimen", ",", "levobupivacaine", "plasma", "concentrations", "were", "within", "safe", "ranges", "." ]
[ "ADVERSE" ]
cardiovascular toxicity
example-78_task2
Sentence: Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. STUDY OBJECTIVE: To evaluate the pharmacokinetic profile of 0.35 mL/kg of 0.5% levobupivacaine during superficial and combined (deep and superficial) cervical plexus block (CPB) in patients undergoing minimally invasive parathyroidectomy. DESIGN: Prospective randomized study. SETTING: Operating theater of a university hospital. PATIENTS: 12 ASA physical status II and III patients (11 women and 1 man), scheduled for minimally invasive parathyroidectomy. INTERVENTIONS: Seven and 5 patients were randomly assigned to receive either superficial or combined CPB, respectively. The superficial CPB was performed with an injection of 0.35 mL/kg of 0.5% levobupivacaine subcutaneously along the posterior border of the sternocleidomastoid muscle and deeper on its medial surface. The combined CPB was initiated by the deep block at the C3 level vertebra by injecting 0.2 mL/kg of 0.5% levobupivacaine, followed by the superficial block with an injection of the remaining 0.15 mL/kg. After completion of the block, venous blood was sampled at the intervals of 5, 10, 15, 20, 30, 45, and 60 minutes. MEASUREMENTS AND MAIN RESULTS: Venous plasma concentrations were measured using gas chromatography-mass spectroscopy. Mean +/- SD of maximal concentrations of levobupivacaine was 0.58 +/- 0.41 mg/L in group superficial and 0.52 +/- 0.28 mg/L in group combined (P = 0.71). The median (range) time required to reach the maximal concentrations was 30 minutes (20-30 min) in group superficial and 20 minutes (15-30 min) in group combined (P = 0.45). The areas under the drug concentration/time curve (AUC(10-60)) were also similar in both groups. No signs of central nervous system or cardiovascular toxicity or other untoward events were observed in any patient. CONCLUSION: With the given dose regimen, levobupivacaine plasma concentrations were within safe ranges. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. STUDY OBJECTIVE: To evaluate the pharmacokinetic profile of 0.35 mL/kg of 0.5% levobupivacaine during superficial and combined (deep and superficial) cervical plexus block (CPB) in patients undergoing minimally invasive parathyroidectomy. DESIGN: Prospective randomized study. SETTING: Operating theater of a university hospital. PATIENTS: 12 ASA physical status II and III patients (11 women and 1 man), scheduled for minimally invasive parathyroidectomy. INTERVENTIONS: Seven and 5 patients were randomly assigned to receive either superficial or combined CPB, respectively. The superficial CPB was performed with an injection of 0.35 mL/kg of 0.5% levobupivacaine subcutaneously along the posterior border of the sternocleidomastoid muscle and deeper on its medial surface. The combined CPB was initiated by the deep block at the C3 level vertebra by injecting 0.2 mL/kg of 0.5% levobupivacaine, followed by the superficial block with an injection of the remaining 0.15 mL/kg. After completion of the block, venous blood was sampled at the intervals of 5, 10, 15, 20, 30, 45, and 60 minutes. MEASUREMENTS AND MAIN RESULTS: Venous plasma concentrations were measured using gas chromatography-mass spectroscopy. Mean +/- SD of maximal concentrations of levobupivacaine was 0.58 +/- 0.41 mg/L in group superficial and 0.52 +/- 0.28 mg/L in group combined (P = 0.71). The median (range) time required to reach the maximal concentrations was 30 minutes (20-30 min) in group superficial and 20 minutes (15-30 min) in group combined (P = 0.45). The areas under the drug concentration/time curve (AUC(10-60)) were also similar in both groups. No signs of central nervous system or cardiovascular toxicity or other untoward events were observed in any patient. CONCLUSION: With the given dose regimen, levobupivacaine plasma concentrations were within safe ranges.
[ "Pharmacokinetics", "of", "levobupivacaine", "0.5", "%", "after", "superficial", "or", "combined", "(", "deep", "and", "superficial", ")", "cervical", "plexus", "block", "in", "patients", "undergoing", "minimally", "invasive", "parathyroidectomy", ".", " ", "STUDY", "OBJECTIVE", ":", "To", "evaluate", "the", "pharmacokinetic", "profile", "of", "0.35", "mL", "/", "kg", "of", "0.5", "%", "levobupivacaine", "during", "superficial", "and", "combined", "(", "deep", "and", "superficial", ")", "cervical", "plexus", "block", "(", "CPB", ")", "in", "patients", "undergoing", "minimally", "invasive", "parathyroidectomy", ".", "DESIGN", ":", "Prospective", "randomized", "study", ".", "SETTING", ":", "Operating", "theater", "of", "a", "university", "hospital", ".", "PATIENTS", ":", "12", "ASA", "physical", "status", "II", "and", "III", "patients", "(", "11", "women", "and", "1", "man", ")", ",", "scheduled", "for", "minimally", "invasive", "parathyroidectomy", ".", "INTERVENTIONS", ":", "Seven", "and", "5", "patients", "were", "randomly", "assigned", "to", "receive", "either", "superficial", "or", "combined", "CPB", ",", "respectively", ".", "The", "superficial", "CPB", "was", "performed", "with", "an", "injection", "of", "0.35", "mL", "/", "kg", "of", "0.5", "%", "levobupivacaine", "subcutaneously", "along", "the", "posterior", "border", "of", "the", "sternocleidomastoid", "muscle", "and", "deeper", "on", "its", "medial", "surface", ".", "The", "combined", "CPB", "was", "initiated", "by", "the", "deep", "block", "at", "the", "C3", "level", "vertebra", "by", "injecting", "0.2", "mL", "/", "kg", "of", "0.5", "%", "levobupivacaine", ",", "followed", "by", "the", "superficial", "block", "with", "an", "injection", "of", "the", "remaining", "0.15", "mL", "/", "kg", ".", "After", "completion", "of", "the", "block", ",", "venous", "blood", "was", "sampled", "at", "the", "intervals", "of", "5", ",", "10", ",", "15", ",", "20", ",", "30", ",", "45", ",", "and", "60", "minutes", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", ":", "Venous", "plasma", "concentrations", "were", "measured", "using", "gas", "chromatography", "-", "mass", "spectroscopy", ".", "Mean", "+", "/-", "SD", "of", "maximal", "concentrations", "of", "levobupivacaine", "was", "0.58", "+", "/-", "0.41", "mg", "/", "L", "in", "group", "superficial", "and", "0.52", "+", "/-", "0.28", "mg", "/", "L", "in", "group", "combined", "(", "P", "=", "0.71", ")", ".", "The", "median", "(", "range", ")", "time", "required", "to", "reach", "the", "maximal", "concentrations", "was", "30", "minutes", "(", "20", "-", "30", "min", ")", "in", "group", "superficial", "and", "20", "minutes", "(", "15", "-", "30", "min", ")", "in", "group", "combined", "(", "P", "=", "0.45", ")", ".", "The", "areas", "under", "the", "drug", "concentration", "/", "time", "curve", "(", "AUC(10", "-", "60", ")", ")", "were", "also", "similar", "in", "both", "groups", ".", "No", "signs", "of", "central", "nervous", "system", "or", "cardiovascular", "toxicity", "or", "other", "untoward", "events", "were", "observed", "in", "any", "patient", ".", "CONCLUSION", ":", "With", "the", "given", "dose", "regimen", ",", "levobupivacaine", "plasma", "concentrations", "were", "within", "safe", "ranges", "." ]
[ "ADVERSE" ]
C / EBP activators is a protein_family_or_group, HIV-1 replication is an other_name, proviral induction is an other_name, monocytic cell lines is a cell_line
26038_task0
Sentence: C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, cell_line, other_name
[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "O" ]
C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines.
[ "C", "/", "EBP", "activators", "are", "required", "for", "HIV-1", "replication", "and", "proviral", "induction", "in", "monocytic", "cell", "lines", "." ]
[ "protein_family_or_group", "(AND other_name other_name)", "cell_line", "cell_type", "other_name", "protein_molecule", "virus", "DNA_domain_or_region", "", "RNA_family_or_group" ]
C / EBP activators is a protein_family_or_group, HIV-1 replication is an other_name, proviral induction is an other_name, monocytic cell lines is a cell_line
26038_task1
Sentence: C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines. Instructions: please typing these entity words according to sentence: C / EBP activators, HIV-1 replication, proviral induction, monocytic cell lines Options: protein_family_or_group, cell_line, other_name
[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "O" ]
C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines.
[ "C", "/", "EBP", "activators", "are", "required", "for", "HIV-1", "replication", "and", "proviral", "induction", "in", "monocytic", "cell", "lines", "." ]
[ "protein_family_or_group", "(AND other_name other_name)", "cell_line", "cell_type", "other_name", "protein_molecule", "virus", "DNA_domain_or_region", "", "RNA_family_or_group" ]
C / EBP activators, HIV-1 replication, proviral induction, monocytic cell lines
26038_task2
Sentence: C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines. Instructions: please extract entity words from the input sentence
[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "O" ]
C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines.
[ "C", "/", "EBP", "activators", "are", "required", "for", "HIV-1", "replication", "and", "proviral", "induction", "in", "monocytic", "cell", "lines", "." ]
[ "protein_family_or_group", "(AND other_name other_name)", "cell_line", "cell_type", "other_name", "protein_molecule", "virus", "DNA_domain_or_region", "", "RNA_family_or_group" ]
Diagnostik is an umlsterm, Therapie is an umlsterm, Dislokation is an umlsterm, Frakturmorphologie is an umlsterm, Techniken is an umlsterm, Schulterfunktion is an umlsterm, anatomiegerechter is an umlsterm, Knochenfragmente is an umlsterm, Patienten is an umlsterm, Schulterendoprothese is an umlsterm, Kopffragments is an umlsterm, Patienten is an umlsterm, Gelenkersatz is an umlsterm, Verhalten is an umlsterm, Schultersteife is an umlsterm, Dislokation is an umlsterm, unfallchirurgische is an umlsterm, Wiederherstellung is an umlsterm
Trauma+Berufskrankheit.0002s180.ger.abstr_task0
Sentence: Humeruskopffrakturen stellen eine Herausforderung an die Diagnostik und die Therapie dar . Gluecklicherweise koennen 70-80% davon konservativ behandelt werden , da sie nicht disloziert sind . Im Fall der Dislokation sind ein differenziertes Verstaendnis der Frakturmorphologie und der zielgerichtete Einsatz osteosynthetischer Techniken unabdingbare Voraussetzung einer guten Schulterfunktion . Ziel jedweder Behandlungsmassnahme ist das Erreichen einer stabilen Situation in moeglichst anatomiegerechter Position . Dies kann ueberwiegend mit minimalinvasiven Zugaengen bzw. unter Schonung der Knochenfragmente erreicht werden . Besonders im Fall der Humeruskopfimpressionsfrakturen ( > 45% ) beim haeufig betroffenen aelteren , aktiven Patienten sehen wir eine primaere Indikation zur Schulterendoprothese . Ebenso stellen die 4-Fragment-Frakturen mit Verschiebung des Kopffragments bei aelteren , biologisch aktiven Patienten eine gelegentliche Indikation zum primaeren Gelenkersatz dar . Sowohl fuer die konservativ als auch fuer die operativ behandelten Humeruskopffrakturen sollte ein differenziertes Nachbehandlungsschema Anwendung finden , um nicht durch zu passives Verhalten eine sekundaere Schultersteife zu initiieren . Auf der anderen Seite sollte ein Nachbehandlungsprogramm auch nicht zur sekundaeren Dislokation fuehren . Die unfallchirurgische Kontrolle der Behandlungsmassnahmen ist daher zwingende Voraussetzung einer bestmoeglichen Wiederherstellung der Funktion . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Humeruskopffrakturen stellen eine Herausforderung an die Diagnostik und die Therapie dar . Gluecklicherweise koennen 70-80% davon konservativ behandelt werden , da sie nicht disloziert sind . Im Fall der Dislokation sind ein differenziertes Verstaendnis der Frakturmorphologie und der zielgerichtete Einsatz osteosynthetischer Techniken unabdingbare Voraussetzung einer guten Schulterfunktion . Ziel jedweder Behandlungsmassnahme ist das Erreichen einer stabilen Situation in moeglichst anatomiegerechter Position . Dies kann ueberwiegend mit minimalinvasiven Zugaengen bzw. unter Schonung der Knochenfragmente erreicht werden . Besonders im Fall der Humeruskopfimpressionsfrakturen ( > 45% ) beim haeufig betroffenen aelteren , aktiven Patienten sehen wir eine primaere Indikation zur Schulterendoprothese . Ebenso stellen die 4-Fragment-Frakturen mit Verschiebung des Kopffragments bei aelteren , biologisch aktiven Patienten eine gelegentliche Indikation zum primaeren Gelenkersatz dar . Sowohl fuer die konservativ als auch fuer die operativ behandelten Humeruskopffrakturen sollte ein differenziertes Nachbehandlungsschema Anwendung finden , um nicht durch zu passives Verhalten eine sekundaere Schultersteife zu initiieren . Auf der anderen Seite sollte ein Nachbehandlungsprogramm auch nicht zur sekundaeren Dislokation fuehren . Die unfallchirurgische Kontrolle der Behandlungsmassnahmen ist daher zwingende Voraussetzung einer bestmoeglichen Wiederherstellung der Funktion .
[ "Humeruskopffrakturen", "stellen", "eine", "Herausforderung", "an", "die", "Diagnostik", "und", "die", "Therapie", "dar", ".", "Gluecklicherweise", "koennen", "70", "-", "80", "%", "davon", "konservativ", "behandelt", "werden", ",", "da", "sie", "nicht", "disloziert", "sind", ".", "Im", "Fall", "der", "Dislokation", "sind", "ein", "differenziertes", "Verstaendnis", "der", "Frakturmorphologie", "und", "der", "zielgerichtete", "Einsatz", "osteosynthetischer", "Techniken", "unabdingbare", "Voraussetzung", "einer", "guten", "Schulterfunktion", ".", "Ziel", "jedweder", "Behandlungsmassnahme", "ist", "das", "Erreichen", "einer", "stabilen", "Situation", "in", "moeglichst", "anatomiegerechter", "Position", ".", "Dies", "kann", "ueberwiegend", "mit", "minimalinvasiven", "Zugaengen", "bzw", ".", "unter", "Schonung", "der", "Knochenfragmente", "erreicht", "werden", ".", "Besonders", "im", "Fall", "der", "Humeruskopfimpressionsfrakturen", "(", ">", "45", "%", ")", "beim", "haeufig", "betroffenen", "aelteren", ",", "aktiven", "Patienten", "sehen", "wir", "eine", "primaere", "Indikation", "zur", "Schulterendoprothese", ".", "Ebenso", "stellen", "die", "4-Fragment", "-", "Frakturen", "mit", "Verschiebung", "des", "Kopffragments", "bei", "aelteren", ",", "biologisch", "aktiven", "Patienten", "eine", "gelegentliche", "Indikation", "zum", "primaeren", "Gelenkersatz", "dar", ".", "Sowohl", "fuer", "die", "konservativ", "als", "auch", "fuer", "die", "operativ", "behandelten", "Humeruskopffrakturen", "sollte", "ein", "differenziertes", "Nachbehandlungsschema", "Anwendung", "finden", ",", "um", "nicht", "durch", "zu", "passives", "Verhalten", "eine", "sekundaere", "Schultersteife", "zu", "initiieren", ".", "Auf", "der", "anderen", "Seite", "sollte", "ein", "Nachbehandlungsprogramm", "auch", "nicht", "zur", "sekundaeren", "Dislokation", "fuehren", ".", "Die", "unfallchirurgische", "Kontrolle", "der", "Behandlungsmassnahmen", "ist", "daher", "zwingende", "Voraussetzung", "einer", "bestmoeglichen", "Wiederherstellung", "der", "Funktion", "." ]
[ "umlsterm" ]
Diagnostik is an umlsterm, Therapie is an umlsterm, Dislokation is an umlsterm, Frakturmorphologie is an umlsterm, Techniken is an umlsterm, Schulterfunktion is an umlsterm, anatomiegerechter is an umlsterm, Knochenfragmente is an umlsterm, Patienten is an umlsterm, Schulterendoprothese is an umlsterm, Kopffragments is an umlsterm, Patienten is an umlsterm, Gelenkersatz is an umlsterm, Verhalten is an umlsterm, Schultersteife is an umlsterm, Dislokation is an umlsterm, unfallchirurgische is an umlsterm, Wiederherstellung is an umlsterm
Trauma+Berufskrankheit.0002s180.ger.abstr_task1
Sentence: Humeruskopffrakturen stellen eine Herausforderung an die Diagnostik und die Therapie dar . Gluecklicherweise koennen 70-80% davon konservativ behandelt werden , da sie nicht disloziert sind . Im Fall der Dislokation sind ein differenziertes Verstaendnis der Frakturmorphologie und der zielgerichtete Einsatz osteosynthetischer Techniken unabdingbare Voraussetzung einer guten Schulterfunktion . Ziel jedweder Behandlungsmassnahme ist das Erreichen einer stabilen Situation in moeglichst anatomiegerechter Position . Dies kann ueberwiegend mit minimalinvasiven Zugaengen bzw. unter Schonung der Knochenfragmente erreicht werden . Besonders im Fall der Humeruskopfimpressionsfrakturen ( > 45% ) beim haeufig betroffenen aelteren , aktiven Patienten sehen wir eine primaere Indikation zur Schulterendoprothese . Ebenso stellen die 4-Fragment-Frakturen mit Verschiebung des Kopffragments bei aelteren , biologisch aktiven Patienten eine gelegentliche Indikation zum primaeren Gelenkersatz dar . Sowohl fuer die konservativ als auch fuer die operativ behandelten Humeruskopffrakturen sollte ein differenziertes Nachbehandlungsschema Anwendung finden , um nicht durch zu passives Verhalten eine sekundaere Schultersteife zu initiieren . Auf der anderen Seite sollte ein Nachbehandlungsprogramm auch nicht zur sekundaeren Dislokation fuehren . Die unfallchirurgische Kontrolle der Behandlungsmassnahmen ist daher zwingende Voraussetzung einer bestmoeglichen Wiederherstellung der Funktion . Instructions: please typing these entity words according to sentence: Diagnostik, Therapie, Dislokation, Frakturmorphologie, Techniken, Schulterfunktion, anatomiegerechter, Knochenfragmente, Patienten, Schulterendoprothese, Kopffragments, Patienten, Gelenkersatz, Verhalten, Schultersteife, Dislokation, unfallchirurgische, Wiederherstellung Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Humeruskopffrakturen stellen eine Herausforderung an die Diagnostik und die Therapie dar . Gluecklicherweise koennen 70-80% davon konservativ behandelt werden , da sie nicht disloziert sind . Im Fall der Dislokation sind ein differenziertes Verstaendnis der Frakturmorphologie und der zielgerichtete Einsatz osteosynthetischer Techniken unabdingbare Voraussetzung einer guten Schulterfunktion . Ziel jedweder Behandlungsmassnahme ist das Erreichen einer stabilen Situation in moeglichst anatomiegerechter Position . Dies kann ueberwiegend mit minimalinvasiven Zugaengen bzw. unter Schonung der Knochenfragmente erreicht werden . Besonders im Fall der Humeruskopfimpressionsfrakturen ( > 45% ) beim haeufig betroffenen aelteren , aktiven Patienten sehen wir eine primaere Indikation zur Schulterendoprothese . Ebenso stellen die 4-Fragment-Frakturen mit Verschiebung des Kopffragments bei aelteren , biologisch aktiven Patienten eine gelegentliche Indikation zum primaeren Gelenkersatz dar . Sowohl fuer die konservativ als auch fuer die operativ behandelten Humeruskopffrakturen sollte ein differenziertes Nachbehandlungsschema Anwendung finden , um nicht durch zu passives Verhalten eine sekundaere Schultersteife zu initiieren . Auf der anderen Seite sollte ein Nachbehandlungsprogramm auch nicht zur sekundaeren Dislokation fuehren . Die unfallchirurgische Kontrolle der Behandlungsmassnahmen ist daher zwingende Voraussetzung einer bestmoeglichen Wiederherstellung der Funktion .
[ "Humeruskopffrakturen", "stellen", "eine", "Herausforderung", "an", "die", "Diagnostik", "und", "die", "Therapie", "dar", ".", "Gluecklicherweise", "koennen", "70", "-", "80", "%", "davon", "konservativ", "behandelt", "werden", ",", "da", "sie", "nicht", "disloziert", "sind", ".", "Im", "Fall", "der", "Dislokation", "sind", "ein", "differenziertes", "Verstaendnis", "der", "Frakturmorphologie", "und", "der", "zielgerichtete", "Einsatz", "osteosynthetischer", "Techniken", "unabdingbare", "Voraussetzung", "einer", "guten", "Schulterfunktion", ".", "Ziel", "jedweder", "Behandlungsmassnahme", "ist", "das", "Erreichen", "einer", "stabilen", "Situation", "in", "moeglichst", "anatomiegerechter", "Position", ".", "Dies", "kann", "ueberwiegend", "mit", "minimalinvasiven", "Zugaengen", "bzw", ".", "unter", "Schonung", "der", "Knochenfragmente", "erreicht", "werden", ".", "Besonders", "im", "Fall", "der", "Humeruskopfimpressionsfrakturen", "(", ">", "45", "%", ")", "beim", "haeufig", "betroffenen", "aelteren", ",", "aktiven", "Patienten", "sehen", "wir", "eine", "primaere", "Indikation", "zur", "Schulterendoprothese", ".", "Ebenso", "stellen", "die", "4-Fragment", "-", "Frakturen", "mit", "Verschiebung", "des", "Kopffragments", "bei", "aelteren", ",", "biologisch", "aktiven", "Patienten", "eine", "gelegentliche", "Indikation", "zum", "primaeren", "Gelenkersatz", "dar", ".", "Sowohl", "fuer", "die", "konservativ", "als", "auch", "fuer", "die", "operativ", "behandelten", "Humeruskopffrakturen", "sollte", "ein", "differenziertes", "Nachbehandlungsschema", "Anwendung", "finden", ",", "um", "nicht", "durch", "zu", "passives", "Verhalten", "eine", "sekundaere", "Schultersteife", "zu", "initiieren", ".", "Auf", "der", "anderen", "Seite", "sollte", "ein", "Nachbehandlungsprogramm", "auch", "nicht", "zur", "sekundaeren", "Dislokation", "fuehren", ".", "Die", "unfallchirurgische", "Kontrolle", "der", "Behandlungsmassnahmen", "ist", "daher", "zwingende", "Voraussetzung", "einer", "bestmoeglichen", "Wiederherstellung", "der", "Funktion", "." ]
[ "umlsterm" ]
Diagnostik, Therapie, Dislokation, Frakturmorphologie, Techniken, Schulterfunktion, anatomiegerechter, Knochenfragmente, Patienten, Schulterendoprothese, Kopffragments, Patienten, Gelenkersatz, Verhalten, Schultersteife, Dislokation, unfallchirurgische, Wiederherstellung
Trauma+Berufskrankheit.0002s180.ger.abstr_task2
Sentence: Humeruskopffrakturen stellen eine Herausforderung an die Diagnostik und die Therapie dar . Gluecklicherweise koennen 70-80% davon konservativ behandelt werden , da sie nicht disloziert sind . Im Fall der Dislokation sind ein differenziertes Verstaendnis der Frakturmorphologie und der zielgerichtete Einsatz osteosynthetischer Techniken unabdingbare Voraussetzung einer guten Schulterfunktion . Ziel jedweder Behandlungsmassnahme ist das Erreichen einer stabilen Situation in moeglichst anatomiegerechter Position . Dies kann ueberwiegend mit minimalinvasiven Zugaengen bzw. unter Schonung der Knochenfragmente erreicht werden . Besonders im Fall der Humeruskopfimpressionsfrakturen ( > 45% ) beim haeufig betroffenen aelteren , aktiven Patienten sehen wir eine primaere Indikation zur Schulterendoprothese . Ebenso stellen die 4-Fragment-Frakturen mit Verschiebung des Kopffragments bei aelteren , biologisch aktiven Patienten eine gelegentliche Indikation zum primaeren Gelenkersatz dar . Sowohl fuer die konservativ als auch fuer die operativ behandelten Humeruskopffrakturen sollte ein differenziertes Nachbehandlungsschema Anwendung finden , um nicht durch zu passives Verhalten eine sekundaere Schultersteife zu initiieren . Auf der anderen Seite sollte ein Nachbehandlungsprogramm auch nicht zur sekundaeren Dislokation fuehren . Die unfallchirurgische Kontrolle der Behandlungsmassnahmen ist daher zwingende Voraussetzung einer bestmoeglichen Wiederherstellung der Funktion . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Humeruskopffrakturen stellen eine Herausforderung an die Diagnostik und die Therapie dar . Gluecklicherweise koennen 70-80% davon konservativ behandelt werden , da sie nicht disloziert sind . Im Fall der Dislokation sind ein differenziertes Verstaendnis der Frakturmorphologie und der zielgerichtete Einsatz osteosynthetischer Techniken unabdingbare Voraussetzung einer guten Schulterfunktion . Ziel jedweder Behandlungsmassnahme ist das Erreichen einer stabilen Situation in moeglichst anatomiegerechter Position . Dies kann ueberwiegend mit minimalinvasiven Zugaengen bzw. unter Schonung der Knochenfragmente erreicht werden . Besonders im Fall der Humeruskopfimpressionsfrakturen ( > 45% ) beim haeufig betroffenen aelteren , aktiven Patienten sehen wir eine primaere Indikation zur Schulterendoprothese . Ebenso stellen die 4-Fragment-Frakturen mit Verschiebung des Kopffragments bei aelteren , biologisch aktiven Patienten eine gelegentliche Indikation zum primaeren Gelenkersatz dar . Sowohl fuer die konservativ als auch fuer die operativ behandelten Humeruskopffrakturen sollte ein differenziertes Nachbehandlungsschema Anwendung finden , um nicht durch zu passives Verhalten eine sekundaere Schultersteife zu initiieren . Auf der anderen Seite sollte ein Nachbehandlungsprogramm auch nicht zur sekundaeren Dislokation fuehren . Die unfallchirurgische Kontrolle der Behandlungsmassnahmen ist daher zwingende Voraussetzung einer bestmoeglichen Wiederherstellung der Funktion .
[ "Humeruskopffrakturen", "stellen", "eine", "Herausforderung", "an", "die", "Diagnostik", "und", "die", "Therapie", "dar", ".", "Gluecklicherweise", "koennen", "70", "-", "80", "%", "davon", "konservativ", "behandelt", "werden", ",", "da", "sie", "nicht", "disloziert", "sind", ".", "Im", "Fall", "der", "Dislokation", "sind", "ein", "differenziertes", "Verstaendnis", "der", "Frakturmorphologie", "und", "der", "zielgerichtete", "Einsatz", "osteosynthetischer", "Techniken", "unabdingbare", "Voraussetzung", "einer", "guten", "Schulterfunktion", ".", "Ziel", "jedweder", "Behandlungsmassnahme", "ist", "das", "Erreichen", "einer", "stabilen", "Situation", "in", "moeglichst", "anatomiegerechter", "Position", ".", "Dies", "kann", "ueberwiegend", "mit", "minimalinvasiven", "Zugaengen", "bzw", ".", "unter", "Schonung", "der", "Knochenfragmente", "erreicht", "werden", ".", "Besonders", "im", "Fall", "der", "Humeruskopfimpressionsfrakturen", "(", ">", "45", "%", ")", "beim", "haeufig", "betroffenen", "aelteren", ",", "aktiven", "Patienten", "sehen", "wir", "eine", "primaere", "Indikation", "zur", "Schulterendoprothese", ".", "Ebenso", "stellen", "die", "4-Fragment", "-", "Frakturen", "mit", "Verschiebung", "des", "Kopffragments", "bei", "aelteren", ",", "biologisch", "aktiven", "Patienten", "eine", "gelegentliche", "Indikation", "zum", "primaeren", "Gelenkersatz", "dar", ".", "Sowohl", "fuer", "die", "konservativ", "als", "auch", "fuer", "die", "operativ", "behandelten", "Humeruskopffrakturen", "sollte", "ein", "differenziertes", "Nachbehandlungsschema", "Anwendung", "finden", ",", "um", "nicht", "durch", "zu", "passives", "Verhalten", "eine", "sekundaere", "Schultersteife", "zu", "initiieren", ".", "Auf", "der", "anderen", "Seite", "sollte", "ein", "Nachbehandlungsprogramm", "auch", "nicht", "zur", "sekundaeren", "Dislokation", "fuehren", ".", "Die", "unfallchirurgische", "Kontrolle", "der", "Behandlungsmassnahmen", "ist", "daher", "zwingende", "Voraussetzung", "einer", "bestmoeglichen", "Wiederherstellung", "der", "Funktion", "." ]
[ "umlsterm" ]
trauma is an umlsterm, retrospective study is an umlsterm, incidence is an umlsterm, trauma is an umlsterm, trauma is an umlsterm, patients is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, children is an umlsterm, trauma is an umlsterm, Patients is an umlsterm, paracentesis is an umlsterm, ultrasonography is an umlsterm, analysis is an umlsterm, urography is an umlsterm, CT scan is an umlsterm, angiography is an umlsterm, Injury is an umlsterm, Scale is an umlsterm, classification is an umlsterm, trauma is an umlsterm
DerUrologeA.00390425.eng.abstr_task0
Sentence: Renal lesions are frequently encountered in blunt pediatric abdominal trauma . In this retrospective study , we analyzed the incidence of renal trauma in these trauma patients to determine which diagnostic and therapeutic approaches were most predictive . From 1976 to 1996 , 308 children sustaining blunt abdominal trauma were admitted to our department . Patients were evaluated using abdominal paracentesis , ultrasonography , and urinary analysis . In specific cases , IV urography , CT scan , and/or angiography were applied . We used the Organ Injury Scale ( OIS ) for classification of renal trauma into five grades . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Renal lesions are frequently encountered in blunt pediatric abdominal trauma . In this retrospective study , we analyzed the incidence of renal trauma in these trauma patients to determine which diagnostic and therapeutic approaches were most predictive . From 1976 to 1996 , 308 children sustaining blunt abdominal trauma were admitted to our department . Patients were evaluated using abdominal paracentesis , ultrasonography , and urinary analysis . In specific cases , IV urography , CT scan , and/or angiography were applied . We used the Organ Injury Scale ( OIS ) for classification of renal trauma into five grades .
[ "Renal", "lesions", "are", "frequently", "encountered", "in", "blunt", "pediatric", "abdominal", "trauma", ".", "In", "this", "retrospective", "study", ",", "we", "analyzed", "the", "incidence", "of", "renal", "trauma", "in", "these", "trauma", "patients", "to", "determine", "which", "diagnostic", "and", "therapeutic", "approaches", "were", "most", "predictive", ".", "From", "1976", "to", "1996", ",", "308", "children", "sustaining", "blunt", "abdominal", "trauma", "were", "admitted", "to", "our", "department", ".", "Patients", "were", "evaluated", "using", "abdominal", "paracentesis", ",", "ultrasonography", ",", "and", "urinary", "analysis", ".", "In", "specific", "cases", ",", "IV", "urography", ",", "CT", "scan", ",", "and", "/", "or", "angiography", "were", "applied", ".", "We", "used", "the", "Organ", "Injury", "Scale", "(", "OIS", ")", "for", "classification", "of", "renal", "trauma", "into", "five", "grades", "." ]
[ "umlsterm" ]
trauma is an umlsterm, retrospective study is an umlsterm, incidence is an umlsterm, trauma is an umlsterm, trauma is an umlsterm, patients is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, children is an umlsterm, trauma is an umlsterm, Patients is an umlsterm, paracentesis is an umlsterm, ultrasonography is an umlsterm, analysis is an umlsterm, urography is an umlsterm, CT scan is an umlsterm, angiography is an umlsterm, Injury is an umlsterm, Scale is an umlsterm, classification is an umlsterm, trauma is an umlsterm
DerUrologeA.00390425.eng.abstr_task1
Sentence: Renal lesions are frequently encountered in blunt pediatric abdominal trauma . In this retrospective study , we analyzed the incidence of renal trauma in these trauma patients to determine which diagnostic and therapeutic approaches were most predictive . From 1976 to 1996 , 308 children sustaining blunt abdominal trauma were admitted to our department . Patients were evaluated using abdominal paracentesis , ultrasonography , and urinary analysis . In specific cases , IV urography , CT scan , and/or angiography were applied . We used the Organ Injury Scale ( OIS ) for classification of renal trauma into five grades . Instructions: please typing these entity words according to sentence: trauma, retrospective study, incidence, trauma, trauma, patients, diagnostic, therapeutic, children, trauma, Patients, paracentesis, ultrasonography, analysis, urography, CT scan, angiography, Injury, Scale, classification, trauma Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Renal lesions are frequently encountered in blunt pediatric abdominal trauma . In this retrospective study , we analyzed the incidence of renal trauma in these trauma patients to determine which diagnostic and therapeutic approaches were most predictive . From 1976 to 1996 , 308 children sustaining blunt abdominal trauma were admitted to our department . Patients were evaluated using abdominal paracentesis , ultrasonography , and urinary analysis . In specific cases , IV urography , CT scan , and/or angiography were applied . We used the Organ Injury Scale ( OIS ) for classification of renal trauma into five grades .
[ "Renal", "lesions", "are", "frequently", "encountered", "in", "blunt", "pediatric", "abdominal", "trauma", ".", "In", "this", "retrospective", "study", ",", "we", "analyzed", "the", "incidence", "of", "renal", "trauma", "in", "these", "trauma", "patients", "to", "determine", "which", "diagnostic", "and", "therapeutic", "approaches", "were", "most", "predictive", ".", "From", "1976", "to", "1996", ",", "308", "children", "sustaining", "blunt", "abdominal", "trauma", "were", "admitted", "to", "our", "department", ".", "Patients", "were", "evaluated", "using", "abdominal", "paracentesis", ",", "ultrasonography", ",", "and", "urinary", "analysis", ".", "In", "specific", "cases", ",", "IV", "urography", ",", "CT", "scan", ",", "and", "/", "or", "angiography", "were", "applied", ".", "We", "used", "the", "Organ", "Injury", "Scale", "(", "OIS", ")", "for", "classification", "of", "renal", "trauma", "into", "five", "grades", "." ]
[ "umlsterm" ]
trauma, retrospective study, incidence, trauma, trauma, patients, diagnostic, therapeutic, children, trauma, Patients, paracentesis, ultrasonography, analysis, urography, CT scan, angiography, Injury, Scale, classification, trauma
DerUrologeA.00390425.eng.abstr_task2
Sentence: Renal lesions are frequently encountered in blunt pediatric abdominal trauma . In this retrospective study , we analyzed the incidence of renal trauma in these trauma patients to determine which diagnostic and therapeutic approaches were most predictive . From 1976 to 1996 , 308 children sustaining blunt abdominal trauma were admitted to our department . Patients were evaluated using abdominal paracentesis , ultrasonography , and urinary analysis . In specific cases , IV urography , CT scan , and/or angiography were applied . We used the Organ Injury Scale ( OIS ) for classification of renal trauma into five grades . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Renal lesions are frequently encountered in blunt pediatric abdominal trauma . In this retrospective study , we analyzed the incidence of renal trauma in these trauma patients to determine which diagnostic and therapeutic approaches were most predictive . From 1976 to 1996 , 308 children sustaining blunt abdominal trauma were admitted to our department . Patients were evaluated using abdominal paracentesis , ultrasonography , and urinary analysis . In specific cases , IV urography , CT scan , and/or angiography were applied . We used the Organ Injury Scale ( OIS ) for classification of renal trauma into five grades .
[ "Renal", "lesions", "are", "frequently", "encountered", "in", "blunt", "pediatric", "abdominal", "trauma", ".", "In", "this", "retrospective", "study", ",", "we", "analyzed", "the", "incidence", "of", "renal", "trauma", "in", "these", "trauma", "patients", "to", "determine", "which", "diagnostic", "and", "therapeutic", "approaches", "were", "most", "predictive", ".", "From", "1976", "to", "1996", ",", "308", "children", "sustaining", "blunt", "abdominal", "trauma", "were", "admitted", "to", "our", "department", ".", "Patients", "were", "evaluated", "using", "abdominal", "paracentesis", ",", "ultrasonography", ",", "and", "urinary", "analysis", ".", "In", "specific", "cases", ",", "IV", "urography", ",", "CT", "scan", ",", "and", "/", "or", "angiography", "were", "applied", ".", "We", "used", "the", "Organ", "Injury", "Scale", "(", "OIS", ")", "for", "classification", "of", "renal", "trauma", "into", "five", "grades", "." ]
[ "umlsterm" ]
IL-4 is a Protein, IL-4 is a Protein, IL-2 is a Protein, CD4 is a Protein, IL-4 is a Protein, IL-2 is a Protein, P0 is a Entity, P1 NFAT - binding elements is a Entity, IL-4 is a Protein, promoter is a Entity, IL-4 is a Protein, promoter is a Entity, CD4 is a Protein, NFAT1 is a Protein, CD4 is a Protein, NFAT1 is a Protein, IL-4 is a Protein, promoter is a Entity, CD4 is a Protein, NFAT1 is a Protein, IL-4 is a Protein, NFAT1 is a Protein, IL-4 is a Protein, promoter is a Entity, CD4 is a Protein, IL-4 is a Protein, NFAT1 is a Protein, IL-4 is a Protein, CD4 is a Protein
901_task0
Sentence: T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells. The repetitive activation of T cells (priming) enhances the expression of many cytokines, such as IL-4, but not others, such as IL-2. Molecular mechanisms underlying selective expression of cytokines by T cells remain poorly understood. Here we show that priming of CD4 T cells selectively enhances IL-4 expression relative to IL-2 expression by a transcriptional mechanism involving nuclear factor of activated T cells (NFAT) proteins. As detected by in vivo footprinting, priming markedly increases the activation-dependent engagement of the P0 and P1 NFAT-binding elements of the IL-4 promoter. Moreover, each proximal P element is essential for optimal IL-4 promoter activity. Activated primed CD4 T cells contain more NFAT1 and support greater NFAT-directed transcription than unprimed CD4 T cells, while activator protein 1 binding and activator protein 1-mediated transcription by both cell types is similar. Increased expression of wild-type NFAT1 substantially increases IL-4 promoter activity in unprimed CD4 T cells, suggesting NFAT1 may be limiting for IL-4 gene expression in this cell type. Furthermore, a truncated form of NFAT1 acts as a dominant-negative, reducing IL-4 promoter activity in primed CD4 T cells and confirming the importance of endogenous NFAT to increased IL-4 gene expression by effector T cells. NFAT1 appears to be the major NFAT family member responsible for the initial increased expression of IL-4 by primed CD4 T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O" ]
T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells. The repetitive activation of T cells (priming) enhances the expression of many cytokines, such as IL-4, but not others, such as IL-2. Molecular mechanisms underlying selective expression of cytokines by T cells remain poorly understood. Here we show that priming of CD4 T cells selectively enhances IL-4 expression relative to IL-2 expression by a transcriptional mechanism involving nuclear factor of activated T cells (NFAT) proteins. As detected by in vivo footprinting, priming markedly increases the activation-dependent engagement of the P0 and P1 NFAT-binding elements of the IL-4 promoter. Moreover, each proximal P element is essential for optimal IL-4 promoter activity. Activated primed CD4 T cells contain more NFAT1 and support greater NFAT-directed transcription than unprimed CD4 T cells, while activator protein 1 binding and activator protein 1-mediated transcription by both cell types is similar. Increased expression of wild-type NFAT1 substantially increases IL-4 promoter activity in unprimed CD4 T cells, suggesting NFAT1 may be limiting for IL-4 gene expression in this cell type. Furthermore, a truncated form of NFAT1 acts as a dominant-negative, reducing IL-4 promoter activity in primed CD4 T cells and confirming the importance of endogenous NFAT to increased IL-4 gene expression by effector T cells. NFAT1 appears to be the major NFAT family member responsible for the initial increased expression of IL-4 by primed CD4 T cells.
[ "T", "cell", "priming", "enhances", "IL-4", "gene", "expression", "by", "increasing", "nuclear", "factor", "of", "activated", "T", "cells", ".", "\n", "The", "repetitive", "activation", "of", "T", "cells", "(", "priming", ")", "enhances", "the", "expression", "of", "many", "cytokines", ",", "such", "as", "IL-4", ",", "but", "not", "others", ",", "such", "as", "IL-2", ".", "Molecular", "mechanisms", "underlying", "selective", "expression", "of", "cytokines", "by", "T", "cells", "remain", "poorly", "understood", ".", "Here", "we", "show", "that", "priming", "of", "CD4", "T", "cells", "selectively", "enhances", "IL-4", "expression", "relative", "to", "IL-2", "expression", "by", "a", "transcriptional", "mechanism", "involving", "nuclear", "factor", "of", "activated", "T", "cells", "(", "NFAT", ")", "proteins", ".", "As", "detected", "by", "in", "vivo", "footprinting", ",", "priming", "markedly", "increases", "the", "activation", "-", "dependent", "engagement", "of", "the", "P0", "and", "P1", "NFAT", "-", "binding", "elements", "of", "the", "IL-4", "promoter", ".", "Moreover", ",", "each", "proximal", "P", "element", "is", "essential", "for", "optimal", "IL-4", "promoter", "activity", ".", "Activated", "primed", "CD4", "T", "cells", "contain", "more", "NFAT1", "and", "support", "greater", "NFAT", "-", "directed", "transcription", "than", "unprimed", "CD4", "T", "cells", ",", "while", "activator", "protein", "1", "binding", "and", "activator", "protein", "1-mediated", "transcription", "by", "both", "cell", "types", "is", "similar", ".", "Increased", "expression", "of", "wild", "-", "type", "NFAT1", "substantially", "increases", "IL-4", "promoter", "activity", "in", "unprimed", "CD4", "T", "cells", ",", "suggesting", "NFAT1", "may", "be", "limiting", "for", "IL-4", "gene", "expression", "in", "this", "cell", "type", ".", "Furthermore", ",", "a", "truncated", "form", "of", "NFAT1", "acts", "as", "a", "dominant", "-", "negative", ",", "reducing", "IL-4", "promoter", "activity", "in", "primed", "CD4", "T", "cells", "and", "confirming", "the", "importance", "of", "endogenous", "NFAT", "to", "increased", "IL-4", "gene", "expression", "by", "effector", "T", "cells", ".", "NFAT1", "appears", "to", "be", "the", "major", "NFAT", "family", "member", "responsible", "for", "the", "initial", "increased", "expression", "of", "IL-4", "by", "primed", "CD4", "T", "cells", "." ]
[ "Entity", "Protein" ]
IL-4 is a Protein, IL-4 is a Protein, IL-2 is a Protein, CD4 is a Protein, IL-4 is a Protein, IL-2 is a Protein, P0 is a Entity, P1 NFAT - binding elements is a Entity, IL-4 is a Protein, promoter is a Entity, IL-4 is a Protein, promoter is a Entity, CD4 is a Protein, NFAT1 is a Protein, CD4 is a Protein, NFAT1 is a Protein, IL-4 is a Protein, promoter is a Entity, CD4 is a Protein, NFAT1 is a Protein, IL-4 is a Protein, NFAT1 is a Protein, IL-4 is a Protein, promoter is a Entity, CD4 is a Protein, IL-4 is a Protein, NFAT1 is a Protein, IL-4 is a Protein, CD4 is a Protein
901_task1
Sentence: T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells. The repetitive activation of T cells (priming) enhances the expression of many cytokines, such as IL-4, but not others, such as IL-2. Molecular mechanisms underlying selective expression of cytokines by T cells remain poorly understood. Here we show that priming of CD4 T cells selectively enhances IL-4 expression relative to IL-2 expression by a transcriptional mechanism involving nuclear factor of activated T cells (NFAT) proteins. As detected by in vivo footprinting, priming markedly increases the activation-dependent engagement of the P0 and P1 NFAT-binding elements of the IL-4 promoter. Moreover, each proximal P element is essential for optimal IL-4 promoter activity. Activated primed CD4 T cells contain more NFAT1 and support greater NFAT-directed transcription than unprimed CD4 T cells, while activator protein 1 binding and activator protein 1-mediated transcription by both cell types is similar. Increased expression of wild-type NFAT1 substantially increases IL-4 promoter activity in unprimed CD4 T cells, suggesting NFAT1 may be limiting for IL-4 gene expression in this cell type. Furthermore, a truncated form of NFAT1 acts as a dominant-negative, reducing IL-4 promoter activity in primed CD4 T cells and confirming the importance of endogenous NFAT to increased IL-4 gene expression by effector T cells. NFAT1 appears to be the major NFAT family member responsible for the initial increased expression of IL-4 by primed CD4 T cells. Instructions: please typing these entity words according to sentence: IL-4, IL-4, IL-2, CD4, IL-4, IL-2, P0, P1 NFAT - binding elements, IL-4, promoter, IL-4, promoter, CD4, NFAT1, CD4, NFAT1, IL-4, promoter, CD4, NFAT1, IL-4, NFAT1, IL-4, promoter, CD4, IL-4, NFAT1, IL-4, CD4 Options: Entity, Protein
[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O" ]
T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells. The repetitive activation of T cells (priming) enhances the expression of many cytokines, such as IL-4, but not others, such as IL-2. Molecular mechanisms underlying selective expression of cytokines by T cells remain poorly understood. Here we show that priming of CD4 T cells selectively enhances IL-4 expression relative to IL-2 expression by a transcriptional mechanism involving nuclear factor of activated T cells (NFAT) proteins. As detected by in vivo footprinting, priming markedly increases the activation-dependent engagement of the P0 and P1 NFAT-binding elements of the IL-4 promoter. Moreover, each proximal P element is essential for optimal IL-4 promoter activity. Activated primed CD4 T cells contain more NFAT1 and support greater NFAT-directed transcription than unprimed CD4 T cells, while activator protein 1 binding and activator protein 1-mediated transcription by both cell types is similar. Increased expression of wild-type NFAT1 substantially increases IL-4 promoter activity in unprimed CD4 T cells, suggesting NFAT1 may be limiting for IL-4 gene expression in this cell type. Furthermore, a truncated form of NFAT1 acts as a dominant-negative, reducing IL-4 promoter activity in primed CD4 T cells and confirming the importance of endogenous NFAT to increased IL-4 gene expression by effector T cells. NFAT1 appears to be the major NFAT family member responsible for the initial increased expression of IL-4 by primed CD4 T cells.
[ "T", "cell", "priming", "enhances", "IL-4", "gene", "expression", "by", "increasing", "nuclear", "factor", "of", "activated", "T", "cells", ".", "\n", "The", "repetitive", "activation", "of", "T", "cells", "(", "priming", ")", "enhances", "the", "expression", "of", "many", "cytokines", ",", "such", "as", "IL-4", ",", "but", "not", "others", ",", "such", "as", "IL-2", ".", "Molecular", "mechanisms", "underlying", "selective", "expression", "of", "cytokines", "by", "T", "cells", "remain", "poorly", "understood", ".", "Here", "we", "show", "that", "priming", "of", "CD4", "T", "cells", "selectively", "enhances", "IL-4", "expression", "relative", "to", "IL-2", "expression", "by", "a", "transcriptional", "mechanism", "involving", "nuclear", "factor", "of", "activated", "T", "cells", "(", "NFAT", ")", "proteins", ".", "As", "detected", "by", "in", "vivo", "footprinting", ",", "priming", "markedly", "increases", "the", "activation", "-", "dependent", "engagement", "of", "the", "P0", "and", "P1", "NFAT", "-", "binding", "elements", "of", "the", "IL-4", "promoter", ".", "Moreover", ",", "each", "proximal", "P", "element", "is", "essential", "for", "optimal", "IL-4", "promoter", "activity", ".", "Activated", "primed", "CD4", "T", "cells", "contain", "more", "NFAT1", "and", "support", "greater", "NFAT", "-", "directed", "transcription", "than", "unprimed", "CD4", "T", "cells", ",", "while", "activator", "protein", "1", "binding", "and", "activator", "protein", "1-mediated", "transcription", "by", "both", "cell", "types", "is", "similar", ".", "Increased", "expression", "of", "wild", "-", "type", "NFAT1", "substantially", "increases", "IL-4", "promoter", "activity", "in", "unprimed", "CD4", "T", "cells", ",", "suggesting", "NFAT1", "may", "be", "limiting", "for", "IL-4", "gene", "expression", "in", "this", "cell", "type", ".", "Furthermore", ",", "a", "truncated", "form", "of", "NFAT1", "acts", "as", "a", "dominant", "-", "negative", ",", "reducing", "IL-4", "promoter", "activity", "in", "primed", "CD4", "T", "cells", "and", "confirming", "the", "importance", "of", "endogenous", "NFAT", "to", "increased", "IL-4", "gene", "expression", "by", "effector", "T", "cells", ".", "NFAT1", "appears", "to", "be", "the", "major", "NFAT", "family", "member", "responsible", "for", "the", "initial", "increased", "expression", "of", "IL-4", "by", "primed", "CD4", "T", "cells", "." ]
[ "Entity", "Protein" ]
IL-4, IL-4, IL-2, CD4, IL-4, IL-2, P0, P1 NFAT - binding elements, IL-4, promoter, IL-4, promoter, CD4, NFAT1, CD4, NFAT1, IL-4, promoter, CD4, NFAT1, IL-4, NFAT1, IL-4, promoter, CD4, IL-4, NFAT1, IL-4, CD4
901_task2
Sentence: T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells. The repetitive activation of T cells (priming) enhances the expression of many cytokines, such as IL-4, but not others, such as IL-2. Molecular mechanisms underlying selective expression of cytokines by T cells remain poorly understood. Here we show that priming of CD4 T cells selectively enhances IL-4 expression relative to IL-2 expression by a transcriptional mechanism involving nuclear factor of activated T cells (NFAT) proteins. As detected by in vivo footprinting, priming markedly increases the activation-dependent engagement of the P0 and P1 NFAT-binding elements of the IL-4 promoter. Moreover, each proximal P element is essential for optimal IL-4 promoter activity. Activated primed CD4 T cells contain more NFAT1 and support greater NFAT-directed transcription than unprimed CD4 T cells, while activator protein 1 binding and activator protein 1-mediated transcription by both cell types is similar. Increased expression of wild-type NFAT1 substantially increases IL-4 promoter activity in unprimed CD4 T cells, suggesting NFAT1 may be limiting for IL-4 gene expression in this cell type. Furthermore, a truncated form of NFAT1 acts as a dominant-negative, reducing IL-4 promoter activity in primed CD4 T cells and confirming the importance of endogenous NFAT to increased IL-4 gene expression by effector T cells. NFAT1 appears to be the major NFAT family member responsible for the initial increased expression of IL-4 by primed CD4 T cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O" ]
T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells. The repetitive activation of T cells (priming) enhances the expression of many cytokines, such as IL-4, but not others, such as IL-2. Molecular mechanisms underlying selective expression of cytokines by T cells remain poorly understood. Here we show that priming of CD4 T cells selectively enhances IL-4 expression relative to IL-2 expression by a transcriptional mechanism involving nuclear factor of activated T cells (NFAT) proteins. As detected by in vivo footprinting, priming markedly increases the activation-dependent engagement of the P0 and P1 NFAT-binding elements of the IL-4 promoter. Moreover, each proximal P element is essential for optimal IL-4 promoter activity. Activated primed CD4 T cells contain more NFAT1 and support greater NFAT-directed transcription than unprimed CD4 T cells, while activator protein 1 binding and activator protein 1-mediated transcription by both cell types is similar. Increased expression of wild-type NFAT1 substantially increases IL-4 promoter activity in unprimed CD4 T cells, suggesting NFAT1 may be limiting for IL-4 gene expression in this cell type. Furthermore, a truncated form of NFAT1 acts as a dominant-negative, reducing IL-4 promoter activity in primed CD4 T cells and confirming the importance of endogenous NFAT to increased IL-4 gene expression by effector T cells. NFAT1 appears to be the major NFAT family member responsible for the initial increased expression of IL-4 by primed CD4 T cells.
[ "T", "cell", "priming", "enhances", "IL-4", "gene", "expression", "by", "increasing", "nuclear", "factor", "of", "activated", "T", "cells", ".", "\n", "The", "repetitive", "activation", "of", "T", "cells", "(", "priming", ")", "enhances", "the", "expression", "of", "many", "cytokines", ",", "such", "as", "IL-4", ",", "but", "not", "others", ",", "such", "as", "IL-2", ".", "Molecular", "mechanisms", "underlying", "selective", "expression", "of", "cytokines", "by", "T", "cells", "remain", "poorly", "understood", ".", "Here", "we", "show", "that", "priming", "of", "CD4", "T", "cells", "selectively", "enhances", "IL-4", "expression", "relative", "to", "IL-2", "expression", "by", "a", "transcriptional", "mechanism", "involving", "nuclear", "factor", "of", "activated", "T", "cells", "(", "NFAT", ")", "proteins", ".", "As", "detected", "by", "in", "vivo", "footprinting", ",", "priming", "markedly", "increases", "the", "activation", "-", "dependent", "engagement", "of", "the", "P0", "and", "P1", "NFAT", "-", "binding", "elements", "of", "the", "IL-4", "promoter", ".", "Moreover", ",", "each", "proximal", "P", "element", "is", "essential", "for", "optimal", "IL-4", "promoter", "activity", ".", "Activated", "primed", "CD4", "T", "cells", "contain", "more", "NFAT1", "and", "support", "greater", "NFAT", "-", "directed", "transcription", "than", "unprimed", "CD4", "T", "cells", ",", "while", "activator", "protein", "1", "binding", "and", "activator", "protein", "1-mediated", "transcription", "by", "both", "cell", "types", "is", "similar", ".", "Increased", "expression", "of", "wild", "-", "type", "NFAT1", "substantially", "increases", "IL-4", "promoter", "activity", "in", "unprimed", "CD4", "T", "cells", ",", "suggesting", "NFAT1", "may", "be", "limiting", "for", "IL-4", "gene", "expression", "in", "this", "cell", "type", ".", "Furthermore", ",", "a", "truncated", "form", "of", "NFAT1", "acts", "as", "a", "dominant", "-", "negative", ",", "reducing", "IL-4", "promoter", "activity", "in", "primed", "CD4", "T", "cells", "and", "confirming", "the", "importance", "of", "endogenous", "NFAT", "to", "increased", "IL-4", "gene", "expression", "by", "effector", "T", "cells", ".", "NFAT1", "appears", "to", "be", "the", "major", "NFAT", "family", "member", "responsible", "for", "the", "initial", "increased", "expression", "of", "IL-4", "by", "primed", "CD4", "T", "cells", "." ]
[ "Entity", "Protein" ]
Muskelschwaeche is an umlsterm, Intensivpatienten is an umlsterm, Intensivbehandlung is an umlsterm
DerAnaesthesist.70460211.ger.abstr_task0
Sentence: Die prolongierte Muskelschwaeche bei Intensivpatienten kann die Entwoehnung von der Beatmung verzoegern und auf diese Weise die Dauer der Intensivbehandlung verlaengern . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Die prolongierte Muskelschwaeche bei Intensivpatienten kann die Entwoehnung von der Beatmung verzoegern und auf diese Weise die Dauer der Intensivbehandlung verlaengern .
[ "Die", "prolongierte", "Muskelschwaeche", "bei", "Intensivpatienten", "kann", "die", "Entwoehnung", "von", "der", "Beatmung", "verzoegern", "und", "auf", "diese", "Weise", "die", "Dauer", "der", "Intensivbehandlung", "verlaengern", "." ]
[ "umlsterm" ]
Muskelschwaeche is an umlsterm, Intensivpatienten is an umlsterm, Intensivbehandlung is an umlsterm
DerAnaesthesist.70460211.ger.abstr_task1
Sentence: Die prolongierte Muskelschwaeche bei Intensivpatienten kann die Entwoehnung von der Beatmung verzoegern und auf diese Weise die Dauer der Intensivbehandlung verlaengern . Instructions: please typing these entity words according to sentence: Muskelschwaeche, Intensivpatienten, Intensivbehandlung Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Die prolongierte Muskelschwaeche bei Intensivpatienten kann die Entwoehnung von der Beatmung verzoegern und auf diese Weise die Dauer der Intensivbehandlung verlaengern .
[ "Die", "prolongierte", "Muskelschwaeche", "bei", "Intensivpatienten", "kann", "die", "Entwoehnung", "von", "der", "Beatmung", "verzoegern", "und", "auf", "diese", "Weise", "die", "Dauer", "der", "Intensivbehandlung", "verlaengern", "." ]
[ "umlsterm" ]
Muskelschwaeche, Intensivpatienten, Intensivbehandlung
DerAnaesthesist.70460211.ger.abstr_task2
Sentence: Die prolongierte Muskelschwaeche bei Intensivpatienten kann die Entwoehnung von der Beatmung verzoegern und auf diese Weise die Dauer der Intensivbehandlung verlaengern . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Die prolongierte Muskelschwaeche bei Intensivpatienten kann die Entwoehnung von der Beatmung verzoegern und auf diese Weise die Dauer der Intensivbehandlung verlaengern .
[ "Die", "prolongierte", "Muskelschwaeche", "bei", "Intensivpatienten", "kann", "die", "Entwoehnung", "von", "der", "Beatmung", "verzoegern", "und", "auf", "diese", "Weise", "die", "Dauer", "der", "Intensivbehandlung", "verlaengern", "." ]
[ "umlsterm" ]
Herz is an umlsterm, Herztransplantation is an umlsterm, Patientenversorgung is an umlsterm, Geraetebedienung is an umlsterm, Herzzentrum is an umlsterm, Berlin is an umlsterm, Patienten is an umlsterm, Erholung is an umlsterm, Leber- is an umlsterm, Nierenversagen is an umlsterm, Erholung is an umlsterm, Myokardfunktion is an umlsterm, selbst is an umlsterm, Blutpumpen is an umlsterm, Patienten is an umlsterm
ZfuerKardiologie.0089vii91.ger.abstr_task0
Sentence: Mechanische Kreislaufunterstuetzungssysteme wurden zunaechst entwickelt , um das versagende Herz permanent zu ersetzen . Heute werden diese Systeme aber hauptsaechlich zur Ueberbrueckung bis zur Herztransplantation eingesetzt . Auf diesem Wege konnten wertvolle Erfahrungen im Umgang mit mechanischen Kreislaufunterstuetzungssystemen gewonnen werden . Wir beschreiben unsere Erfahrungen , die wir in den zurueckliegenden Jahren auf dem Gebiet der Indikationsstellung , postoperativen Patientenversorgung und Geraetebedienung am Deutschen Herzzentrum Berlin haben sammeln koennen . Hier wurde 1987 mit dem Einsatz von Assistsystemen begonnen . Bisher wurden ueber 450 Patienten mit derartigen Systemen von uns versorgt . Die mechanische Kreislaufunterstuetzung fuehrt nicht nur zur Erholung von sekundaeren Organschaeden infolge des kardiogenen Schocks wie Leber- und Nierenversagen , sondern kann auch eine Erholung der Myokardfunktion selbst bewirken . Neue kleinere und effektivere Blutpumpen , eroeffnen neue Moeglichkeiten des Einsatzes . In Zukunft werden mehr Patienten mit derartigen Systemen ausgestattet werden , wobei nunmehr auch der permanente Einsatz diskutiert werden kann . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mechanische Kreislaufunterstuetzungssysteme wurden zunaechst entwickelt , um das versagende Herz permanent zu ersetzen . Heute werden diese Systeme aber hauptsaechlich zur Ueberbrueckung bis zur Herztransplantation eingesetzt . Auf diesem Wege konnten wertvolle Erfahrungen im Umgang mit mechanischen Kreislaufunterstuetzungssystemen gewonnen werden . Wir beschreiben unsere Erfahrungen , die wir in den zurueckliegenden Jahren auf dem Gebiet der Indikationsstellung , postoperativen Patientenversorgung und Geraetebedienung am Deutschen Herzzentrum Berlin haben sammeln koennen . Hier wurde 1987 mit dem Einsatz von Assistsystemen begonnen . Bisher wurden ueber 450 Patienten mit derartigen Systemen von uns versorgt . Die mechanische Kreislaufunterstuetzung fuehrt nicht nur zur Erholung von sekundaeren Organschaeden infolge des kardiogenen Schocks wie Leber- und Nierenversagen , sondern kann auch eine Erholung der Myokardfunktion selbst bewirken . Neue kleinere und effektivere Blutpumpen , eroeffnen neue Moeglichkeiten des Einsatzes . In Zukunft werden mehr Patienten mit derartigen Systemen ausgestattet werden , wobei nunmehr auch der permanente Einsatz diskutiert werden kann .
[ "Mechanische", "Kreislaufunterstuetzungssysteme", "wurden", "zunaechst", "entwickelt", ",", "um", "das", "versagende", "Herz", "permanent", "zu", "ersetzen", ".", "Heute", "werden", "diese", "Systeme", "aber", "hauptsaechlich", "zur", "Ueberbrueckung", "bis", "zur", "Herztransplantation", "eingesetzt", ".", "Auf", "diesem", "Wege", "konnten", "wertvolle", "Erfahrungen", "im", "Umgang", "mit", "mechanischen", "Kreislaufunterstuetzungssystemen", "gewonnen", "werden", ".", "Wir", "beschreiben", "unsere", "Erfahrungen", ",", "die", "wir", "in", "den", "zurueckliegenden", "Jahren", "auf", "dem", "Gebiet", "der", "Indikationsstellung", ",", "postoperativen", "Patientenversorgung", "und", "Geraetebedienung", "am", "Deutschen", "Herzzentrum", "Berlin", "haben", "sammeln", "koennen", ".", "Hier", "wurde", "1987", "mit", "dem", "Einsatz", "von", "Assistsystemen", "begonnen", ".", "Bisher", "wurden", "ueber", "450", "Patienten", "mit", "derartigen", "Systemen", "von", "uns", "versorgt", ".", "Die", "mechanische", "Kreislaufunterstuetzung", "fuehrt", "nicht", "nur", "zur", "Erholung", "von", "sekundaeren", "Organschaeden", "infolge", "des", "kardiogenen", "Schocks", "wie", "Leber-", "und", "Nierenversagen", ",", "sondern", "kann", "auch", "eine", "Erholung", "der", "Myokardfunktion", "selbst", "bewirken", ".", "Neue", "kleinere", "und", "effektivere", "Blutpumpen", ",", "eroeffnen", "neue", "Moeglichkeiten", "des", "Einsatzes", ".", "In", "Zukunft", "werden", "mehr", "Patienten", "mit", "derartigen", "Systemen", "ausgestattet", "werden", ",", "wobei", "nunmehr", "auch", "der", "permanente", "Einsatz", "diskutiert", "werden", "kann", "." ]
[ "umlsterm" ]
Herz is an umlsterm, Herztransplantation is an umlsterm, Patientenversorgung is an umlsterm, Geraetebedienung is an umlsterm, Herzzentrum is an umlsterm, Berlin is an umlsterm, Patienten is an umlsterm, Erholung is an umlsterm, Leber- is an umlsterm, Nierenversagen is an umlsterm, Erholung is an umlsterm, Myokardfunktion is an umlsterm, selbst is an umlsterm, Blutpumpen is an umlsterm, Patienten is an umlsterm
ZfuerKardiologie.0089vii91.ger.abstr_task1
Sentence: Mechanische Kreislaufunterstuetzungssysteme wurden zunaechst entwickelt , um das versagende Herz permanent zu ersetzen . Heute werden diese Systeme aber hauptsaechlich zur Ueberbrueckung bis zur Herztransplantation eingesetzt . Auf diesem Wege konnten wertvolle Erfahrungen im Umgang mit mechanischen Kreislaufunterstuetzungssystemen gewonnen werden . Wir beschreiben unsere Erfahrungen , die wir in den zurueckliegenden Jahren auf dem Gebiet der Indikationsstellung , postoperativen Patientenversorgung und Geraetebedienung am Deutschen Herzzentrum Berlin haben sammeln koennen . Hier wurde 1987 mit dem Einsatz von Assistsystemen begonnen . Bisher wurden ueber 450 Patienten mit derartigen Systemen von uns versorgt . Die mechanische Kreislaufunterstuetzung fuehrt nicht nur zur Erholung von sekundaeren Organschaeden infolge des kardiogenen Schocks wie Leber- und Nierenversagen , sondern kann auch eine Erholung der Myokardfunktion selbst bewirken . Neue kleinere und effektivere Blutpumpen , eroeffnen neue Moeglichkeiten des Einsatzes . In Zukunft werden mehr Patienten mit derartigen Systemen ausgestattet werden , wobei nunmehr auch der permanente Einsatz diskutiert werden kann . Instructions: please typing these entity words according to sentence: Herz, Herztransplantation, Patientenversorgung, Geraetebedienung, Herzzentrum, Berlin, Patienten, Erholung, Leber-, Nierenversagen, Erholung, Myokardfunktion, selbst, Blutpumpen, Patienten Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mechanische Kreislaufunterstuetzungssysteme wurden zunaechst entwickelt , um das versagende Herz permanent zu ersetzen . Heute werden diese Systeme aber hauptsaechlich zur Ueberbrueckung bis zur Herztransplantation eingesetzt . Auf diesem Wege konnten wertvolle Erfahrungen im Umgang mit mechanischen Kreislaufunterstuetzungssystemen gewonnen werden . Wir beschreiben unsere Erfahrungen , die wir in den zurueckliegenden Jahren auf dem Gebiet der Indikationsstellung , postoperativen Patientenversorgung und Geraetebedienung am Deutschen Herzzentrum Berlin haben sammeln koennen . Hier wurde 1987 mit dem Einsatz von Assistsystemen begonnen . Bisher wurden ueber 450 Patienten mit derartigen Systemen von uns versorgt . Die mechanische Kreislaufunterstuetzung fuehrt nicht nur zur Erholung von sekundaeren Organschaeden infolge des kardiogenen Schocks wie Leber- und Nierenversagen , sondern kann auch eine Erholung der Myokardfunktion selbst bewirken . Neue kleinere und effektivere Blutpumpen , eroeffnen neue Moeglichkeiten des Einsatzes . In Zukunft werden mehr Patienten mit derartigen Systemen ausgestattet werden , wobei nunmehr auch der permanente Einsatz diskutiert werden kann .
[ "Mechanische", "Kreislaufunterstuetzungssysteme", "wurden", "zunaechst", "entwickelt", ",", "um", "das", "versagende", "Herz", "permanent", "zu", "ersetzen", ".", "Heute", "werden", "diese", "Systeme", "aber", "hauptsaechlich", "zur", "Ueberbrueckung", "bis", "zur", "Herztransplantation", "eingesetzt", ".", "Auf", "diesem", "Wege", "konnten", "wertvolle", "Erfahrungen", "im", "Umgang", "mit", "mechanischen", "Kreislaufunterstuetzungssystemen", "gewonnen", "werden", ".", "Wir", "beschreiben", "unsere", "Erfahrungen", ",", "die", "wir", "in", "den", "zurueckliegenden", "Jahren", "auf", "dem", "Gebiet", "der", "Indikationsstellung", ",", "postoperativen", "Patientenversorgung", "und", "Geraetebedienung", "am", "Deutschen", "Herzzentrum", "Berlin", "haben", "sammeln", "koennen", ".", "Hier", "wurde", "1987", "mit", "dem", "Einsatz", "von", "Assistsystemen", "begonnen", ".", "Bisher", "wurden", "ueber", "450", "Patienten", "mit", "derartigen", "Systemen", "von", "uns", "versorgt", ".", "Die", "mechanische", "Kreislaufunterstuetzung", "fuehrt", "nicht", "nur", "zur", "Erholung", "von", "sekundaeren", "Organschaeden", "infolge", "des", "kardiogenen", "Schocks", "wie", "Leber-", "und", "Nierenversagen", ",", "sondern", "kann", "auch", "eine", "Erholung", "der", "Myokardfunktion", "selbst", "bewirken", ".", "Neue", "kleinere", "und", "effektivere", "Blutpumpen", ",", "eroeffnen", "neue", "Moeglichkeiten", "des", "Einsatzes", ".", "In", "Zukunft", "werden", "mehr", "Patienten", "mit", "derartigen", "Systemen", "ausgestattet", "werden", ",", "wobei", "nunmehr", "auch", "der", "permanente", "Einsatz", "diskutiert", "werden", "kann", "." ]
[ "umlsterm" ]
Herz, Herztransplantation, Patientenversorgung, Geraetebedienung, Herzzentrum, Berlin, Patienten, Erholung, Leber-, Nierenversagen, Erholung, Myokardfunktion, selbst, Blutpumpen, Patienten
ZfuerKardiologie.0089vii91.ger.abstr_task2
Sentence: Mechanische Kreislaufunterstuetzungssysteme wurden zunaechst entwickelt , um das versagende Herz permanent zu ersetzen . Heute werden diese Systeme aber hauptsaechlich zur Ueberbrueckung bis zur Herztransplantation eingesetzt . Auf diesem Wege konnten wertvolle Erfahrungen im Umgang mit mechanischen Kreislaufunterstuetzungssystemen gewonnen werden . Wir beschreiben unsere Erfahrungen , die wir in den zurueckliegenden Jahren auf dem Gebiet der Indikationsstellung , postoperativen Patientenversorgung und Geraetebedienung am Deutschen Herzzentrum Berlin haben sammeln koennen . Hier wurde 1987 mit dem Einsatz von Assistsystemen begonnen . Bisher wurden ueber 450 Patienten mit derartigen Systemen von uns versorgt . Die mechanische Kreislaufunterstuetzung fuehrt nicht nur zur Erholung von sekundaeren Organschaeden infolge des kardiogenen Schocks wie Leber- und Nierenversagen , sondern kann auch eine Erholung der Myokardfunktion selbst bewirken . Neue kleinere und effektivere Blutpumpen , eroeffnen neue Moeglichkeiten des Einsatzes . In Zukunft werden mehr Patienten mit derartigen Systemen ausgestattet werden , wobei nunmehr auch der permanente Einsatz diskutiert werden kann . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mechanische Kreislaufunterstuetzungssysteme wurden zunaechst entwickelt , um das versagende Herz permanent zu ersetzen . Heute werden diese Systeme aber hauptsaechlich zur Ueberbrueckung bis zur Herztransplantation eingesetzt . Auf diesem Wege konnten wertvolle Erfahrungen im Umgang mit mechanischen Kreislaufunterstuetzungssystemen gewonnen werden . Wir beschreiben unsere Erfahrungen , die wir in den zurueckliegenden Jahren auf dem Gebiet der Indikationsstellung , postoperativen Patientenversorgung und Geraetebedienung am Deutschen Herzzentrum Berlin haben sammeln koennen . Hier wurde 1987 mit dem Einsatz von Assistsystemen begonnen . Bisher wurden ueber 450 Patienten mit derartigen Systemen von uns versorgt . Die mechanische Kreislaufunterstuetzung fuehrt nicht nur zur Erholung von sekundaeren Organschaeden infolge des kardiogenen Schocks wie Leber- und Nierenversagen , sondern kann auch eine Erholung der Myokardfunktion selbst bewirken . Neue kleinere und effektivere Blutpumpen , eroeffnen neue Moeglichkeiten des Einsatzes . In Zukunft werden mehr Patienten mit derartigen Systemen ausgestattet werden , wobei nunmehr auch der permanente Einsatz diskutiert werden kann .
[ "Mechanische", "Kreislaufunterstuetzungssysteme", "wurden", "zunaechst", "entwickelt", ",", "um", "das", "versagende", "Herz", "permanent", "zu", "ersetzen", ".", "Heute", "werden", "diese", "Systeme", "aber", "hauptsaechlich", "zur", "Ueberbrueckung", "bis", "zur", "Herztransplantation", "eingesetzt", ".", "Auf", "diesem", "Wege", "konnten", "wertvolle", "Erfahrungen", "im", "Umgang", "mit", "mechanischen", "Kreislaufunterstuetzungssystemen", "gewonnen", "werden", ".", "Wir", "beschreiben", "unsere", "Erfahrungen", ",", "die", "wir", "in", "den", "zurueckliegenden", "Jahren", "auf", "dem", "Gebiet", "der", "Indikationsstellung", ",", "postoperativen", "Patientenversorgung", "und", "Geraetebedienung", "am", "Deutschen", "Herzzentrum", "Berlin", "haben", "sammeln", "koennen", ".", "Hier", "wurde", "1987", "mit", "dem", "Einsatz", "von", "Assistsystemen", "begonnen", ".", "Bisher", "wurden", "ueber", "450", "Patienten", "mit", "derartigen", "Systemen", "von", "uns", "versorgt", ".", "Die", "mechanische", "Kreislaufunterstuetzung", "fuehrt", "nicht", "nur", "zur", "Erholung", "von", "sekundaeren", "Organschaeden", "infolge", "des", "kardiogenen", "Schocks", "wie", "Leber-", "und", "Nierenversagen", ",", "sondern", "kann", "auch", "eine", "Erholung", "der", "Myokardfunktion", "selbst", "bewirken", ".", "Neue", "kleinere", "und", "effektivere", "Blutpumpen", ",", "eroeffnen", "neue", "Moeglichkeiten", "des", "Einsatzes", ".", "In", "Zukunft", "werden", "mehr", "Patienten", "mit", "derartigen", "Systemen", "ausgestattet", "werden", ",", "wobei", "nunmehr", "auch", "der", "permanente", "Einsatz", "diskutiert", "werden", "kann", "." ]
[ "umlsterm" ]
Gruppenbehandlung is an umlsterm, Patienten is an umlsterm, Schmerzen is an umlsterm, Bewegungsapparat is an umlsterm, Patienten is an umlsterm, Kontrollueberzeugungen is an umlsterm, Schmerzen is an umlsterm, Gymnastikuebungen is an umlsterm, Effizienz is an umlsterm, Schmerzbekaempfung is an umlsterm
DerSchmerz.70110165.ger.abstr_task0
Sentence: Anhand einer schriftlichen Nachbefragung wurden 89 Teilnehmer bezueglich der langfristigen Effekte einer integrierten Gruppenbehandlung fuer Patienten mit chronischen Schmerzen am Bewegungsapparat untersucht . 61 vollstaendige Frageboegen konnten ausgewertet werden ( 31% Drop-outs ) . Die 18 gebesserten Patienten erreichten signifikant niedrigere Scores in der Beschwerdenliste als die 33 unveraenderten und 10 verschlechterten . Sie waren in ihren Kontrollueberzeugungen staerker internal orientiert und sich um mehr positive und negative Einfluesse auf die Schmerzen bewusst . Die kognitiven Ablenkstrategien wurden unbedeutend haeufiger ( 83,6% ) langfristig weitergefuehrt als die Gymnastikuebungen und mindestens eines der Entspannungsverfahren ( je 80,3% ) . Die Effizienz der verschiedenen Verfahren zur Schmerzbekaempfung wurde sehr aehnlich bewertet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Anhand einer schriftlichen Nachbefragung wurden 89 Teilnehmer bezueglich der langfristigen Effekte einer integrierten Gruppenbehandlung fuer Patienten mit chronischen Schmerzen am Bewegungsapparat untersucht . 61 vollstaendige Frageboegen konnten ausgewertet werden ( 31% Drop-outs ) . Die 18 gebesserten Patienten erreichten signifikant niedrigere Scores in der Beschwerdenliste als die 33 unveraenderten und 10 verschlechterten . Sie waren in ihren Kontrollueberzeugungen staerker internal orientiert und sich um mehr positive und negative Einfluesse auf die Schmerzen bewusst . Die kognitiven Ablenkstrategien wurden unbedeutend haeufiger ( 83,6% ) langfristig weitergefuehrt als die Gymnastikuebungen und mindestens eines der Entspannungsverfahren ( je 80,3% ) . Die Effizienz der verschiedenen Verfahren zur Schmerzbekaempfung wurde sehr aehnlich bewertet .
[ "Anhand", "einer", "schriftlichen", "Nachbefragung", "wurden", "89", "Teilnehmer", "bezueglich", "der", "langfristigen", "Effekte", "einer", "integrierten", "Gruppenbehandlung", "fuer", "Patienten", "mit", "chronischen", "Schmerzen", "am", "Bewegungsapparat", "untersucht", ".", "61", "vollstaendige", "Frageboegen", "konnten", "ausgewertet", "werden", "(", "31", "%", "Drop", "-", "outs", ")", ".", "Die", "18", "gebesserten", "Patienten", "erreichten", "signifikant", "niedrigere", "Scores", "in", "der", "Beschwerdenliste", "als", "die", "33", "unveraenderten", "und", "10", "verschlechterten", ".", "Sie", "waren", "in", "ihren", "Kontrollueberzeugungen", "staerker", "internal", "orientiert", "und", "sich", "um", "mehr", "positive", "und", "negative", "Einfluesse", "auf", "die", "Schmerzen", "bewusst", ".", "Die", "kognitiven", "Ablenkstrategien", "wurden", "unbedeutend", "haeufiger", "(", "83,6", "%", ")", "langfristig", "weitergefuehrt", "als", "die", "Gymnastikuebungen", "und", "mindestens", "eines", "der", "Entspannungsverfahren", "(", "je", "80,3", "%", ")", ".", "Die", "Effizienz", "der", "verschiedenen", "Verfahren", "zur", "Schmerzbekaempfung", "wurde", "sehr", "aehnlich", "bewertet", "." ]
[ "umlsterm" ]
Gruppenbehandlung is an umlsterm, Patienten is an umlsterm, Schmerzen is an umlsterm, Bewegungsapparat is an umlsterm, Patienten is an umlsterm, Kontrollueberzeugungen is an umlsterm, Schmerzen is an umlsterm, Gymnastikuebungen is an umlsterm, Effizienz is an umlsterm, Schmerzbekaempfung is an umlsterm
DerSchmerz.70110165.ger.abstr_task1
Sentence: Anhand einer schriftlichen Nachbefragung wurden 89 Teilnehmer bezueglich der langfristigen Effekte einer integrierten Gruppenbehandlung fuer Patienten mit chronischen Schmerzen am Bewegungsapparat untersucht . 61 vollstaendige Frageboegen konnten ausgewertet werden ( 31% Drop-outs ) . Die 18 gebesserten Patienten erreichten signifikant niedrigere Scores in der Beschwerdenliste als die 33 unveraenderten und 10 verschlechterten . Sie waren in ihren Kontrollueberzeugungen staerker internal orientiert und sich um mehr positive und negative Einfluesse auf die Schmerzen bewusst . Die kognitiven Ablenkstrategien wurden unbedeutend haeufiger ( 83,6% ) langfristig weitergefuehrt als die Gymnastikuebungen und mindestens eines der Entspannungsverfahren ( je 80,3% ) . Die Effizienz der verschiedenen Verfahren zur Schmerzbekaempfung wurde sehr aehnlich bewertet . Instructions: please typing these entity words according to sentence: Gruppenbehandlung, Patienten, Schmerzen, Bewegungsapparat, Patienten, Kontrollueberzeugungen, Schmerzen, Gymnastikuebungen, Effizienz, Schmerzbekaempfung Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Anhand einer schriftlichen Nachbefragung wurden 89 Teilnehmer bezueglich der langfristigen Effekte einer integrierten Gruppenbehandlung fuer Patienten mit chronischen Schmerzen am Bewegungsapparat untersucht . 61 vollstaendige Frageboegen konnten ausgewertet werden ( 31% Drop-outs ) . Die 18 gebesserten Patienten erreichten signifikant niedrigere Scores in der Beschwerdenliste als die 33 unveraenderten und 10 verschlechterten . Sie waren in ihren Kontrollueberzeugungen staerker internal orientiert und sich um mehr positive und negative Einfluesse auf die Schmerzen bewusst . Die kognitiven Ablenkstrategien wurden unbedeutend haeufiger ( 83,6% ) langfristig weitergefuehrt als die Gymnastikuebungen und mindestens eines der Entspannungsverfahren ( je 80,3% ) . Die Effizienz der verschiedenen Verfahren zur Schmerzbekaempfung wurde sehr aehnlich bewertet .
[ "Anhand", "einer", "schriftlichen", "Nachbefragung", "wurden", "89", "Teilnehmer", "bezueglich", "der", "langfristigen", "Effekte", "einer", "integrierten", "Gruppenbehandlung", "fuer", "Patienten", "mit", "chronischen", "Schmerzen", "am", "Bewegungsapparat", "untersucht", ".", "61", "vollstaendige", "Frageboegen", "konnten", "ausgewertet", "werden", "(", "31", "%", "Drop", "-", "outs", ")", ".", "Die", "18", "gebesserten", "Patienten", "erreichten", "signifikant", "niedrigere", "Scores", "in", "der", "Beschwerdenliste", "als", "die", "33", "unveraenderten", "und", "10", "verschlechterten", ".", "Sie", "waren", "in", "ihren", "Kontrollueberzeugungen", "staerker", "internal", "orientiert", "und", "sich", "um", "mehr", "positive", "und", "negative", "Einfluesse", "auf", "die", "Schmerzen", "bewusst", ".", "Die", "kognitiven", "Ablenkstrategien", "wurden", "unbedeutend", "haeufiger", "(", "83,6", "%", ")", "langfristig", "weitergefuehrt", "als", "die", "Gymnastikuebungen", "und", "mindestens", "eines", "der", "Entspannungsverfahren", "(", "je", "80,3", "%", ")", ".", "Die", "Effizienz", "der", "verschiedenen", "Verfahren", "zur", "Schmerzbekaempfung", "wurde", "sehr", "aehnlich", "bewertet", "." ]
[ "umlsterm" ]
Gruppenbehandlung, Patienten, Schmerzen, Bewegungsapparat, Patienten, Kontrollueberzeugungen, Schmerzen, Gymnastikuebungen, Effizienz, Schmerzbekaempfung
DerSchmerz.70110165.ger.abstr_task2
Sentence: Anhand einer schriftlichen Nachbefragung wurden 89 Teilnehmer bezueglich der langfristigen Effekte einer integrierten Gruppenbehandlung fuer Patienten mit chronischen Schmerzen am Bewegungsapparat untersucht . 61 vollstaendige Frageboegen konnten ausgewertet werden ( 31% Drop-outs ) . Die 18 gebesserten Patienten erreichten signifikant niedrigere Scores in der Beschwerdenliste als die 33 unveraenderten und 10 verschlechterten . Sie waren in ihren Kontrollueberzeugungen staerker internal orientiert und sich um mehr positive und negative Einfluesse auf die Schmerzen bewusst . Die kognitiven Ablenkstrategien wurden unbedeutend haeufiger ( 83,6% ) langfristig weitergefuehrt als die Gymnastikuebungen und mindestens eines der Entspannungsverfahren ( je 80,3% ) . Die Effizienz der verschiedenen Verfahren zur Schmerzbekaempfung wurde sehr aehnlich bewertet . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Anhand einer schriftlichen Nachbefragung wurden 89 Teilnehmer bezueglich der langfristigen Effekte einer integrierten Gruppenbehandlung fuer Patienten mit chronischen Schmerzen am Bewegungsapparat untersucht . 61 vollstaendige Frageboegen konnten ausgewertet werden ( 31% Drop-outs ) . Die 18 gebesserten Patienten erreichten signifikant niedrigere Scores in der Beschwerdenliste als die 33 unveraenderten und 10 verschlechterten . Sie waren in ihren Kontrollueberzeugungen staerker internal orientiert und sich um mehr positive und negative Einfluesse auf die Schmerzen bewusst . Die kognitiven Ablenkstrategien wurden unbedeutend haeufiger ( 83,6% ) langfristig weitergefuehrt als die Gymnastikuebungen und mindestens eines der Entspannungsverfahren ( je 80,3% ) . Die Effizienz der verschiedenen Verfahren zur Schmerzbekaempfung wurde sehr aehnlich bewertet .
[ "Anhand", "einer", "schriftlichen", "Nachbefragung", "wurden", "89", "Teilnehmer", "bezueglich", "der", "langfristigen", "Effekte", "einer", "integrierten", "Gruppenbehandlung", "fuer", "Patienten", "mit", "chronischen", "Schmerzen", "am", "Bewegungsapparat", "untersucht", ".", "61", "vollstaendige", "Frageboegen", "konnten", "ausgewertet", "werden", "(", "31", "%", "Drop", "-", "outs", ")", ".", "Die", "18", "gebesserten", "Patienten", "erreichten", "signifikant", "niedrigere", "Scores", "in", "der", "Beschwerdenliste", "als", "die", "33", "unveraenderten", "und", "10", "verschlechterten", ".", "Sie", "waren", "in", "ihren", "Kontrollueberzeugungen", "staerker", "internal", "orientiert", "und", "sich", "um", "mehr", "positive", "und", "negative", "Einfluesse", "auf", "die", "Schmerzen", "bewusst", ".", "Die", "kognitiven", "Ablenkstrategien", "wurden", "unbedeutend", "haeufiger", "(", "83,6", "%", ")", "langfristig", "weitergefuehrt", "als", "die", "Gymnastikuebungen", "und", "mindestens", "eines", "der", "Entspannungsverfahren", "(", "je", "80,3", "%", ")", ".", "Die", "Effizienz", "der", "verschiedenen", "Verfahren", "zur", "Schmerzbekaempfung", "wurde", "sehr", "aehnlich", "bewertet", "." ]
[ "umlsterm" ]
nNOS is a GENE-Y, sGC is a GENE-N, cocaine is a CHEMICAL, phosphodiesterase 5 is a GENE-Y
23579428_task0
Sentence: Involvement of nNOS/NO/sGC/cGMP signaling pathway in cocaine sensitization and in the associated hippocampal alterations: does phosphodiesterase 5 inhibition help to drug vulnerability? Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL, GENE-Y, GENE-N
[ "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]
Involvement of nNOS/NO/sGC/cGMP signaling pathway in cocaine sensitization and in the associated hippocampal alterations: does phosphodiesterase 5 inhibition help to drug vulnerability?
[ "Involvement", "of", "nNOS", "/", "NO", "/", "sGC", "/", "cGMP", "signaling", "pathway", "in", "cocaine", "sensitization", "and", "in", "the", "associated", "hippocampal", "alterations", ":", "does", "phosphodiesterase", "5", "inhibition", "help", "to", "drug", "vulnerability", "?" ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
nNOS is a GENE-Y, sGC is a GENE-N, cocaine is a CHEMICAL, phosphodiesterase 5 is a GENE-Y
23579428_task1
Sentence: Involvement of nNOS/NO/sGC/cGMP signaling pathway in cocaine sensitization and in the associated hippocampal alterations: does phosphodiesterase 5 inhibition help to drug vulnerability? Instructions: please typing these entity words according to sentence: nNOS, sGC, cocaine, phosphodiesterase 5 Options: CHEMICAL, GENE-Y, GENE-N
[ "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]
Involvement of nNOS/NO/sGC/cGMP signaling pathway in cocaine sensitization and in the associated hippocampal alterations: does phosphodiesterase 5 inhibition help to drug vulnerability?
[ "Involvement", "of", "nNOS", "/", "NO", "/", "sGC", "/", "cGMP", "signaling", "pathway", "in", "cocaine", "sensitization", "and", "in", "the", "associated", "hippocampal", "alterations", ":", "does", "phosphodiesterase", "5", "inhibition", "help", "to", "drug", "vulnerability", "?" ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
nNOS, sGC, cocaine, phosphodiesterase 5
23579428_task2
Sentence: Involvement of nNOS/NO/sGC/cGMP signaling pathway in cocaine sensitization and in the associated hippocampal alterations: does phosphodiesterase 5 inhibition help to drug vulnerability? Instructions: please extract entity words from the input sentence
[ "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]
Involvement of nNOS/NO/sGC/cGMP signaling pathway in cocaine sensitization and in the associated hippocampal alterations: does phosphodiesterase 5 inhibition help to drug vulnerability?
[ "Involvement", "of", "nNOS", "/", "NO", "/", "sGC", "/", "cGMP", "signaling", "pathway", "in", "cocaine", "sensitization", "and", "in", "the", "associated", "hippocampal", "alterations", ":", "does", "phosphodiesterase", "5", "inhibition", "help", "to", "drug", "vulnerability", "?" ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Active or past is a Scope, psychotic disorder is a Condition, psychotic affective state is a Condition, Mental Retardation is a Condition, Autistic Spectrum Disorder is a Condition, Prominent personality disorder is a Condition, Cardiac or neurologic active medical condition is a Scope, past CVA / TIA ( Cardiovascular Accident / Transient Ischemic Attack ) or any other unstable medical condition is a Scope, Chronic is a Temporal, nasal congestion is a Condition, Active or recent is a Scope, drug or alcohol abuse is a Scope, Substantial is a Qualifier, suicidality is a Condition, admission is a Procedure
NCT02644629_exc_task0
Sentence: Active or past psychotic disorder, including a history of psychotic affective state Mental Retardation or Autistic Spectrum Disorder Prominent personality disorder Cardiac or neurologic active medical condition, including past CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack) or any other unstable medical condition. Chronic nasal congestion Active or recent drug or alcohol abuse Substantial suicidality in a patient requiring admission but refuses to do so, and signs an "against medical advice" release form as part of clinical evaluation, and does not answer the terms for involuntary admission. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Procedure, Scope
[ "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "B-Condition", "O", "O", "O", "O", "B-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Active or past psychotic disorder, including a history of psychotic affective state Mental Retardation or Autistic Spectrum Disorder Prominent personality disorder Cardiac or neurologic active medical condition, including past CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack) or any other unstable medical condition. Chronic nasal congestion Active or recent drug or alcohol abuse Substantial suicidality in a patient requiring admission but refuses to do so, and signs an "against medical advice" release form as part of clinical evaluation, and does not answer the terms for involuntary admission.
[ "Active", "or", "past", "psychotic", "disorder", ",", "including", "a", "history", "of", "psychotic", "affective", "state", "\n", "Mental", "Retardation", "or", "Autistic", "Spectrum", "Disorder", "\n", "Prominent", "personality", "disorder", "\n", "Cardiac", "or", "neurologic", "active", "medical", "condition", ",", "including", "past", "CVA", "/", "TIA", "(", "Cardiovascular", "Accident", "/", "Transient", "Ischemic", "Attack", ")", "or", "any", "other", "unstable", "medical", "condition", ".", "\n", "Chronic", "nasal", "congestion", "\n", "Active", "or", "recent", "drug", "or", "alcohol", "abuse", "\n", "Substantial", "suicidality", "in", "a", "patient", "requiring", "admission", "but", "refuses", "to", "do", "so", ",", "and", "signs", "an", "\"", "against", "medical", "advice", "\"", "release", "form", "as", "part", "of", "clinical", "evaluation", ",", "and", "does", "not", "answer", "the", "terms", "for", "involuntary", "admission", ".", "\n" ]
[ "Scope", "Condition", "Qualifier", "Procedure", "Temporal" ]
Active or past is a Scope, psychotic disorder is a Condition, psychotic affective state is a Condition, Mental Retardation is a Condition, Autistic Spectrum Disorder is a Condition, Prominent personality disorder is a Condition, Cardiac or neurologic active medical condition is a Scope, past CVA / TIA ( Cardiovascular Accident / Transient Ischemic Attack ) or any other unstable medical condition is a Scope, Chronic is a Temporal, nasal congestion is a Condition, Active or recent is a Scope, drug or alcohol abuse is a Scope, Substantial is a Qualifier, suicidality is a Condition, admission is a Procedure
NCT02644629_exc_task1
Sentence: Active or past psychotic disorder, including a history of psychotic affective state Mental Retardation or Autistic Spectrum Disorder Prominent personality disorder Cardiac or neurologic active medical condition, including past CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack) or any other unstable medical condition. Chronic nasal congestion Active or recent drug or alcohol abuse Substantial suicidality in a patient requiring admission but refuses to do so, and signs an "against medical advice" release form as part of clinical evaluation, and does not answer the terms for involuntary admission. Instructions: please typing these entity words according to sentence: Active or past, psychotic disorder, psychotic affective state, Mental Retardation, Autistic Spectrum Disorder, Prominent personality disorder, Cardiac or neurologic active medical condition, past CVA / TIA ( Cardiovascular Accident / Transient Ischemic Attack ) or any other unstable medical condition, Chronic, nasal congestion, Active or recent, drug or alcohol abuse, Substantial, suicidality, admission Options: Temporal, Condition, Qualifier, Procedure, Scope
[ "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "B-Condition", "O", "O", "O", "O", "B-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Active or past psychotic disorder, including a history of psychotic affective state Mental Retardation or Autistic Spectrum Disorder Prominent personality disorder Cardiac or neurologic active medical condition, including past CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack) or any other unstable medical condition. Chronic nasal congestion Active or recent drug or alcohol abuse Substantial suicidality in a patient requiring admission but refuses to do so, and signs an "against medical advice" release form as part of clinical evaluation, and does not answer the terms for involuntary admission.
[ "Active", "or", "past", "psychotic", "disorder", ",", "including", "a", "history", "of", "psychotic", "affective", "state", "\n", "Mental", "Retardation", "or", "Autistic", "Spectrum", "Disorder", "\n", "Prominent", "personality", "disorder", "\n", "Cardiac", "or", "neurologic", "active", "medical", "condition", ",", "including", "past", "CVA", "/", "TIA", "(", "Cardiovascular", "Accident", "/", "Transient", "Ischemic", "Attack", ")", "or", "any", "other", "unstable", "medical", "condition", ".", "\n", "Chronic", "nasal", "congestion", "\n", "Active", "or", "recent", "drug", "or", "alcohol", "abuse", "\n", "Substantial", "suicidality", "in", "a", "patient", "requiring", "admission", "but", "refuses", "to", "do", "so", ",", "and", "signs", "an", "\"", "against", "medical", "advice", "\"", "release", "form", "as", "part", "of", "clinical", "evaluation", ",", "and", "does", "not", "answer", "the", "terms", "for", "involuntary", "admission", ".", "\n" ]
[ "Scope", "Condition", "Qualifier", "Procedure", "Temporal" ]
Active or past, psychotic disorder, psychotic affective state, Mental Retardation, Autistic Spectrum Disorder, Prominent personality disorder, Cardiac or neurologic active medical condition, past CVA / TIA ( Cardiovascular Accident / Transient Ischemic Attack ) or any other unstable medical condition, Chronic, nasal congestion, Active or recent, drug or alcohol abuse, Substantial, suicidality, admission
NCT02644629_exc_task2
Sentence: Active or past psychotic disorder, including a history of psychotic affective state Mental Retardation or Autistic Spectrum Disorder Prominent personality disorder Cardiac or neurologic active medical condition, including past CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack) or any other unstable medical condition. Chronic nasal congestion Active or recent drug or alcohol abuse Substantial suicidality in a patient requiring admission but refuses to do so, and signs an "against medical advice" release form as part of clinical evaluation, and does not answer the terms for involuntary admission. Instructions: please extract entity words from the input sentence
[ "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "B-Condition", "O", "O", "O", "O", "B-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Active or past psychotic disorder, including a history of psychotic affective state Mental Retardation or Autistic Spectrum Disorder Prominent personality disorder Cardiac or neurologic active medical condition, including past CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack) or any other unstable medical condition. Chronic nasal congestion Active or recent drug or alcohol abuse Substantial suicidality in a patient requiring admission but refuses to do so, and signs an "against medical advice" release form as part of clinical evaluation, and does not answer the terms for involuntary admission.
[ "Active", "or", "past", "psychotic", "disorder", ",", "including", "a", "history", "of", "psychotic", "affective", "state", "\n", "Mental", "Retardation", "or", "Autistic", "Spectrum", "Disorder", "\n", "Prominent", "personality", "disorder", "\n", "Cardiac", "or", "neurologic", "active", "medical", "condition", ",", "including", "past", "CVA", "/", "TIA", "(", "Cardiovascular", "Accident", "/", "Transient", "Ischemic", "Attack", ")", "or", "any", "other", "unstable", "medical", "condition", ".", "\n", "Chronic", "nasal", "congestion", "\n", "Active", "or", "recent", "drug", "or", "alcohol", "abuse", "\n", "Substantial", "suicidality", "in", "a", "patient", "requiring", "admission", "but", "refuses", "to", "do", "so", ",", "and", "signs", "an", "\"", "against", "medical", "advice", "\"", "release", "form", "as", "part", "of", "clinical", "evaluation", ",", "and", "does", "not", "answer", "the", "terms", "for", "involuntary", "admission", ".", "\n" ]
[ "Scope", "Condition", "Qualifier", "Procedure", "Temporal" ]
Sandra is a NOMBRE_SUJETO_ASISTENCIA, Tobar Alvarez is a NOMBRE_SUJETO_ASISTENCIA, 8942634 is a ID_SUJETO_ASISTENCIA, 32 78456397 48 is a ID_ASEGURAMIENTO, Valladolid is a TERRITORIO, 47021 is a TERRITORIO, 15/02/1957 is a FECHAS, España is a PAIS, 47 años is a EDAD_SUJETO_ASISTENCIA, 07/07/2004 is a FECHAS, Alejandro Sálamo Rubiales is a NOMBRE_PERSONAL_SANITARIO, 47 47 87921 is a ID_TITULACION_PERSONAL_SANITARIO, año 2000 is a FECHAS, 47 años is a EDAD_SUJETO_ASISTENCIA, Mayo de 2003 is a FECHAS, Noviembre de 2003 is a FECHAS, Alejandro Sálamo Rubiales is a NOMBRE_PERSONAL_SANITARIO, Hospital Clínico Universitario is a HOSPITAL, C/ Ramón y Cajal , 3 is a CALLE, E-47005 is a TERRITORIO, Valladolid is a TERRITORIO, asrubiales@hotmail.com is a CORREO_ELECTRONICO
261_task0
Sentence: Datos del paciente. Nombre: Sandra. Apellidos: Tobar Alvarez. NHC: 8942634. NASS: 32 78456397 48. Domicilio: C/ Castilla y León, 3, 4 D. Localidad/ Provincia: Valladolid. CP: 47021. Datos asistenciales. Fecha de nacimiento: 15/02/1957. País de nacimiento: España. Edad: 47 años Sexo: H. Fecha de Ingreso: 07/07/2004. Médico: Alejandro Sálamo Rubiales NºCol: 47 47 87921. Informe clínico del paciente: En el año 2000, a los 47 años de edad a la paciente se le practicó una mastectomía por un carcinoma ductal infiltrante de mama estadio IIIB (T4a N1). Los receptores hormonales eran positivos, al igual que el Herceptest (+++). Recibió tratamiento complementario con quimioterapia (CMF), radioterapia y tamoxifeno. En Mayo de 2003 se detectó una recidiva ósea cervical que ocasionaba compromiso medular. Fue tratada con cirugía y radioterapia local. Posteriormente comenzó tratamiento con letrozol. En Noviembre de 2003 se confirmó una progresión tumoral ósea y ganglionar (supraclavicular). Comenzó entonces tratamiento citostático paliativo con epirrubicina, docetaxel y trastuzumab. En las semanas siguientes presentó un empeoramiento sintomático importante pero transitorio; la evolución de estos síntomas se describe en unas anotaciones de la propia paciente que luego nos facilitó. De manera simultánea se encontró una elevación del CA153 y de la fosfatasa alcalina que posteriormente se fue reduciendo hasta normalizarse (Gráfica 1). Desde el punto de vista clínico, la captación en la gammagrafía ósea no sufrió cambios relevantes pero la adenopatía supraclavicular alcanzó una respuesta completa. La duración de la respuesta fue de diez meses, tras los cuales presentó progresión ósea y hepática. Se encuentra recibiendo una nueva línea de quimioterapia con aparente estabilización de la enfermedad. Responsable clínico: Dr. Alejandro Sálamo Rubiales Oncología Médica Hospital Clínico Universitario C/ Ramón y Cajal, 3 E-47005 Valladolid E-mail: asrubiales@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO
[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Sandra. Apellidos: Tobar Alvarez. NHC: 8942634. NASS: 32 78456397 48. Domicilio: C/ Castilla y León, 3, 4 D. Localidad/ Provincia: Valladolid. CP: 47021. Datos asistenciales. Fecha de nacimiento: 15/02/1957. País de nacimiento: España. Edad: 47 años Sexo: H. Fecha de Ingreso: 07/07/2004. Médico: Alejandro Sálamo Rubiales NºCol: 47 47 87921. Informe clínico del paciente: En el año 2000, a los 47 años de edad a la paciente se le practicó una mastectomía por un carcinoma ductal infiltrante de mama estadio IIIB (T4a N1). Los receptores hormonales eran positivos, al igual que el Herceptest (+++). Recibió tratamiento complementario con quimioterapia (CMF), radioterapia y tamoxifeno. En Mayo de 2003 se detectó una recidiva ósea cervical que ocasionaba compromiso medular. Fue tratada con cirugía y radioterapia local. Posteriormente comenzó tratamiento con letrozol. En Noviembre de 2003 se confirmó una progresión tumoral ósea y ganglionar (supraclavicular). Comenzó entonces tratamiento citostático paliativo con epirrubicina, docetaxel y trastuzumab. En las semanas siguientes presentó un empeoramiento sintomático importante pero transitorio; la evolución de estos síntomas se describe en unas anotaciones de la propia paciente que luego nos facilitó. De manera simultánea se encontró una elevación del CA153 y de la fosfatasa alcalina que posteriormente se fue reduciendo hasta normalizarse (Gráfica 1). Desde el punto de vista clínico, la captación en la gammagrafía ósea no sufrió cambios relevantes pero la adenopatía supraclavicular alcanzó una respuesta completa. La duración de la respuesta fue de diez meses, tras los cuales presentó progresión ósea y hepática. Se encuentra recibiendo una nueva línea de quimioterapia con aparente estabilización de la enfermedad. Responsable clínico: Dr. Alejandro Sálamo Rubiales Oncología Médica Hospital Clínico Universitario C/ Ramón y Cajal, 3 E-47005 Valladolid E-mail: asrubiales@hotmail.com
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Sandra", ".", "\n", "Apellidos", ":", "Tobar", "Alvarez", ".", "\n", "NHC", ":", "8942634", ".", "\n", "NASS", ":", "32", "78456397", "48", ".", "\n", "Domicilio", ":", "C/", "Castilla", "y", "León", ",", "3", ",", "4", "D.", "\n", "Localidad/", "Provincia", ":", "Valladolid", ".", "\n", "CP", ":", "47021", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/02/1957", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "47", "años", "Sexo", ":", " ", "H.", "\n", "Fecha", "de", "Ingreso", ":", "07/07/2004", ".", "\n", "Médico", ":", "Alejandro", "Sálamo", "Rubiales", "NºCol", ":", "47", "47", "87921", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "En", "el", "año", "2000", ",", "a", "los", "47", "años", "de", "edad", "a", "la", "paciente", "se", "le", "practicó", "una", "mastectomía", "por", "un", "carcinoma", "ductal", "infiltrante", "de", "mama", "estadio", "IIIB", "(", "T4a", "N1", ")", ".", "Los", "receptores", "hormonales", "eran", "positivos", ",", "al", "igual", "que", "el", "Herceptest", "(", "+", "+", "+", ")", ".", "Recibió", "tratamiento", "complementario", "con", "quimioterapia", "(", "CMF", ")", ",", "radioterapia", "y", "tamoxifeno", ".", "En", "Mayo", "de", "2003", "se", "detectó", "una", "recidiva", "ósea", "cervical", "que", "ocasionaba", "compromiso", "medular", ".", "Fue", "tratada", "con", "cirugía", "y", "radioterapia", "local", ".", "Posteriormente", "comenzó", "tratamiento", "con", "letrozol", ".", "En", "Noviembre", "de", "2003", "se", "confirmó", "una", "progresión", "tumoral", "ósea", "y", "ganglionar", "(", "supraclavicular", ")", ".", "Comenzó", "entonces", "tratamiento", "citostático", "paliativo", "con", "epirrubicina", ",", "docetaxel", "y", "trastuzumab", ".", "En", "las", "semanas", "siguientes", "presentó", "un", "empeoramiento", "sintomático", "importante", "pero", "transitorio", ";", "la", "evolución", "de", "estos", "síntomas", "se", "describe", "en", "unas", "anotaciones", "de", "la", "propia", "paciente", "que", "luego", "nos", "facilitó", ".", "De", "manera", "simultánea", "se", "encontró", "una", "elevación", "del", "CA153", "y", "de", "la", "fosfatasa", "alcalina", "que", "posteriormente", "se", "fue", "reduciendo", "hasta", "normalizarse", "(", "Gráfica", "1", ")", ".", "Desde", "el", "punto", "de", "vista", "clínico", ",", "la", "captación", "en", "la", "gammagrafía", "ósea", "no", "sufrió", "cambios", "relevantes", "pero", "la", "adenopatía", "supraclavicular", "alcanzó", "una", "respuesta", "completa", ".", "La", "duración", "de", "la", "respuesta", "fue", "de", "diez", "meses", ",", "tras", "los", "cuales", "presentó", "progresión", "ósea", "y", "hepática", ".", "Se", "encuentra", "recibiendo", "una", "nueva", "línea", "de", "quimioterapia", "con", "aparente", "estabilización", "de", "la", "enfermedad", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Alejandro", "Sálamo", "Rubiales", "Oncología", "Médica", "Hospital", "Clínico", "Universitario", "C/", "Ramón", "y", "Cajal", ",", "3", "E-47005", "Valladolid", "E", "-", "mail", ":", "asrubiales@hotmail.com", "\n" ]
[ "HOSPITAL", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "FECHAS", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Sandra is a NOMBRE_SUJETO_ASISTENCIA, Tobar Alvarez is a NOMBRE_SUJETO_ASISTENCIA, 8942634 is a ID_SUJETO_ASISTENCIA, 32 78456397 48 is a ID_ASEGURAMIENTO, Valladolid is a TERRITORIO, 47021 is a TERRITORIO, 15/02/1957 is a FECHAS, España is a PAIS, 47 años is a EDAD_SUJETO_ASISTENCIA, 07/07/2004 is a FECHAS, Alejandro Sálamo Rubiales is a NOMBRE_PERSONAL_SANITARIO, 47 47 87921 is a ID_TITULACION_PERSONAL_SANITARIO, año 2000 is a FECHAS, 47 años is a EDAD_SUJETO_ASISTENCIA, Mayo de 2003 is a FECHAS, Noviembre de 2003 is a FECHAS, Alejandro Sálamo Rubiales is a NOMBRE_PERSONAL_SANITARIO, Hospital Clínico Universitario is a HOSPITAL, C/ Ramón y Cajal , 3 is a CALLE, E-47005 is a TERRITORIO, Valladolid is a TERRITORIO, asrubiales@hotmail.com is a CORREO_ELECTRONICO
261_task1
Sentence: Datos del paciente. Nombre: Sandra. Apellidos: Tobar Alvarez. NHC: 8942634. NASS: 32 78456397 48. Domicilio: C/ Castilla y León, 3, 4 D. Localidad/ Provincia: Valladolid. CP: 47021. Datos asistenciales. Fecha de nacimiento: 15/02/1957. País de nacimiento: España. Edad: 47 años Sexo: H. Fecha de Ingreso: 07/07/2004. Médico: Alejandro Sálamo Rubiales NºCol: 47 47 87921. Informe clínico del paciente: En el año 2000, a los 47 años de edad a la paciente se le practicó una mastectomía por un carcinoma ductal infiltrante de mama estadio IIIB (T4a N1). Los receptores hormonales eran positivos, al igual que el Herceptest (+++). Recibió tratamiento complementario con quimioterapia (CMF), radioterapia y tamoxifeno. En Mayo de 2003 se detectó una recidiva ósea cervical que ocasionaba compromiso medular. Fue tratada con cirugía y radioterapia local. Posteriormente comenzó tratamiento con letrozol. En Noviembre de 2003 se confirmó una progresión tumoral ósea y ganglionar (supraclavicular). Comenzó entonces tratamiento citostático paliativo con epirrubicina, docetaxel y trastuzumab. En las semanas siguientes presentó un empeoramiento sintomático importante pero transitorio; la evolución de estos síntomas se describe en unas anotaciones de la propia paciente que luego nos facilitó. De manera simultánea se encontró una elevación del CA153 y de la fosfatasa alcalina que posteriormente se fue reduciendo hasta normalizarse (Gráfica 1). Desde el punto de vista clínico, la captación en la gammagrafía ósea no sufrió cambios relevantes pero la adenopatía supraclavicular alcanzó una respuesta completa. La duración de la respuesta fue de diez meses, tras los cuales presentó progresión ósea y hepática. Se encuentra recibiendo una nueva línea de quimioterapia con aparente estabilización de la enfermedad. Responsable clínico: Dr. Alejandro Sálamo Rubiales Oncología Médica Hospital Clínico Universitario C/ Ramón y Cajal, 3 E-47005 Valladolid E-mail: asrubiales@hotmail.com Instructions: please typing these entity words according to sentence: Sandra, Tobar Alvarez, 8942634, 32 78456397 48, Valladolid, 47021, 15/02/1957, España, 47 años, 07/07/2004, Alejandro Sálamo Rubiales, 47 47 87921, año 2000, 47 años, Mayo de 2003, Noviembre de 2003, Alejandro Sálamo Rubiales, Hospital Clínico Universitario, C/ Ramón y Cajal , 3, E-47005, Valladolid, asrubiales@hotmail.com Options: TERRITORIO, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO
[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Sandra. Apellidos: Tobar Alvarez. NHC: 8942634. NASS: 32 78456397 48. Domicilio: C/ Castilla y León, 3, 4 D. Localidad/ Provincia: Valladolid. CP: 47021. Datos asistenciales. Fecha de nacimiento: 15/02/1957. País de nacimiento: España. Edad: 47 años Sexo: H. Fecha de Ingreso: 07/07/2004. Médico: Alejandro Sálamo Rubiales NºCol: 47 47 87921. Informe clínico del paciente: En el año 2000, a los 47 años de edad a la paciente se le practicó una mastectomía por un carcinoma ductal infiltrante de mama estadio IIIB (T4a N1). Los receptores hormonales eran positivos, al igual que el Herceptest (+++). Recibió tratamiento complementario con quimioterapia (CMF), radioterapia y tamoxifeno. En Mayo de 2003 se detectó una recidiva ósea cervical que ocasionaba compromiso medular. Fue tratada con cirugía y radioterapia local. Posteriormente comenzó tratamiento con letrozol. En Noviembre de 2003 se confirmó una progresión tumoral ósea y ganglionar (supraclavicular). Comenzó entonces tratamiento citostático paliativo con epirrubicina, docetaxel y trastuzumab. En las semanas siguientes presentó un empeoramiento sintomático importante pero transitorio; la evolución de estos síntomas se describe en unas anotaciones de la propia paciente que luego nos facilitó. De manera simultánea se encontró una elevación del CA153 y de la fosfatasa alcalina que posteriormente se fue reduciendo hasta normalizarse (Gráfica 1). Desde el punto de vista clínico, la captación en la gammagrafía ósea no sufrió cambios relevantes pero la adenopatía supraclavicular alcanzó una respuesta completa. La duración de la respuesta fue de diez meses, tras los cuales presentó progresión ósea y hepática. Se encuentra recibiendo una nueva línea de quimioterapia con aparente estabilización de la enfermedad. Responsable clínico: Dr. Alejandro Sálamo Rubiales Oncología Médica Hospital Clínico Universitario C/ Ramón y Cajal, 3 E-47005 Valladolid E-mail: asrubiales@hotmail.com
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Sandra", ".", "\n", "Apellidos", ":", "Tobar", "Alvarez", ".", "\n", "NHC", ":", "8942634", ".", "\n", "NASS", ":", "32", "78456397", "48", ".", "\n", "Domicilio", ":", "C/", "Castilla", "y", "León", ",", "3", ",", "4", "D.", "\n", "Localidad/", "Provincia", ":", "Valladolid", ".", "\n", "CP", ":", "47021", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/02/1957", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "47", "años", "Sexo", ":", " ", "H.", "\n", "Fecha", "de", "Ingreso", ":", "07/07/2004", ".", "\n", "Médico", ":", "Alejandro", "Sálamo", "Rubiales", "NºCol", ":", "47", "47", "87921", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "En", "el", "año", "2000", ",", "a", "los", "47", "años", "de", "edad", "a", "la", "paciente", "se", "le", "practicó", "una", "mastectomía", "por", "un", "carcinoma", "ductal", "infiltrante", "de", "mama", "estadio", "IIIB", "(", "T4a", "N1", ")", ".", "Los", "receptores", "hormonales", "eran", "positivos", ",", "al", "igual", "que", "el", "Herceptest", "(", "+", "+", "+", ")", ".", "Recibió", "tratamiento", "complementario", "con", "quimioterapia", "(", "CMF", ")", ",", "radioterapia", "y", "tamoxifeno", ".", "En", "Mayo", "de", "2003", "se", "detectó", "una", "recidiva", "ósea", "cervical", "que", "ocasionaba", "compromiso", "medular", ".", "Fue", "tratada", "con", "cirugía", "y", "radioterapia", "local", ".", "Posteriormente", "comenzó", "tratamiento", "con", "letrozol", ".", "En", "Noviembre", "de", "2003", "se", "confirmó", "una", "progresión", "tumoral", "ósea", "y", "ganglionar", "(", "supraclavicular", ")", ".", "Comenzó", "entonces", "tratamiento", "citostático", "paliativo", "con", "epirrubicina", ",", "docetaxel", "y", "trastuzumab", ".", "En", "las", "semanas", "siguientes", "presentó", "un", "empeoramiento", "sintomático", "importante", "pero", "transitorio", ";", "la", "evolución", "de", "estos", "síntomas", "se", "describe", "en", "unas", "anotaciones", "de", "la", "propia", "paciente", "que", "luego", "nos", "facilitó", ".", "De", "manera", "simultánea", "se", "encontró", "una", "elevación", "del", "CA153", "y", "de", "la", "fosfatasa", "alcalina", "que", "posteriormente", "se", "fue", "reduciendo", "hasta", "normalizarse", "(", "Gráfica", "1", ")", ".", "Desde", "el", "punto", "de", "vista", "clínico", ",", "la", "captación", "en", "la", "gammagrafía", "ósea", "no", "sufrió", "cambios", "relevantes", "pero", "la", "adenopatía", "supraclavicular", "alcanzó", "una", "respuesta", "completa", ".", "La", "duración", "de", "la", "respuesta", "fue", "de", "diez", "meses", ",", "tras", "los", "cuales", "presentó", "progresión", "ósea", "y", "hepática", ".", "Se", "encuentra", "recibiendo", "una", "nueva", "línea", "de", "quimioterapia", "con", "aparente", "estabilización", "de", "la", "enfermedad", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Alejandro", "Sálamo", "Rubiales", "Oncología", "Médica", "Hospital", "Clínico", "Universitario", "C/", "Ramón", "y", "Cajal", ",", "3", "E-47005", "Valladolid", "E", "-", "mail", ":", "asrubiales@hotmail.com", "\n" ]
[ "HOSPITAL", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "FECHAS", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Sandra, Tobar Alvarez, 8942634, 32 78456397 48, Valladolid, 47021, 15/02/1957, España, 47 años, 07/07/2004, Alejandro Sálamo Rubiales, 47 47 87921, año 2000, 47 años, Mayo de 2003, Noviembre de 2003, Alejandro Sálamo Rubiales, Hospital Clínico Universitario, C/ Ramón y Cajal , 3, E-47005, Valladolid, asrubiales@hotmail.com
261_task2
Sentence: Datos del paciente. Nombre: Sandra. Apellidos: Tobar Alvarez. NHC: 8942634. NASS: 32 78456397 48. Domicilio: C/ Castilla y León, 3, 4 D. Localidad/ Provincia: Valladolid. CP: 47021. Datos asistenciales. Fecha de nacimiento: 15/02/1957. País de nacimiento: España. Edad: 47 años Sexo: H. Fecha de Ingreso: 07/07/2004. Médico: Alejandro Sálamo Rubiales NºCol: 47 47 87921. Informe clínico del paciente: En el año 2000, a los 47 años de edad a la paciente se le practicó una mastectomía por un carcinoma ductal infiltrante de mama estadio IIIB (T4a N1). Los receptores hormonales eran positivos, al igual que el Herceptest (+++). Recibió tratamiento complementario con quimioterapia (CMF), radioterapia y tamoxifeno. En Mayo de 2003 se detectó una recidiva ósea cervical que ocasionaba compromiso medular. Fue tratada con cirugía y radioterapia local. Posteriormente comenzó tratamiento con letrozol. En Noviembre de 2003 se confirmó una progresión tumoral ósea y ganglionar (supraclavicular). Comenzó entonces tratamiento citostático paliativo con epirrubicina, docetaxel y trastuzumab. En las semanas siguientes presentó un empeoramiento sintomático importante pero transitorio; la evolución de estos síntomas se describe en unas anotaciones de la propia paciente que luego nos facilitó. De manera simultánea se encontró una elevación del CA153 y de la fosfatasa alcalina que posteriormente se fue reduciendo hasta normalizarse (Gráfica 1). Desde el punto de vista clínico, la captación en la gammagrafía ósea no sufrió cambios relevantes pero la adenopatía supraclavicular alcanzó una respuesta completa. La duración de la respuesta fue de diez meses, tras los cuales presentó progresión ósea y hepática. Se encuentra recibiendo una nueva línea de quimioterapia con aparente estabilización de la enfermedad. Responsable clínico: Dr. Alejandro Sálamo Rubiales Oncología Médica Hospital Clínico Universitario C/ Ramón y Cajal, 3 E-47005 Valladolid E-mail: asrubiales@hotmail.com Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Sandra. Apellidos: Tobar Alvarez. NHC: 8942634. NASS: 32 78456397 48. Domicilio: C/ Castilla y León, 3, 4 D. Localidad/ Provincia: Valladolid. CP: 47021. Datos asistenciales. Fecha de nacimiento: 15/02/1957. País de nacimiento: España. Edad: 47 años Sexo: H. Fecha de Ingreso: 07/07/2004. Médico: Alejandro Sálamo Rubiales NºCol: 47 47 87921. Informe clínico del paciente: En el año 2000, a los 47 años de edad a la paciente se le practicó una mastectomía por un carcinoma ductal infiltrante de mama estadio IIIB (T4a N1). Los receptores hormonales eran positivos, al igual que el Herceptest (+++). Recibió tratamiento complementario con quimioterapia (CMF), radioterapia y tamoxifeno. En Mayo de 2003 se detectó una recidiva ósea cervical que ocasionaba compromiso medular. Fue tratada con cirugía y radioterapia local. Posteriormente comenzó tratamiento con letrozol. En Noviembre de 2003 se confirmó una progresión tumoral ósea y ganglionar (supraclavicular). Comenzó entonces tratamiento citostático paliativo con epirrubicina, docetaxel y trastuzumab. En las semanas siguientes presentó un empeoramiento sintomático importante pero transitorio; la evolución de estos síntomas se describe en unas anotaciones de la propia paciente que luego nos facilitó. De manera simultánea se encontró una elevación del CA153 y de la fosfatasa alcalina que posteriormente se fue reduciendo hasta normalizarse (Gráfica 1). Desde el punto de vista clínico, la captación en la gammagrafía ósea no sufrió cambios relevantes pero la adenopatía supraclavicular alcanzó una respuesta completa. La duración de la respuesta fue de diez meses, tras los cuales presentó progresión ósea y hepática. Se encuentra recibiendo una nueva línea de quimioterapia con aparente estabilización de la enfermedad. Responsable clínico: Dr. Alejandro Sálamo Rubiales Oncología Médica Hospital Clínico Universitario C/ Ramón y Cajal, 3 E-47005 Valladolid E-mail: asrubiales@hotmail.com
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Sandra", ".", "\n", "Apellidos", ":", "Tobar", "Alvarez", ".", "\n", "NHC", ":", "8942634", ".", "\n", "NASS", ":", "32", "78456397", "48", ".", "\n", "Domicilio", ":", "C/", "Castilla", "y", "León", ",", "3", ",", "4", "D.", "\n", "Localidad/", "Provincia", ":", "Valladolid", ".", "\n", "CP", ":", "47021", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/02/1957", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "47", "años", "Sexo", ":", " ", "H.", "\n", "Fecha", "de", "Ingreso", ":", "07/07/2004", ".", "\n", "Médico", ":", "Alejandro", "Sálamo", "Rubiales", "NºCol", ":", "47", "47", "87921", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "En", "el", "año", "2000", ",", "a", "los", "47", "años", "de", "edad", "a", "la", "paciente", "se", "le", "practicó", "una", "mastectomía", "por", "un", "carcinoma", "ductal", "infiltrante", "de", "mama", "estadio", "IIIB", "(", "T4a", "N1", ")", ".", "Los", "receptores", "hormonales", "eran", "positivos", ",", "al", "igual", "que", "el", "Herceptest", "(", "+", "+", "+", ")", ".", "Recibió", "tratamiento", "complementario", "con", "quimioterapia", "(", "CMF", ")", ",", "radioterapia", "y", "tamoxifeno", ".", "En", "Mayo", "de", "2003", "se", "detectó", "una", "recidiva", "ósea", "cervical", "que", "ocasionaba", "compromiso", "medular", ".", "Fue", "tratada", "con", "cirugía", "y", "radioterapia", "local", ".", "Posteriormente", "comenzó", "tratamiento", "con", "letrozol", ".", "En", "Noviembre", "de", "2003", "se", "confirmó", "una", "progresión", "tumoral", "ósea", "y", "ganglionar", "(", "supraclavicular", ")", ".", "Comenzó", "entonces", "tratamiento", "citostático", "paliativo", "con", "epirrubicina", ",", "docetaxel", "y", "trastuzumab", ".", "En", "las", "semanas", "siguientes", "presentó", "un", "empeoramiento", "sintomático", "importante", "pero", "transitorio", ";", "la", "evolución", "de", "estos", "síntomas", "se", "describe", "en", "unas", "anotaciones", "de", "la", "propia", "paciente", "que", "luego", "nos", "facilitó", ".", "De", "manera", "simultánea", "se", "encontró", "una", "elevación", "del", "CA153", "y", "de", "la", "fosfatasa", "alcalina", "que", "posteriormente", "se", "fue", "reduciendo", "hasta", "normalizarse", "(", "Gráfica", "1", ")", ".", "Desde", "el", "punto", "de", "vista", "clínico", ",", "la", "captación", "en", "la", "gammagrafía", "ósea", "no", "sufrió", "cambios", "relevantes", "pero", "la", "adenopatía", "supraclavicular", "alcanzó", "una", "respuesta", "completa", ".", "La", "duración", "de", "la", "respuesta", "fue", "de", "diez", "meses", ",", "tras", "los", "cuales", "presentó", "progresión", "ósea", "y", "hepática", ".", "Se", "encuentra", "recibiendo", "una", "nueva", "línea", "de", "quimioterapia", "con", "aparente", "estabilización", "de", "la", "enfermedad", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Alejandro", "Sálamo", "Rubiales", "Oncología", "Médica", "Hospital", "Clínico", "Universitario", "C/", "Ramón", "y", "Cajal", ",", "3", "E-47005", "Valladolid", "E", "-", "mail", ":", "asrubiales@hotmail.com", "\n" ]
[ "HOSPITAL", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "FECHAS", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Ets-1 is a protein, TNF - alpha promoter is a DNA
1.0alpha7.train.29_task0
Sentence: Inducer-specific binding of Ets-1 to the endogenous TNF-alpha promoter. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA, protein
[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "I-DNA", "I-DNA", "I-DNA", "O" ]
Inducer-specific binding of Ets-1 to the endogenous TNF-alpha promoter.
[ "Inducer", "-", "specific", "binding", "of", "Ets-1", "to", "the", "endogenous", "TNF", "-", "alpha", "promoter", "." ]
[ "DNA", "protein" ]
Ets-1 is a protein, TNF - alpha promoter is a DNA
1.0alpha7.train.29_task1
Sentence: Inducer-specific binding of Ets-1 to the endogenous TNF-alpha promoter. Instructions: please typing these entity words according to sentence: Ets-1, TNF - alpha promoter Options: DNA, protein
[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "I-DNA", "I-DNA", "I-DNA", "O" ]
Inducer-specific binding of Ets-1 to the endogenous TNF-alpha promoter.
[ "Inducer", "-", "specific", "binding", "of", "Ets-1", "to", "the", "endogenous", "TNF", "-", "alpha", "promoter", "." ]
[ "DNA", "protein" ]
Ets-1, TNF - alpha promoter
1.0alpha7.train.29_task2
Sentence: Inducer-specific binding of Ets-1 to the endogenous TNF-alpha promoter. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "I-DNA", "I-DNA", "I-DNA", "O" ]
Inducer-specific binding of Ets-1 to the endogenous TNF-alpha promoter.
[ "Inducer", "-", "specific", "binding", "of", "Ets-1", "to", "the", "endogenous", "TNF", "-", "alpha", "promoter", "." ]
[ "DNA", "protein" ]
IL-4 is a Protein, CD40 is a Protein, IL-4 is a Protein, signal transducers and activators of transcription ( STAT ) 6 is a Protein, STAT6 is a Protein, IL-4 is a Protein, CD40 is a Protein, CD40 is a Protein, CD23 is a Protein, STAT6 is a Protein, IL-4 is a Protein
809_task0
Sentence: A thiol antioxidant regulates IgE isotype switching by inhibiting activation of nuclear factor-kappaB. The binding site for nuclear factor-kappaB (NF-kappaB) is present at the promoter region of the germline Cepsilon gene, but there is little information on whether this factor is involved in regulating IgE synthesis by human B cells. Accordingly, we studied the role of NF-kappaB in germline Cepsilon transcription by using two human Burkitt's lymphoma B cell lines, DND39 and DG75. In both cell lines, n-acetyl-L-cysteine (NAC), a potent thiol antioxidant, inhibited the triggering of the nuclear expression of NF-kappaB by IL-4 and by anti-CD40 monoclonal antibody. Although IL-4 activated signal transducers and activators of transcription (STAT) 6 in addition to NF-kappaB, NAC treatment or the transfection of decoy oligodeoxynucleotides for NF-kappaB or STAT6 only partly blocked IL-4-induced germline Cepsilon transcription. However, these two decoy oligodeoxynucleotides together almost completely abrogated IL-4-induced germline Cepsilon transcription. Of note, CD40-mediated enhancement of IL-4-driven germline Cepsilon transcription was markedly decreased by NAC or by a decoy oligodeoxynucleotide for NF-kappaB. The effect of NAC was also examined on deletional switch recombination underlying the isotype switch to IgE. NAC inhibited the generation of Smu/Sepsilon switch fragments in normal human B cells costimulated with IL-4 and anti-CD40 monoclonal antibody. It also abolished IL-4-induced upregulation of CD40 but promoted upregulation of CD23. These results suggest that coordination of NF-kappaB and STAT6 may be required for induction of germline Cepsilon transcription by IL-4, and that CD40-mediated NF-kappaB activation may be important in regulating both enhancement of germline Cepsilon transcription and class switching to IgE. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A thiol antioxidant regulates IgE isotype switching by inhibiting activation of nuclear factor-kappaB. The binding site for nuclear factor-kappaB (NF-kappaB) is present at the promoter region of the germline Cepsilon gene, but there is little information on whether this factor is involved in regulating IgE synthesis by human B cells. Accordingly, we studied the role of NF-kappaB in germline Cepsilon transcription by using two human Burkitt's lymphoma B cell lines, DND39 and DG75. In both cell lines, n-acetyl-L-cysteine (NAC), a potent thiol antioxidant, inhibited the triggering of the nuclear expression of NF-kappaB by IL-4 and by anti-CD40 monoclonal antibody. Although IL-4 activated signal transducers and activators of transcription (STAT) 6 in addition to NF-kappaB, NAC treatment or the transfection of decoy oligodeoxynucleotides for NF-kappaB or STAT6 only partly blocked IL-4-induced germline Cepsilon transcription. However, these two decoy oligodeoxynucleotides together almost completely abrogated IL-4-induced germline Cepsilon transcription. Of note, CD40-mediated enhancement of IL-4-driven germline Cepsilon transcription was markedly decreased by NAC or by a decoy oligodeoxynucleotide for NF-kappaB. The effect of NAC was also examined on deletional switch recombination underlying the isotype switch to IgE. NAC inhibited the generation of Smu/Sepsilon switch fragments in normal human B cells costimulated with IL-4 and anti-CD40 monoclonal antibody. It also abolished IL-4-induced upregulation of CD40 but promoted upregulation of CD23. These results suggest that coordination of NF-kappaB and STAT6 may be required for induction of germline Cepsilon transcription by IL-4, and that CD40-mediated NF-kappaB activation may be important in regulating both enhancement of germline Cepsilon transcription and class switching to IgE.
[ "A", "thiol", "antioxidant", "regulates", "IgE", "isotype", "switching", "by", "inhibiting", "activation", "of", "nuclear", "factor", "-", "kappaB.", "\n", "The", "binding", "site", "for", "nuclear", "factor", "-", "kappaB", "(", "NF", "-", "kappaB", ")", "is", "present", "at", "the", "promoter", "region", "of", "the", "germline", "Cepsilon", "gene", ",", "but", "there", "is", "little", "information", "on", "whether", "this", "factor", "is", "involved", "in", "regulating", "IgE", "synthesis", "by", "human", "B", "cells", ".", "Accordingly", ",", "we", "studied", "the", "role", "of", "NF", "-", "kappaB", "in", "germline", "Cepsilon", "transcription", "by", "using", "two", "human", "Burkitt", "'s", "lymphoma", "B", "cell", "lines", ",", "DND39", "and", "DG75", ".", "In", "both", "cell", "lines", ",", "n", "-", "acetyl", "-", "L", "-", "cysteine", "(", "NAC", ")", ",", "a", "potent", "thiol", "antioxidant", ",", "inhibited", "the", "triggering", "of", "the", "nuclear", "expression", "of", "NF", "-", "kappaB", "by", "IL-4", "and", "by", "anti", "-", "CD40", "monoclonal", "antibody", ".", "Although", "IL-4", "activated", "signal", "transducers", "and", "activators", "of", "transcription", "(", "STAT", ")", "6", "in", "addition", "to", "NF", "-", "kappaB", ",", "NAC", "treatment", "or", "the", "transfection", "of", "decoy", "oligodeoxynucleotides", "for", "NF", "-", "kappaB", "or", "STAT6", "only", "partly", "blocked", "IL-4-induced", "germline", "Cepsilon", "transcription", ".", "However", ",", "these", "two", "decoy", "oligodeoxynucleotides", "together", "almost", "completely", "abrogated", "IL-4-induced", "germline", "Cepsilon", "transcription", ".", "Of", "note", ",", "CD40-mediated", "enhancement", "of", "IL-4-driven", "germline", "Cepsilon", "transcription", "was", "markedly", "decreased", "by", "NAC", "or", "by", "a", "decoy", "oligodeoxynucleotide", "for", "NF", "-", "kappaB.", "The", "effect", "of", "NAC", "was", "also", "examined", "on", "deletional", "switch", "recombination", "underlying", "the", "isotype", "switch", "to", "IgE.", "NAC", "inhibited", "the", "generation", "of", "Smu", "/", "Sepsilon", "switch", "fragments", "in", "normal", "human", "B", "cells", "costimulated", "with", "IL-4", "and", "anti", "-", "CD40", "monoclonal", "antibody", ".", "It", "also", "abolished", "IL-4-induced", "upregulation", "of", "CD40", "but", "promoted", "upregulation", "of", "CD23", ".", "These", "results", "suggest", "that", "coordination", "of", "NF", "-", "kappaB", "and", "STAT6", "may", "be", "required", "for", "induction", "of", "germline", "Cepsilon", "transcription", "by", "IL-4", ",", "and", "that", "CD40-mediated", "NF", "-", "kappaB", "activation", "may", "be", "important", "in", "regulating", "both", "enhancement", "of", "germline", "Cepsilon", "transcription", "and", "class", "switching", "to", "IgE." ]
[ "Protein" ]
IL-4 is a Protein, CD40 is a Protein, IL-4 is a Protein, signal transducers and activators of transcription ( STAT ) 6 is a Protein, STAT6 is a Protein, IL-4 is a Protein, CD40 is a Protein, CD40 is a Protein, CD23 is a Protein, STAT6 is a Protein, IL-4 is a Protein
809_task1
Sentence: A thiol antioxidant regulates IgE isotype switching by inhibiting activation of nuclear factor-kappaB. The binding site for nuclear factor-kappaB (NF-kappaB) is present at the promoter region of the germline Cepsilon gene, but there is little information on whether this factor is involved in regulating IgE synthesis by human B cells. Accordingly, we studied the role of NF-kappaB in germline Cepsilon transcription by using two human Burkitt's lymphoma B cell lines, DND39 and DG75. In both cell lines, n-acetyl-L-cysteine (NAC), a potent thiol antioxidant, inhibited the triggering of the nuclear expression of NF-kappaB by IL-4 and by anti-CD40 monoclonal antibody. Although IL-4 activated signal transducers and activators of transcription (STAT) 6 in addition to NF-kappaB, NAC treatment or the transfection of decoy oligodeoxynucleotides for NF-kappaB or STAT6 only partly blocked IL-4-induced germline Cepsilon transcription. However, these two decoy oligodeoxynucleotides together almost completely abrogated IL-4-induced germline Cepsilon transcription. Of note, CD40-mediated enhancement of IL-4-driven germline Cepsilon transcription was markedly decreased by NAC or by a decoy oligodeoxynucleotide for NF-kappaB. The effect of NAC was also examined on deletional switch recombination underlying the isotype switch to IgE. NAC inhibited the generation of Smu/Sepsilon switch fragments in normal human B cells costimulated with IL-4 and anti-CD40 monoclonal antibody. It also abolished IL-4-induced upregulation of CD40 but promoted upregulation of CD23. These results suggest that coordination of NF-kappaB and STAT6 may be required for induction of germline Cepsilon transcription by IL-4, and that CD40-mediated NF-kappaB activation may be important in regulating both enhancement of germline Cepsilon transcription and class switching to IgE. Instructions: please typing these entity words according to sentence: IL-4, CD40, IL-4, signal transducers and activators of transcription ( STAT ) 6, STAT6, IL-4, CD40, CD40, CD23, STAT6, IL-4 Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A thiol antioxidant regulates IgE isotype switching by inhibiting activation of nuclear factor-kappaB. The binding site for nuclear factor-kappaB (NF-kappaB) is present at the promoter region of the germline Cepsilon gene, but there is little information on whether this factor is involved in regulating IgE synthesis by human B cells. Accordingly, we studied the role of NF-kappaB in germline Cepsilon transcription by using two human Burkitt's lymphoma B cell lines, DND39 and DG75. In both cell lines, n-acetyl-L-cysteine (NAC), a potent thiol antioxidant, inhibited the triggering of the nuclear expression of NF-kappaB by IL-4 and by anti-CD40 monoclonal antibody. Although IL-4 activated signal transducers and activators of transcription (STAT) 6 in addition to NF-kappaB, NAC treatment or the transfection of decoy oligodeoxynucleotides for NF-kappaB or STAT6 only partly blocked IL-4-induced germline Cepsilon transcription. However, these two decoy oligodeoxynucleotides together almost completely abrogated IL-4-induced germline Cepsilon transcription. Of note, CD40-mediated enhancement of IL-4-driven germline Cepsilon transcription was markedly decreased by NAC or by a decoy oligodeoxynucleotide for NF-kappaB. The effect of NAC was also examined on deletional switch recombination underlying the isotype switch to IgE. NAC inhibited the generation of Smu/Sepsilon switch fragments in normal human B cells costimulated with IL-4 and anti-CD40 monoclonal antibody. It also abolished IL-4-induced upregulation of CD40 but promoted upregulation of CD23. These results suggest that coordination of NF-kappaB and STAT6 may be required for induction of germline Cepsilon transcription by IL-4, and that CD40-mediated NF-kappaB activation may be important in regulating both enhancement of germline Cepsilon transcription and class switching to IgE.
[ "A", "thiol", "antioxidant", "regulates", "IgE", "isotype", "switching", "by", "inhibiting", "activation", "of", "nuclear", "factor", "-", "kappaB.", "\n", "The", "binding", "site", "for", "nuclear", "factor", "-", "kappaB", "(", "NF", "-", "kappaB", ")", "is", "present", "at", "the", "promoter", "region", "of", "the", "germline", "Cepsilon", "gene", ",", "but", "there", "is", "little", "information", "on", "whether", "this", "factor", "is", "involved", "in", "regulating", "IgE", "synthesis", "by", "human", "B", "cells", ".", "Accordingly", ",", "we", "studied", "the", "role", "of", "NF", "-", "kappaB", "in", "germline", "Cepsilon", "transcription", "by", "using", "two", "human", "Burkitt", "'s", "lymphoma", "B", "cell", "lines", ",", "DND39", "and", "DG75", ".", "In", "both", "cell", "lines", ",", "n", "-", "acetyl", "-", "L", "-", "cysteine", "(", "NAC", ")", ",", "a", "potent", "thiol", "antioxidant", ",", "inhibited", "the", "triggering", "of", "the", "nuclear", "expression", "of", "NF", "-", "kappaB", "by", "IL-4", "and", "by", "anti", "-", "CD40", "monoclonal", "antibody", ".", "Although", "IL-4", "activated", "signal", "transducers", "and", "activators", "of", "transcription", "(", "STAT", ")", "6", "in", "addition", "to", "NF", "-", "kappaB", ",", "NAC", "treatment", "or", "the", "transfection", "of", "decoy", "oligodeoxynucleotides", "for", "NF", "-", "kappaB", "or", "STAT6", "only", "partly", "blocked", "IL-4-induced", "germline", "Cepsilon", "transcription", ".", "However", ",", "these", "two", "decoy", "oligodeoxynucleotides", "together", "almost", "completely", "abrogated", "IL-4-induced", "germline", "Cepsilon", "transcription", ".", "Of", "note", ",", "CD40-mediated", "enhancement", "of", "IL-4-driven", "germline", "Cepsilon", "transcription", "was", "markedly", "decreased", "by", "NAC", "or", "by", "a", "decoy", "oligodeoxynucleotide", "for", "NF", "-", "kappaB.", "The", "effect", "of", "NAC", "was", "also", "examined", "on", "deletional", "switch", "recombination", "underlying", "the", "isotype", "switch", "to", "IgE.", "NAC", "inhibited", "the", "generation", "of", "Smu", "/", "Sepsilon", "switch", "fragments", "in", "normal", "human", "B", "cells", "costimulated", "with", "IL-4", "and", "anti", "-", "CD40", "monoclonal", "antibody", ".", "It", "also", "abolished", "IL-4-induced", "upregulation", "of", "CD40", "but", "promoted", "upregulation", "of", "CD23", ".", "These", "results", "suggest", "that", "coordination", "of", "NF", "-", "kappaB", "and", "STAT6", "may", "be", "required", "for", "induction", "of", "germline", "Cepsilon", "transcription", "by", "IL-4", ",", "and", "that", "CD40-mediated", "NF", "-", "kappaB", "activation", "may", "be", "important", "in", "regulating", "both", "enhancement", "of", "germline", "Cepsilon", "transcription", "and", "class", "switching", "to", "IgE." ]
[ "Protein" ]
IL-4, CD40, IL-4, signal transducers and activators of transcription ( STAT ) 6, STAT6, IL-4, CD40, CD40, CD23, STAT6, IL-4
809_task2
Sentence: A thiol antioxidant regulates IgE isotype switching by inhibiting activation of nuclear factor-kappaB. The binding site for nuclear factor-kappaB (NF-kappaB) is present at the promoter region of the germline Cepsilon gene, but there is little information on whether this factor is involved in regulating IgE synthesis by human B cells. Accordingly, we studied the role of NF-kappaB in germline Cepsilon transcription by using two human Burkitt's lymphoma B cell lines, DND39 and DG75. In both cell lines, n-acetyl-L-cysteine (NAC), a potent thiol antioxidant, inhibited the triggering of the nuclear expression of NF-kappaB by IL-4 and by anti-CD40 monoclonal antibody. Although IL-4 activated signal transducers and activators of transcription (STAT) 6 in addition to NF-kappaB, NAC treatment or the transfection of decoy oligodeoxynucleotides for NF-kappaB or STAT6 only partly blocked IL-4-induced germline Cepsilon transcription. However, these two decoy oligodeoxynucleotides together almost completely abrogated IL-4-induced germline Cepsilon transcription. Of note, CD40-mediated enhancement of IL-4-driven germline Cepsilon transcription was markedly decreased by NAC or by a decoy oligodeoxynucleotide for NF-kappaB. The effect of NAC was also examined on deletional switch recombination underlying the isotype switch to IgE. NAC inhibited the generation of Smu/Sepsilon switch fragments in normal human B cells costimulated with IL-4 and anti-CD40 monoclonal antibody. It also abolished IL-4-induced upregulation of CD40 but promoted upregulation of CD23. These results suggest that coordination of NF-kappaB and STAT6 may be required for induction of germline Cepsilon transcription by IL-4, and that CD40-mediated NF-kappaB activation may be important in regulating both enhancement of germline Cepsilon transcription and class switching to IgE. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A thiol antioxidant regulates IgE isotype switching by inhibiting activation of nuclear factor-kappaB. The binding site for nuclear factor-kappaB (NF-kappaB) is present at the promoter region of the germline Cepsilon gene, but there is little information on whether this factor is involved in regulating IgE synthesis by human B cells. Accordingly, we studied the role of NF-kappaB in germline Cepsilon transcription by using two human Burkitt's lymphoma B cell lines, DND39 and DG75. In both cell lines, n-acetyl-L-cysteine (NAC), a potent thiol antioxidant, inhibited the triggering of the nuclear expression of NF-kappaB by IL-4 and by anti-CD40 monoclonal antibody. Although IL-4 activated signal transducers and activators of transcription (STAT) 6 in addition to NF-kappaB, NAC treatment or the transfection of decoy oligodeoxynucleotides for NF-kappaB or STAT6 only partly blocked IL-4-induced germline Cepsilon transcription. However, these two decoy oligodeoxynucleotides together almost completely abrogated IL-4-induced germline Cepsilon transcription. Of note, CD40-mediated enhancement of IL-4-driven germline Cepsilon transcription was markedly decreased by NAC or by a decoy oligodeoxynucleotide for NF-kappaB. The effect of NAC was also examined on deletional switch recombination underlying the isotype switch to IgE. NAC inhibited the generation of Smu/Sepsilon switch fragments in normal human B cells costimulated with IL-4 and anti-CD40 monoclonal antibody. It also abolished IL-4-induced upregulation of CD40 but promoted upregulation of CD23. These results suggest that coordination of NF-kappaB and STAT6 may be required for induction of germline Cepsilon transcription by IL-4, and that CD40-mediated NF-kappaB activation may be important in regulating both enhancement of germline Cepsilon transcription and class switching to IgE.
[ "A", "thiol", "antioxidant", "regulates", "IgE", "isotype", "switching", "by", "inhibiting", "activation", "of", "nuclear", "factor", "-", "kappaB.", "\n", "The", "binding", "site", "for", "nuclear", "factor", "-", "kappaB", "(", "NF", "-", "kappaB", ")", "is", "present", "at", "the", "promoter", "region", "of", "the", "germline", "Cepsilon", "gene", ",", "but", "there", "is", "little", "information", "on", "whether", "this", "factor", "is", "involved", "in", "regulating", "IgE", "synthesis", "by", "human", "B", "cells", ".", "Accordingly", ",", "we", "studied", "the", "role", "of", "NF", "-", "kappaB", "in", "germline", "Cepsilon", "transcription", "by", "using", "two", "human", "Burkitt", "'s", "lymphoma", "B", "cell", "lines", ",", "DND39", "and", "DG75", ".", "In", "both", "cell", "lines", ",", "n", "-", "acetyl", "-", "L", "-", "cysteine", "(", "NAC", ")", ",", "a", "potent", "thiol", "antioxidant", ",", "inhibited", "the", "triggering", "of", "the", "nuclear", "expression", "of", "NF", "-", "kappaB", "by", "IL-4", "and", "by", "anti", "-", "CD40", "monoclonal", "antibody", ".", "Although", "IL-4", "activated", "signal", "transducers", "and", "activators", "of", "transcription", "(", "STAT", ")", "6", "in", "addition", "to", "NF", "-", "kappaB", ",", "NAC", "treatment", "or", "the", "transfection", "of", "decoy", "oligodeoxynucleotides", "for", "NF", "-", "kappaB", "or", "STAT6", "only", "partly", "blocked", "IL-4-induced", "germline", "Cepsilon", "transcription", ".", "However", ",", "these", "two", "decoy", "oligodeoxynucleotides", "together", "almost", "completely", "abrogated", "IL-4-induced", "germline", "Cepsilon", "transcription", ".", "Of", "note", ",", "CD40-mediated", "enhancement", "of", "IL-4-driven", "germline", "Cepsilon", "transcription", "was", "markedly", "decreased", "by", "NAC", "or", "by", "a", "decoy", "oligodeoxynucleotide", "for", "NF", "-", "kappaB.", "The", "effect", "of", "NAC", "was", "also", "examined", "on", "deletional", "switch", "recombination", "underlying", "the", "isotype", "switch", "to", "IgE.", "NAC", "inhibited", "the", "generation", "of", "Smu", "/", "Sepsilon", "switch", "fragments", "in", "normal", "human", "B", "cells", "costimulated", "with", "IL-4", "and", "anti", "-", "CD40", "monoclonal", "antibody", ".", "It", "also", "abolished", "IL-4-induced", "upregulation", "of", "CD40", "but", "promoted", "upregulation", "of", "CD23", ".", "These", "results", "suggest", "that", "coordination", "of", "NF", "-", "kappaB", "and", "STAT6", "may", "be", "required", "for", "induction", "of", "germline", "Cepsilon", "transcription", "by", "IL-4", ",", "and", "that", "CD40-mediated", "NF", "-", "kappaB", "activation", "may", "be", "important", "in", "regulating", "both", "enhancement", "of", "germline", "Cepsilon", "transcription", "and", "class", "switching", "to", "IgE." ]
[ "Protein" ]
Oct2 is a Protein, Oct2 is a Protein, Oct2 is a Protein, Oct2 is a Protein, Oct2 is a Protein, Oct2 is a Protein, Oct2 is a Protein, Oct1 is a Protein, Oct2 is a Protein
1620119_task0
Sentence: Oct2 transactivation from a remote enhancer position requires a B-cell-restricted activity. Previous cotransfection experiments had demonstrated that ectopic expression of the lymphocyte-specific transcription factor Oct2 could efficiently activate a promoter containing an octamer motif. Oct2 expression was unable to stimulate a multimerized octamer enhancer element in HeLa cells, however. We have tested a variety of Oct2 isoforms generated by alternative splicing for the capability to activate an octamer enhancer in nonlymphoid cells and a B-cell line. Our analyses show that several Oct2 isoforms can stimulate from a remote position but that this stimulation is restricted to B cells. This result indicates the involvement of either a B-cell-specific cofactor or a specific modification of a cofactor or the Oct2 protein in Oct2-mediated enhancer activation. Mutational analyses indicate that the carboxy-terminal domain of Oct2 is critical for enhancer activation. Moreover, this domain conferred enhancing activity when fused to the Oct1 protein, which by itself was unable to stimulate from a remote position. The glutamine-rich activation domain present in the amino-terminal portion of Oct2 and the POU domain contribute only marginally to the transactivation function from a distal position. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Oct2 transactivation from a remote enhancer position requires a B-cell-restricted activity. Previous cotransfection experiments had demonstrated that ectopic expression of the lymphocyte-specific transcription factor Oct2 could efficiently activate a promoter containing an octamer motif. Oct2 expression was unable to stimulate a multimerized octamer enhancer element in HeLa cells, however. We have tested a variety of Oct2 isoforms generated by alternative splicing for the capability to activate an octamer enhancer in nonlymphoid cells and a B-cell line. Our analyses show that several Oct2 isoforms can stimulate from a remote position but that this stimulation is restricted to B cells. This result indicates the involvement of either a B-cell-specific cofactor or a specific modification of a cofactor or the Oct2 protein in Oct2-mediated enhancer activation. Mutational analyses indicate that the carboxy-terminal domain of Oct2 is critical for enhancer activation. Moreover, this domain conferred enhancing activity when fused to the Oct1 protein, which by itself was unable to stimulate from a remote position. The glutamine-rich activation domain present in the amino-terminal portion of Oct2 and the POU domain contribute only marginally to the transactivation function from a distal position.
[ "Oct2", "transactivation", "from", "a", "remote", "enhancer", "position", "requires", "a", "B", "-", "cell", "-", "restricted", "activity", ".", "\n", "Previous", "cotransfection", "experiments", "had", "demonstrated", "that", "ectopic", "expression", "of", "the", "lymphocyte", "-", "specific", "transcription", "factor", "Oct2", "could", "efficiently", "activate", "a", "promoter", "containing", "an", "octamer", "motif", ".", "Oct2", "expression", "was", "unable", "to", "stimulate", "a", "multimerized", "octamer", "enhancer", "element", "in", "HeLa", "cells", ",", "however", ".", "We", "have", "tested", "a", "variety", "of", "Oct2", "isoforms", "generated", "by", "alternative", "splicing", "for", "the", "capability", "to", "activate", "an", "octamer", "enhancer", "in", "nonlymphoid", "cells", "and", "a", "B", "-", "cell", "line", ".", "Our", "analyses", "show", "that", "several", "Oct2", "isoforms", "can", "stimulate", "from", "a", "remote", "position", "but", "that", "this", "stimulation", "is", "restricted", "to", "B", "cells", ".", "This", "result", "indicates", "the", "involvement", "of", "either", "a", "B", "-", "cell", "-", "specific", "cofactor", "or", "a", "specific", "modification", "of", "a", "cofactor", "or", "the", "Oct2", "protein", "in", "Oct2-mediated", "enhancer", "activation", ".", "Mutational", "analyses", "indicate", "that", "the", "carboxy", "-", "terminal", "domain", "of", "Oct2", "is", "critical", "for", "enhancer", "activation", ".", "Moreover", ",", "this", "domain", "conferred", "enhancing", "activity", "when", "fused", "to", "the", "Oct1", "protein", ",", "which", "by", "itself", "was", "unable", "to", "stimulate", "from", "a", "remote", "position", ".", "The", "glutamine", "-", "rich", "activation", "domain", "present", "in", "the", "amino", "-", "terminal", "portion", "of", "Oct2", "and", "the", "POU", "domain", "contribute", "only", "marginally", "to", "the", "transactivation", "function", "from", "a", "distal", "position", "." ]
[ "Protein" ]
Oct2 is a Protein, Oct2 is a Protein, Oct2 is a Protein, Oct2 is a Protein, Oct2 is a Protein, Oct2 is a Protein, Oct2 is a Protein, Oct1 is a Protein, Oct2 is a Protein
1620119_task1
Sentence: Oct2 transactivation from a remote enhancer position requires a B-cell-restricted activity. Previous cotransfection experiments had demonstrated that ectopic expression of the lymphocyte-specific transcription factor Oct2 could efficiently activate a promoter containing an octamer motif. Oct2 expression was unable to stimulate a multimerized octamer enhancer element in HeLa cells, however. We have tested a variety of Oct2 isoforms generated by alternative splicing for the capability to activate an octamer enhancer in nonlymphoid cells and a B-cell line. Our analyses show that several Oct2 isoforms can stimulate from a remote position but that this stimulation is restricted to B cells. This result indicates the involvement of either a B-cell-specific cofactor or a specific modification of a cofactor or the Oct2 protein in Oct2-mediated enhancer activation. Mutational analyses indicate that the carboxy-terminal domain of Oct2 is critical for enhancer activation. Moreover, this domain conferred enhancing activity when fused to the Oct1 protein, which by itself was unable to stimulate from a remote position. The glutamine-rich activation domain present in the amino-terminal portion of Oct2 and the POU domain contribute only marginally to the transactivation function from a distal position. Instructions: please typing these entity words according to sentence: Oct2, Oct2, Oct2, Oct2, Oct2, Oct2, Oct2, Oct1, Oct2 Options: Protein
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Oct2 transactivation from a remote enhancer position requires a B-cell-restricted activity. Previous cotransfection experiments had demonstrated that ectopic expression of the lymphocyte-specific transcription factor Oct2 could efficiently activate a promoter containing an octamer motif. Oct2 expression was unable to stimulate a multimerized octamer enhancer element in HeLa cells, however. We have tested a variety of Oct2 isoforms generated by alternative splicing for the capability to activate an octamer enhancer in nonlymphoid cells and a B-cell line. Our analyses show that several Oct2 isoforms can stimulate from a remote position but that this stimulation is restricted to B cells. This result indicates the involvement of either a B-cell-specific cofactor or a specific modification of a cofactor or the Oct2 protein in Oct2-mediated enhancer activation. Mutational analyses indicate that the carboxy-terminal domain of Oct2 is critical for enhancer activation. Moreover, this domain conferred enhancing activity when fused to the Oct1 protein, which by itself was unable to stimulate from a remote position. The glutamine-rich activation domain present in the amino-terminal portion of Oct2 and the POU domain contribute only marginally to the transactivation function from a distal position.
[ "Oct2", "transactivation", "from", "a", "remote", "enhancer", "position", "requires", "a", "B", "-", "cell", "-", "restricted", "activity", ".", "\n", "Previous", "cotransfection", "experiments", "had", "demonstrated", "that", "ectopic", "expression", "of", "the", "lymphocyte", "-", "specific", "transcription", "factor", "Oct2", "could", "efficiently", "activate", "a", "promoter", "containing", "an", "octamer", "motif", ".", "Oct2", "expression", "was", "unable", "to", "stimulate", "a", "multimerized", "octamer", "enhancer", "element", "in", "HeLa", "cells", ",", "however", ".", "We", "have", "tested", "a", "variety", "of", "Oct2", "isoforms", "generated", "by", "alternative", "splicing", "for", "the", "capability", "to", "activate", "an", "octamer", "enhancer", "in", "nonlymphoid", "cells", "and", "a", "B", "-", "cell", "line", ".", "Our", "analyses", "show", "that", "several", "Oct2", "isoforms", "can", "stimulate", "from", "a", "remote", "position", "but", "that", "this", "stimulation", "is", "restricted", "to", "B", "cells", ".", "This", "result", "indicates", "the", "involvement", "of", "either", "a", "B", "-", "cell", "-", "specific", "cofactor", "or", "a", "specific", "modification", "of", "a", "cofactor", "or", "the", "Oct2", "protein", "in", "Oct2-mediated", "enhancer", "activation", ".", "Mutational", "analyses", "indicate", "that", "the", "carboxy", "-", "terminal", "domain", "of", "Oct2", "is", "critical", "for", "enhancer", "activation", ".", "Moreover", ",", "this", "domain", "conferred", "enhancing", "activity", "when", "fused", "to", "the", "Oct1", "protein", ",", "which", "by", "itself", "was", "unable", "to", "stimulate", "from", "a", "remote", "position", ".", "The", "glutamine", "-", "rich", "activation", "domain", "present", "in", "the", "amino", "-", "terminal", "portion", "of", "Oct2", "and", "the", "POU", "domain", "contribute", "only", "marginally", "to", "the", "transactivation", "function", "from", "a", "distal", "position", "." ]
[ "Protein" ]
Oct2, Oct2, Oct2, Oct2, Oct2, Oct2, Oct2, Oct1, Oct2
1620119_task2
Sentence: Oct2 transactivation from a remote enhancer position requires a B-cell-restricted activity. Previous cotransfection experiments had demonstrated that ectopic expression of the lymphocyte-specific transcription factor Oct2 could efficiently activate a promoter containing an octamer motif. Oct2 expression was unable to stimulate a multimerized octamer enhancer element in HeLa cells, however. We have tested a variety of Oct2 isoforms generated by alternative splicing for the capability to activate an octamer enhancer in nonlymphoid cells and a B-cell line. Our analyses show that several Oct2 isoforms can stimulate from a remote position but that this stimulation is restricted to B cells. This result indicates the involvement of either a B-cell-specific cofactor or a specific modification of a cofactor or the Oct2 protein in Oct2-mediated enhancer activation. Mutational analyses indicate that the carboxy-terminal domain of Oct2 is critical for enhancer activation. Moreover, this domain conferred enhancing activity when fused to the Oct1 protein, which by itself was unable to stimulate from a remote position. The glutamine-rich activation domain present in the amino-terminal portion of Oct2 and the POU domain contribute only marginally to the transactivation function from a distal position. Instructions: please extract entity words from the input sentence
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Oct2 transactivation from a remote enhancer position requires a B-cell-restricted activity. Previous cotransfection experiments had demonstrated that ectopic expression of the lymphocyte-specific transcription factor Oct2 could efficiently activate a promoter containing an octamer motif. Oct2 expression was unable to stimulate a multimerized octamer enhancer element in HeLa cells, however. We have tested a variety of Oct2 isoforms generated by alternative splicing for the capability to activate an octamer enhancer in nonlymphoid cells and a B-cell line. Our analyses show that several Oct2 isoforms can stimulate from a remote position but that this stimulation is restricted to B cells. This result indicates the involvement of either a B-cell-specific cofactor or a specific modification of a cofactor or the Oct2 protein in Oct2-mediated enhancer activation. Mutational analyses indicate that the carboxy-terminal domain of Oct2 is critical for enhancer activation. Moreover, this domain conferred enhancing activity when fused to the Oct1 protein, which by itself was unable to stimulate from a remote position. The glutamine-rich activation domain present in the amino-terminal portion of Oct2 and the POU domain contribute only marginally to the transactivation function from a distal position.
[ "Oct2", "transactivation", "from", "a", "remote", "enhancer", "position", "requires", "a", "B", "-", "cell", "-", "restricted", "activity", ".", "\n", "Previous", "cotransfection", "experiments", "had", "demonstrated", "that", "ectopic", "expression", "of", "the", "lymphocyte", "-", "specific", "transcription", "factor", "Oct2", "could", "efficiently", "activate", "a", "promoter", "containing", "an", "octamer", "motif", ".", "Oct2", "expression", "was", "unable", "to", "stimulate", "a", "multimerized", "octamer", "enhancer", "element", "in", "HeLa", "cells", ",", "however", ".", "We", "have", "tested", "a", "variety", "of", "Oct2", "isoforms", "generated", "by", "alternative", "splicing", "for", "the", "capability", "to", "activate", "an", "octamer", "enhancer", "in", "nonlymphoid", "cells", "and", "a", "B", "-", "cell", "line", ".", "Our", "analyses", "show", "that", "several", "Oct2", "isoforms", "can", "stimulate", "from", "a", "remote", "position", "but", "that", "this", "stimulation", "is", "restricted", "to", "B", "cells", ".", "This", "result", "indicates", "the", "involvement", "of", "either", "a", "B", "-", "cell", "-", "specific", "cofactor", "or", "a", "specific", "modification", "of", "a", "cofactor", "or", "the", "Oct2", "protein", "in", "Oct2-mediated", "enhancer", "activation", ".", "Mutational", "analyses", "indicate", "that", "the", "carboxy", "-", "terminal", "domain", "of", "Oct2", "is", "critical", "for", "enhancer", "activation", ".", "Moreover", ",", "this", "domain", "conferred", "enhancing", "activity", "when", "fused", "to", "the", "Oct1", "protein", ",", "which", "by", "itself", "was", "unable", "to", "stimulate", "from", "a", "remote", "position", ".", "The", "glutamine", "-", "rich", "activation", "domain", "present", "in", "the", "amino", "-", "terminal", "portion", "of", "Oct2", "and", "the", "POU", "domain", "contribute", "only", "marginally", "to", "the", "transactivation", "function", "from", "a", "distal", "position", "." ]
[ "Protein" ]
function is an umlsterm, role is an umlsterm, pathogenesis is an umlsterm, disease is an umlsterm, ulcerative colitis is an umlsterm, therapy is an umlsterm, inflammatory bowel disease is an umlsterm, antibiotics is an umlsterm, therapy is an umlsterm, inflammatory bowel diseases is an umlsterm, release is an umlsterm, 5-aminosalicylic acid is an umlsterm, therapy is an umlsterm, side effects is an umlsterm, Future is an umlsterm, therapeutic is an umlsterm, therapy is an umlsterm, cytokines is an umlsterm, cytokine is an umlsterm, antibodies is an umlsterm, Maintenance is an umlsterm, therapy is an umlsterm, antioxidants is an umlsterm, uncertainty is an umlsterm, cause is an umlsterm, inflammatory bowel diseases is an umlsterm, control is an umlsterm, disease is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, inflammatory bowel diseases is an umlsterm
DerRadiologe.80380003.eng.abstr_task0
Sentence: Recent studies indicate that the normal intestinal flora , an exagerated reaction of the intestinal immun system and a decreased epithelial barrier function of the gut play an important role in the pathogenesis of Crohn's disease and ulcerative colitis . The medical therapy of inflammatory bowel disease aims to correct these alterations . Aminosalicylates , corticosteroides , immunsuppressants and antibiotics are the four main groups of substances which are currently used for the therapy of inflammatory bowel diseases . Slow release formulation allow specific targeting of 5-aminosalicylic acid to the inflamed sections of the gut ; with budesonid a corticosteroide therapy with minimal systemic side effects is possible . Future therapeutic options include specific immuno-modulatory therapy with cytokines or cytokine antibodies . Maintenance therapy may , conceivably , be performed with probiotics or antioxidants . Therefore , despite continued uncertainty about the cause of inflammatory bowel diseases , recent advances nourish the hope for further improvement of the control of disease activity and a better quality of life for patients with inflammatory bowel diseases . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]
Recent studies indicate that the normal intestinal flora , an exagerated reaction of the intestinal immun system and a decreased epithelial barrier function of the gut play an important role in the pathogenesis of Crohn's disease and ulcerative colitis . The medical therapy of inflammatory bowel disease aims to correct these alterations . Aminosalicylates , corticosteroides , immunsuppressants and antibiotics are the four main groups of substances which are currently used for the therapy of inflammatory bowel diseases . Slow release formulation allow specific targeting of 5-aminosalicylic acid to the inflamed sections of the gut ; with budesonid a corticosteroide therapy with minimal systemic side effects is possible . Future therapeutic options include specific immuno-modulatory therapy with cytokines or cytokine antibodies . Maintenance therapy may , conceivably , be performed with probiotics or antioxidants . Therefore , despite continued uncertainty about the cause of inflammatory bowel diseases , recent advances nourish the hope for further improvement of the control of disease activity and a better quality of life for patients with inflammatory bowel diseases .
[ "Recent", "studies", "indicate", "that", "the", "normal", "intestinal", "flora", ",", "an", "exagerated", "reaction", "of", "the", "intestinal", "immun", "system", "and", "a", "decreased", "epithelial", "barrier", "function", "of", "the", "gut", "play", "an", "important", "role", "in", "the", "pathogenesis", "of", "Crohn", "'s", "disease", "and", "ulcerative", "colitis", ".", "The", "medical", "therapy", "of", "inflammatory", "bowel", "disease", "aims", "to", "correct", "these", "alterations", ".", "Aminosalicylates", ",", "corticosteroides", ",", "immunsuppressants", "and", "antibiotics", "are", "the", "four", "main", "groups", "of", "substances", "which", "are", "currently", "used", "for", "the", "therapy", "of", "inflammatory", "bowel", "diseases", ".", "Slow", "release", "formulation", "allow", "specific", "targeting", "of", "5-aminosalicylic", "acid", "to", "the", "inflamed", "sections", "of", "the", "gut", ";", "with", "budesonid", "a", "corticosteroide", "therapy", "with", "minimal", "systemic", "side", "effects", "is", "possible", ".", "Future", "therapeutic", "options", "include", "specific", "immuno", "-", "modulatory", "therapy", "with", "cytokines", "or", "cytokine", "antibodies", ".", "Maintenance", "therapy", "may", ",", "conceivably", ",", "be", "performed", "with", "probiotics", "or", "antioxidants", ".", "Therefore", ",", "despite", "continued", "uncertainty", "about", "the", "cause", "of", "inflammatory", "bowel", "diseases", ",", "recent", "advances", "nourish", "the", "hope", "for", "further", "improvement", "of", "the", "control", "of", "disease", "activity", "and", "a", "better", "quality", "of", "life", "for", "patients", "with", "inflammatory", "bowel", "diseases", "." ]
[ "umlsterm" ]
function is an umlsterm, role is an umlsterm, pathogenesis is an umlsterm, disease is an umlsterm, ulcerative colitis is an umlsterm, therapy is an umlsterm, inflammatory bowel disease is an umlsterm, antibiotics is an umlsterm, therapy is an umlsterm, inflammatory bowel diseases is an umlsterm, release is an umlsterm, 5-aminosalicylic acid is an umlsterm, therapy is an umlsterm, side effects is an umlsterm, Future is an umlsterm, therapeutic is an umlsterm, therapy is an umlsterm, cytokines is an umlsterm, cytokine is an umlsterm, antibodies is an umlsterm, Maintenance is an umlsterm, therapy is an umlsterm, antioxidants is an umlsterm, uncertainty is an umlsterm, cause is an umlsterm, inflammatory bowel diseases is an umlsterm, control is an umlsterm, disease is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, inflammatory bowel diseases is an umlsterm
DerRadiologe.80380003.eng.abstr_task1
Sentence: Recent studies indicate that the normal intestinal flora , an exagerated reaction of the intestinal immun system and a decreased epithelial barrier function of the gut play an important role in the pathogenesis of Crohn's disease and ulcerative colitis . The medical therapy of inflammatory bowel disease aims to correct these alterations . Aminosalicylates , corticosteroides , immunsuppressants and antibiotics are the four main groups of substances which are currently used for the therapy of inflammatory bowel diseases . Slow release formulation allow specific targeting of 5-aminosalicylic acid to the inflamed sections of the gut ; with budesonid a corticosteroide therapy with minimal systemic side effects is possible . Future therapeutic options include specific immuno-modulatory therapy with cytokines or cytokine antibodies . Maintenance therapy may , conceivably , be performed with probiotics or antioxidants . Therefore , despite continued uncertainty about the cause of inflammatory bowel diseases , recent advances nourish the hope for further improvement of the control of disease activity and a better quality of life for patients with inflammatory bowel diseases . Instructions: please typing these entity words according to sentence: function, role, pathogenesis, disease, ulcerative colitis, therapy, inflammatory bowel disease, antibiotics, therapy, inflammatory bowel diseases, release, 5-aminosalicylic acid, therapy, side effects, Future, therapeutic, therapy, cytokines, cytokine, antibodies, Maintenance, therapy, antioxidants, uncertainty, cause, inflammatory bowel diseases, control, disease, quality of life, patients, inflammatory bowel diseases Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]
Recent studies indicate that the normal intestinal flora , an exagerated reaction of the intestinal immun system and a decreased epithelial barrier function of the gut play an important role in the pathogenesis of Crohn's disease and ulcerative colitis . The medical therapy of inflammatory bowel disease aims to correct these alterations . Aminosalicylates , corticosteroides , immunsuppressants and antibiotics are the four main groups of substances which are currently used for the therapy of inflammatory bowel diseases . Slow release formulation allow specific targeting of 5-aminosalicylic acid to the inflamed sections of the gut ; with budesonid a corticosteroide therapy with minimal systemic side effects is possible . Future therapeutic options include specific immuno-modulatory therapy with cytokines or cytokine antibodies . Maintenance therapy may , conceivably , be performed with probiotics or antioxidants . Therefore , despite continued uncertainty about the cause of inflammatory bowel diseases , recent advances nourish the hope for further improvement of the control of disease activity and a better quality of life for patients with inflammatory bowel diseases .
[ "Recent", "studies", "indicate", "that", "the", "normal", "intestinal", "flora", ",", "an", "exagerated", "reaction", "of", "the", "intestinal", "immun", "system", "and", "a", "decreased", "epithelial", "barrier", "function", "of", "the", "gut", "play", "an", "important", "role", "in", "the", "pathogenesis", "of", "Crohn", "'s", "disease", "and", "ulcerative", "colitis", ".", "The", "medical", "therapy", "of", "inflammatory", "bowel", "disease", "aims", "to", "correct", "these", "alterations", ".", "Aminosalicylates", ",", "corticosteroides", ",", "immunsuppressants", "and", "antibiotics", "are", "the", "four", "main", "groups", "of", "substances", "which", "are", "currently", "used", "for", "the", "therapy", "of", "inflammatory", "bowel", "diseases", ".", "Slow", "release", "formulation", "allow", "specific", "targeting", "of", "5-aminosalicylic", "acid", "to", "the", "inflamed", "sections", "of", "the", "gut", ";", "with", "budesonid", "a", "corticosteroide", "therapy", "with", "minimal", "systemic", "side", "effects", "is", "possible", ".", "Future", "therapeutic", "options", "include", "specific", "immuno", "-", "modulatory", "therapy", "with", "cytokines", "or", "cytokine", "antibodies", ".", "Maintenance", "therapy", "may", ",", "conceivably", ",", "be", "performed", "with", "probiotics", "or", "antioxidants", ".", "Therefore", ",", "despite", "continued", "uncertainty", "about", "the", "cause", "of", "inflammatory", "bowel", "diseases", ",", "recent", "advances", "nourish", "the", "hope", "for", "further", "improvement", "of", "the", "control", "of", "disease", "activity", "and", "a", "better", "quality", "of", "life", "for", "patients", "with", "inflammatory", "bowel", "diseases", "." ]
[ "umlsterm" ]
function, role, pathogenesis, disease, ulcerative colitis, therapy, inflammatory bowel disease, antibiotics, therapy, inflammatory bowel diseases, release, 5-aminosalicylic acid, therapy, side effects, Future, therapeutic, therapy, cytokines, cytokine, antibodies, Maintenance, therapy, antioxidants, uncertainty, cause, inflammatory bowel diseases, control, disease, quality of life, patients, inflammatory bowel diseases
DerRadiologe.80380003.eng.abstr_task2
Sentence: Recent studies indicate that the normal intestinal flora , an exagerated reaction of the intestinal immun system and a decreased epithelial barrier function of the gut play an important role in the pathogenesis of Crohn's disease and ulcerative colitis . The medical therapy of inflammatory bowel disease aims to correct these alterations . Aminosalicylates , corticosteroides , immunsuppressants and antibiotics are the four main groups of substances which are currently used for the therapy of inflammatory bowel diseases . Slow release formulation allow specific targeting of 5-aminosalicylic acid to the inflamed sections of the gut ; with budesonid a corticosteroide therapy with minimal systemic side effects is possible . Future therapeutic options include specific immuno-modulatory therapy with cytokines or cytokine antibodies . Maintenance therapy may , conceivably , be performed with probiotics or antioxidants . Therefore , despite continued uncertainty about the cause of inflammatory bowel diseases , recent advances nourish the hope for further improvement of the control of disease activity and a better quality of life for patients with inflammatory bowel diseases . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]
Recent studies indicate that the normal intestinal flora , an exagerated reaction of the intestinal immun system and a decreased epithelial barrier function of the gut play an important role in the pathogenesis of Crohn's disease and ulcerative colitis . The medical therapy of inflammatory bowel disease aims to correct these alterations . Aminosalicylates , corticosteroides , immunsuppressants and antibiotics are the four main groups of substances which are currently used for the therapy of inflammatory bowel diseases . Slow release formulation allow specific targeting of 5-aminosalicylic acid to the inflamed sections of the gut ; with budesonid a corticosteroide therapy with minimal systemic side effects is possible . Future therapeutic options include specific immuno-modulatory therapy with cytokines or cytokine antibodies . Maintenance therapy may , conceivably , be performed with probiotics or antioxidants . Therefore , despite continued uncertainty about the cause of inflammatory bowel diseases , recent advances nourish the hope for further improvement of the control of disease activity and a better quality of life for patients with inflammatory bowel diseases .
[ "Recent", "studies", "indicate", "that", "the", "normal", "intestinal", "flora", ",", "an", "exagerated", "reaction", "of", "the", "intestinal", "immun", "system", "and", "a", "decreased", "epithelial", "barrier", "function", "of", "the", "gut", "play", "an", "important", "role", "in", "the", "pathogenesis", "of", "Crohn", "'s", "disease", "and", "ulcerative", "colitis", ".", "The", "medical", "therapy", "of", "inflammatory", "bowel", "disease", "aims", "to", "correct", "these", "alterations", ".", "Aminosalicylates", ",", "corticosteroides", ",", "immunsuppressants", "and", "antibiotics", "are", "the", "four", "main", "groups", "of", "substances", "which", "are", "currently", "used", "for", "the", "therapy", "of", "inflammatory", "bowel", "diseases", ".", "Slow", "release", "formulation", "allow", "specific", "targeting", "of", "5-aminosalicylic", "acid", "to", "the", "inflamed", "sections", "of", "the", "gut", ";", "with", "budesonid", "a", "corticosteroide", "therapy", "with", "minimal", "systemic", "side", "effects", "is", "possible", ".", "Future", "therapeutic", "options", "include", "specific", "immuno", "-", "modulatory", "therapy", "with", "cytokines", "or", "cytokine", "antibodies", ".", "Maintenance", "therapy", "may", ",", "conceivably", ",", "be", "performed", "with", "probiotics", "or", "antioxidants", ".", "Therefore", ",", "despite", "continued", "uncertainty", "about", "the", "cause", "of", "inflammatory", "bowel", "diseases", ",", "recent", "advances", "nourish", "the", "hope", "for", "further", "improvement", "of", "the", "control", "of", "disease", "activity", "and", "a", "better", "quality", "of", "life", "for", "patients", "with", "inflammatory", "bowel", "diseases", "." ]
[ "umlsterm" ]
G6PC2 is a GENE-Y, Glucose is a CHEMICAL, Insulin is a GENE-Y, glucose is a CHEMICAL, G6PC2 is a GENE-Y, insulin is a GENE-Y, glucose is a CHEMICAL, G6PC2 is a GENE-Y, glucose-6-phosphatase catalytic subunit is a GENE-Y, G6pc2 is a GENE-Y, G6pc2 is a GENE-Y, insulin is a GENE-N, glucose is a CHEMICAL, G6pc2 is a GENE-Y, G6pc2 is a GENE-Y, glucose is a CHEMICAL, insulin is a GENE-N, insulin is a GENE-N, glucose is a CHEMICAL, G6pc2 is a GENE-Y, Glucose-6-phosphatase is a GENE-Y, calcium is a CHEMICAL, G6pc2 is a GENE-Y, G6pc2 is a GENE-Y, glucose-6-phosphate is a CHEMICAL
1925_task0
Sentence: G6PC2: A Negative Regulator of Basal Glucose-Stimulated Insulin Secretion. Elevated fasting blood glucose (FBG) is associated with increased risk for the development of type 2 diabetes and cardiovascular-associated mortality. Genome-wide association studies (GWAS) have linked polymorphisms in G6PC2 with variations in FBG and body fat, although not insulin sensitivity or glucose tolerance. G6PC2 encodes an islet-specific, endoplasmic reticulum-resident glucose-6-phosphatase catalytic subunit. A combination of in situ perfused pancreas, in vitro isolated islet, and in vivo analyses were used to explore the function of G6pc2 in mice. G6pc2 deletion had little effect on insulin sensitivity and glucose tolerance, whereas body fat was reduced in female G6pc2 knockout (KO) mice on both a chow and high-fat diet, observations that are all consistent with human GWAS data. G6pc2 deletion resulted in a leftward shift in the dose-response curve for glucose-stimulated insulin secretion (GSIS). As a consequence, under fasting conditions in which plasma insulin levels were identical, blood glucose levels were reduced in G6pc2 KO mice, again consistent with human GWAS data. Glucose-6-phosphatase activity was reduced, whereas basal cytoplasmic calcium levels were elevated in islets isolated from G6pc2 KO mice. These data suggest that G6pc2 represents a novel, negative regulator of basal GSIS that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL
[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]
G6PC2: A Negative Regulator of Basal Glucose-Stimulated Insulin Secretion. Elevated fasting blood glucose (FBG) is associated with increased risk for the development of type 2 diabetes and cardiovascular-associated mortality. Genome-wide association studies (GWAS) have linked polymorphisms in G6PC2 with variations in FBG and body fat, although not insulin sensitivity or glucose tolerance. G6PC2 encodes an islet-specific, endoplasmic reticulum-resident glucose-6-phosphatase catalytic subunit. A combination of in situ perfused pancreas, in vitro isolated islet, and in vivo analyses were used to explore the function of G6pc2 in mice. G6pc2 deletion had little effect on insulin sensitivity and glucose tolerance, whereas body fat was reduced in female G6pc2 knockout (KO) mice on both a chow and high-fat diet, observations that are all consistent with human GWAS data. G6pc2 deletion resulted in a leftward shift in the dose-response curve for glucose-stimulated insulin secretion (GSIS). As a consequence, under fasting conditions in which plasma insulin levels were identical, blood glucose levels were reduced in G6pc2 KO mice, again consistent with human GWAS data. Glucose-6-phosphatase activity was reduced, whereas basal cytoplasmic calcium levels were elevated in islets isolated from G6pc2 KO mice. These data suggest that G6pc2 represents a novel, negative regulator of basal GSIS that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux.
[ "G6PC2", ":", "A", "Negative", "Regulator", "of", "Basal", "Glucose", "-", "Stimulated", "Insulin", "Secretion", ".", "\n", "Elevated", "fasting", "blood", "glucose", "(", "FBG", ")", "is", "associated", "with", "increased", "risk", "for", "the", "development", "of", "type", "2", "diabetes", "and", "cardiovascular", "-", "associated", "mortality", ".", "Genome", "-", "wide", "association", "studies", "(", "GWAS", ")", "have", "linked", "polymorphisms", "in", "G6PC2", "with", "variations", "in", "FBG", "and", "body", "fat", ",", "although", "not", "insulin", "sensitivity", "or", "glucose", "tolerance", ".", "G6PC2", "encodes", "an", "islet", "-", "specific", ",", "endoplasmic", "reticulum", "-", "resident", "glucose-6-phosphatase", "catalytic", "subunit", ".", "A", "combination", "of", "in", "situ", "perfused", "pancreas", ",", "in", "vitro", "isolated", "islet", ",", "and", "in", "vivo", "analyses", "were", "used", "to", "explore", "the", "function", "of", "G6pc2", "in", "mice", ".", "G6pc2", "deletion", "had", "little", "effect", "on", "insulin", "sensitivity", "and", "glucose", "tolerance", ",", "whereas", "body", "fat", "was", "reduced", "in", "female", "G6pc2", "knockout", "(", "KO", ")", "mice", "on", "both", "a", "chow", "and", "high", "-", "fat", "diet", ",", "observations", "that", "are", "all", "consistent", "with", "human", "GWAS", "data", ".", "G6pc2", "deletion", "resulted", "in", "a", "leftward", "shift", "in", "the", "dose", "-", "response", "curve", "for", "glucose", "-", "stimulated", "insulin", "secretion", "(", "GSIS", ")", ".", "As", "a", "consequence", ",", "under", "fasting", "conditions", "in", "which", "plasma", "insulin", "levels", "were", "identical", ",", "blood", "glucose", "levels", "were", "reduced", "in", "G6pc2", "KO", "mice", ",", "again", "consistent", "with", "human", "GWAS", "data", ".", "Glucose-6-phosphatase", "activity", "was", "reduced", ",", "whereas", "basal", "cytoplasmic", "calcium", "levels", "were", "elevated", "in", "islets", "isolated", "from", "G6pc2", "KO", "mice", ".", "These", "data", "suggest", "that", "G6pc2", "represents", "a", "novel", ",", "negative", "regulator", "of", "basal", "GSIS", "that", "acts", "by", "hydrolyzing", "glucose-6-phosphate", ",", "thereby", "reducing", "glycolytic", "flux", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
G6PC2 is a GENE-Y, Glucose is a CHEMICAL, Insulin is a GENE-Y, glucose is a CHEMICAL, G6PC2 is a GENE-Y, insulin is a GENE-Y, glucose is a CHEMICAL, G6PC2 is a GENE-Y, glucose-6-phosphatase catalytic subunit is a GENE-Y, G6pc2 is a GENE-Y, G6pc2 is a GENE-Y, insulin is a GENE-N, glucose is a CHEMICAL, G6pc2 is a GENE-Y, G6pc2 is a GENE-Y, glucose is a CHEMICAL, insulin is a GENE-N, insulin is a GENE-N, glucose is a CHEMICAL, G6pc2 is a GENE-Y, Glucose-6-phosphatase is a GENE-Y, calcium is a CHEMICAL, G6pc2 is a GENE-Y, G6pc2 is a GENE-Y, glucose-6-phosphate is a CHEMICAL
1925_task1
Sentence: G6PC2: A Negative Regulator of Basal Glucose-Stimulated Insulin Secretion. Elevated fasting blood glucose (FBG) is associated with increased risk for the development of type 2 diabetes and cardiovascular-associated mortality. Genome-wide association studies (GWAS) have linked polymorphisms in G6PC2 with variations in FBG and body fat, although not insulin sensitivity or glucose tolerance. G6PC2 encodes an islet-specific, endoplasmic reticulum-resident glucose-6-phosphatase catalytic subunit. A combination of in situ perfused pancreas, in vitro isolated islet, and in vivo analyses were used to explore the function of G6pc2 in mice. G6pc2 deletion had little effect on insulin sensitivity and glucose tolerance, whereas body fat was reduced in female G6pc2 knockout (KO) mice on both a chow and high-fat diet, observations that are all consistent with human GWAS data. G6pc2 deletion resulted in a leftward shift in the dose-response curve for glucose-stimulated insulin secretion (GSIS). As a consequence, under fasting conditions in which plasma insulin levels were identical, blood glucose levels were reduced in G6pc2 KO mice, again consistent with human GWAS data. Glucose-6-phosphatase activity was reduced, whereas basal cytoplasmic calcium levels were elevated in islets isolated from G6pc2 KO mice. These data suggest that G6pc2 represents a novel, negative regulator of basal GSIS that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux. Instructions: please typing these entity words according to sentence: G6PC2, Glucose, Insulin, glucose, G6PC2, insulin, glucose, G6PC2, glucose-6-phosphatase catalytic subunit, G6pc2, G6pc2, insulin, glucose, G6pc2, G6pc2, glucose, insulin, insulin, glucose, G6pc2, Glucose-6-phosphatase, calcium, G6pc2, G6pc2, glucose-6-phosphate Options: GENE-N, GENE-Y, CHEMICAL
[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]
G6PC2: A Negative Regulator of Basal Glucose-Stimulated Insulin Secretion. Elevated fasting blood glucose (FBG) is associated with increased risk for the development of type 2 diabetes and cardiovascular-associated mortality. Genome-wide association studies (GWAS) have linked polymorphisms in G6PC2 with variations in FBG and body fat, although not insulin sensitivity or glucose tolerance. G6PC2 encodes an islet-specific, endoplasmic reticulum-resident glucose-6-phosphatase catalytic subunit. A combination of in situ perfused pancreas, in vitro isolated islet, and in vivo analyses were used to explore the function of G6pc2 in mice. G6pc2 deletion had little effect on insulin sensitivity and glucose tolerance, whereas body fat was reduced in female G6pc2 knockout (KO) mice on both a chow and high-fat diet, observations that are all consistent with human GWAS data. G6pc2 deletion resulted in a leftward shift in the dose-response curve for glucose-stimulated insulin secretion (GSIS). As a consequence, under fasting conditions in which plasma insulin levels were identical, blood glucose levels were reduced in G6pc2 KO mice, again consistent with human GWAS data. Glucose-6-phosphatase activity was reduced, whereas basal cytoplasmic calcium levels were elevated in islets isolated from G6pc2 KO mice. These data suggest that G6pc2 represents a novel, negative regulator of basal GSIS that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux.
[ "G6PC2", ":", "A", "Negative", "Regulator", "of", "Basal", "Glucose", "-", "Stimulated", "Insulin", "Secretion", ".", "\n", "Elevated", "fasting", "blood", "glucose", "(", "FBG", ")", "is", "associated", "with", "increased", "risk", "for", "the", "development", "of", "type", "2", "diabetes", "and", "cardiovascular", "-", "associated", "mortality", ".", "Genome", "-", "wide", "association", "studies", "(", "GWAS", ")", "have", "linked", "polymorphisms", "in", "G6PC2", "with", "variations", "in", "FBG", "and", "body", "fat", ",", "although", "not", "insulin", "sensitivity", "or", "glucose", "tolerance", ".", "G6PC2", "encodes", "an", "islet", "-", "specific", ",", "endoplasmic", "reticulum", "-", "resident", "glucose-6-phosphatase", "catalytic", "subunit", ".", "A", "combination", "of", "in", "situ", "perfused", "pancreas", ",", "in", "vitro", "isolated", "islet", ",", "and", "in", "vivo", "analyses", "were", "used", "to", "explore", "the", "function", "of", "G6pc2", "in", "mice", ".", "G6pc2", "deletion", "had", "little", "effect", "on", "insulin", "sensitivity", "and", "glucose", "tolerance", ",", "whereas", "body", "fat", "was", "reduced", "in", "female", "G6pc2", "knockout", "(", "KO", ")", "mice", "on", "both", "a", "chow", "and", "high", "-", "fat", "diet", ",", "observations", "that", "are", "all", "consistent", "with", "human", "GWAS", "data", ".", "G6pc2", "deletion", "resulted", "in", "a", "leftward", "shift", "in", "the", "dose", "-", "response", "curve", "for", "glucose", "-", "stimulated", "insulin", "secretion", "(", "GSIS", ")", ".", "As", "a", "consequence", ",", "under", "fasting", "conditions", "in", "which", "plasma", "insulin", "levels", "were", "identical", ",", "blood", "glucose", "levels", "were", "reduced", "in", "G6pc2", "KO", "mice", ",", "again", "consistent", "with", "human", "GWAS", "data", ".", "Glucose-6-phosphatase", "activity", "was", "reduced", ",", "whereas", "basal", "cytoplasmic", "calcium", "levels", "were", "elevated", "in", "islets", "isolated", "from", "G6pc2", "KO", "mice", ".", "These", "data", "suggest", "that", "G6pc2", "represents", "a", "novel", ",", "negative", "regulator", "of", "basal", "GSIS", "that", "acts", "by", "hydrolyzing", "glucose-6-phosphate", ",", "thereby", "reducing", "glycolytic", "flux", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
G6PC2, Glucose, Insulin, glucose, G6PC2, insulin, glucose, G6PC2, glucose-6-phosphatase catalytic subunit, G6pc2, G6pc2, insulin, glucose, G6pc2, G6pc2, glucose, insulin, insulin, glucose, G6pc2, Glucose-6-phosphatase, calcium, G6pc2, G6pc2, glucose-6-phosphate
1925_task2
Sentence: G6PC2: A Negative Regulator of Basal Glucose-Stimulated Insulin Secretion. Elevated fasting blood glucose (FBG) is associated with increased risk for the development of type 2 diabetes and cardiovascular-associated mortality. Genome-wide association studies (GWAS) have linked polymorphisms in G6PC2 with variations in FBG and body fat, although not insulin sensitivity or glucose tolerance. G6PC2 encodes an islet-specific, endoplasmic reticulum-resident glucose-6-phosphatase catalytic subunit. A combination of in situ perfused pancreas, in vitro isolated islet, and in vivo analyses were used to explore the function of G6pc2 in mice. G6pc2 deletion had little effect on insulin sensitivity and glucose tolerance, whereas body fat was reduced in female G6pc2 knockout (KO) mice on both a chow and high-fat diet, observations that are all consistent with human GWAS data. G6pc2 deletion resulted in a leftward shift in the dose-response curve for glucose-stimulated insulin secretion (GSIS). As a consequence, under fasting conditions in which plasma insulin levels were identical, blood glucose levels were reduced in G6pc2 KO mice, again consistent with human GWAS data. Glucose-6-phosphatase activity was reduced, whereas basal cytoplasmic calcium levels were elevated in islets isolated from G6pc2 KO mice. These data suggest that G6pc2 represents a novel, negative regulator of basal GSIS that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]
G6PC2: A Negative Regulator of Basal Glucose-Stimulated Insulin Secretion. Elevated fasting blood glucose (FBG) is associated with increased risk for the development of type 2 diabetes and cardiovascular-associated mortality. Genome-wide association studies (GWAS) have linked polymorphisms in G6PC2 with variations in FBG and body fat, although not insulin sensitivity or glucose tolerance. G6PC2 encodes an islet-specific, endoplasmic reticulum-resident glucose-6-phosphatase catalytic subunit. A combination of in situ perfused pancreas, in vitro isolated islet, and in vivo analyses were used to explore the function of G6pc2 in mice. G6pc2 deletion had little effect on insulin sensitivity and glucose tolerance, whereas body fat was reduced in female G6pc2 knockout (KO) mice on both a chow and high-fat diet, observations that are all consistent with human GWAS data. G6pc2 deletion resulted in a leftward shift in the dose-response curve for glucose-stimulated insulin secretion (GSIS). As a consequence, under fasting conditions in which plasma insulin levels were identical, blood glucose levels were reduced in G6pc2 KO mice, again consistent with human GWAS data. Glucose-6-phosphatase activity was reduced, whereas basal cytoplasmic calcium levels were elevated in islets isolated from G6pc2 KO mice. These data suggest that G6pc2 represents a novel, negative regulator of basal GSIS that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux.
[ "G6PC2", ":", "A", "Negative", "Regulator", "of", "Basal", "Glucose", "-", "Stimulated", "Insulin", "Secretion", ".", "\n", "Elevated", "fasting", "blood", "glucose", "(", "FBG", ")", "is", "associated", "with", "increased", "risk", "for", "the", "development", "of", "type", "2", "diabetes", "and", "cardiovascular", "-", "associated", "mortality", ".", "Genome", "-", "wide", "association", "studies", "(", "GWAS", ")", "have", "linked", "polymorphisms", "in", "G6PC2", "with", "variations", "in", "FBG", "and", "body", "fat", ",", "although", "not", "insulin", "sensitivity", "or", "glucose", "tolerance", ".", "G6PC2", "encodes", "an", "islet", "-", "specific", ",", "endoplasmic", "reticulum", "-", "resident", "glucose-6-phosphatase", "catalytic", "subunit", ".", "A", "combination", "of", "in", "situ", "perfused", "pancreas", ",", "in", "vitro", "isolated", "islet", ",", "and", "in", "vivo", "analyses", "were", "used", "to", "explore", "the", "function", "of", "G6pc2", "in", "mice", ".", "G6pc2", "deletion", "had", "little", "effect", "on", "insulin", "sensitivity", "and", "glucose", "tolerance", ",", "whereas", "body", "fat", "was", "reduced", "in", "female", "G6pc2", "knockout", "(", "KO", ")", "mice", "on", "both", "a", "chow", "and", "high", "-", "fat", "diet", ",", "observations", "that", "are", "all", "consistent", "with", "human", "GWAS", "data", ".", "G6pc2", "deletion", "resulted", "in", "a", "leftward", "shift", "in", "the", "dose", "-", "response", "curve", "for", "glucose", "-", "stimulated", "insulin", "secretion", "(", "GSIS", ")", ".", "As", "a", "consequence", ",", "under", "fasting", "conditions", "in", "which", "plasma", "insulin", "levels", "were", "identical", ",", "blood", "glucose", "levels", "were", "reduced", "in", "G6pc2", "KO", "mice", ",", "again", "consistent", "with", "human", "GWAS", "data", ".", "Glucose-6-phosphatase", "activity", "was", "reduced", ",", "whereas", "basal", "cytoplasmic", "calcium", "levels", "were", "elevated", "in", "islets", "isolated", "from", "G6pc2", "KO", "mice", ".", "These", "data", "suggest", "that", "G6pc2", "represents", "a", "novel", ",", "negative", "regulator", "of", "basal", "GSIS", "that", "acts", "by", "hydrolyzing", "glucose-6-phosphate", ",", "thereby", "reducing", "glycolytic", "flux", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
tumoral maligna is a MORFOLOGIA_NEOPLASIA, adenopatías supraclaviculares is a MORFOLOGIA_NEOPLASIA, metastásicas is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, tumor de cordones sexuales / estroma gonadal maligno is a MORFOLOGIA_NEOPLASIA, tumor de células de Sertoli , estroma gonadal pobremente diferenciado is a MORFOLOGIA_NEOPLASIA, tumor de células de la granulosa is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, Tumor de cordones sexuales / estroma gonadal maligno ( OMS 2004 ) pT3 cN1 cM1a is a MORFOLOGIA_NEOPLASIA, lesión osteolítica en L5 is a MORFOLOGIA_NEOPLASIA
245_task0
Sentence: Anamnesis Varón de 77 años con antecedentes personales de dislipemia, hernias discales no intervenidas y sin antecedentes de criptorquidia. Acudió a su médico de atención primaria por aumento del tamaño del escroto de 6 meses de evolución. El aumento de tamaño fue progresivo y asimétrico. No presentó fiebre ni aumento de la temperatura a nivel escrotal. El paciente fue derivado al servicio de Urología para completar el estudio. Se realizó una ecografía escrotal donde se observó una lesión sólida, hipoecoica y bien definida aunque no se delimitó cápsula, siendo estos hallazgos sugestivos de una lesión sólida tumoral maligna. El paciente fue sometido a una orquiectomía inguinal derecha sin incidencias. Exploración física ECOG 0. Hemodinamicamente estable y afebril. La exploración física por aparatos fue anodina. No se palparon adenopatías supraclaviculares, axilares o inguinales. No se observó presencia de ginecomastia. La cicatriz de la orquiectomía inguinal derecha se encontraba reciente pero sin signos de complicación. Pruebas complementarias » TC de tórax, abdomen y pelvis de extensión: En mediastino y regiones hiliares se visualizaron varias imágenes nodulares la mayoría subcentimétricas sugestivas de pequeñas adenopatías inespecíficas, existiendo una de tamaño ligeramente superior al centímetro en localización paratraqueal derecha. » En abdomen se visualizaron abundantes adenopatías retroperitoneales de tamaño significativo en los grupos inter-aortocava, posteriores a la vena cava inferior, paraaórticos izquierdos, así como en la bifurcación aortoilíaca compatibles con adenopatías metastásicas. » PET-TC de extensión realizado para la caracterización de las adenopatías de significado incierto objetivadas en TC: Se observó una lesión intensamente hipermetabólica sugestiva de malignidad en el espacio supraclavicular. En tórax se objetivaron múltiples adenopatías mediastínicas e hiliares discretamente hipermetabólicas no sugestivas de malignidad. En abdomen y pelvis se confirmaron los hallazgos del TC visualizándose múltiples adenopatías hipermetabólicas sugestivas de malignidad a nivel reroperitoneal. » Hemograma: sin alteraciones. » Bioquímica incluyendo perfil renal, hepático y lipídico sin alteraciones. La LDH, AFP y la beta-HCG realizados previos a la cirugía se encontraban dentro de los límites de la normalidad. » Anatomía patológica de la orquiectomía inguinal derecha: tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) con componentes de tumor de células de Sertoli, estroma gonadal pobremente diferenciado y áreas de morfología sugestiva de componente de tumor de células de la granulosa. La malignidad queda acreditada por el tamaño (más de 5 cm), necrosis, su comportamiento infiltrante de albugínea, cubiertas testiculares, epidídimo y cordón espermático, permeación vascular en túnica vasculosa y alto índice proliferativo. Diagnóstico Tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) pT3 cN1 cM1a S0, estadio IIIA. Tratamiento Se presentó el caso en el comité multidisciplinar de tumores genitourinario y se decidió inicar tratamiento poliquimioterápico de 1ª línea según el esquema TIP (paclitaxel, ifosfamida, cisplatino). Evolución Tras haber completado 6 ciclos de tratamiento quimioterápico según el esquema TIP de Octubre de 2014 hasta Febrero de 2015, se observó una respuesta clínica parcial. Como toxicidades se registraron astenia grado 1, vómitos grado 1 y neuropatía grado 1. En TC de Julio de 2015 se objetivó un progreso adenopático a nivel retroperitoneal por lo que recibió una segunda línea de tratamiento con 6 ciclos de carboplatino y paclitaxel. Presentó astenia grado 1 y por neuropatía grado 3 se suspendió el paclitaxel tras el tercer ciclo. En Febrero de 2016 se realizó nuevo TC de reevaluación y además se solicitó una gammagrafía ósea por molestias lumbares. En el TC se objetivó una nueva progresión ganglionar y, en la gammagrafía ósea se observó de forma indirecta una lesión osteolítica en L5. En Marzo de 2016 se remitió a radioterapia antiálgica, recibiendo una dosis total de 3000cGy fraccionada en 10 sesiones. Tras finalizar el tratamiento radioterápico inició en Abril 2016 tratamiento quimiotrápico de tercera con cisplatino asociado a etopósido durante 5 días cada 21 días. Actualmente el paciente ha recibido 3 ciclos del tratamiento con cisplatino y etopósido con aceptable tolerancia y solo presentó astenia grado 1 como única toxicidad. Se solicitó una TC de reevaluación que se encuentra pendiente de realizar. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Varón de 77 años con antecedentes personales de dislipemia, hernias discales no intervenidas y sin antecedentes de criptorquidia. Acudió a su médico de atención primaria por aumento del tamaño del escroto de 6 meses de evolución. El aumento de tamaño fue progresivo y asimétrico. No presentó fiebre ni aumento de la temperatura a nivel escrotal. El paciente fue derivado al servicio de Urología para completar el estudio. Se realizó una ecografía escrotal donde se observó una lesión sólida, hipoecoica y bien definida aunque no se delimitó cápsula, siendo estos hallazgos sugestivos de una lesión sólida tumoral maligna. El paciente fue sometido a una orquiectomía inguinal derecha sin incidencias. Exploración física ECOG 0. Hemodinamicamente estable y afebril. La exploración física por aparatos fue anodina. No se palparon adenopatías supraclaviculares, axilares o inguinales. No se observó presencia de ginecomastia. La cicatriz de la orquiectomía inguinal derecha se encontraba reciente pero sin signos de complicación. Pruebas complementarias » TC de tórax, abdomen y pelvis de extensión: En mediastino y regiones hiliares se visualizaron varias imágenes nodulares la mayoría subcentimétricas sugestivas de pequeñas adenopatías inespecíficas, existiendo una de tamaño ligeramente superior al centímetro en localización paratraqueal derecha. » En abdomen se visualizaron abundantes adenopatías retroperitoneales de tamaño significativo en los grupos inter-aortocava, posteriores a la vena cava inferior, paraaórticos izquierdos, así como en la bifurcación aortoilíaca compatibles con adenopatías metastásicas. » PET-TC de extensión realizado para la caracterización de las adenopatías de significado incierto objetivadas en TC: Se observó una lesión intensamente hipermetabólica sugestiva de malignidad en el espacio supraclavicular. En tórax se objetivaron múltiples adenopatías mediastínicas e hiliares discretamente hipermetabólicas no sugestivas de malignidad. En abdomen y pelvis se confirmaron los hallazgos del TC visualizándose múltiples adenopatías hipermetabólicas sugestivas de malignidad a nivel reroperitoneal. » Hemograma: sin alteraciones. » Bioquímica incluyendo perfil renal, hepático y lipídico sin alteraciones. La LDH, AFP y la beta-HCG realizados previos a la cirugía se encontraban dentro de los límites de la normalidad. » Anatomía patológica de la orquiectomía inguinal derecha: tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) con componentes de tumor de células de Sertoli, estroma gonadal pobremente diferenciado y áreas de morfología sugestiva de componente de tumor de células de la granulosa. La malignidad queda acreditada por el tamaño (más de 5 cm), necrosis, su comportamiento infiltrante de albugínea, cubiertas testiculares, epidídimo y cordón espermático, permeación vascular en túnica vasculosa y alto índice proliferativo. Diagnóstico Tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) pT3 cN1 cM1a S0, estadio IIIA. Tratamiento Se presentó el caso en el comité multidisciplinar de tumores genitourinario y se decidió inicar tratamiento poliquimioterápico de 1ª línea según el esquema TIP (paclitaxel, ifosfamida, cisplatino). Evolución Tras haber completado 6 ciclos de tratamiento quimioterápico según el esquema TIP de Octubre de 2014 hasta Febrero de 2015, se observó una respuesta clínica parcial. Como toxicidades se registraron astenia grado 1, vómitos grado 1 y neuropatía grado 1. En TC de Julio de 2015 se objetivó un progreso adenopático a nivel retroperitoneal por lo que recibió una segunda línea de tratamiento con 6 ciclos de carboplatino y paclitaxel. Presentó astenia grado 1 y por neuropatía grado 3 se suspendió el paclitaxel tras el tercer ciclo. En Febrero de 2016 se realizó nuevo TC de reevaluación y además se solicitó una gammagrafía ósea por molestias lumbares. En el TC se objetivó una nueva progresión ganglionar y, en la gammagrafía ósea se observó de forma indirecta una lesión osteolítica en L5. En Marzo de 2016 se remitió a radioterapia antiálgica, recibiendo una dosis total de 3000cGy fraccionada en 10 sesiones. Tras finalizar el tratamiento radioterápico inició en Abril 2016 tratamiento quimiotrápico de tercera con cisplatino asociado a etopósido durante 5 días cada 21 días. Actualmente el paciente ha recibido 3 ciclos del tratamiento con cisplatino y etopósido con aceptable tolerancia y solo presentó astenia grado 1 como única toxicidad. Se solicitó una TC de reevaluación que se encuentra pendiente de realizar.
[ "Anamnesis", "\n", "Varón", "de", "77", "años", "con", "antecedentes", "personales", "de", "dislipemia", ",", "hernias", "discales", "no", "intervenidas", "y", "sin", "antecedentes", "de", "criptorquidia", ".", "\n", "Acudió", "a", "su", "médico", "de", "atención", "primaria", "por", "aumento", "del", "tamaño", "del", "escroto", "de", "6", "meses", "de", "evolución", ".", "\n", "El", "aumento", "de", "tamaño", "fue", "progresivo", "y", "asimétrico", ".", "No", "presentó", "fiebre", "ni", "aumento", "de", "la", "temperatura", "a", "nivel", "escrotal", ".", "\n", "El", "paciente", "fue", "derivado", "al", "servicio", "de", "Urología", "para", "completar", "el", "estudio", ".", "Se", "realizó", "una", "ecografía", "escrotal", "donde", "se", "observó", "una", "lesión", "sólida", ",", "hipoecoica", "y", "bien", "definida", "aunque", "no", "se", "delimitó", "cápsula", ",", "siendo", "estos", "hallazgos", "sugestivos", "de", "una", "lesión", "sólida", "tumoral", "maligna", ".", "El", "paciente", "fue", "sometido", "a", "una", "orquiectomía", "inguinal", "derecha", "sin", "incidencias", ".", "\n \n", "Exploración", "física", "\n", "ECOG", "0", ".", "Hemodinamicamente", "estable", "y", "afebril", ".", "La", "exploración", "física", "por", "aparatos", "fue", "anodina", ".", "No", "se", "palparon", "adenopatías", "supraclaviculares", ",", "axilares", "o", "inguinales", ".", "No", "se", "observó", "presencia", "de", "ginecomastia", ".", "La", "cicatriz", "de", "la", "orquiectomía", "inguinal", "derecha", "se", "encontraba", "reciente", "pero", "sin", "signos", "de", "complicación", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "TC", "de", "tórax", ",", "abdomen", "y", "pelvis", "de", "extensión", ":", "En", "mediastino", "y", "regiones", "hiliares", "se", "visualizaron", "varias", "imágenes", "nodulares", "la", "mayoría", "subcentimétricas", "sugestivas", "de", "pequeñas", "adenopatías", "inespecíficas", ",", "existiendo", "una", "de", "tamaño", "ligeramente", "superior", "al", "centímetro", "en", "localización", "paratraqueal", "derecha", ".", "\n", "»", "En", "abdomen", "se", "visualizaron", "abundantes", "adenopatías", "retroperitoneales", "de", "tamaño", "significativo", "en", "los", "grupos", "inter", "-", "aortocava", ",", "posteriores", "a", "la", "vena", "cava", "inferior", ",", "paraaórticos", "izquierdos", ",", "así", "como", "en", "la", "bifurcación", "aortoilíaca", "compatibles", "con", "adenopatías", "metastásicas", ".", "\n", "»", "PET", "-", "TC", "de", "extensión", "realizado", "para", "la", "caracterización", "de", "las", "adenopatías", "de", "significado", "incierto", "objetivadas", "en", "TC", ":", "Se", "observó", "una", "lesión", "intensamente", "hipermetabólica", "sugestiva", "de", "malignidad", "en", "el", "espacio", "supraclavicular", ".", "En", "tórax", "se", "objetivaron", "múltiples", "adenopatías", "mediastínicas", "e", "hiliares", "discretamente", "hipermetabólicas", "no", "sugestivas", "de", "malignidad", ".", "En", "abdomen", "y", "pelvis", "se", "confirmaron", "los", "hallazgos", "del", "TC", "visualizándose", "múltiples", "adenopatías", "hipermetabólicas", "sugestivas", "de", "malignidad", "a", "nivel", "reroperitoneal", ".", "\n", "»", "Hemograma", ":", "sin", "alteraciones", ".", "\n", "»", "Bioquímica", "incluyendo", "perfil", "renal", ",", "hepático", "y", "lipídico", "sin", "alteraciones", ".", "La", "LDH", ",", "AFP", "y", "la", "beta", "-", "HCG", "realizados", "previos", "a", "la", "cirugía", "se", "encontraban", "dentro", "de", "los", "límites", "de", "la", "normalidad", ".", "\n", "»", "Anatomía", "patológica", "de", "la", "orquiectomía", "inguinal", "derecha", ":", "tumor", "de", "cordones", "sexuales", "/", "estroma", "gonadal", "maligno", "(", "OMS", "2004", ")", "con", "componentes", "de", "tumor", "de", "células", "de", "Sertoli", ",", "estroma", "gonadal", "pobremente", "diferenciado", "y", "áreas", "de", "morfología", "sugestiva", "de", "componente", "de", "tumor", "de", "células", "de", "la", "granulosa", ".", "La", "malignidad", "queda", "acreditada", "por", "el", "tamaño", "(", "más", "de", "5", "cm", ")", ",", "necrosis", ",", "su", "comportamiento", "infiltrante", "de", "albugínea", ",", "cubiertas", "testiculares", ",", "epidídimo", "y", "cordón", "espermático", ",", "permeación", "vascular", "en", "túnica", "vasculosa", "y", "alto", "índice", "proliferativo", ".", "\n\n", "Diagnóstico", "\n", "Tumor", "de", "cordones", "sexuales", "/", "estroma", "gonadal", "maligno", "(", "OMS", "2004", ")", "pT3", "cN1", "cM1a", "S0", ",", "estadio", "IIIA", ".", "\n\n", "Tratamiento", "\n", "Se", "presentó", "el", "caso", "en", "el", "comité", "multidisciplinar", "de", "tumores", "genitourinario", "y", "se", "decidió", "inicar", "tratamiento", "poliquimioterápico", "de", "1ª", "línea", "según", "el", "esquema", "TIP", "(", "paclitaxel", ",", "ifosfamida", ",", "cisplatino", ")", ".", "\n\n", "Evolución", "\n", "Tras", "haber", "completado", "6", "ciclos", "de", "tratamiento", "quimioterápico", "según", "el", "esquema", "TIP", "de", "Octubre", "de", "2014", "hasta", "Febrero", "de", "2015", ",", "se", "observó", "una", "respuesta", "clínica", "parcial", ".", "Como", "toxicidades", "se", "registraron", "astenia", "grado", "1", ",", "vómitos", "grado", "1", "y", "neuropatía", "grado", "1", ".", "\n", "En", "TC", "de", "Julio", "de", "2015", "se", "objetivó", "un", "progreso", "adenopático", "a", "nivel", "retroperitoneal", "por", "lo", "que", "recibió", "una", "segunda", "línea", "de", "tratamiento", "con", "6", "ciclos", "de", "carboplatino", "y", "paclitaxel", ".", "Presentó", "astenia", "grado", "1", "y", "por", "neuropatía", "grado", "3", "se", "suspendió", "el", "paclitaxel", "tras", "el", "tercer", "ciclo", ".", "\n", "En", "Febrero", "de", "2016", "se", "realizó", "nuevo", "TC", "de", "reevaluación", "y", "además", "se", "solicitó", "una", "gammagrafía", "ósea", "por", "molestias", "lumbares", ".", "En", "el", "TC", "se", "objetivó", "una", "nueva", "progresión", "ganglionar", "y", ",", "en", "la", "gammagrafía", "ósea", "se", "observó", "de", "forma", "indirecta", "una", "lesión", "osteolítica", "en", "L5", ".", "En", "Marzo", "de", "2016", "se", "remitió", "a", "radioterapia", "antiálgica", ",", "recibiendo", "una", "dosis", "total", "de", "3000cGy", "fraccionada", "en", "10", "sesiones", ".", "Tras", "finalizar", "el", "tratamiento", "radioterápico", "inició", "en", "Abril", "2016", "tratamiento", "quimiotrápico", "de", "tercera", "con", "cisplatino", "asociado", "a", "etopósido", "durante", "5", "días", "cada", "21", "días", ".", "\n", "Actualmente", "el", "paciente", "ha", "recibido", "3", "ciclos", "del", "tratamiento", "con", "cisplatino", "y", "etopósido", "con", "aceptable", "tolerancia", "y", "solo", "presentó", "astenia", "grado", "1", "como", "única", "toxicidad", ".", "Se", "solicitó", "una", "TC", "de", "reevaluación", "que", "se", "encuentra", "pendiente", "de", "realizar", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
tumoral maligna is a MORFOLOGIA_NEOPLASIA, adenopatías supraclaviculares is a MORFOLOGIA_NEOPLASIA, metastásicas is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, tumor de cordones sexuales / estroma gonadal maligno is a MORFOLOGIA_NEOPLASIA, tumor de células de Sertoli , estroma gonadal pobremente diferenciado is a MORFOLOGIA_NEOPLASIA, tumor de células de la granulosa is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, Tumor de cordones sexuales / estroma gonadal maligno ( OMS 2004 ) pT3 cN1 cM1a is a MORFOLOGIA_NEOPLASIA, lesión osteolítica en L5 is a MORFOLOGIA_NEOPLASIA
245_task1
Sentence: Anamnesis Varón de 77 años con antecedentes personales de dislipemia, hernias discales no intervenidas y sin antecedentes de criptorquidia. Acudió a su médico de atención primaria por aumento del tamaño del escroto de 6 meses de evolución. El aumento de tamaño fue progresivo y asimétrico. No presentó fiebre ni aumento de la temperatura a nivel escrotal. El paciente fue derivado al servicio de Urología para completar el estudio. Se realizó una ecografía escrotal donde se observó una lesión sólida, hipoecoica y bien definida aunque no se delimitó cápsula, siendo estos hallazgos sugestivos de una lesión sólida tumoral maligna. El paciente fue sometido a una orquiectomía inguinal derecha sin incidencias. Exploración física ECOG 0. Hemodinamicamente estable y afebril. La exploración física por aparatos fue anodina. No se palparon adenopatías supraclaviculares, axilares o inguinales. No se observó presencia de ginecomastia. La cicatriz de la orquiectomía inguinal derecha se encontraba reciente pero sin signos de complicación. Pruebas complementarias » TC de tórax, abdomen y pelvis de extensión: En mediastino y regiones hiliares se visualizaron varias imágenes nodulares la mayoría subcentimétricas sugestivas de pequeñas adenopatías inespecíficas, existiendo una de tamaño ligeramente superior al centímetro en localización paratraqueal derecha. » En abdomen se visualizaron abundantes adenopatías retroperitoneales de tamaño significativo en los grupos inter-aortocava, posteriores a la vena cava inferior, paraaórticos izquierdos, así como en la bifurcación aortoilíaca compatibles con adenopatías metastásicas. » PET-TC de extensión realizado para la caracterización de las adenopatías de significado incierto objetivadas en TC: Se observó una lesión intensamente hipermetabólica sugestiva de malignidad en el espacio supraclavicular. En tórax se objetivaron múltiples adenopatías mediastínicas e hiliares discretamente hipermetabólicas no sugestivas de malignidad. En abdomen y pelvis se confirmaron los hallazgos del TC visualizándose múltiples adenopatías hipermetabólicas sugestivas de malignidad a nivel reroperitoneal. » Hemograma: sin alteraciones. » Bioquímica incluyendo perfil renal, hepático y lipídico sin alteraciones. La LDH, AFP y la beta-HCG realizados previos a la cirugía se encontraban dentro de los límites de la normalidad. » Anatomía patológica de la orquiectomía inguinal derecha: tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) con componentes de tumor de células de Sertoli, estroma gonadal pobremente diferenciado y áreas de morfología sugestiva de componente de tumor de células de la granulosa. La malignidad queda acreditada por el tamaño (más de 5 cm), necrosis, su comportamiento infiltrante de albugínea, cubiertas testiculares, epidídimo y cordón espermático, permeación vascular en túnica vasculosa y alto índice proliferativo. Diagnóstico Tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) pT3 cN1 cM1a S0, estadio IIIA. Tratamiento Se presentó el caso en el comité multidisciplinar de tumores genitourinario y se decidió inicar tratamiento poliquimioterápico de 1ª línea según el esquema TIP (paclitaxel, ifosfamida, cisplatino). Evolución Tras haber completado 6 ciclos de tratamiento quimioterápico según el esquema TIP de Octubre de 2014 hasta Febrero de 2015, se observó una respuesta clínica parcial. Como toxicidades se registraron astenia grado 1, vómitos grado 1 y neuropatía grado 1. En TC de Julio de 2015 se objetivó un progreso adenopático a nivel retroperitoneal por lo que recibió una segunda línea de tratamiento con 6 ciclos de carboplatino y paclitaxel. Presentó astenia grado 1 y por neuropatía grado 3 se suspendió el paclitaxel tras el tercer ciclo. En Febrero de 2016 se realizó nuevo TC de reevaluación y además se solicitó una gammagrafía ósea por molestias lumbares. En el TC se objetivó una nueva progresión ganglionar y, en la gammagrafía ósea se observó de forma indirecta una lesión osteolítica en L5. En Marzo de 2016 se remitió a radioterapia antiálgica, recibiendo una dosis total de 3000cGy fraccionada en 10 sesiones. Tras finalizar el tratamiento radioterápico inició en Abril 2016 tratamiento quimiotrápico de tercera con cisplatino asociado a etopósido durante 5 días cada 21 días. Actualmente el paciente ha recibido 3 ciclos del tratamiento con cisplatino y etopósido con aceptable tolerancia y solo presentó astenia grado 1 como única toxicidad. Se solicitó una TC de reevaluación que se encuentra pendiente de realizar. Instructions: please typing these entity words according to sentence: tumoral maligna, adenopatías supraclaviculares, metastásicas, malignidad, malignidad, malignidad, tumor de cordones sexuales / estroma gonadal maligno, tumor de células de Sertoli , estroma gonadal pobremente diferenciado, tumor de células de la granulosa, malignidad, Tumor de cordones sexuales / estroma gonadal maligno ( OMS 2004 ) pT3 cN1 cM1a, lesión osteolítica en L5 Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Varón de 77 años con antecedentes personales de dislipemia, hernias discales no intervenidas y sin antecedentes de criptorquidia. Acudió a su médico de atención primaria por aumento del tamaño del escroto de 6 meses de evolución. El aumento de tamaño fue progresivo y asimétrico. No presentó fiebre ni aumento de la temperatura a nivel escrotal. El paciente fue derivado al servicio de Urología para completar el estudio. Se realizó una ecografía escrotal donde se observó una lesión sólida, hipoecoica y bien definida aunque no se delimitó cápsula, siendo estos hallazgos sugestivos de una lesión sólida tumoral maligna. El paciente fue sometido a una orquiectomía inguinal derecha sin incidencias. Exploración física ECOG 0. Hemodinamicamente estable y afebril. La exploración física por aparatos fue anodina. No se palparon adenopatías supraclaviculares, axilares o inguinales. No se observó presencia de ginecomastia. La cicatriz de la orquiectomía inguinal derecha se encontraba reciente pero sin signos de complicación. Pruebas complementarias » TC de tórax, abdomen y pelvis de extensión: En mediastino y regiones hiliares se visualizaron varias imágenes nodulares la mayoría subcentimétricas sugestivas de pequeñas adenopatías inespecíficas, existiendo una de tamaño ligeramente superior al centímetro en localización paratraqueal derecha. » En abdomen se visualizaron abundantes adenopatías retroperitoneales de tamaño significativo en los grupos inter-aortocava, posteriores a la vena cava inferior, paraaórticos izquierdos, así como en la bifurcación aortoilíaca compatibles con adenopatías metastásicas. » PET-TC de extensión realizado para la caracterización de las adenopatías de significado incierto objetivadas en TC: Se observó una lesión intensamente hipermetabólica sugestiva de malignidad en el espacio supraclavicular. En tórax se objetivaron múltiples adenopatías mediastínicas e hiliares discretamente hipermetabólicas no sugestivas de malignidad. En abdomen y pelvis se confirmaron los hallazgos del TC visualizándose múltiples adenopatías hipermetabólicas sugestivas de malignidad a nivel reroperitoneal. » Hemograma: sin alteraciones. » Bioquímica incluyendo perfil renal, hepático y lipídico sin alteraciones. La LDH, AFP y la beta-HCG realizados previos a la cirugía se encontraban dentro de los límites de la normalidad. » Anatomía patológica de la orquiectomía inguinal derecha: tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) con componentes de tumor de células de Sertoli, estroma gonadal pobremente diferenciado y áreas de morfología sugestiva de componente de tumor de células de la granulosa. La malignidad queda acreditada por el tamaño (más de 5 cm), necrosis, su comportamiento infiltrante de albugínea, cubiertas testiculares, epidídimo y cordón espermático, permeación vascular en túnica vasculosa y alto índice proliferativo. Diagnóstico Tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) pT3 cN1 cM1a S0, estadio IIIA. Tratamiento Se presentó el caso en el comité multidisciplinar de tumores genitourinario y se decidió inicar tratamiento poliquimioterápico de 1ª línea según el esquema TIP (paclitaxel, ifosfamida, cisplatino). Evolución Tras haber completado 6 ciclos de tratamiento quimioterápico según el esquema TIP de Octubre de 2014 hasta Febrero de 2015, se observó una respuesta clínica parcial. Como toxicidades se registraron astenia grado 1, vómitos grado 1 y neuropatía grado 1. En TC de Julio de 2015 se objetivó un progreso adenopático a nivel retroperitoneal por lo que recibió una segunda línea de tratamiento con 6 ciclos de carboplatino y paclitaxel. Presentó astenia grado 1 y por neuropatía grado 3 se suspendió el paclitaxel tras el tercer ciclo. En Febrero de 2016 se realizó nuevo TC de reevaluación y además se solicitó una gammagrafía ósea por molestias lumbares. En el TC se objetivó una nueva progresión ganglionar y, en la gammagrafía ósea se observó de forma indirecta una lesión osteolítica en L5. En Marzo de 2016 se remitió a radioterapia antiálgica, recibiendo una dosis total de 3000cGy fraccionada en 10 sesiones. Tras finalizar el tratamiento radioterápico inició en Abril 2016 tratamiento quimiotrápico de tercera con cisplatino asociado a etopósido durante 5 días cada 21 días. Actualmente el paciente ha recibido 3 ciclos del tratamiento con cisplatino y etopósido con aceptable tolerancia y solo presentó astenia grado 1 como única toxicidad. Se solicitó una TC de reevaluación que se encuentra pendiente de realizar.
[ "Anamnesis", "\n", "Varón", "de", "77", "años", "con", "antecedentes", "personales", "de", "dislipemia", ",", "hernias", "discales", "no", "intervenidas", "y", "sin", "antecedentes", "de", "criptorquidia", ".", "\n", "Acudió", "a", "su", "médico", "de", "atención", "primaria", "por", "aumento", "del", "tamaño", "del", "escroto", "de", "6", "meses", "de", "evolución", ".", "\n", "El", "aumento", "de", "tamaño", "fue", "progresivo", "y", "asimétrico", ".", "No", "presentó", "fiebre", "ni", "aumento", "de", "la", "temperatura", "a", "nivel", "escrotal", ".", "\n", "El", "paciente", "fue", "derivado", "al", "servicio", "de", "Urología", "para", "completar", "el", "estudio", ".", "Se", "realizó", "una", "ecografía", "escrotal", "donde", "se", "observó", "una", "lesión", "sólida", ",", "hipoecoica", "y", "bien", "definida", "aunque", "no", "se", "delimitó", "cápsula", ",", "siendo", "estos", "hallazgos", "sugestivos", "de", "una", "lesión", "sólida", "tumoral", "maligna", ".", "El", "paciente", "fue", "sometido", "a", "una", "orquiectomía", "inguinal", "derecha", "sin", "incidencias", ".", "\n \n", "Exploración", "física", "\n", "ECOG", "0", ".", "Hemodinamicamente", "estable", "y", "afebril", ".", "La", "exploración", "física", "por", "aparatos", "fue", "anodina", ".", "No", "se", "palparon", "adenopatías", "supraclaviculares", ",", "axilares", "o", "inguinales", ".", "No", "se", "observó", "presencia", "de", "ginecomastia", ".", "La", "cicatriz", "de", "la", "orquiectomía", "inguinal", "derecha", "se", "encontraba", "reciente", "pero", "sin", "signos", "de", "complicación", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "TC", "de", "tórax", ",", "abdomen", "y", "pelvis", "de", "extensión", ":", "En", "mediastino", "y", "regiones", "hiliares", "se", "visualizaron", "varias", "imágenes", "nodulares", "la", "mayoría", "subcentimétricas", "sugestivas", "de", "pequeñas", "adenopatías", "inespecíficas", ",", "existiendo", "una", "de", "tamaño", "ligeramente", "superior", "al", "centímetro", "en", "localización", "paratraqueal", "derecha", ".", "\n", "»", "En", "abdomen", "se", "visualizaron", "abundantes", "adenopatías", "retroperitoneales", "de", "tamaño", "significativo", "en", "los", "grupos", "inter", "-", "aortocava", ",", "posteriores", "a", "la", "vena", "cava", "inferior", ",", "paraaórticos", "izquierdos", ",", "así", "como", "en", "la", "bifurcación", "aortoilíaca", "compatibles", "con", "adenopatías", "metastásicas", ".", "\n", "»", "PET", "-", "TC", "de", "extensión", "realizado", "para", "la", "caracterización", "de", "las", "adenopatías", "de", "significado", "incierto", "objetivadas", "en", "TC", ":", "Se", "observó", "una", "lesión", "intensamente", "hipermetabólica", "sugestiva", "de", "malignidad", "en", "el", "espacio", "supraclavicular", ".", "En", "tórax", "se", "objetivaron", "múltiples", "adenopatías", "mediastínicas", "e", "hiliares", "discretamente", "hipermetabólicas", "no", "sugestivas", "de", "malignidad", ".", "En", "abdomen", "y", "pelvis", "se", "confirmaron", "los", "hallazgos", "del", "TC", "visualizándose", "múltiples", "adenopatías", "hipermetabólicas", "sugestivas", "de", "malignidad", "a", "nivel", "reroperitoneal", ".", "\n", "»", "Hemograma", ":", "sin", "alteraciones", ".", "\n", "»", "Bioquímica", "incluyendo", "perfil", "renal", ",", "hepático", "y", "lipídico", "sin", "alteraciones", ".", "La", "LDH", ",", "AFP", "y", "la", "beta", "-", "HCG", "realizados", "previos", "a", "la", "cirugía", "se", "encontraban", "dentro", "de", "los", "límites", "de", "la", "normalidad", ".", "\n", "»", "Anatomía", "patológica", "de", "la", "orquiectomía", "inguinal", "derecha", ":", "tumor", "de", "cordones", "sexuales", "/", "estroma", "gonadal", "maligno", "(", "OMS", "2004", ")", "con", "componentes", "de", "tumor", "de", "células", "de", "Sertoli", ",", "estroma", "gonadal", "pobremente", "diferenciado", "y", "áreas", "de", "morfología", "sugestiva", "de", "componente", "de", "tumor", "de", "células", "de", "la", "granulosa", ".", "La", "malignidad", "queda", "acreditada", "por", "el", "tamaño", "(", "más", "de", "5", "cm", ")", ",", "necrosis", ",", "su", "comportamiento", "infiltrante", "de", "albugínea", ",", "cubiertas", "testiculares", ",", "epidídimo", "y", "cordón", "espermático", ",", "permeación", "vascular", "en", "túnica", "vasculosa", "y", "alto", "índice", "proliferativo", ".", "\n\n", "Diagnóstico", "\n", "Tumor", "de", "cordones", "sexuales", "/", "estroma", "gonadal", "maligno", "(", "OMS", "2004", ")", "pT3", "cN1", "cM1a", "S0", ",", "estadio", "IIIA", ".", "\n\n", "Tratamiento", "\n", "Se", "presentó", "el", "caso", "en", "el", "comité", "multidisciplinar", "de", "tumores", "genitourinario", "y", "se", "decidió", "inicar", "tratamiento", "poliquimioterápico", "de", "1ª", "línea", "según", "el", "esquema", "TIP", "(", "paclitaxel", ",", "ifosfamida", ",", "cisplatino", ")", ".", "\n\n", "Evolución", "\n", "Tras", "haber", "completado", "6", "ciclos", "de", "tratamiento", "quimioterápico", "según", "el", "esquema", "TIP", "de", "Octubre", "de", "2014", "hasta", "Febrero", "de", "2015", ",", "se", "observó", "una", "respuesta", "clínica", "parcial", ".", "Como", "toxicidades", "se", "registraron", "astenia", "grado", "1", ",", "vómitos", "grado", "1", "y", "neuropatía", "grado", "1", ".", "\n", "En", "TC", "de", "Julio", "de", "2015", "se", "objetivó", "un", "progreso", "adenopático", "a", "nivel", "retroperitoneal", "por", "lo", "que", "recibió", "una", "segunda", "línea", "de", "tratamiento", "con", "6", "ciclos", "de", "carboplatino", "y", "paclitaxel", ".", "Presentó", "astenia", "grado", "1", "y", "por", "neuropatía", "grado", "3", "se", "suspendió", "el", "paclitaxel", "tras", "el", "tercer", "ciclo", ".", "\n", "En", "Febrero", "de", "2016", "se", "realizó", "nuevo", "TC", "de", "reevaluación", "y", "además", "se", "solicitó", "una", "gammagrafía", "ósea", "por", "molestias", "lumbares", ".", "En", "el", "TC", "se", "objetivó", "una", "nueva", "progresión", "ganglionar", "y", ",", "en", "la", "gammagrafía", "ósea", "se", "observó", "de", "forma", "indirecta", "una", "lesión", "osteolítica", "en", "L5", ".", "En", "Marzo", "de", "2016", "se", "remitió", "a", "radioterapia", "antiálgica", ",", "recibiendo", "una", "dosis", "total", "de", "3000cGy", "fraccionada", "en", "10", "sesiones", ".", "Tras", "finalizar", "el", "tratamiento", "radioterápico", "inició", "en", "Abril", "2016", "tratamiento", "quimiotrápico", "de", "tercera", "con", "cisplatino", "asociado", "a", "etopósido", "durante", "5", "días", "cada", "21", "días", ".", "\n", "Actualmente", "el", "paciente", "ha", "recibido", "3", "ciclos", "del", "tratamiento", "con", "cisplatino", "y", "etopósido", "con", "aceptable", "tolerancia", "y", "solo", "presentó", "astenia", "grado", "1", "como", "única", "toxicidad", ".", "Se", "solicitó", "una", "TC", "de", "reevaluación", "que", "se", "encuentra", "pendiente", "de", "realizar", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
tumoral maligna, adenopatías supraclaviculares, metastásicas, malignidad, malignidad, malignidad, tumor de cordones sexuales / estroma gonadal maligno, tumor de células de Sertoli , estroma gonadal pobremente diferenciado, tumor de células de la granulosa, malignidad, Tumor de cordones sexuales / estroma gonadal maligno ( OMS 2004 ) pT3 cN1 cM1a, lesión osteolítica en L5
245_task2
Sentence: Anamnesis Varón de 77 años con antecedentes personales de dislipemia, hernias discales no intervenidas y sin antecedentes de criptorquidia. Acudió a su médico de atención primaria por aumento del tamaño del escroto de 6 meses de evolución. El aumento de tamaño fue progresivo y asimétrico. No presentó fiebre ni aumento de la temperatura a nivel escrotal. El paciente fue derivado al servicio de Urología para completar el estudio. Se realizó una ecografía escrotal donde se observó una lesión sólida, hipoecoica y bien definida aunque no se delimitó cápsula, siendo estos hallazgos sugestivos de una lesión sólida tumoral maligna. El paciente fue sometido a una orquiectomía inguinal derecha sin incidencias. Exploración física ECOG 0. Hemodinamicamente estable y afebril. La exploración física por aparatos fue anodina. No se palparon adenopatías supraclaviculares, axilares o inguinales. No se observó presencia de ginecomastia. La cicatriz de la orquiectomía inguinal derecha se encontraba reciente pero sin signos de complicación. Pruebas complementarias » TC de tórax, abdomen y pelvis de extensión: En mediastino y regiones hiliares se visualizaron varias imágenes nodulares la mayoría subcentimétricas sugestivas de pequeñas adenopatías inespecíficas, existiendo una de tamaño ligeramente superior al centímetro en localización paratraqueal derecha. » En abdomen se visualizaron abundantes adenopatías retroperitoneales de tamaño significativo en los grupos inter-aortocava, posteriores a la vena cava inferior, paraaórticos izquierdos, así como en la bifurcación aortoilíaca compatibles con adenopatías metastásicas. » PET-TC de extensión realizado para la caracterización de las adenopatías de significado incierto objetivadas en TC: Se observó una lesión intensamente hipermetabólica sugestiva de malignidad en el espacio supraclavicular. En tórax se objetivaron múltiples adenopatías mediastínicas e hiliares discretamente hipermetabólicas no sugestivas de malignidad. En abdomen y pelvis se confirmaron los hallazgos del TC visualizándose múltiples adenopatías hipermetabólicas sugestivas de malignidad a nivel reroperitoneal. » Hemograma: sin alteraciones. » Bioquímica incluyendo perfil renal, hepático y lipídico sin alteraciones. La LDH, AFP y la beta-HCG realizados previos a la cirugía se encontraban dentro de los límites de la normalidad. » Anatomía patológica de la orquiectomía inguinal derecha: tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) con componentes de tumor de células de Sertoli, estroma gonadal pobremente diferenciado y áreas de morfología sugestiva de componente de tumor de células de la granulosa. La malignidad queda acreditada por el tamaño (más de 5 cm), necrosis, su comportamiento infiltrante de albugínea, cubiertas testiculares, epidídimo y cordón espermático, permeación vascular en túnica vasculosa y alto índice proliferativo. Diagnóstico Tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) pT3 cN1 cM1a S0, estadio IIIA. Tratamiento Se presentó el caso en el comité multidisciplinar de tumores genitourinario y se decidió inicar tratamiento poliquimioterápico de 1ª línea según el esquema TIP (paclitaxel, ifosfamida, cisplatino). Evolución Tras haber completado 6 ciclos de tratamiento quimioterápico según el esquema TIP de Octubre de 2014 hasta Febrero de 2015, se observó una respuesta clínica parcial. Como toxicidades se registraron astenia grado 1, vómitos grado 1 y neuropatía grado 1. En TC de Julio de 2015 se objetivó un progreso adenopático a nivel retroperitoneal por lo que recibió una segunda línea de tratamiento con 6 ciclos de carboplatino y paclitaxel. Presentó astenia grado 1 y por neuropatía grado 3 se suspendió el paclitaxel tras el tercer ciclo. En Febrero de 2016 se realizó nuevo TC de reevaluación y además se solicitó una gammagrafía ósea por molestias lumbares. En el TC se objetivó una nueva progresión ganglionar y, en la gammagrafía ósea se observó de forma indirecta una lesión osteolítica en L5. En Marzo de 2016 se remitió a radioterapia antiálgica, recibiendo una dosis total de 3000cGy fraccionada en 10 sesiones. Tras finalizar el tratamiento radioterápico inició en Abril 2016 tratamiento quimiotrápico de tercera con cisplatino asociado a etopósido durante 5 días cada 21 días. Actualmente el paciente ha recibido 3 ciclos del tratamiento con cisplatino y etopósido con aceptable tolerancia y solo presentó astenia grado 1 como única toxicidad. Se solicitó una TC de reevaluación que se encuentra pendiente de realizar. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Varón de 77 años con antecedentes personales de dislipemia, hernias discales no intervenidas y sin antecedentes de criptorquidia. Acudió a su médico de atención primaria por aumento del tamaño del escroto de 6 meses de evolución. El aumento de tamaño fue progresivo y asimétrico. No presentó fiebre ni aumento de la temperatura a nivel escrotal. El paciente fue derivado al servicio de Urología para completar el estudio. Se realizó una ecografía escrotal donde se observó una lesión sólida, hipoecoica y bien definida aunque no se delimitó cápsula, siendo estos hallazgos sugestivos de una lesión sólida tumoral maligna. El paciente fue sometido a una orquiectomía inguinal derecha sin incidencias. Exploración física ECOG 0. Hemodinamicamente estable y afebril. La exploración física por aparatos fue anodina. No se palparon adenopatías supraclaviculares, axilares o inguinales. No se observó presencia de ginecomastia. La cicatriz de la orquiectomía inguinal derecha se encontraba reciente pero sin signos de complicación. Pruebas complementarias » TC de tórax, abdomen y pelvis de extensión: En mediastino y regiones hiliares se visualizaron varias imágenes nodulares la mayoría subcentimétricas sugestivas de pequeñas adenopatías inespecíficas, existiendo una de tamaño ligeramente superior al centímetro en localización paratraqueal derecha. » En abdomen se visualizaron abundantes adenopatías retroperitoneales de tamaño significativo en los grupos inter-aortocava, posteriores a la vena cava inferior, paraaórticos izquierdos, así como en la bifurcación aortoilíaca compatibles con adenopatías metastásicas. » PET-TC de extensión realizado para la caracterización de las adenopatías de significado incierto objetivadas en TC: Se observó una lesión intensamente hipermetabólica sugestiva de malignidad en el espacio supraclavicular. En tórax se objetivaron múltiples adenopatías mediastínicas e hiliares discretamente hipermetabólicas no sugestivas de malignidad. En abdomen y pelvis se confirmaron los hallazgos del TC visualizándose múltiples adenopatías hipermetabólicas sugestivas de malignidad a nivel reroperitoneal. » Hemograma: sin alteraciones. » Bioquímica incluyendo perfil renal, hepático y lipídico sin alteraciones. La LDH, AFP y la beta-HCG realizados previos a la cirugía se encontraban dentro de los límites de la normalidad. » Anatomía patológica de la orquiectomía inguinal derecha: tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) con componentes de tumor de células de Sertoli, estroma gonadal pobremente diferenciado y áreas de morfología sugestiva de componente de tumor de células de la granulosa. La malignidad queda acreditada por el tamaño (más de 5 cm), necrosis, su comportamiento infiltrante de albugínea, cubiertas testiculares, epidídimo y cordón espermático, permeación vascular en túnica vasculosa y alto índice proliferativo. Diagnóstico Tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) pT3 cN1 cM1a S0, estadio IIIA. Tratamiento Se presentó el caso en el comité multidisciplinar de tumores genitourinario y se decidió inicar tratamiento poliquimioterápico de 1ª línea según el esquema TIP (paclitaxel, ifosfamida, cisplatino). Evolución Tras haber completado 6 ciclos de tratamiento quimioterápico según el esquema TIP de Octubre de 2014 hasta Febrero de 2015, se observó una respuesta clínica parcial. Como toxicidades se registraron astenia grado 1, vómitos grado 1 y neuropatía grado 1. En TC de Julio de 2015 se objetivó un progreso adenopático a nivel retroperitoneal por lo que recibió una segunda línea de tratamiento con 6 ciclos de carboplatino y paclitaxel. Presentó astenia grado 1 y por neuropatía grado 3 se suspendió el paclitaxel tras el tercer ciclo. En Febrero de 2016 se realizó nuevo TC de reevaluación y además se solicitó una gammagrafía ósea por molestias lumbares. En el TC se objetivó una nueva progresión ganglionar y, en la gammagrafía ósea se observó de forma indirecta una lesión osteolítica en L5. En Marzo de 2016 se remitió a radioterapia antiálgica, recibiendo una dosis total de 3000cGy fraccionada en 10 sesiones. Tras finalizar el tratamiento radioterápico inició en Abril 2016 tratamiento quimiotrápico de tercera con cisplatino asociado a etopósido durante 5 días cada 21 días. Actualmente el paciente ha recibido 3 ciclos del tratamiento con cisplatino y etopósido con aceptable tolerancia y solo presentó astenia grado 1 como única toxicidad. Se solicitó una TC de reevaluación que se encuentra pendiente de realizar.
[ "Anamnesis", "\n", "Varón", "de", "77", "años", "con", "antecedentes", "personales", "de", "dislipemia", ",", "hernias", "discales", "no", "intervenidas", "y", "sin", "antecedentes", "de", "criptorquidia", ".", "\n", "Acudió", "a", "su", "médico", "de", "atención", "primaria", "por", "aumento", "del", "tamaño", "del", "escroto", "de", "6", "meses", "de", "evolución", ".", "\n", "El", "aumento", "de", "tamaño", "fue", "progresivo", "y", "asimétrico", ".", "No", "presentó", "fiebre", "ni", "aumento", "de", "la", "temperatura", "a", "nivel", "escrotal", ".", "\n", "El", "paciente", "fue", "derivado", "al", "servicio", "de", "Urología", "para", "completar", "el", "estudio", ".", "Se", "realizó", "una", "ecografía", "escrotal", "donde", "se", "observó", "una", "lesión", "sólida", ",", "hipoecoica", "y", "bien", "definida", "aunque", "no", "se", "delimitó", "cápsula", ",", "siendo", "estos", "hallazgos", "sugestivos", "de", "una", "lesión", "sólida", "tumoral", "maligna", ".", "El", "paciente", "fue", "sometido", "a", "una", "orquiectomía", "inguinal", "derecha", "sin", "incidencias", ".", "\n \n", "Exploración", "física", "\n", "ECOG", "0", ".", "Hemodinamicamente", "estable", "y", "afebril", ".", "La", "exploración", "física", "por", "aparatos", "fue", "anodina", ".", "No", "se", "palparon", "adenopatías", "supraclaviculares", ",", "axilares", "o", "inguinales", ".", "No", "se", "observó", "presencia", "de", "ginecomastia", ".", "La", "cicatriz", "de", "la", "orquiectomía", "inguinal", "derecha", "se", "encontraba", "reciente", "pero", "sin", "signos", "de", "complicación", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "TC", "de", "tórax", ",", "abdomen", "y", "pelvis", "de", "extensión", ":", "En", "mediastino", "y", "regiones", "hiliares", "se", "visualizaron", "varias", "imágenes", "nodulares", "la", "mayoría", "subcentimétricas", "sugestivas", "de", "pequeñas", "adenopatías", "inespecíficas", ",", "existiendo", "una", "de", "tamaño", "ligeramente", "superior", "al", "centímetro", "en", "localización", "paratraqueal", "derecha", ".", "\n", "»", "En", "abdomen", "se", "visualizaron", "abundantes", "adenopatías", "retroperitoneales", "de", "tamaño", "significativo", "en", "los", "grupos", "inter", "-", "aortocava", ",", "posteriores", "a", "la", "vena", "cava", "inferior", ",", "paraaórticos", "izquierdos", ",", "así", "como", "en", "la", "bifurcación", "aortoilíaca", "compatibles", "con", "adenopatías", "metastásicas", ".", "\n", "»", "PET", "-", "TC", "de", "extensión", "realizado", "para", "la", "caracterización", "de", "las", "adenopatías", "de", "significado", "incierto", "objetivadas", "en", "TC", ":", "Se", "observó", "una", "lesión", "intensamente", "hipermetabólica", "sugestiva", "de", "malignidad", "en", "el", "espacio", "supraclavicular", ".", "En", "tórax", "se", "objetivaron", "múltiples", "adenopatías", "mediastínicas", "e", "hiliares", "discretamente", "hipermetabólicas", "no", "sugestivas", "de", "malignidad", ".", "En", "abdomen", "y", "pelvis", "se", "confirmaron", "los", "hallazgos", "del", "TC", "visualizándose", "múltiples", "adenopatías", "hipermetabólicas", "sugestivas", "de", "malignidad", "a", "nivel", "reroperitoneal", ".", "\n", "»", "Hemograma", ":", "sin", "alteraciones", ".", "\n", "»", "Bioquímica", "incluyendo", "perfil", "renal", ",", "hepático", "y", "lipídico", "sin", "alteraciones", ".", "La", "LDH", ",", "AFP", "y", "la", "beta", "-", "HCG", "realizados", "previos", "a", "la", "cirugía", "se", "encontraban", "dentro", "de", "los", "límites", "de", "la", "normalidad", ".", "\n", "»", "Anatomía", "patológica", "de", "la", "orquiectomía", "inguinal", "derecha", ":", "tumor", "de", "cordones", "sexuales", "/", "estroma", "gonadal", "maligno", "(", "OMS", "2004", ")", "con", "componentes", "de", "tumor", "de", "células", "de", "Sertoli", ",", "estroma", "gonadal", "pobremente", "diferenciado", "y", "áreas", "de", "morfología", "sugestiva", "de", "componente", "de", "tumor", "de", "células", "de", "la", "granulosa", ".", "La", "malignidad", "queda", "acreditada", "por", "el", "tamaño", "(", "más", "de", "5", "cm", ")", ",", "necrosis", ",", "su", "comportamiento", "infiltrante", "de", "albugínea", ",", "cubiertas", "testiculares", ",", "epidídimo", "y", "cordón", "espermático", ",", "permeación", "vascular", "en", "túnica", "vasculosa", "y", "alto", "índice", "proliferativo", ".", "\n\n", "Diagnóstico", "\n", "Tumor", "de", "cordones", "sexuales", "/", "estroma", "gonadal", "maligno", "(", "OMS", "2004", ")", "pT3", "cN1", "cM1a", "S0", ",", "estadio", "IIIA", ".", "\n\n", "Tratamiento", "\n", "Se", "presentó", "el", "caso", "en", "el", "comité", "multidisciplinar", "de", "tumores", "genitourinario", "y", "se", "decidió", "inicar", "tratamiento", "poliquimioterápico", "de", "1ª", "línea", "según", "el", "esquema", "TIP", "(", "paclitaxel", ",", "ifosfamida", ",", "cisplatino", ")", ".", "\n\n", "Evolución", "\n", "Tras", "haber", "completado", "6", "ciclos", "de", "tratamiento", "quimioterápico", "según", "el", "esquema", "TIP", "de", "Octubre", "de", "2014", "hasta", "Febrero", "de", "2015", ",", "se", "observó", "una", "respuesta", "clínica", "parcial", ".", "Como", "toxicidades", "se", "registraron", "astenia", "grado", "1", ",", "vómitos", "grado", "1", "y", "neuropatía", "grado", "1", ".", "\n", "En", "TC", "de", "Julio", "de", "2015", "se", "objetivó", "un", "progreso", "adenopático", "a", "nivel", "retroperitoneal", "por", "lo", "que", "recibió", "una", "segunda", "línea", "de", "tratamiento", "con", "6", "ciclos", "de", "carboplatino", "y", "paclitaxel", ".", "Presentó", "astenia", "grado", "1", "y", "por", "neuropatía", "grado", "3", "se", "suspendió", "el", "paclitaxel", "tras", "el", "tercer", "ciclo", ".", "\n", "En", "Febrero", "de", "2016", "se", "realizó", "nuevo", "TC", "de", "reevaluación", "y", "además", "se", "solicitó", "una", "gammagrafía", "ósea", "por", "molestias", "lumbares", ".", "En", "el", "TC", "se", "objetivó", "una", "nueva", "progresión", "ganglionar", "y", ",", "en", "la", "gammagrafía", "ósea", "se", "observó", "de", "forma", "indirecta", "una", "lesión", "osteolítica", "en", "L5", ".", "En", "Marzo", "de", "2016", "se", "remitió", "a", "radioterapia", "antiálgica", ",", "recibiendo", "una", "dosis", "total", "de", "3000cGy", "fraccionada", "en", "10", "sesiones", ".", "Tras", "finalizar", "el", "tratamiento", "radioterápico", "inició", "en", "Abril", "2016", "tratamiento", "quimiotrápico", "de", "tercera", "con", "cisplatino", "asociado", "a", "etopósido", "durante", "5", "días", "cada", "21", "días", ".", "\n", "Actualmente", "el", "paciente", "ha", "recibido", "3", "ciclos", "del", "tratamiento", "con", "cisplatino", "y", "etopósido", "con", "aceptable", "tolerancia", "y", "solo", "presentó", "astenia", "grado", "1", "como", "única", "toxicidad", ".", "Se", "solicitó", "una", "TC", "de", "reevaluación", "que", "se", "encuentra", "pendiente", "de", "realizar", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
Arformoterol is a CHEMICAL, ( R , R)-eformoterol is a CHEMICAL, ( R , R)-formoterol is a CHEMICAL, arformoterol tartrate is a CHEMICAL, eformoterol is a CHEMICAL, formoterol is a CHEMICAL, R , R - eformoterol is a CHEMICAL, R , R - formoterol is a CHEMICAL, arformoterol is a CHEMICAL, R , R - formoterol is a CHEMICAL, beta(2)-adrenoceptor is a GENE-Y, formoterol is a CHEMICAL, eformoterol is a CHEMICAL, arformoterol is a CHEMICAL, levosalbutamol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL
8482_task0
Sentence: Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral centres and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor believes that arformoterol has the potential to be a once-daily therapy with a rapid onset of action and a duration of effect exceeding 12 hours. In 1995, Sepracor acquired New England Pharmaceuticals, a manufacturer of metered-dose and dry powder inhalers, for the purpose of preparing formulations of levosalbutamol and arformoterol. Phase II dose-ranging clinical studies of arformoterol as a longer-acting, complementary bronchodilator were completed successfully in the fourth quarter of 2000. Phase III trials of arformoterol began in September 2001. The indications for the drug appeared to be asthma and chronic obstructive pulmonary disease (COPD). However, an update of the pharmaceutical product information on the Sepracor website in September 2003 listed COPD maintenance therapy as the only indication for arformoterol. In October 2002, Sepracor stated that two pivotal phase III studies were ongoing in 1600 patients. Sepracor estimates that its NDA submission for arformoterol, which is projected for the first half of 2004, will include approximately 3000 adult subjects. Sepracor stated in July 2003 that it had completed more than 100 preclinical studies and initiated or completed 15 clinical studies for arformoterol inhalation solution for the treatment of bronchospasm in patients with COPD. In addition, Sepracor stated that the two pivotal phase III studies in 1600 patients were still progressing. In 1995, European patents were granted to Sepracor for the use of arformoterol in the treatment of asthma, and the US patent application was pending. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral centres and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor believes that arformoterol has the potential to be a once-daily therapy with a rapid onset of action and a duration of effect exceeding 12 hours. In 1995, Sepracor acquired New England Pharmaceuticals, a manufacturer of metered-dose and dry powder inhalers, for the purpose of preparing formulations of levosalbutamol and arformoterol. Phase II dose-ranging clinical studies of arformoterol as a longer-acting, complementary bronchodilator were completed successfully in the fourth quarter of 2000. Phase III trials of arformoterol began in September 2001. The indications for the drug appeared to be asthma and chronic obstructive pulmonary disease (COPD). However, an update of the pharmaceutical product information on the Sepracor website in September 2003 listed COPD maintenance therapy as the only indication for arformoterol. In October 2002, Sepracor stated that two pivotal phase III studies were ongoing in 1600 patients. Sepracor estimates that its NDA submission for arformoterol, which is projected for the first half of 2004, will include approximately 3000 adult subjects. Sepracor stated in July 2003 that it had completed more than 100 preclinical studies and initiated or completed 15 clinical studies for arformoterol inhalation solution for the treatment of bronchospasm in patients with COPD. In addition, Sepracor stated that the two pivotal phase III studies in 1600 patients were still progressing. In 1995, European patents were granted to Sepracor for the use of arformoterol in the treatment of asthma, and the US patent application was pending.
[ "Arformoterol", ":", "(", "R", ",", "R)-eformoterol", ",", "(", "R", ",", "R)-formoterol", ",", "arformoterol", "tartrate", ",", "eformoterol", "-", "sepracor", ",", "formoterol", "-", "sepracor", ",", "R", ",", "R", "-", "eformoterol", ",", "R", ",", "R", "-", "formoterol", ".", "\n", "Sepracor", "in", "the", "US", "is", "developing", "arformoterol", "[", "R", ",", "R", "-", "formoterol", "]", ",", "a", "single", "isomer", "form", "of", "the", "beta(2)-adrenoceptor", "agonist", "formoterol", "[", "eformoterol", "]", ".", "This", "isomer", "contains", "two", "chiral", "centres", "and", "is", "being", "developed", "as", "an", "inhaled", "preparation", "for", "the", "treatment", "of", "respiratory", "disorders", ".", "Sepracor", "believes", "that", "arformoterol", "has", "the", "potential", "to", "be", "a", "once", "-", "daily", "therapy", "with", "a", "rapid", "onset", "of", "action", "and", "a", "duration", "of", "effect", "exceeding", "12", "hours", ".", "In", "1995", ",", "Sepracor", "acquired", "New", "England", "Pharmaceuticals", ",", "a", "manufacturer", "of", "metered", "-", "dose", "and", "dry", "powder", "inhalers", ",", "for", "the", "purpose", "of", "preparing", "formulations", "of", "levosalbutamol", "and", "arformoterol", ".", "Phase", "II", "dose", "-", "ranging", "clinical", "studies", "of", "arformoterol", "as", "a", "longer", "-", "acting", ",", "complementary", "bronchodilator", "were", "completed", "successfully", "in", "the", "fourth", "quarter", "of", "2000", ".", "Phase", "III", "trials", "of", "arformoterol", "began", "in", "September", "2001", ".", "The", "indications", "for", "the", "drug", "appeared", "to", "be", "asthma", "and", "chronic", "obstructive", "pulmonary", "disease", "(", "COPD", ")", ".", "However", ",", "an", "update", "of", "the", "pharmaceutical", "product", "information", "on", "the", "Sepracor", "website", "in", "September", "2003", "listed", "COPD", "maintenance", "therapy", "as", "the", "only", "indication", "for", "arformoterol", ".", "In", "October", "2002", ",", "Sepracor", "stated", "that", "two", "pivotal", "phase", "III", "studies", "were", "ongoing", "in", "1600", "patients", ".", "Sepracor", "estimates", "that", "its", "NDA", "submission", "for", "arformoterol", ",", "which", "is", "projected", "for", "the", "first", "half", "of", "2004", ",", "will", "include", "approximately", "3000", "adult", "subjects", ".", "Sepracor", "stated", "in", "July", "2003", "that", "it", "had", "completed", "more", "than", "100", "preclinical", "studies", "and", "initiated", "or", "completed", "15", "clinical", "studies", "for", "arformoterol", "inhalation", "solution", "for", "the", "treatment", "of", "bronchospasm", "in", "patients", "with", "COPD", ".", "In", "addition", ",", "Sepracor", "stated", "that", "the", "two", "pivotal", "phase", "III", "studies", "in", "1600", "patients", "were", "still", "progressing", ".", "In", "1995", ",", "European", "patents", "were", "granted", "to", "Sepracor", "for", "the", "use", "of", "arformoterol", "in", "the", "treatment", "of", "asthma", ",", "and", "the", "US", "patent", "application", "was", "pending", "." ]
[ "CHEMICAL", "GENE-Y" ]
Arformoterol is a CHEMICAL, ( R , R)-eformoterol is a CHEMICAL, ( R , R)-formoterol is a CHEMICAL, arformoterol tartrate is a CHEMICAL, eformoterol is a CHEMICAL, formoterol is a CHEMICAL, R , R - eformoterol is a CHEMICAL, R , R - formoterol is a CHEMICAL, arformoterol is a CHEMICAL, R , R - formoterol is a CHEMICAL, beta(2)-adrenoceptor is a GENE-Y, formoterol is a CHEMICAL, eformoterol is a CHEMICAL, arformoterol is a CHEMICAL, levosalbutamol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL, arformoterol is a CHEMICAL
8482_task1
Sentence: Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral centres and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor believes that arformoterol has the potential to be a once-daily therapy with a rapid onset of action and a duration of effect exceeding 12 hours. In 1995, Sepracor acquired New England Pharmaceuticals, a manufacturer of metered-dose and dry powder inhalers, for the purpose of preparing formulations of levosalbutamol and arformoterol. Phase II dose-ranging clinical studies of arformoterol as a longer-acting, complementary bronchodilator were completed successfully in the fourth quarter of 2000. Phase III trials of arformoterol began in September 2001. The indications for the drug appeared to be asthma and chronic obstructive pulmonary disease (COPD). However, an update of the pharmaceutical product information on the Sepracor website in September 2003 listed COPD maintenance therapy as the only indication for arformoterol. In October 2002, Sepracor stated that two pivotal phase III studies were ongoing in 1600 patients. Sepracor estimates that its NDA submission for arformoterol, which is projected for the first half of 2004, will include approximately 3000 adult subjects. Sepracor stated in July 2003 that it had completed more than 100 preclinical studies and initiated or completed 15 clinical studies for arformoterol inhalation solution for the treatment of bronchospasm in patients with COPD. In addition, Sepracor stated that the two pivotal phase III studies in 1600 patients were still progressing. In 1995, European patents were granted to Sepracor for the use of arformoterol in the treatment of asthma, and the US patent application was pending. Instructions: please typing these entity words according to sentence: Arformoterol, ( R , R)-eformoterol, ( R , R)-formoterol, arformoterol tartrate, eformoterol, formoterol, R , R - eformoterol, R , R - formoterol, arformoterol, R , R - formoterol, beta(2)-adrenoceptor, formoterol, eformoterol, arformoterol, levosalbutamol, arformoterol, arformoterol, arformoterol, arformoterol, arformoterol, arformoterol, arformoterol Options: GENE-Y, CHEMICAL
[ "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral centres and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor believes that arformoterol has the potential to be a once-daily therapy with a rapid onset of action and a duration of effect exceeding 12 hours. In 1995, Sepracor acquired New England Pharmaceuticals, a manufacturer of metered-dose and dry powder inhalers, for the purpose of preparing formulations of levosalbutamol and arformoterol. Phase II dose-ranging clinical studies of arformoterol as a longer-acting, complementary bronchodilator were completed successfully in the fourth quarter of 2000. Phase III trials of arformoterol began in September 2001. The indications for the drug appeared to be asthma and chronic obstructive pulmonary disease (COPD). However, an update of the pharmaceutical product information on the Sepracor website in September 2003 listed COPD maintenance therapy as the only indication for arformoterol. In October 2002, Sepracor stated that two pivotal phase III studies were ongoing in 1600 patients. Sepracor estimates that its NDA submission for arformoterol, which is projected for the first half of 2004, will include approximately 3000 adult subjects. Sepracor stated in July 2003 that it had completed more than 100 preclinical studies and initiated or completed 15 clinical studies for arformoterol inhalation solution for the treatment of bronchospasm in patients with COPD. In addition, Sepracor stated that the two pivotal phase III studies in 1600 patients were still progressing. In 1995, European patents were granted to Sepracor for the use of arformoterol in the treatment of asthma, and the US patent application was pending.
[ "Arformoterol", ":", "(", "R", ",", "R)-eformoterol", ",", "(", "R", ",", "R)-formoterol", ",", "arformoterol", "tartrate", ",", "eformoterol", "-", "sepracor", ",", "formoterol", "-", "sepracor", ",", "R", ",", "R", "-", "eformoterol", ",", "R", ",", "R", "-", "formoterol", ".", "\n", "Sepracor", "in", "the", "US", "is", "developing", "arformoterol", "[", "R", ",", "R", "-", "formoterol", "]", ",", "a", "single", "isomer", "form", "of", "the", "beta(2)-adrenoceptor", "agonist", "formoterol", "[", "eformoterol", "]", ".", "This", "isomer", "contains", "two", "chiral", "centres", "and", "is", "being", "developed", "as", "an", "inhaled", "preparation", "for", "the", "treatment", "of", "respiratory", "disorders", ".", "Sepracor", "believes", "that", "arformoterol", "has", "the", "potential", "to", "be", "a", "once", "-", "daily", "therapy", "with", "a", "rapid", "onset", "of", "action", "and", "a", "duration", "of", "effect", "exceeding", "12", "hours", ".", "In", "1995", ",", "Sepracor", "acquired", "New", "England", "Pharmaceuticals", ",", "a", "manufacturer", "of", "metered", "-", "dose", "and", "dry", "powder", "inhalers", ",", "for", "the", "purpose", "of", "preparing", "formulations", "of", "levosalbutamol", "and", "arformoterol", ".", "Phase", "II", "dose", "-", "ranging", "clinical", "studies", "of", "arformoterol", "as", "a", "longer", "-", "acting", ",", "complementary", "bronchodilator", "were", "completed", "successfully", "in", "the", "fourth", "quarter", "of", "2000", ".", "Phase", "III", "trials", "of", "arformoterol", "began", "in", "September", "2001", ".", "The", "indications", "for", "the", "drug", "appeared", "to", "be", "asthma", "and", "chronic", "obstructive", "pulmonary", "disease", "(", "COPD", ")", ".", "However", ",", "an", "update", "of", "the", "pharmaceutical", "product", "information", "on", "the", "Sepracor", "website", "in", "September", "2003", "listed", "COPD", "maintenance", "therapy", "as", "the", "only", "indication", "for", "arformoterol", ".", "In", "October", "2002", ",", "Sepracor", "stated", "that", "two", "pivotal", "phase", "III", "studies", "were", "ongoing", "in", "1600", "patients", ".", "Sepracor", "estimates", "that", "its", "NDA", "submission", "for", "arformoterol", ",", "which", "is", "projected", "for", "the", "first", "half", "of", "2004", ",", "will", "include", "approximately", "3000", "adult", "subjects", ".", "Sepracor", "stated", "in", "July", "2003", "that", "it", "had", "completed", "more", "than", "100", "preclinical", "studies", "and", "initiated", "or", "completed", "15", "clinical", "studies", "for", "arformoterol", "inhalation", "solution", "for", "the", "treatment", "of", "bronchospasm", "in", "patients", "with", "COPD", ".", "In", "addition", ",", "Sepracor", "stated", "that", "the", "two", "pivotal", "phase", "III", "studies", "in", "1600", "patients", "were", "still", "progressing", ".", "In", "1995", ",", "European", "patents", "were", "granted", "to", "Sepracor", "for", "the", "use", "of", "arformoterol", "in", "the", "treatment", "of", "asthma", ",", "and", "the", "US", "patent", "application", "was", "pending", "." ]
[ "CHEMICAL", "GENE-Y" ]
Arformoterol, ( R , R)-eformoterol, ( R , R)-formoterol, arformoterol tartrate, eformoterol, formoterol, R , R - eformoterol, R , R - formoterol, arformoterol, R , R - formoterol, beta(2)-adrenoceptor, formoterol, eformoterol, arformoterol, levosalbutamol, arformoterol, arformoterol, arformoterol, arformoterol, arformoterol, arformoterol, arformoterol
8482_task2
Sentence: Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral centres and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor believes that arformoterol has the potential to be a once-daily therapy with a rapid onset of action and a duration of effect exceeding 12 hours. In 1995, Sepracor acquired New England Pharmaceuticals, a manufacturer of metered-dose and dry powder inhalers, for the purpose of preparing formulations of levosalbutamol and arformoterol. Phase II dose-ranging clinical studies of arformoterol as a longer-acting, complementary bronchodilator were completed successfully in the fourth quarter of 2000. Phase III trials of arformoterol began in September 2001. The indications for the drug appeared to be asthma and chronic obstructive pulmonary disease (COPD). However, an update of the pharmaceutical product information on the Sepracor website in September 2003 listed COPD maintenance therapy as the only indication for arformoterol. In October 2002, Sepracor stated that two pivotal phase III studies were ongoing in 1600 patients. Sepracor estimates that its NDA submission for arformoterol, which is projected for the first half of 2004, will include approximately 3000 adult subjects. Sepracor stated in July 2003 that it had completed more than 100 preclinical studies and initiated or completed 15 clinical studies for arformoterol inhalation solution for the treatment of bronchospasm in patients with COPD. In addition, Sepracor stated that the two pivotal phase III studies in 1600 patients were still progressing. In 1995, European patents were granted to Sepracor for the use of arformoterol in the treatment of asthma, and the US patent application was pending. Instructions: please extract entity words from the input sentence
[ "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral centres and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor believes that arformoterol has the potential to be a once-daily therapy with a rapid onset of action and a duration of effect exceeding 12 hours. In 1995, Sepracor acquired New England Pharmaceuticals, a manufacturer of metered-dose and dry powder inhalers, for the purpose of preparing formulations of levosalbutamol and arformoterol. Phase II dose-ranging clinical studies of arformoterol as a longer-acting, complementary bronchodilator were completed successfully in the fourth quarter of 2000. Phase III trials of arformoterol began in September 2001. The indications for the drug appeared to be asthma and chronic obstructive pulmonary disease (COPD). However, an update of the pharmaceutical product information on the Sepracor website in September 2003 listed COPD maintenance therapy as the only indication for arformoterol. In October 2002, Sepracor stated that two pivotal phase III studies were ongoing in 1600 patients. Sepracor estimates that its NDA submission for arformoterol, which is projected for the first half of 2004, will include approximately 3000 adult subjects. Sepracor stated in July 2003 that it had completed more than 100 preclinical studies and initiated or completed 15 clinical studies for arformoterol inhalation solution for the treatment of bronchospasm in patients with COPD. In addition, Sepracor stated that the two pivotal phase III studies in 1600 patients were still progressing. In 1995, European patents were granted to Sepracor for the use of arformoterol in the treatment of asthma, and the US patent application was pending.
[ "Arformoterol", ":", "(", "R", ",", "R)-eformoterol", ",", "(", "R", ",", "R)-formoterol", ",", "arformoterol", "tartrate", ",", "eformoterol", "-", "sepracor", ",", "formoterol", "-", "sepracor", ",", "R", ",", "R", "-", "eformoterol", ",", "R", ",", "R", "-", "formoterol", ".", "\n", "Sepracor", "in", "the", "US", "is", "developing", "arformoterol", "[", "R", ",", "R", "-", "formoterol", "]", ",", "a", "single", "isomer", "form", "of", "the", "beta(2)-adrenoceptor", "agonist", "formoterol", "[", "eformoterol", "]", ".", "This", "isomer", "contains", "two", "chiral", "centres", "and", "is", "being", "developed", "as", "an", "inhaled", "preparation", "for", "the", "treatment", "of", "respiratory", "disorders", ".", "Sepracor", "believes", "that", "arformoterol", "has", "the", "potential", "to", "be", "a", "once", "-", "daily", "therapy", "with", "a", "rapid", "onset", "of", "action", "and", "a", "duration", "of", "effect", "exceeding", "12", "hours", ".", "In", "1995", ",", "Sepracor", "acquired", "New", "England", "Pharmaceuticals", ",", "a", "manufacturer", "of", "metered", "-", "dose", "and", "dry", "powder", "inhalers", ",", "for", "the", "purpose", "of", "preparing", "formulations", "of", "levosalbutamol", "and", "arformoterol", ".", "Phase", "II", "dose", "-", "ranging", "clinical", "studies", "of", "arformoterol", "as", "a", "longer", "-", "acting", ",", "complementary", "bronchodilator", "were", "completed", "successfully", "in", "the", "fourth", "quarter", "of", "2000", ".", "Phase", "III", "trials", "of", "arformoterol", "began", "in", "September", "2001", ".", "The", "indications", "for", "the", "drug", "appeared", "to", "be", "asthma", "and", "chronic", "obstructive", "pulmonary", "disease", "(", "COPD", ")", ".", "However", ",", "an", "update", "of", "the", "pharmaceutical", "product", "information", "on", "the", "Sepracor", "website", "in", "September", "2003", "listed", "COPD", "maintenance", "therapy", "as", "the", "only", "indication", "for", "arformoterol", ".", "In", "October", "2002", ",", "Sepracor", "stated", "that", "two", "pivotal", "phase", "III", "studies", "were", "ongoing", "in", "1600", "patients", ".", "Sepracor", "estimates", "that", "its", "NDA", "submission", "for", "arformoterol", ",", "which", "is", "projected", "for", "the", "first", "half", "of", "2004", ",", "will", "include", "approximately", "3000", "adult", "subjects", ".", "Sepracor", "stated", "in", "July", "2003", "that", "it", "had", "completed", "more", "than", "100", "preclinical", "studies", "and", "initiated", "or", "completed", "15", "clinical", "studies", "for", "arformoterol", "inhalation", "solution", "for", "the", "treatment", "of", "bronchospasm", "in", "patients", "with", "COPD", ".", "In", "addition", ",", "Sepracor", "stated", "that", "the", "two", "pivotal", "phase", "III", "studies", "in", "1600", "patients", "were", "still", "progressing", ".", "In", "1995", ",", "European", "patents", "were", "granted", "to", "Sepracor", "for", "the", "use", "of", "arformoterol", "in", "the", "treatment", "of", "asthma", ",", "and", "the", "US", "patent", "application", "was", "pending", "." ]
[ "CHEMICAL", "GENE-Y" ]
neoplasia is a MORFOLOGIA_NEOPLASIA, Adenopatía supraclavicular is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, intratumoral is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumor mal diferenciado is a MORFOLOGIA_NEOPLASIA, estesioneuroblastoma de alto grado is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, Estesioneuroblastoma is a MORFOLOGIA_NEOPLASIA, estesioneuroblastoma is a MORFOLOGIA_NEOPLASIA, M1 is a MORFOLOGIA_NEOPLASIA, afectación de glándula hipofisaria is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, lesiones óseas is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, M1 is a MORFOLOGIA_NEOPLASIA
315_task0
Sentence: Anamnesis Mujer de 51 años sin AMC. No hábitos tóxicos. ANTECEDENTES PATOLÓGICOS: Epilepsia en tratamiento con Tegretol. Sin crisis desde hacía > 10 años. ANTECEDENTES FAMILIARES: Padre con neoplasia de colon. Primer síntoma: La paciente en diciembre de 2010 consulta en ORL por sensación de taponamiento nasal de predominio izquierdo acompañado de rinorrea, lagrimeo y anosmia progresiva, iniciando tratamiento con corticoides, con mejoría sintomática. En enero de 2011 reconsulta por autopalpación de adenopatías a nivel submandibular izquierdo, indoloras y con crecimiento progresivo. Exploración física » Constantes: HMD estable. ECOG 0. » Adenopatías laterocervicales bilaterales de 5 cm aprox. y de consistencia dura. Adenopatía supraclavicular izquierda de 1-2 cm. » Rinoscopia: Fosa nasal izquierda se objetiva abundante rinorrea, y se aprecia una lesión violácea que ocupa la mayor parte de la fosa. » Resto EF normal. Pruebas complementarias » Analítica (03/03/11): Hemograma normal; LDH: 758, FA: 116, colesterol: 286.3, ferritina: 172.9, resto de BQ normal; IgM EBV: negativo, IgG EBV: positivo. » TAC cervical (04/03/11): Ocupación de seno esfenoidal, celdas etmoidales y seno maxilar izquierdo, con signos de destrucción de celdas etmoidales y pared medial del seno maxilar que se extiende hasta cornete. Múltiples adenopatías a nivel retroauricular, submentoniano, cadena yugular, supraclaviculares, y a nivel mediastínico, paraaórtico y paratraqueal. » RNM de base de cráneo (16/03/2011): Extensa tumoración en fosa nasal, invade las celdas etmoidales y seno frontal con afectación y destrucción ósea a nivel de las paredes de los senos maxilares y ambas órbitas con sospecha de invasión de la parte anterior de la órbita izquierda. Destrucción ósea de la fosa craneal anterior a nivel de la lámina cribosa del lado izquierdo con invasión tumoral intracraneal que muestra pequeña imagen quística intratumoral. El parénquima cerebral del lóbulo frontal izquierdo se encuentra desplazado, compatible con edema por efecto masa de la tumoración. Se observa engrosamiento de la glándula hipofisaria con afectación de contraste iv heterogénea sugestivo de metástasis. » PAAF adenopatía cervical izquierda (08/03/11): Imagen citológica de tumor mal diferenciado compatible con estesioneuroblastoma de alto grado. Inmunohistoquímica: Positivo para vimentina, CD56, sinaptofisina, NSE y cromogranina. Negativo para CK y CD4 » Biopsia tumoración fosa nasal (08/03/11): Estesioneuroblastoma. Grado III/IV de la clasificación de Hyams. Diagnóstico Se presenta en comité de tumores de ORL (22/03/11): Se orienta como mujer de 51 años diagnosticada de estesioneuroblastoma olfatorio. » Según TNM: cT4 (por invasión cerebral), N1 (adenopatías cervicales), M1 (probable afectación de glándula hipofisaria). Estadio IV. » Según clasificación de Kadish: estadio C (invasión de estructuras adyacentes). Tratamiento Dado que es una paciente metastásica se decide inicio de tratamiento con QT paliativa según esquema CDDP 80 mg/m2 (día 1) y VP16 100mg/m2 (días 1-3) cada 21 días. La paciente inicia QT el día 18/04/11 realizando un total de 6 ciclos, que finaliza el día 10/08/11. Evolución Se solicita RNM de valoración de respuesta: » RNM de base de cráneo (16/08/11): Persistencia de la afectación tumoral residual ósea en la fosa craneal anterior a nivel de la lámina cribosa, de la pared posterior de las celdas etmoidales, del seno esfenoidal izquierdo. Reducción completa del componente tumoral intracraneal frontal izq. Desaparición del edema cerebral subyacente. Discreta disminución del engrosamiento de la hipófisis. Dada la respuesta radiológica se deriva a comité de ORL de HUGTiP para valoración de cirugía radical; realizándose el día 21/10/11 vaciamiento cervical radical modificado bilateral en un primer tiempo. La paciente pendiente de cirugía del tumor primario (que se realizaría en un segundo tiempo) presenta clínica de taponamiento nasal por lo que ante la sospecha de recidiva se solicita TAC- PET » TAC-PET (28/11/11): Extensa recidiva tumoral a nivel de fosa nasal, celdillas etmoidales (claro predominio derecho), con infiltración de estructuras adyacentes (órbita, seno maxilar derecho, probablemente pared lateral derecha de nasofaringe) y extensión intracraneal con infiltración de región basal del lóbulo frontal izquierdo. Múltiples lesiones óseas en calota craneal, en columna dorso-lumbar, en escápula izquierda, región lateral de 4º arco y 7º arcos costales derechos, hueso ilíaco derecho e izquierdo, y cuello femoral bilateral, isquion izquierdo y rama del pubis derecha, en relación con afectación metastásica múltiple. Se vuelve a presentar en comité descartándose la cirugía sobre el tumor primario y decidiéndose ante la actual progresión clínica y radiológica a menos de 3 meses de fin de QT realizar RDT local con intención paliativa. Post RDT, en febrero de 2012 presenta clínica de inestabilidad cefálica realizándose: » TAC de cráneo (08/02/12): Múltiples M1 cerebrales. Por lo que se inicia RT holocraneal paliativa el día 21/02/12. El 22/02/12 la paciente ingresa por clínica de compresión cervical (estridor laríngeo, disfonía y disnea) por compresión del conglomerado adenopático Dado la enfermedad avanzada y la situación clínica actual se decide inicio de tratamiento sintomático siendo éxitus el día 25/02/12. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Mujer de 51 años sin AMC. No hábitos tóxicos. ANTECEDENTES PATOLÓGICOS: Epilepsia en tratamiento con Tegretol. Sin crisis desde hacía > 10 años. ANTECEDENTES FAMILIARES: Padre con neoplasia de colon. Primer síntoma: La paciente en diciembre de 2010 consulta en ORL por sensación de taponamiento nasal de predominio izquierdo acompañado de rinorrea, lagrimeo y anosmia progresiva, iniciando tratamiento con corticoides, con mejoría sintomática. En enero de 2011 reconsulta por autopalpación de adenopatías a nivel submandibular izquierdo, indoloras y con crecimiento progresivo. Exploración física » Constantes: HMD estable. ECOG 0. » Adenopatías laterocervicales bilaterales de 5 cm aprox. y de consistencia dura. Adenopatía supraclavicular izquierda de 1-2 cm. » Rinoscopia: Fosa nasal izquierda se objetiva abundante rinorrea, y se aprecia una lesión violácea que ocupa la mayor parte de la fosa. » Resto EF normal. Pruebas complementarias » Analítica (03/03/11): Hemograma normal; LDH: 758, FA: 116, colesterol: 286.3, ferritina: 172.9, resto de BQ normal; IgM EBV: negativo, IgG EBV: positivo. » TAC cervical (04/03/11): Ocupación de seno esfenoidal, celdas etmoidales y seno maxilar izquierdo, con signos de destrucción de celdas etmoidales y pared medial del seno maxilar que se extiende hasta cornete. Múltiples adenopatías a nivel retroauricular, submentoniano, cadena yugular, supraclaviculares, y a nivel mediastínico, paraaórtico y paratraqueal. » RNM de base de cráneo (16/03/2011): Extensa tumoración en fosa nasal, invade las celdas etmoidales y seno frontal con afectación y destrucción ósea a nivel de las paredes de los senos maxilares y ambas órbitas con sospecha de invasión de la parte anterior de la órbita izquierda. Destrucción ósea de la fosa craneal anterior a nivel de la lámina cribosa del lado izquierdo con invasión tumoral intracraneal que muestra pequeña imagen quística intratumoral. El parénquima cerebral del lóbulo frontal izquierdo se encuentra desplazado, compatible con edema por efecto masa de la tumoración. Se observa engrosamiento de la glándula hipofisaria con afectación de contraste iv heterogénea sugestivo de metástasis. » PAAF adenopatía cervical izquierda (08/03/11): Imagen citológica de tumor mal diferenciado compatible con estesioneuroblastoma de alto grado. Inmunohistoquímica: Positivo para vimentina, CD56, sinaptofisina, NSE y cromogranina. Negativo para CK y CD4 » Biopsia tumoración fosa nasal (08/03/11): Estesioneuroblastoma. Grado III/IV de la clasificación de Hyams. Diagnóstico Se presenta en comité de tumores de ORL (22/03/11): Se orienta como mujer de 51 años diagnosticada de estesioneuroblastoma olfatorio. » Según TNM: cT4 (por invasión cerebral), N1 (adenopatías cervicales), M1 (probable afectación de glándula hipofisaria). Estadio IV. » Según clasificación de Kadish: estadio C (invasión de estructuras adyacentes). Tratamiento Dado que es una paciente metastásica se decide inicio de tratamiento con QT paliativa según esquema CDDP 80 mg/m2 (día 1) y VP16 100mg/m2 (días 1-3) cada 21 días. La paciente inicia QT el día 18/04/11 realizando un total de 6 ciclos, que finaliza el día 10/08/11. Evolución Se solicita RNM de valoración de respuesta: » RNM de base de cráneo (16/08/11): Persistencia de la afectación tumoral residual ósea en la fosa craneal anterior a nivel de la lámina cribosa, de la pared posterior de las celdas etmoidales, del seno esfenoidal izquierdo. Reducción completa del componente tumoral intracraneal frontal izq. Desaparición del edema cerebral subyacente. Discreta disminución del engrosamiento de la hipófisis. Dada la respuesta radiológica se deriva a comité de ORL de HUGTiP para valoración de cirugía radical; realizándose el día 21/10/11 vaciamiento cervical radical modificado bilateral en un primer tiempo. La paciente pendiente de cirugía del tumor primario (que se realizaría en un segundo tiempo) presenta clínica de taponamiento nasal por lo que ante la sospecha de recidiva se solicita TAC- PET » TAC-PET (28/11/11): Extensa recidiva tumoral a nivel de fosa nasal, celdillas etmoidales (claro predominio derecho), con infiltración de estructuras adyacentes (órbita, seno maxilar derecho, probablemente pared lateral derecha de nasofaringe) y extensión intracraneal con infiltración de región basal del lóbulo frontal izquierdo. Múltiples lesiones óseas en calota craneal, en columna dorso-lumbar, en escápula izquierda, región lateral de 4º arco y 7º arcos costales derechos, hueso ilíaco derecho e izquierdo, y cuello femoral bilateral, isquion izquierdo y rama del pubis derecha, en relación con afectación metastásica múltiple. Se vuelve a presentar en comité descartándose la cirugía sobre el tumor primario y decidiéndose ante la actual progresión clínica y radiológica a menos de 3 meses de fin de QT realizar RDT local con intención paliativa. Post RDT, en febrero de 2012 presenta clínica de inestabilidad cefálica realizándose: » TAC de cráneo (08/02/12): Múltiples M1 cerebrales. Por lo que se inicia RT holocraneal paliativa el día 21/02/12. El 22/02/12 la paciente ingresa por clínica de compresión cervical (estridor laríngeo, disfonía y disnea) por compresión del conglomerado adenopático Dado la enfermedad avanzada y la situación clínica actual se decide inicio de tratamiento sintomático siendo éxitus el día 25/02/12.
[ "Anamnesis", "\n", "Mujer", "de", "51", "años", "sin", "AMC", ".", "No", "hábitos", "tóxicos", ".", "\n", "ANTECEDENTES", "PATOLÓGICOS", ":", "Epilepsia", "en", "tratamiento", "con", "Tegretol", ".", "Sin", "crisis", "desde", "hacía", ">", "10", "años", ".", "\n", "ANTECEDENTES", "FAMILIARES", ":", "Padre", "con", "neoplasia", "de", "colon", ".", "\n", "Primer", "síntoma", ":", "La", "paciente", "en", "diciembre", "de", "2010", "consulta", "en", "ORL", "por", "sensación", "de", "taponamiento", "nasal", "de", "predominio", "izquierdo", "acompañado", "de", "rinorrea", ",", "lagrimeo", "y", "anosmia", "progresiva", ",", "iniciando", "tratamiento", "con", "corticoides", ",", "con", "mejoría", "sintomática", ".", "\n", "En", "enero", "de", "2011", "reconsulta", "por", "autopalpación", "de", "adenopatías", "a", "nivel", "submandibular", "izquierdo", ",", "indoloras", "y", "con", "crecimiento", "progresivo", ".", "\n\n", "Exploración", "física", "\n", "»", "Constantes", ":", "HMD", "estable", ".", "ECOG", "0", ".", "\n", "»", "Adenopatías", "laterocervicales", "bilaterales", "de", "5", "cm", "aprox", ".", "y", "de", "consistencia", "dura", ".", "Adenopatía", "supraclavicular", "izquierda", "de", "1", "-", "2", "cm", ".", "\n", "»", "Rinoscopia", ":", "Fosa", "nasal", "izquierda", "se", "objetiva", "abundante", "rinorrea", ",", "y", "se", "aprecia", "una", "lesión", "violácea", "que", "ocupa", "la", "mayor", "parte", "de", "la", "fosa", ".", "\n", "»", "Resto", "EF", "normal", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Analítica", "(", "03/03/11", "):", "Hemograma", "normal", ";", "LDH", ":", "758", ",", "FA", ":", "116", ",", "colesterol", ":", "286.3", ",", "ferritina", ":", "172.9", ",", "resto", "de", "BQ", "normal", ";", "IgM", "EBV", ":", "negativo", ",", "IgG", "EBV", ":", "positivo", ".", "\n", "»", "TAC", "cervical", "(", "04/03/11", "):", "Ocupación", "de", "seno", "esfenoidal", ",", "celdas", "etmoidales", "y", "seno", "maxilar", "izquierdo", ",", "con", "signos", "de", "destrucción", "de", "celdas", "etmoidales", "y", "pared", "medial", "del", "seno", "maxilar", "que", "se", "extiende", "hasta", "cornete", ".", "Múltiples", "adenopatías", "a", "nivel", "retroauricular", ",", "submentoniano", ",", "cadena", "yugular", ",", "supraclaviculares", ",", "y", "a", "nivel", "mediastínico", ",", "paraaórtico", "y", "paratraqueal", ".", "\n", "»", "RNM", "de", "base", "de", "cráneo", "(", "16/03/2011", "):", "Extensa", "tumoración", "en", "fosa", "nasal", ",", "invade", "las", "celdas", "etmoidales", "y", "seno", "frontal", "con", "afectación", "y", "destrucción", "ósea", "a", "nivel", "de", "las", "paredes", "de", "los", "senos", "maxilares", "y", "ambas", "órbitas", "con", "sospecha", "de", "invasión", "de", "la", "parte", "anterior", "de", "la", "órbita", "izquierda", ".", "Destrucción", "ósea", "de", "la", "fosa", "craneal", "anterior", "a", "nivel", "de", "la", "lámina", "cribosa", "del", "lado", "izquierdo", "con", "invasión", "tumoral", "intracraneal", "que", "muestra", "pequeña", "imagen", "quística", "intratumoral", ".", "El", "parénquima", "cerebral", "del", "lóbulo", "frontal", "izquierdo", "se", "encuentra", "desplazado", ",", "compatible", "con", "edema", "por", "efecto", "masa", "de", "la", "tumoración", ".", "Se", "observa", "engrosamiento", "de", "la", "glándula", "hipofisaria", "con", "afectación", "de", "contraste", "iv", "heterogénea", "sugestivo", "de", "metástasis", ".", "\n", "»", "PAAF", "adenopatía", "cervical", "izquierda", "(", "08/03/11", "):", "Imagen", "citológica", "de", "tumor", "mal", "diferenciado", "compatible", "con", "estesioneuroblastoma", "de", "alto", "grado", ".", "Inmunohistoquímica", ":", "Positivo", "para", "vimentina", ",", "CD56", ",", "sinaptofisina", ",", "NSE", "y", "cromogranina", ".", "Negativo", "para", "CK", "y", "CD4", "\n", "»", "Biopsia", "tumoración", "fosa", "nasal", "(", "08/03/11", "):", "Estesioneuroblastoma", ".", "Grado", "III", "/", "IV", "de", "la", "clasificación", "de", "Hyams", ".", "\n\n", "Diagnóstico", "\n", "Se", "presenta", "en", "comité", "de", "tumores", "de", "ORL", "(", "22/03/11", "):", "\n", "Se", "orienta", "como", "mujer", "de", "51", "años", "diagnosticada", "de", "estesioneuroblastoma", "olfatorio", ".", "\n", "»", "Según", "TNM", ":", "cT4", "(", "por", "invasión", "cerebral", ")", ",", "N1", "(", "adenopatías", "cervicales", ")", ",", "M1", "(", "probable", "afectación", "de", "glándula", "hipofisaria", ")", ".", "Estadio", "IV", ".", "\n", "»", "Según", "clasificación", "de", "Kadish", ":", "estadio", "C", "(", "invasión", "de", "estructuras", "adyacentes", ")", ".", "\n\n", "Tratamiento", "\n", "Dado", "que", "es", "una", "paciente", "metastásica", "se", "decide", "inicio", "de", "tratamiento", "con", "QT", "paliativa", "según", "esquema", "CDDP", "80", "mg", "/", "m2", "(", "día", "1", ")", "y", "VP16", "100mg", "/", "m2", "(", "días", "1", "-", "3", ")", "cada", "21", "días", ".", "\n", "La", "paciente", "inicia", "QT", "el", "día", "18/04/11", "realizando", "un", "total", "de", "6", "ciclos", ",", "que", "finaliza", "el", "día", "10/08/11", ".", "\n\n", "Evolución", "\n", "Se", "solicita", "RNM", "de", "valoración", "de", "respuesta", ":", "\n", "»", "RNM", "de", "base", "de", "cráneo", "(", "16/08/11", "):", "Persistencia", "de", "la", "afectación", "tumoral", "residual", "ósea", "en", "la", "fosa", "craneal", "anterior", "a", "nivel", "de", "la", "lámina", "cribosa", ",", "de", "la", "pared", "posterior", "de", "las", "celdas", "etmoidales", ",", "del", "seno", "esfenoidal", "izquierdo", ".", "Reducción", "completa", "del", "componente", "tumoral", "intracraneal", "frontal", "izq", ".", "Desaparición", "del", "edema", "cerebral", "subyacente", ".", "Discreta", "disminución", "del", "engrosamiento", "de", "la", "hipófisis", ".", "\n", "Dada", "la", "respuesta", "radiológica", "se", "deriva", "a", "comité", "de", "ORL", "de", "HUGTiP", "para", "valoración", "de", "cirugía", "radical", ";", "realizándose", "el", "día", "21/10/11", "vaciamiento", "cervical", "radical", "modificado", "bilateral", "en", "un", "primer", "tiempo", ".", "\n", "La", "paciente", "pendiente", "de", "cirugía", "del", "tumor", "primario", "(", "que", "se", "realizaría", "en", "un", "segundo", "tiempo", ")", "presenta", "clínica", "de", "taponamiento", "nasal", "por", "lo", "que", "ante", "la", "sospecha", "de", "recidiva", "se", "solicita", "TAC-", "PET", "\n", "»", "TAC", "-", "PET", "(", "28/11/11", "):", "Extensa", "recidiva", "tumoral", "a", "nivel", "de", "fosa", "nasal", ",", "celdillas", "etmoidales", "(", "claro", "predominio", "derecho", ")", ",", "con", "infiltración", "de", "estructuras", "adyacentes", "(", "órbita", ",", "seno", "maxilar", "derecho", ",", "probablemente", "pared", "lateral", "derecha", "de", "nasofaringe", ")", "y", "extensión", "intracraneal", "con", "infiltración", "de", "región", "basal", "del", "lóbulo", "frontal", "izquierdo", ".", "Múltiples", "lesiones", "óseas", "en", "calota", "craneal", ",", "en", "columna", "dorso", "-", "lumbar", ",", "en", "escápula", "izquierda", ",", "región", "lateral", "de", "4º", "arco", "y", "7º", "arcos", "costales", "derechos", ",", "hueso", "ilíaco", "derecho", "e", "izquierdo", ",", "y", "cuello", "femoral", "bilateral", ",", "isquion", "izquierdo", "y", "rama", "del", "pubis", "derecha", ",", "en", "relación", "con", "afectación", "metastásica", "múltiple", ".", "\n", "Se", "vuelve", "a", "presentar", "en", "comité", "descartándose", "la", "cirugía", "sobre", "el", "tumor", "primario", "y", "decidiéndose", "ante", "la", "actual", "progresión", "clínica", "y", "radiológica", "a", "menos", "de", "3", "meses", "de", "fin", "de", "QT", "realizar", "RDT", "local", "con", "intención", "paliativa", ".", "\n", "Post", "RDT", ",", "en", "febrero", "de", "2012", "presenta", "clínica", "de", "inestabilidad", "cefálica", "realizándose", ":", "\n", "»", "TAC", "de", "cráneo", "(", "08/02/12", "):", "Múltiples", "M1", "cerebrales", ".", "\n", "Por", "lo", "que", "se", "inicia", "RT", "holocraneal", "paliativa", "el", "día", "21/02/12", ".", "\n", "El", "22/02/12", "la", "paciente", "ingresa", "por", "clínica", "de", "compresión", "cervical", "(", "estridor", "laríngeo", ",", "disfonía", "y", "disnea", ")", "por", "compresión", "del", "conglomerado", "adenopático", "\n", "Dado", "la", "enfermedad", "avanzada", "y", "la", "situación", "clínica", "actual", "se", "decide", "inicio", "de", "tratamiento", "sintomático", "siendo", "éxitus", "el", "día", "25/02/12", ".", "\n" ]
[ "MORFOLOGIA_NEOPLASIA" ]
neoplasia is a MORFOLOGIA_NEOPLASIA, Adenopatía supraclavicular is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, intratumoral is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumor mal diferenciado is a MORFOLOGIA_NEOPLASIA, estesioneuroblastoma de alto grado is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, Estesioneuroblastoma is a MORFOLOGIA_NEOPLASIA, estesioneuroblastoma is a MORFOLOGIA_NEOPLASIA, M1 is a MORFOLOGIA_NEOPLASIA, afectación de glándula hipofisaria is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, lesiones óseas is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, M1 is a MORFOLOGIA_NEOPLASIA
315_task1
Sentence: Anamnesis Mujer de 51 años sin AMC. No hábitos tóxicos. ANTECEDENTES PATOLÓGICOS: Epilepsia en tratamiento con Tegretol. Sin crisis desde hacía > 10 años. ANTECEDENTES FAMILIARES: Padre con neoplasia de colon. Primer síntoma: La paciente en diciembre de 2010 consulta en ORL por sensación de taponamiento nasal de predominio izquierdo acompañado de rinorrea, lagrimeo y anosmia progresiva, iniciando tratamiento con corticoides, con mejoría sintomática. En enero de 2011 reconsulta por autopalpación de adenopatías a nivel submandibular izquierdo, indoloras y con crecimiento progresivo. Exploración física » Constantes: HMD estable. ECOG 0. » Adenopatías laterocervicales bilaterales de 5 cm aprox. y de consistencia dura. Adenopatía supraclavicular izquierda de 1-2 cm. » Rinoscopia: Fosa nasal izquierda se objetiva abundante rinorrea, y se aprecia una lesión violácea que ocupa la mayor parte de la fosa. » Resto EF normal. Pruebas complementarias » Analítica (03/03/11): Hemograma normal; LDH: 758, FA: 116, colesterol: 286.3, ferritina: 172.9, resto de BQ normal; IgM EBV: negativo, IgG EBV: positivo. » TAC cervical (04/03/11): Ocupación de seno esfenoidal, celdas etmoidales y seno maxilar izquierdo, con signos de destrucción de celdas etmoidales y pared medial del seno maxilar que se extiende hasta cornete. Múltiples adenopatías a nivel retroauricular, submentoniano, cadena yugular, supraclaviculares, y a nivel mediastínico, paraaórtico y paratraqueal. » RNM de base de cráneo (16/03/2011): Extensa tumoración en fosa nasal, invade las celdas etmoidales y seno frontal con afectación y destrucción ósea a nivel de las paredes de los senos maxilares y ambas órbitas con sospecha de invasión de la parte anterior de la órbita izquierda. Destrucción ósea de la fosa craneal anterior a nivel de la lámina cribosa del lado izquierdo con invasión tumoral intracraneal que muestra pequeña imagen quística intratumoral. El parénquima cerebral del lóbulo frontal izquierdo se encuentra desplazado, compatible con edema por efecto masa de la tumoración. Se observa engrosamiento de la glándula hipofisaria con afectación de contraste iv heterogénea sugestivo de metástasis. » PAAF adenopatía cervical izquierda (08/03/11): Imagen citológica de tumor mal diferenciado compatible con estesioneuroblastoma de alto grado. Inmunohistoquímica: Positivo para vimentina, CD56, sinaptofisina, NSE y cromogranina. Negativo para CK y CD4 » Biopsia tumoración fosa nasal (08/03/11): Estesioneuroblastoma. Grado III/IV de la clasificación de Hyams. Diagnóstico Se presenta en comité de tumores de ORL (22/03/11): Se orienta como mujer de 51 años diagnosticada de estesioneuroblastoma olfatorio. » Según TNM: cT4 (por invasión cerebral), N1 (adenopatías cervicales), M1 (probable afectación de glándula hipofisaria). Estadio IV. » Según clasificación de Kadish: estadio C (invasión de estructuras adyacentes). Tratamiento Dado que es una paciente metastásica se decide inicio de tratamiento con QT paliativa según esquema CDDP 80 mg/m2 (día 1) y VP16 100mg/m2 (días 1-3) cada 21 días. La paciente inicia QT el día 18/04/11 realizando un total de 6 ciclos, que finaliza el día 10/08/11. Evolución Se solicita RNM de valoración de respuesta: » RNM de base de cráneo (16/08/11): Persistencia de la afectación tumoral residual ósea en la fosa craneal anterior a nivel de la lámina cribosa, de la pared posterior de las celdas etmoidales, del seno esfenoidal izquierdo. Reducción completa del componente tumoral intracraneal frontal izq. Desaparición del edema cerebral subyacente. Discreta disminución del engrosamiento de la hipófisis. Dada la respuesta radiológica se deriva a comité de ORL de HUGTiP para valoración de cirugía radical; realizándose el día 21/10/11 vaciamiento cervical radical modificado bilateral en un primer tiempo. La paciente pendiente de cirugía del tumor primario (que se realizaría en un segundo tiempo) presenta clínica de taponamiento nasal por lo que ante la sospecha de recidiva se solicita TAC- PET » TAC-PET (28/11/11): Extensa recidiva tumoral a nivel de fosa nasal, celdillas etmoidales (claro predominio derecho), con infiltración de estructuras adyacentes (órbita, seno maxilar derecho, probablemente pared lateral derecha de nasofaringe) y extensión intracraneal con infiltración de región basal del lóbulo frontal izquierdo. Múltiples lesiones óseas en calota craneal, en columna dorso-lumbar, en escápula izquierda, región lateral de 4º arco y 7º arcos costales derechos, hueso ilíaco derecho e izquierdo, y cuello femoral bilateral, isquion izquierdo y rama del pubis derecha, en relación con afectación metastásica múltiple. Se vuelve a presentar en comité descartándose la cirugía sobre el tumor primario y decidiéndose ante la actual progresión clínica y radiológica a menos de 3 meses de fin de QT realizar RDT local con intención paliativa. Post RDT, en febrero de 2012 presenta clínica de inestabilidad cefálica realizándose: » TAC de cráneo (08/02/12): Múltiples M1 cerebrales. Por lo que se inicia RT holocraneal paliativa el día 21/02/12. El 22/02/12 la paciente ingresa por clínica de compresión cervical (estridor laríngeo, disfonía y disnea) por compresión del conglomerado adenopático Dado la enfermedad avanzada y la situación clínica actual se decide inicio de tratamiento sintomático siendo éxitus el día 25/02/12. Instructions: please typing these entity words according to sentence: neoplasia, Adenopatía supraclavicular, tumoración, tumoral, intratumoral, tumoración, metástasis, tumor mal diferenciado, estesioneuroblastoma de alto grado, tumoración, Estesioneuroblastoma, estesioneuroblastoma, M1, afectación de glándula hipofisaria, metastásica, tumoral, tumoral, tumor, tumoral, lesiones óseas, metastásica, tumor, M1 Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Mujer de 51 años sin AMC. No hábitos tóxicos. ANTECEDENTES PATOLÓGICOS: Epilepsia en tratamiento con Tegretol. Sin crisis desde hacía > 10 años. ANTECEDENTES FAMILIARES: Padre con neoplasia de colon. Primer síntoma: La paciente en diciembre de 2010 consulta en ORL por sensación de taponamiento nasal de predominio izquierdo acompañado de rinorrea, lagrimeo y anosmia progresiva, iniciando tratamiento con corticoides, con mejoría sintomática. En enero de 2011 reconsulta por autopalpación de adenopatías a nivel submandibular izquierdo, indoloras y con crecimiento progresivo. Exploración física » Constantes: HMD estable. ECOG 0. » Adenopatías laterocervicales bilaterales de 5 cm aprox. y de consistencia dura. Adenopatía supraclavicular izquierda de 1-2 cm. » Rinoscopia: Fosa nasal izquierda se objetiva abundante rinorrea, y se aprecia una lesión violácea que ocupa la mayor parte de la fosa. » Resto EF normal. Pruebas complementarias » Analítica (03/03/11): Hemograma normal; LDH: 758, FA: 116, colesterol: 286.3, ferritina: 172.9, resto de BQ normal; IgM EBV: negativo, IgG EBV: positivo. » TAC cervical (04/03/11): Ocupación de seno esfenoidal, celdas etmoidales y seno maxilar izquierdo, con signos de destrucción de celdas etmoidales y pared medial del seno maxilar que se extiende hasta cornete. Múltiples adenopatías a nivel retroauricular, submentoniano, cadena yugular, supraclaviculares, y a nivel mediastínico, paraaórtico y paratraqueal. » RNM de base de cráneo (16/03/2011): Extensa tumoración en fosa nasal, invade las celdas etmoidales y seno frontal con afectación y destrucción ósea a nivel de las paredes de los senos maxilares y ambas órbitas con sospecha de invasión de la parte anterior de la órbita izquierda. Destrucción ósea de la fosa craneal anterior a nivel de la lámina cribosa del lado izquierdo con invasión tumoral intracraneal que muestra pequeña imagen quística intratumoral. El parénquima cerebral del lóbulo frontal izquierdo se encuentra desplazado, compatible con edema por efecto masa de la tumoración. Se observa engrosamiento de la glándula hipofisaria con afectación de contraste iv heterogénea sugestivo de metástasis. » PAAF adenopatía cervical izquierda (08/03/11): Imagen citológica de tumor mal diferenciado compatible con estesioneuroblastoma de alto grado. Inmunohistoquímica: Positivo para vimentina, CD56, sinaptofisina, NSE y cromogranina. Negativo para CK y CD4 » Biopsia tumoración fosa nasal (08/03/11): Estesioneuroblastoma. Grado III/IV de la clasificación de Hyams. Diagnóstico Se presenta en comité de tumores de ORL (22/03/11): Se orienta como mujer de 51 años diagnosticada de estesioneuroblastoma olfatorio. » Según TNM: cT4 (por invasión cerebral), N1 (adenopatías cervicales), M1 (probable afectación de glándula hipofisaria). Estadio IV. » Según clasificación de Kadish: estadio C (invasión de estructuras adyacentes). Tratamiento Dado que es una paciente metastásica se decide inicio de tratamiento con QT paliativa según esquema CDDP 80 mg/m2 (día 1) y VP16 100mg/m2 (días 1-3) cada 21 días. La paciente inicia QT el día 18/04/11 realizando un total de 6 ciclos, que finaliza el día 10/08/11. Evolución Se solicita RNM de valoración de respuesta: » RNM de base de cráneo (16/08/11): Persistencia de la afectación tumoral residual ósea en la fosa craneal anterior a nivel de la lámina cribosa, de la pared posterior de las celdas etmoidales, del seno esfenoidal izquierdo. Reducción completa del componente tumoral intracraneal frontal izq. Desaparición del edema cerebral subyacente. Discreta disminución del engrosamiento de la hipófisis. Dada la respuesta radiológica se deriva a comité de ORL de HUGTiP para valoración de cirugía radical; realizándose el día 21/10/11 vaciamiento cervical radical modificado bilateral en un primer tiempo. La paciente pendiente de cirugía del tumor primario (que se realizaría en un segundo tiempo) presenta clínica de taponamiento nasal por lo que ante la sospecha de recidiva se solicita TAC- PET » TAC-PET (28/11/11): Extensa recidiva tumoral a nivel de fosa nasal, celdillas etmoidales (claro predominio derecho), con infiltración de estructuras adyacentes (órbita, seno maxilar derecho, probablemente pared lateral derecha de nasofaringe) y extensión intracraneal con infiltración de región basal del lóbulo frontal izquierdo. Múltiples lesiones óseas en calota craneal, en columna dorso-lumbar, en escápula izquierda, región lateral de 4º arco y 7º arcos costales derechos, hueso ilíaco derecho e izquierdo, y cuello femoral bilateral, isquion izquierdo y rama del pubis derecha, en relación con afectación metastásica múltiple. Se vuelve a presentar en comité descartándose la cirugía sobre el tumor primario y decidiéndose ante la actual progresión clínica y radiológica a menos de 3 meses de fin de QT realizar RDT local con intención paliativa. Post RDT, en febrero de 2012 presenta clínica de inestabilidad cefálica realizándose: » TAC de cráneo (08/02/12): Múltiples M1 cerebrales. Por lo que se inicia RT holocraneal paliativa el día 21/02/12. El 22/02/12 la paciente ingresa por clínica de compresión cervical (estridor laríngeo, disfonía y disnea) por compresión del conglomerado adenopático Dado la enfermedad avanzada y la situación clínica actual se decide inicio de tratamiento sintomático siendo éxitus el día 25/02/12.
[ "Anamnesis", "\n", "Mujer", "de", "51", "años", "sin", "AMC", ".", "No", "hábitos", "tóxicos", ".", "\n", "ANTECEDENTES", "PATOLÓGICOS", ":", "Epilepsia", "en", "tratamiento", "con", "Tegretol", ".", "Sin", "crisis", "desde", "hacía", ">", "10", "años", ".", "\n", "ANTECEDENTES", "FAMILIARES", ":", "Padre", "con", "neoplasia", "de", "colon", ".", "\n", "Primer", "síntoma", ":", "La", "paciente", "en", "diciembre", "de", "2010", "consulta", "en", "ORL", "por", "sensación", "de", "taponamiento", "nasal", "de", "predominio", "izquierdo", "acompañado", "de", "rinorrea", ",", "lagrimeo", "y", "anosmia", "progresiva", ",", "iniciando", "tratamiento", "con", "corticoides", ",", "con", "mejoría", "sintomática", ".", "\n", "En", "enero", "de", "2011", "reconsulta", "por", "autopalpación", "de", "adenopatías", "a", "nivel", "submandibular", "izquierdo", ",", "indoloras", "y", "con", "crecimiento", "progresivo", ".", "\n\n", "Exploración", "física", "\n", "»", "Constantes", ":", "HMD", "estable", ".", "ECOG", "0", ".", "\n", "»", "Adenopatías", "laterocervicales", "bilaterales", "de", "5", "cm", "aprox", ".", "y", "de", "consistencia", "dura", ".", "Adenopatía", "supraclavicular", "izquierda", "de", "1", "-", "2", "cm", ".", "\n", "»", "Rinoscopia", ":", "Fosa", "nasal", "izquierda", "se", "objetiva", "abundante", "rinorrea", ",", "y", "se", "aprecia", "una", "lesión", "violácea", "que", "ocupa", "la", "mayor", "parte", "de", "la", "fosa", ".", "\n", "»", "Resto", "EF", "normal", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Analítica", "(", "03/03/11", "):", "Hemograma", "normal", ";", "LDH", ":", "758", ",", "FA", ":", "116", ",", "colesterol", ":", "286.3", ",", "ferritina", ":", "172.9", ",", "resto", "de", "BQ", "normal", ";", "IgM", "EBV", ":", "negativo", ",", "IgG", "EBV", ":", "positivo", ".", "\n", "»", "TAC", "cervical", "(", "04/03/11", "):", "Ocupación", "de", "seno", "esfenoidal", ",", "celdas", "etmoidales", "y", "seno", "maxilar", "izquierdo", ",", "con", "signos", "de", "destrucción", "de", "celdas", "etmoidales", "y", "pared", "medial", "del", "seno", "maxilar", "que", "se", "extiende", "hasta", "cornete", ".", "Múltiples", "adenopatías", "a", "nivel", "retroauricular", ",", "submentoniano", ",", "cadena", "yugular", ",", "supraclaviculares", ",", "y", "a", "nivel", "mediastínico", ",", "paraaórtico", "y", "paratraqueal", ".", "\n", "»", "RNM", "de", "base", "de", "cráneo", "(", "16/03/2011", "):", "Extensa", "tumoración", "en", "fosa", "nasal", ",", "invade", "las", "celdas", "etmoidales", "y", "seno", "frontal", "con", "afectación", "y", "destrucción", "ósea", "a", "nivel", "de", "las", "paredes", "de", "los", "senos", "maxilares", "y", "ambas", "órbitas", "con", "sospecha", "de", "invasión", "de", "la", "parte", "anterior", "de", "la", "órbita", "izquierda", ".", "Destrucción", "ósea", "de", "la", "fosa", "craneal", "anterior", "a", "nivel", "de", "la", "lámina", "cribosa", "del", "lado", "izquierdo", "con", "invasión", "tumoral", "intracraneal", "que", "muestra", "pequeña", "imagen", "quística", "intratumoral", ".", "El", "parénquima", "cerebral", "del", "lóbulo", "frontal", "izquierdo", "se", "encuentra", "desplazado", ",", "compatible", "con", "edema", "por", "efecto", "masa", "de", "la", "tumoración", ".", "Se", "observa", "engrosamiento", "de", "la", "glándula", "hipofisaria", "con", "afectación", "de", "contraste", "iv", "heterogénea", "sugestivo", "de", "metástasis", ".", "\n", "»", "PAAF", "adenopatía", "cervical", "izquierda", "(", "08/03/11", "):", "Imagen", "citológica", "de", "tumor", "mal", "diferenciado", "compatible", "con", "estesioneuroblastoma", "de", "alto", "grado", ".", "Inmunohistoquímica", ":", "Positivo", "para", "vimentina", ",", "CD56", ",", "sinaptofisina", ",", "NSE", "y", "cromogranina", ".", "Negativo", "para", "CK", "y", "CD4", "\n", "»", "Biopsia", "tumoración", "fosa", "nasal", "(", "08/03/11", "):", "Estesioneuroblastoma", ".", "Grado", "III", "/", "IV", "de", "la", "clasificación", "de", "Hyams", ".", "\n\n", "Diagnóstico", "\n", "Se", "presenta", "en", "comité", "de", "tumores", "de", "ORL", "(", "22/03/11", "):", "\n", "Se", "orienta", "como", "mujer", "de", "51", "años", "diagnosticada", "de", "estesioneuroblastoma", "olfatorio", ".", "\n", "»", "Según", "TNM", ":", "cT4", "(", "por", "invasión", "cerebral", ")", ",", "N1", "(", "adenopatías", "cervicales", ")", ",", "M1", "(", "probable", "afectación", "de", "glándula", "hipofisaria", ")", ".", "Estadio", "IV", ".", "\n", "»", "Según", "clasificación", "de", "Kadish", ":", "estadio", "C", "(", "invasión", "de", "estructuras", "adyacentes", ")", ".", "\n\n", "Tratamiento", "\n", "Dado", "que", "es", "una", "paciente", "metastásica", "se", "decide", "inicio", "de", "tratamiento", "con", "QT", "paliativa", "según", "esquema", "CDDP", "80", "mg", "/", "m2", "(", "día", "1", ")", "y", "VP16", "100mg", "/", "m2", "(", "días", "1", "-", "3", ")", "cada", "21", "días", ".", "\n", "La", "paciente", "inicia", "QT", "el", "día", "18/04/11", "realizando", "un", "total", "de", "6", "ciclos", ",", "que", "finaliza", "el", "día", "10/08/11", ".", "\n\n", "Evolución", "\n", "Se", "solicita", "RNM", "de", "valoración", "de", "respuesta", ":", "\n", "»", "RNM", "de", "base", "de", "cráneo", "(", "16/08/11", "):", "Persistencia", "de", "la", "afectación", "tumoral", "residual", "ósea", "en", "la", "fosa", "craneal", "anterior", "a", "nivel", "de", "la", "lámina", "cribosa", ",", "de", "la", "pared", "posterior", "de", "las", "celdas", "etmoidales", ",", "del", "seno", "esfenoidal", "izquierdo", ".", "Reducción", "completa", "del", "componente", "tumoral", "intracraneal", "frontal", "izq", ".", "Desaparición", "del", "edema", "cerebral", "subyacente", ".", "Discreta", "disminución", "del", "engrosamiento", "de", "la", "hipófisis", ".", "\n", "Dada", "la", "respuesta", "radiológica", "se", "deriva", "a", "comité", "de", "ORL", "de", "HUGTiP", "para", "valoración", "de", "cirugía", "radical", ";", "realizándose", "el", "día", "21/10/11", "vaciamiento", "cervical", "radical", "modificado", "bilateral", "en", "un", "primer", "tiempo", ".", "\n", "La", "paciente", "pendiente", "de", "cirugía", "del", "tumor", "primario", "(", "que", "se", "realizaría", "en", "un", "segundo", "tiempo", ")", "presenta", "clínica", "de", "taponamiento", "nasal", "por", "lo", "que", "ante", "la", "sospecha", "de", "recidiva", "se", "solicita", "TAC-", "PET", "\n", "»", "TAC", "-", "PET", "(", "28/11/11", "):", "Extensa", "recidiva", "tumoral", "a", "nivel", "de", "fosa", "nasal", ",", "celdillas", "etmoidales", "(", "claro", "predominio", "derecho", ")", ",", "con", "infiltración", "de", "estructuras", "adyacentes", "(", "órbita", ",", "seno", "maxilar", "derecho", ",", "probablemente", "pared", "lateral", "derecha", "de", "nasofaringe", ")", "y", "extensión", "intracraneal", "con", "infiltración", "de", "región", "basal", "del", "lóbulo", "frontal", "izquierdo", ".", "Múltiples", "lesiones", "óseas", "en", "calota", "craneal", ",", "en", "columna", "dorso", "-", "lumbar", ",", "en", "escápula", "izquierda", ",", "región", "lateral", "de", "4º", "arco", "y", "7º", "arcos", "costales", "derechos", ",", "hueso", "ilíaco", "derecho", "e", "izquierdo", ",", "y", "cuello", "femoral", "bilateral", ",", "isquion", "izquierdo", "y", "rama", "del", "pubis", "derecha", ",", "en", "relación", "con", "afectación", "metastásica", "múltiple", ".", "\n", "Se", "vuelve", "a", "presentar", "en", "comité", "descartándose", "la", "cirugía", "sobre", "el", "tumor", "primario", "y", "decidiéndose", "ante", "la", "actual", "progresión", "clínica", "y", "radiológica", "a", "menos", "de", "3", "meses", "de", "fin", "de", "QT", "realizar", "RDT", "local", "con", "intención", "paliativa", ".", "\n", "Post", "RDT", ",", "en", "febrero", "de", "2012", "presenta", "clínica", "de", "inestabilidad", "cefálica", "realizándose", ":", "\n", "»", "TAC", "de", "cráneo", "(", "08/02/12", "):", "Múltiples", "M1", "cerebrales", ".", "\n", "Por", "lo", "que", "se", "inicia", "RT", "holocraneal", "paliativa", "el", "día", "21/02/12", ".", "\n", "El", "22/02/12", "la", "paciente", "ingresa", "por", "clínica", "de", "compresión", "cervical", "(", "estridor", "laríngeo", ",", "disfonía", "y", "disnea", ")", "por", "compresión", "del", "conglomerado", "adenopático", "\n", "Dado", "la", "enfermedad", "avanzada", "y", "la", "situación", "clínica", "actual", "se", "decide", "inicio", "de", "tratamiento", "sintomático", "siendo", "éxitus", "el", "día", "25/02/12", ".", "\n" ]
[ "MORFOLOGIA_NEOPLASIA" ]
neoplasia, Adenopatía supraclavicular, tumoración, tumoral, intratumoral, tumoración, metástasis, tumor mal diferenciado, estesioneuroblastoma de alto grado, tumoración, Estesioneuroblastoma, estesioneuroblastoma, M1, afectación de glándula hipofisaria, metastásica, tumoral, tumoral, tumor, tumoral, lesiones óseas, metastásica, tumor, M1
315_task2
Sentence: Anamnesis Mujer de 51 años sin AMC. No hábitos tóxicos. ANTECEDENTES PATOLÓGICOS: Epilepsia en tratamiento con Tegretol. Sin crisis desde hacía > 10 años. ANTECEDENTES FAMILIARES: Padre con neoplasia de colon. Primer síntoma: La paciente en diciembre de 2010 consulta en ORL por sensación de taponamiento nasal de predominio izquierdo acompañado de rinorrea, lagrimeo y anosmia progresiva, iniciando tratamiento con corticoides, con mejoría sintomática. En enero de 2011 reconsulta por autopalpación de adenopatías a nivel submandibular izquierdo, indoloras y con crecimiento progresivo. Exploración física » Constantes: HMD estable. ECOG 0. » Adenopatías laterocervicales bilaterales de 5 cm aprox. y de consistencia dura. Adenopatía supraclavicular izquierda de 1-2 cm. » Rinoscopia: Fosa nasal izquierda se objetiva abundante rinorrea, y se aprecia una lesión violácea que ocupa la mayor parte de la fosa. » Resto EF normal. Pruebas complementarias » Analítica (03/03/11): Hemograma normal; LDH: 758, FA: 116, colesterol: 286.3, ferritina: 172.9, resto de BQ normal; IgM EBV: negativo, IgG EBV: positivo. » TAC cervical (04/03/11): Ocupación de seno esfenoidal, celdas etmoidales y seno maxilar izquierdo, con signos de destrucción de celdas etmoidales y pared medial del seno maxilar que se extiende hasta cornete. Múltiples adenopatías a nivel retroauricular, submentoniano, cadena yugular, supraclaviculares, y a nivel mediastínico, paraaórtico y paratraqueal. » RNM de base de cráneo (16/03/2011): Extensa tumoración en fosa nasal, invade las celdas etmoidales y seno frontal con afectación y destrucción ósea a nivel de las paredes de los senos maxilares y ambas órbitas con sospecha de invasión de la parte anterior de la órbita izquierda. Destrucción ósea de la fosa craneal anterior a nivel de la lámina cribosa del lado izquierdo con invasión tumoral intracraneal que muestra pequeña imagen quística intratumoral. El parénquima cerebral del lóbulo frontal izquierdo se encuentra desplazado, compatible con edema por efecto masa de la tumoración. Se observa engrosamiento de la glándula hipofisaria con afectación de contraste iv heterogénea sugestivo de metástasis. » PAAF adenopatía cervical izquierda (08/03/11): Imagen citológica de tumor mal diferenciado compatible con estesioneuroblastoma de alto grado. Inmunohistoquímica: Positivo para vimentina, CD56, sinaptofisina, NSE y cromogranina. Negativo para CK y CD4 » Biopsia tumoración fosa nasal (08/03/11): Estesioneuroblastoma. Grado III/IV de la clasificación de Hyams. Diagnóstico Se presenta en comité de tumores de ORL (22/03/11): Se orienta como mujer de 51 años diagnosticada de estesioneuroblastoma olfatorio. » Según TNM: cT4 (por invasión cerebral), N1 (adenopatías cervicales), M1 (probable afectación de glándula hipofisaria). Estadio IV. » Según clasificación de Kadish: estadio C (invasión de estructuras adyacentes). Tratamiento Dado que es una paciente metastásica se decide inicio de tratamiento con QT paliativa según esquema CDDP 80 mg/m2 (día 1) y VP16 100mg/m2 (días 1-3) cada 21 días. La paciente inicia QT el día 18/04/11 realizando un total de 6 ciclos, que finaliza el día 10/08/11. Evolución Se solicita RNM de valoración de respuesta: » RNM de base de cráneo (16/08/11): Persistencia de la afectación tumoral residual ósea en la fosa craneal anterior a nivel de la lámina cribosa, de la pared posterior de las celdas etmoidales, del seno esfenoidal izquierdo. Reducción completa del componente tumoral intracraneal frontal izq. Desaparición del edema cerebral subyacente. Discreta disminución del engrosamiento de la hipófisis. Dada la respuesta radiológica se deriva a comité de ORL de HUGTiP para valoración de cirugía radical; realizándose el día 21/10/11 vaciamiento cervical radical modificado bilateral en un primer tiempo. La paciente pendiente de cirugía del tumor primario (que se realizaría en un segundo tiempo) presenta clínica de taponamiento nasal por lo que ante la sospecha de recidiva se solicita TAC- PET » TAC-PET (28/11/11): Extensa recidiva tumoral a nivel de fosa nasal, celdillas etmoidales (claro predominio derecho), con infiltración de estructuras adyacentes (órbita, seno maxilar derecho, probablemente pared lateral derecha de nasofaringe) y extensión intracraneal con infiltración de región basal del lóbulo frontal izquierdo. Múltiples lesiones óseas en calota craneal, en columna dorso-lumbar, en escápula izquierda, región lateral de 4º arco y 7º arcos costales derechos, hueso ilíaco derecho e izquierdo, y cuello femoral bilateral, isquion izquierdo y rama del pubis derecha, en relación con afectación metastásica múltiple. Se vuelve a presentar en comité descartándose la cirugía sobre el tumor primario y decidiéndose ante la actual progresión clínica y radiológica a menos de 3 meses de fin de QT realizar RDT local con intención paliativa. Post RDT, en febrero de 2012 presenta clínica de inestabilidad cefálica realizándose: » TAC de cráneo (08/02/12): Múltiples M1 cerebrales. Por lo que se inicia RT holocraneal paliativa el día 21/02/12. El 22/02/12 la paciente ingresa por clínica de compresión cervical (estridor laríngeo, disfonía y disnea) por compresión del conglomerado adenopático Dado la enfermedad avanzada y la situación clínica actual se decide inicio de tratamiento sintomático siendo éxitus el día 25/02/12. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Mujer de 51 años sin AMC. No hábitos tóxicos. ANTECEDENTES PATOLÓGICOS: Epilepsia en tratamiento con Tegretol. Sin crisis desde hacía > 10 años. ANTECEDENTES FAMILIARES: Padre con neoplasia de colon. Primer síntoma: La paciente en diciembre de 2010 consulta en ORL por sensación de taponamiento nasal de predominio izquierdo acompañado de rinorrea, lagrimeo y anosmia progresiva, iniciando tratamiento con corticoides, con mejoría sintomática. En enero de 2011 reconsulta por autopalpación de adenopatías a nivel submandibular izquierdo, indoloras y con crecimiento progresivo. Exploración física » Constantes: HMD estable. ECOG 0. » Adenopatías laterocervicales bilaterales de 5 cm aprox. y de consistencia dura. Adenopatía supraclavicular izquierda de 1-2 cm. » Rinoscopia: Fosa nasal izquierda se objetiva abundante rinorrea, y se aprecia una lesión violácea que ocupa la mayor parte de la fosa. » Resto EF normal. Pruebas complementarias » Analítica (03/03/11): Hemograma normal; LDH: 758, FA: 116, colesterol: 286.3, ferritina: 172.9, resto de BQ normal; IgM EBV: negativo, IgG EBV: positivo. » TAC cervical (04/03/11): Ocupación de seno esfenoidal, celdas etmoidales y seno maxilar izquierdo, con signos de destrucción de celdas etmoidales y pared medial del seno maxilar que se extiende hasta cornete. Múltiples adenopatías a nivel retroauricular, submentoniano, cadena yugular, supraclaviculares, y a nivel mediastínico, paraaórtico y paratraqueal. » RNM de base de cráneo (16/03/2011): Extensa tumoración en fosa nasal, invade las celdas etmoidales y seno frontal con afectación y destrucción ósea a nivel de las paredes de los senos maxilares y ambas órbitas con sospecha de invasión de la parte anterior de la órbita izquierda. Destrucción ósea de la fosa craneal anterior a nivel de la lámina cribosa del lado izquierdo con invasión tumoral intracraneal que muestra pequeña imagen quística intratumoral. El parénquima cerebral del lóbulo frontal izquierdo se encuentra desplazado, compatible con edema por efecto masa de la tumoración. Se observa engrosamiento de la glándula hipofisaria con afectación de contraste iv heterogénea sugestivo de metástasis. » PAAF adenopatía cervical izquierda (08/03/11): Imagen citológica de tumor mal diferenciado compatible con estesioneuroblastoma de alto grado. Inmunohistoquímica: Positivo para vimentina, CD56, sinaptofisina, NSE y cromogranina. Negativo para CK y CD4 » Biopsia tumoración fosa nasal (08/03/11): Estesioneuroblastoma. Grado III/IV de la clasificación de Hyams. Diagnóstico Se presenta en comité de tumores de ORL (22/03/11): Se orienta como mujer de 51 años diagnosticada de estesioneuroblastoma olfatorio. » Según TNM: cT4 (por invasión cerebral), N1 (adenopatías cervicales), M1 (probable afectación de glándula hipofisaria). Estadio IV. » Según clasificación de Kadish: estadio C (invasión de estructuras adyacentes). Tratamiento Dado que es una paciente metastásica se decide inicio de tratamiento con QT paliativa según esquema CDDP 80 mg/m2 (día 1) y VP16 100mg/m2 (días 1-3) cada 21 días. La paciente inicia QT el día 18/04/11 realizando un total de 6 ciclos, que finaliza el día 10/08/11. Evolución Se solicita RNM de valoración de respuesta: » RNM de base de cráneo (16/08/11): Persistencia de la afectación tumoral residual ósea en la fosa craneal anterior a nivel de la lámina cribosa, de la pared posterior de las celdas etmoidales, del seno esfenoidal izquierdo. Reducción completa del componente tumoral intracraneal frontal izq. Desaparición del edema cerebral subyacente. Discreta disminución del engrosamiento de la hipófisis. Dada la respuesta radiológica se deriva a comité de ORL de HUGTiP para valoración de cirugía radical; realizándose el día 21/10/11 vaciamiento cervical radical modificado bilateral en un primer tiempo. La paciente pendiente de cirugía del tumor primario (que se realizaría en un segundo tiempo) presenta clínica de taponamiento nasal por lo que ante la sospecha de recidiva se solicita TAC- PET » TAC-PET (28/11/11): Extensa recidiva tumoral a nivel de fosa nasal, celdillas etmoidales (claro predominio derecho), con infiltración de estructuras adyacentes (órbita, seno maxilar derecho, probablemente pared lateral derecha de nasofaringe) y extensión intracraneal con infiltración de región basal del lóbulo frontal izquierdo. Múltiples lesiones óseas en calota craneal, en columna dorso-lumbar, en escápula izquierda, región lateral de 4º arco y 7º arcos costales derechos, hueso ilíaco derecho e izquierdo, y cuello femoral bilateral, isquion izquierdo y rama del pubis derecha, en relación con afectación metastásica múltiple. Se vuelve a presentar en comité descartándose la cirugía sobre el tumor primario y decidiéndose ante la actual progresión clínica y radiológica a menos de 3 meses de fin de QT realizar RDT local con intención paliativa. Post RDT, en febrero de 2012 presenta clínica de inestabilidad cefálica realizándose: » TAC de cráneo (08/02/12): Múltiples M1 cerebrales. Por lo que se inicia RT holocraneal paliativa el día 21/02/12. El 22/02/12 la paciente ingresa por clínica de compresión cervical (estridor laríngeo, disfonía y disnea) por compresión del conglomerado adenopático Dado la enfermedad avanzada y la situación clínica actual se decide inicio de tratamiento sintomático siendo éxitus el día 25/02/12.
[ "Anamnesis", "\n", "Mujer", "de", "51", "años", "sin", "AMC", ".", "No", "hábitos", "tóxicos", ".", "\n", "ANTECEDENTES", "PATOLÓGICOS", ":", "Epilepsia", "en", "tratamiento", "con", "Tegretol", ".", "Sin", "crisis", "desde", "hacía", ">", "10", "años", ".", "\n", "ANTECEDENTES", "FAMILIARES", ":", "Padre", "con", "neoplasia", "de", "colon", ".", "\n", "Primer", "síntoma", ":", "La", "paciente", "en", "diciembre", "de", "2010", "consulta", "en", "ORL", "por", "sensación", "de", "taponamiento", "nasal", "de", "predominio", "izquierdo", "acompañado", "de", "rinorrea", ",", "lagrimeo", "y", "anosmia", "progresiva", ",", "iniciando", "tratamiento", "con", "corticoides", ",", "con", "mejoría", "sintomática", ".", "\n", "En", "enero", "de", "2011", "reconsulta", "por", "autopalpación", "de", "adenopatías", "a", "nivel", "submandibular", "izquierdo", ",", "indoloras", "y", "con", "crecimiento", "progresivo", ".", "\n\n", "Exploración", "física", "\n", "»", "Constantes", ":", "HMD", "estable", ".", "ECOG", "0", ".", "\n", "»", "Adenopatías", "laterocervicales", "bilaterales", "de", "5", "cm", "aprox", ".", "y", "de", "consistencia", "dura", ".", "Adenopatía", "supraclavicular", "izquierda", "de", "1", "-", "2", "cm", ".", "\n", "»", "Rinoscopia", ":", "Fosa", "nasal", "izquierda", "se", "objetiva", "abundante", "rinorrea", ",", "y", "se", "aprecia", "una", "lesión", "violácea", "que", "ocupa", "la", "mayor", "parte", "de", "la", "fosa", ".", "\n", "»", "Resto", "EF", "normal", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Analítica", "(", "03/03/11", "):", "Hemograma", "normal", ";", "LDH", ":", "758", ",", "FA", ":", "116", ",", "colesterol", ":", "286.3", ",", "ferritina", ":", "172.9", ",", "resto", "de", "BQ", "normal", ";", "IgM", "EBV", ":", "negativo", ",", "IgG", "EBV", ":", "positivo", ".", "\n", "»", "TAC", "cervical", "(", "04/03/11", "):", "Ocupación", "de", "seno", "esfenoidal", ",", "celdas", "etmoidales", "y", "seno", "maxilar", "izquierdo", ",", "con", "signos", "de", "destrucción", "de", "celdas", "etmoidales", "y", "pared", "medial", "del", "seno", "maxilar", "que", "se", "extiende", "hasta", "cornete", ".", "Múltiples", "adenopatías", "a", "nivel", "retroauricular", ",", "submentoniano", ",", "cadena", "yugular", ",", "supraclaviculares", ",", "y", "a", "nivel", "mediastínico", ",", "paraaórtico", "y", "paratraqueal", ".", "\n", "»", "RNM", "de", "base", "de", "cráneo", "(", "16/03/2011", "):", "Extensa", "tumoración", "en", "fosa", "nasal", ",", "invade", "las", "celdas", "etmoidales", "y", "seno", "frontal", "con", "afectación", "y", "destrucción", "ósea", "a", "nivel", "de", "las", "paredes", "de", "los", "senos", "maxilares", "y", "ambas", "órbitas", "con", "sospecha", "de", "invasión", "de", "la", "parte", "anterior", "de", "la", "órbita", "izquierda", ".", "Destrucción", "ósea", "de", "la", "fosa", "craneal", "anterior", "a", "nivel", "de", "la", "lámina", "cribosa", "del", "lado", "izquierdo", "con", "invasión", "tumoral", "intracraneal", "que", "muestra", "pequeña", "imagen", "quística", "intratumoral", ".", "El", "parénquima", "cerebral", "del", "lóbulo", "frontal", "izquierdo", "se", "encuentra", "desplazado", ",", "compatible", "con", "edema", "por", "efecto", "masa", "de", "la", "tumoración", ".", "Se", "observa", "engrosamiento", "de", "la", "glándula", "hipofisaria", "con", "afectación", "de", "contraste", "iv", "heterogénea", "sugestivo", "de", "metástasis", ".", "\n", "»", "PAAF", "adenopatía", "cervical", "izquierda", "(", "08/03/11", "):", "Imagen", "citológica", "de", "tumor", "mal", "diferenciado", "compatible", "con", "estesioneuroblastoma", "de", "alto", "grado", ".", "Inmunohistoquímica", ":", "Positivo", "para", "vimentina", ",", "CD56", ",", "sinaptofisina", ",", "NSE", "y", "cromogranina", ".", "Negativo", "para", "CK", "y", "CD4", "\n", "»", "Biopsia", "tumoración", "fosa", "nasal", "(", "08/03/11", "):", "Estesioneuroblastoma", ".", "Grado", "III", "/", "IV", "de", "la", "clasificación", "de", "Hyams", ".", "\n\n", "Diagnóstico", "\n", "Se", "presenta", "en", "comité", "de", "tumores", "de", "ORL", "(", "22/03/11", "):", "\n", "Se", "orienta", "como", "mujer", "de", "51", "años", "diagnosticada", "de", "estesioneuroblastoma", "olfatorio", ".", "\n", "»", "Según", "TNM", ":", "cT4", "(", "por", "invasión", "cerebral", ")", ",", "N1", "(", "adenopatías", "cervicales", ")", ",", "M1", "(", "probable", "afectación", "de", "glándula", "hipofisaria", ")", ".", "Estadio", "IV", ".", "\n", "»", "Según", "clasificación", "de", "Kadish", ":", "estadio", "C", "(", "invasión", "de", "estructuras", "adyacentes", ")", ".", "\n\n", "Tratamiento", "\n", "Dado", "que", "es", "una", "paciente", "metastásica", "se", "decide", "inicio", "de", "tratamiento", "con", "QT", "paliativa", "según", "esquema", "CDDP", "80", "mg", "/", "m2", "(", "día", "1", ")", "y", "VP16", "100mg", "/", "m2", "(", "días", "1", "-", "3", ")", "cada", "21", "días", ".", "\n", "La", "paciente", "inicia", "QT", "el", "día", "18/04/11", "realizando", "un", "total", "de", "6", "ciclos", ",", "que", "finaliza", "el", "día", "10/08/11", ".", "\n\n", "Evolución", "\n", "Se", "solicita", "RNM", "de", "valoración", "de", "respuesta", ":", "\n", "»", "RNM", "de", "base", "de", "cráneo", "(", "16/08/11", "):", "Persistencia", "de", "la", "afectación", "tumoral", "residual", "ósea", "en", "la", "fosa", "craneal", "anterior", "a", "nivel", "de", "la", "lámina", "cribosa", ",", "de", "la", "pared", "posterior", "de", "las", "celdas", "etmoidales", ",", "del", "seno", "esfenoidal", "izquierdo", ".", "Reducción", "completa", "del", "componente", "tumoral", "intracraneal", "frontal", "izq", ".", "Desaparición", "del", "edema", "cerebral", "subyacente", ".", "Discreta", "disminución", "del", "engrosamiento", "de", "la", "hipófisis", ".", "\n", "Dada", "la", "respuesta", "radiológica", "se", "deriva", "a", "comité", "de", "ORL", "de", "HUGTiP", "para", "valoración", "de", "cirugía", "radical", ";", "realizándose", "el", "día", "21/10/11", "vaciamiento", "cervical", "radical", "modificado", "bilateral", "en", "un", "primer", "tiempo", ".", "\n", "La", "paciente", "pendiente", "de", "cirugía", "del", "tumor", "primario", "(", "que", "se", "realizaría", "en", "un", "segundo", "tiempo", ")", "presenta", "clínica", "de", "taponamiento", "nasal", "por", "lo", "que", "ante", "la", "sospecha", "de", "recidiva", "se", "solicita", "TAC-", "PET", "\n", "»", "TAC", "-", "PET", "(", "28/11/11", "):", "Extensa", "recidiva", "tumoral", "a", "nivel", "de", "fosa", "nasal", ",", "celdillas", "etmoidales", "(", "claro", "predominio", "derecho", ")", ",", "con", "infiltración", "de", "estructuras", "adyacentes", "(", "órbita", ",", "seno", "maxilar", "derecho", ",", "probablemente", "pared", "lateral", "derecha", "de", "nasofaringe", ")", "y", "extensión", "intracraneal", "con", "infiltración", "de", "región", "basal", "del", "lóbulo", "frontal", "izquierdo", ".", "Múltiples", "lesiones", "óseas", "en", "calota", "craneal", ",", "en", "columna", "dorso", "-", "lumbar", ",", "en", "escápula", "izquierda", ",", "región", "lateral", "de", "4º", "arco", "y", "7º", "arcos", "costales", "derechos", ",", "hueso", "ilíaco", "derecho", "e", "izquierdo", ",", "y", "cuello", "femoral", "bilateral", ",", "isquion", "izquierdo", "y", "rama", "del", "pubis", "derecha", ",", "en", "relación", "con", "afectación", "metastásica", "múltiple", ".", "\n", "Se", "vuelve", "a", "presentar", "en", "comité", "descartándose", "la", "cirugía", "sobre", "el", "tumor", "primario", "y", "decidiéndose", "ante", "la", "actual", "progresión", "clínica", "y", "radiológica", "a", "menos", "de", "3", "meses", "de", "fin", "de", "QT", "realizar", "RDT", "local", "con", "intención", "paliativa", ".", "\n", "Post", "RDT", ",", "en", "febrero", "de", "2012", "presenta", "clínica", "de", "inestabilidad", "cefálica", "realizándose", ":", "\n", "»", "TAC", "de", "cráneo", "(", "08/02/12", "):", "Múltiples", "M1", "cerebrales", ".", "\n", "Por", "lo", "que", "se", "inicia", "RT", "holocraneal", "paliativa", "el", "día", "21/02/12", ".", "\n", "El", "22/02/12", "la", "paciente", "ingresa", "por", "clínica", "de", "compresión", "cervical", "(", "estridor", "laríngeo", ",", "disfonía", "y", "disnea", ")", "por", "compresión", "del", "conglomerado", "adenopático", "\n", "Dado", "la", "enfermedad", "avanzada", "y", "la", "situación", "clínica", "actual", "se", "decide", "inicio", "de", "tratamiento", "sintomático", "siendo", "éxitus", "el", "día", "25/02/12", ".", "\n" ]
[ "MORFOLOGIA_NEOPLASIA" ]
lactose is a CHEMICAL
3089818_task0
Sentence: Intestinal permeability and lactose hydrolysis in human rotaviral gastroenteritis assessed simultaneously by non-invasive differential sugar permeation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL
[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Intestinal permeability and lactose hydrolysis in human rotaviral gastroenteritis assessed simultaneously by non-invasive differential sugar permeation.
[ "Intestinal", "permeability", "and", "lactose", "hydrolysis", "in", "human", "rotaviral", "gastroenteritis", "assessed", "simultaneously", "by", "non", "-", "invasive", "differential", "sugar", "permeation", "." ]
[ "CHEMICAL", "GENE-Y" ]
lactose is a CHEMICAL
3089818_task1
Sentence: Intestinal permeability and lactose hydrolysis in human rotaviral gastroenteritis assessed simultaneously by non-invasive differential sugar permeation. Instructions: please typing these entity words according to sentence: lactose Options: CHEMICAL
[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Intestinal permeability and lactose hydrolysis in human rotaviral gastroenteritis assessed simultaneously by non-invasive differential sugar permeation.
[ "Intestinal", "permeability", "and", "lactose", "hydrolysis", "in", "human", "rotaviral", "gastroenteritis", "assessed", "simultaneously", "by", "non", "-", "invasive", "differential", "sugar", "permeation", "." ]
[ "CHEMICAL", "GENE-Y" ]
lactose
3089818_task2
Sentence: Intestinal permeability and lactose hydrolysis in human rotaviral gastroenteritis assessed simultaneously by non-invasive differential sugar permeation. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Intestinal permeability and lactose hydrolysis in human rotaviral gastroenteritis assessed simultaneously by non-invasive differential sugar permeation.
[ "Intestinal", "permeability", "and", "lactose", "hydrolysis", "in", "human", "rotaviral", "gastroenteritis", "assessed", "simultaneously", "by", "non", "-", "invasive", "differential", "sugar", "permeation", "." ]
[ "CHEMICAL", "GENE-Y" ]
Differentialdiagnose is an umlsterm, Thrombozytenwertes is an umlsterm, Knochenmarks is an umlsterm, Leukaemie is an umlsterm, Polycythaemia vera is an umlsterm, Thrombozythaemie is an umlsterm, thrombozythaemisch is an umlsterm, Myelofibrose is an umlsterm, Eisenspeicher is an umlsterm, Normalverteilung is an umlsterm, Myelofibrose is an umlsterm
DerPathologe.00210031.ger.abstr_task0
Sentence: Die Differentialdiagnose eines erhoehten Thrombozytenwertes ( > =500x109/l), der insbesondere bei wiederholter Bestimmung gefunden wird , beinhaltet eine Abgrenzung zwischen reaktiven Ursachen im Rahmen ganz unterschiedlicher Grundleiden und einer neoplastischen bzw. myeloproliferativen Systemerkrankung ( CMPE ) . Neben haematologischen Befunden , vor allem jedoch der Entwicklung der einzelnen Laborparameter im Verlaufe der Erkrankung kommt der Histopathologie des Knochenmarks eine wegweisende diagnostische Bedeutung zu . Charakteristische Veraenderungen betreffen nicht nur die Megakaryopoese , sondern auch die uebrigen Zellreihen und das Interstitium . Waehrend bei dem megakaryozytenreichen Subtyp der chronischen myeloischen Leukaemie ( CML ) und beim 5q--Syndrom ( MDS ) abnorm differenzierte Mikromegakaryozyten vorherrschen , ist die Polycythaemia vera ( PV ) durch einen pleomorphen Aspekt dieser Zellreihe und die essentielle Thrombozythaemie ( ET ) durch zahlreiche Riesenformen gekennzeichnet , die einen stark gelappten Kern ( sog . Hirschgeweih-Kerne ) aufweisen . Die klare Trennung einer ET von thrombozythaemisch verlaufenden Formen der idiopathischen Myelofibrose ( IMF ) ist durchaus moeglich , vorausgestzt man beachtet die ausgepraegten Atypien der Megakaryopoese , welche letztere Entitaet auszeichnen . Zudem besitzt die CML eine vorherrschende granulozytaere Zellreihe , waehrend die PV durch eine trilineare Proliferation ( Panmyelose ) mit prominenter erythropoetischer Proliferation gekennzeichnet ist . Eine signifikante Reduktion dieser Zelllinie ist bei der CML und weniger bei der IMF vorhanden . Die CMPE lassen eine deutliche Spannbreite der Retikulumzellsiderose erkennen , die von fehlendem Eisenspeicher ( PV ) ueber ganz spaerliche Ablagerungen ( CML bis hin zur Normalverteilung ( ET ) ) reicht . Aehnliche Befunde sind hinsichtlich einer ( retikulaeren ) Myelofibrose zu erheben , die gewoehnlich bei der ET fehlt , vereinzelt bei der PV besteht und bei der CML und IMF in ganz unterschiedlicher Auspraegung vorhanden ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Differentialdiagnose eines erhoehten Thrombozytenwertes ( > =500x109/l), der insbesondere bei wiederholter Bestimmung gefunden wird , beinhaltet eine Abgrenzung zwischen reaktiven Ursachen im Rahmen ganz unterschiedlicher Grundleiden und einer neoplastischen bzw. myeloproliferativen Systemerkrankung ( CMPE ) . Neben haematologischen Befunden , vor allem jedoch der Entwicklung der einzelnen Laborparameter im Verlaufe der Erkrankung kommt der Histopathologie des Knochenmarks eine wegweisende diagnostische Bedeutung zu . Charakteristische Veraenderungen betreffen nicht nur die Megakaryopoese , sondern auch die uebrigen Zellreihen und das Interstitium . Waehrend bei dem megakaryozytenreichen Subtyp der chronischen myeloischen Leukaemie ( CML ) und beim 5q--Syndrom ( MDS ) abnorm differenzierte Mikromegakaryozyten vorherrschen , ist die Polycythaemia vera ( PV ) durch einen pleomorphen Aspekt dieser Zellreihe und die essentielle Thrombozythaemie ( ET ) durch zahlreiche Riesenformen gekennzeichnet , die einen stark gelappten Kern ( sog . Hirschgeweih-Kerne ) aufweisen . Die klare Trennung einer ET von thrombozythaemisch verlaufenden Formen der idiopathischen Myelofibrose ( IMF ) ist durchaus moeglich , vorausgestzt man beachtet die ausgepraegten Atypien der Megakaryopoese , welche letztere Entitaet auszeichnen . Zudem besitzt die CML eine vorherrschende granulozytaere Zellreihe , waehrend die PV durch eine trilineare Proliferation ( Panmyelose ) mit prominenter erythropoetischer Proliferation gekennzeichnet ist . Eine signifikante Reduktion dieser Zelllinie ist bei der CML und weniger bei der IMF vorhanden . Die CMPE lassen eine deutliche Spannbreite der Retikulumzellsiderose erkennen , die von fehlendem Eisenspeicher ( PV ) ueber ganz spaerliche Ablagerungen ( CML bis hin zur Normalverteilung ( ET ) ) reicht . Aehnliche Befunde sind hinsichtlich einer ( retikulaeren ) Myelofibrose zu erheben , die gewoehnlich bei der ET fehlt , vereinzelt bei der PV besteht und bei der CML und IMF in ganz unterschiedlicher Auspraegung vorhanden ist .
[ "Die", "Differentialdiagnose", "eines", "erhoehten", "Thrombozytenwertes", "(", ">", "=", "500x109", "/", "l", ")", ",", "der", "insbesondere", "bei", "wiederholter", "Bestimmung", "gefunden", "wird", ",", "beinhaltet", "eine", "Abgrenzung", "zwischen", "reaktiven", "Ursachen", "im", "Rahmen", "ganz", "unterschiedlicher", "Grundleiden", "und", "einer", "neoplastischen", "bzw", ".", "myeloproliferativen", "Systemerkrankung", "(", "CMPE", ")", ".", "Neben", "haematologischen", "Befunden", ",", "vor", "allem", "jedoch", "der", "Entwicklung", "der", "einzelnen", "Laborparameter", "im", "Verlaufe", "der", "Erkrankung", "kommt", "der", "Histopathologie", "des", "Knochenmarks", "eine", "wegweisende", "diagnostische", "Bedeutung", "zu", ".", "Charakteristische", "Veraenderungen", "betreffen", "nicht", "nur", "die", "Megakaryopoese", ",", "sondern", "auch", "die", "uebrigen", "Zellreihen", "und", "das", "Interstitium", ".", "Waehrend", "bei", "dem", "megakaryozytenreichen", "Subtyp", "der", "chronischen", "myeloischen", "Leukaemie", "(", "CML", ")", "und", "beim", "5q", "--", "Syndrom", "(", "MDS", ")", "abnorm", "differenzierte", "Mikromegakaryozyten", "vorherrschen", ",", "ist", "die", "Polycythaemia", "vera", "(", "PV", ")", "durch", "einen", "pleomorphen", "Aspekt", "dieser", "Zellreihe", "und", "die", "essentielle", "Thrombozythaemie", "(", "ET", ")", "durch", "zahlreiche", "Riesenformen", "gekennzeichnet", ",", "die", "einen", "stark", "gelappten", "Kern", "(", "sog", ".", "Hirschgeweih", "-", "Kerne", ")", "aufweisen", ".", "Die", "klare", "Trennung", "einer", "ET", "von", "thrombozythaemisch", "verlaufenden", "Formen", "der", "idiopathischen", "Myelofibrose", "(", "IMF", ")", "ist", "durchaus", "moeglich", ",", "vorausgestzt", "man", "beachtet", "die", "ausgepraegten", "Atypien", "der", "Megakaryopoese", ",", "welche", "letztere", "Entitaet", "auszeichnen", ".", "Zudem", "besitzt", "die", "CML", "eine", "vorherrschende", "granulozytaere", "Zellreihe", ",", "waehrend", "die", "PV", "durch", "eine", "trilineare", "Proliferation", "(", "Panmyelose", ")", "mit", "prominenter", "erythropoetischer", "Proliferation", "gekennzeichnet", "ist", ".", "Eine", "signifikante", "Reduktion", "dieser", "Zelllinie", "ist", "bei", "der", "CML", "und", "weniger", "bei", "der", "IMF", "vorhanden", ".", "Die", "CMPE", "lassen", "eine", "deutliche", "Spannbreite", "der", "Retikulumzellsiderose", "erkennen", ",", "die", "von", "fehlendem", "Eisenspeicher", "(", "PV", ")", "ueber", "ganz", "spaerliche", "Ablagerungen", "(", "CML", "bis", "hin", "zur", "Normalverteilung", "(", "ET", ")", ")", "reicht", ".", "Aehnliche", "Befunde", "sind", "hinsichtlich", "einer", "(", "retikulaeren", ")", "Myelofibrose", "zu", "erheben", ",", "die", "gewoehnlich", "bei", "der", "ET", "fehlt", ",", "vereinzelt", "bei", "der", "PV", "besteht", "und", "bei", "der", "CML", "und", "IMF", "in", "ganz", "unterschiedlicher", "Auspraegung", "vorhanden", "ist", "." ]
[ "umlsterm" ]